Celyad SA
Annual Report 2021

Plain-text annual report

Annual Report 2021 www.celyad.com 2021 ANNUAL REPORT 2021 Annual Report Table of Contents SHAREHOLDERS NEWSLETTER 1. ACTIVITY REPORT .............................................................................................................................. 10 1.1 Who we are - Business Overview ................................................................................................. 10 1.2 Our Strategy ................................................................................................................................. 13 1.3 What differentiates Celyad Oncology? .......................................................................................... 15 1.4 Our Activities and R&D ................................................................................................................. 16 1.5 Lead Programs ............................................................................................................................. 18 1.6 Licensing and Collaboration Agreements ..................................................................................... 22 1.7 Our Manufacturing Capabilities ..................................................................................................... 26 1.8 Our shareholding structure ........................................................................................................... 26 1.9 Post balance sheet events ............................................................................................................ 26 1.10 Our capital expenditures ............................................................................................................... 27 1.11 Financial review of the year ending December 31, 2021 .............................................................. 27 1.11.1. Analysis of the consolidated income statement .............................................................. 27 1.11.2. Analysis of the consolidated statements of financial position ......................................... 29 ........................................................ 32 1.11.3. Analysis of the consolidated net cash burn rate 1.12 Personnel ...................................................................................................................................... 33 1.13 Environment .................................................................................................................................. 33 1.14 Going concern ......................................................................................................................... 33 1.15 Risks and uncertainties ................................................................................................................. 34 1.16 Events and circumstances that could have a significant impact on the future .............................. 35 2. CORPORATE GOVERNANCE ............................................................................................................. 36 2.1 General ......................................................................................................................................... 36 2.2 Board of Directors ......................................................................................................................... 36 2.2.1. Composition of the Board of Directors ............................................................................ 36 2.2.2. Board resolutions ............................................................................................................ 40 2.2.3. Director Independence ................................................................................................... 41 2.2.4. Role of the Board in Risk Oversight ................................................................................ 42 2.2.5. Committees within the Board of Directors ....................................................................... 42 2.2.6. Meetings of the Board and the committees..................................................................... 44 2.3 Executive Committee .................................................................................................................... 45 2.4 Conflict of Interest of Directors and members of the Executive Committee and transactions with affiliated companies ...................................................................................................................... 48 2.4.1. General ........................................................................................................................... 48 2.4.2. Conflicts of interest of Directors ...................................................................................... 48 2.4.3. Existing conflicts of interest of members of the Board of Directors ................................. 48 2.4.4. Related Party Transactions ............................................................................................. 52 2.4.5. Transactions with affiliates .............................................................................................. 52 2.4.6. Code of Business Conduct and Ethics ............................................................................ 52 2.4.7. Market abuse regulations................................................................................................ 53 2.5 Corporate Governance Code ........................................................................................................ 53 2.6 Remuneration Policy ..................................................................................................................... 54 2.6.1. Introduction ..................................................................................................................... 54 2.6.2. Remuneration of the Board of Directors ......................................................................... 54 2.6.3. Remuneration of the Executive Committee..................................................................... 56 2.6.4. Deviations from this Policy .............................................................................................. 60 2.7 Remuneration report ..................................................................................................................... 61 2.7.1. Introduction ..................................................................................................................... 61 2.7.2. Total Remuneration ........................................................................................................ 62 2.7.3. Share-based Remuneration ............................................................................................ 65 2.7.4. Termination Indemnities ................................................................................................. 75 2.7.5. Use of the possibility to reclaim the variable remuneration ............................................. 75 Page 3 | 180 2021 Annual Report 2.7.6. Deviations from the Remuneration Policy ....................................................................... 75 2.7.7. Evolution of the remuneration and the performance of the company and ratio ............... 75 2.7.8. Taking into consideration of the vote of the shareholders ............................................... 76 2.7.9. Statutory Auditor ............................................................................................................. 76 2.8 Description of the principal risks associated to the activities of the Group .................................... 77 2.8.1. Risk Management ........................................................................................................... 77 2.8.2. Organization and values ................................................................................................. 77 2.8.3. Risks analysis ................................................................................................................. 78 2.8.4. Risks related to the Company’s financial position and capital requirements ................... 78 2.8.5. Risks related to Company’s business activities and industry .......................................... 80 2.8.6. Risks related to clinical development....................................................................... 82 2.8.7. Risks related to legal and regulatory risks .............................................................. 85 2.8.8. Risks related to intellectual property ....................................................................... 86 2.8.9. Post-authorisation risks .............................................................................................. 89 2.8.10. Risks linked to the Company’s reliance on third parties ....................................... 89 2.8.11. Risks related to the shares ........................................................................................ 91 2.8.12. Audit activities ................................................................................................................. 93 2.8.13. Controls, supervision and correctives actions ................................................................. 93 3. GROUP STRUCTURE, SHAREHOLDING AND SHARE CAPITAL .................................................... 95 3.1 Group structure ............................................................................................................................. 95 3.2 Capital increase and issuance of shares ...................................................................................... 96 3.3 Warrants plans .............................................................................................................................. 97 3.4 Changes to the share capital ........................................................................................................ 98 3.5 Major Shareholders....................................................................................................................... 98 3.6 Anti-takeover provisions under Belgian laws ................................................................................ 99 3.7 Financial services ....................................................................................................................... 102 4. CONSOLIDATED FINANCIAL STATEMENTS .................................................................................. 103 4.1 Responsibility statement ............................................................................................................. 103 4.2 Statutory auditor’s report to the general meeting of shareholders of Celyad Oncology SA for the year ended December 31, 2021 (consolidated financial statements) ......................................... 104 4.3 Consolidated financial statements as at December 31, 2021 ..................................................... 109 4.3.1. Consolidated statements of financial position ............................................................... 109 4.3.2. Consolidated statements of comprehensive loss .......................................................... 110 4.3.3. Consolidated statements of changes in equity .............................................................. 111 4.3.4. Consolidated statements of Cash flows ........................................................................ 112 5. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS ....................................................... 113 5.1 General information .................................................................................................................... 113 5.2 Basis of preparation and significant accounting policies ............................................................. 113 5.2.1. Basis of preparation ...................................................................................................... 113 5.2.2. Consolidation ................................................................................................................ 115 5.2.3. Foreign currency translation ......................................................................................... 115 5.2.4. Revenue ....................................................................................................................... 116 5.2.5. Other income ................................................................................................................ 117 5.2.6. Intangible assets ........................................................................................................... 119 5.2.7. Property, plant and equipment ...................................................................................... 121 Leases .......................................................................................................................... 121 5.2.8. 5.2.9. Impairment of non-financial assets ............................................................................... 122 5.2.10. Cash and cash equivalents ........................................................................................... 123 5.2.11. Financial assets ............................................................................................................ 123 5.2.12. Financial liabilities ......................................................................................................... 125 5.2.13. Provisions ..................................................................................................................... 126 5.2.14. Income Taxes ............................................................................................................... 128 5.2.15. Earnings (loss) per share .............................................................................................. 128 Page 4 | 180 2021 Annual Report 5.2.16. Equity ........................................................................................................................... 129 5.3 Risk Management ....................................................................................................................... 129 ........................................................................ 130 5.4 Critical accounting estimates and judgments 5.5 Operating segment information ................................................................................................... 132 Intangible assets ......................................................................................................................... 133 5.6 Intangible assets details and balance roll forward ........................................................ 133 5.6.1. Impairment testing ........................................................................................................ 135 5.6.2. 5.7 Property, plant and equipment .................................................................................................... 137 5.8 Non-current trade receivables and other non-current assets ...................................................... 138 5.9 Trade receivables and other current assets ................................................................................ 139 5.10 Short-term investments ............................................................................................................... 139 5.11 Cash and cash equivalents ......................................................................................................... 139 5.12 Subsidiaries fully consolidated .................................................................................................... 140 5.13 Share Capital .............................................................................................................................. 140 5.14 Share-based payments ............................................................................................................... 145 5.15 Post-employment benefits .......................................................................................................... 149 5.16 Recoverable Cash Advances ...................................................................................................... 151 5.17 Other non-current liabilities ......................................................................................................... 153 5.18 Trade payables and other current liabilities ................................................................................ 153 5.19 Financial liabilities ....................................................................................................................... 154 5.19.1. Maturity analysis ........................................................................................................... 154 5.19.2. Changes in liabilities arising from financing activities ................................................... 155 5.20 Financial instruments .................................................................................................................. 156 5.20.1. Financial instruments not reported at fair value on statement of financial position ....... 156 5.20.2. Financial instruments reported at fair value on statement of financial position ............. 156 5.21 Income taxes .............................................................................................................................. 159 5.22 Other reserves ............................................................................................................................ 161 5.23 Revenue ..................................................................................................................................... 161 5.24 Research and Development expenses ....................................................................................... 162 5.25 General and Administrative expenses ........................................................................................ 162 5.26 Depreciation and amortization .................................................................................................... 163 5.27 Employee benefit expenses ........................................................................................................ 163 5.28 Change in fair value of contingent consideration, other income and other expenses ................. 163 5.29 Non-recurring operating income and expenses .......................................................................... 165 5.30 Leases ........................................................................................................................................ 165 5.31 Finance income and expenses ................................................................................................... 167 5.32 Loss per share ............................................................................................................................ 167 5.33 Contingent assets and liabilities .................................................................................................. 167 5.34 Commitments .............................................................................................................................. 168 5.34.1. Celdara ......................................................................................................................... 168 5.34.2. Horizon Discovery / PerkinElmer .................................................................................. 169 5.34.3. Other Commitments ...................................................................................................... 170 5.35 Related-party transactions .......................................................................................................... 170 5.35.1. Remuneration of key management ............................................................................... 170 5.35.2. Transactions with non-executive directors .................................................................... 171 5.35.3. Transactions with shareholders .................................................................................... 171 5.36 Events after the close of the fiscal year ...................................................................................... 171 5.37 Statutory accounts as of December 31, 2021 and 2020 according to Belgian GAAP ................. 172 5.37.1. Balance Sheet .............................................................................................................. 172 5.37.2. Income statement ......................................................................................................... 173 5.37.3. Notes ............................................................................................................................ 174 5.37.4. Summary of valuation rules .......................................................................................... 178 Page 5 | 180 2021 Annual Report Page 6 | 180 2021 Annual Report ANNUAL REPORT 2021 This Annual Report (the “Report”) is dated March 24, 2022 and contains all required information as per the Belgian Code of the Companies and Associations (the “CCA”). The affiliates included in this Report are Celyad Oncology SA, Biological Manufacturing Services SA, Celyad Inc., and CorQuest Medical Inc. Celyad Oncology SA and its affiliates will be collectively referred to as “the Company”, “the Group”, “Celyad”, “we” or “us”. LANGUAGE OF THE REPORT The Company publishes this Report in French, in accordance with Belgian laws. The Company also provides an English translation. In case of a difference of interpretation, the French version will prevail. AVAILABILITY OF THE REPORT A printed copy of the Report is available free of charge upon request to: Celyad Oncology SA Investor Relations Rue Edouard Belin 2, B-1435 Mont-Saint-Guibert, Belgium Tel: +32 10 394100 E-mail: investors@celyad.com An electronic version of this Report is available on the Company website: http://www.celyad.com/investors/regulated-information FORWARD LOOKING STATEMENTS This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding: the KEYNOTE-B79 trial and the clinical hold. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation. Page 7 | 180 2021 Annual Report Shareholder Letter Dear Shareholder, Over 2021, the hard work and dedication of the entire Celyad Oncology team has helped us to continue to make steady progress advancing our mission to develop next-generation allogeneic CAR T candidates that offer new therapeutic options to cancer patients with poor prognosis. Our development pipeline has continued to transition to an allogeneic strategy centered around i) our single-step engineering, All-in-One vector approach and ii) our proprietary non-gene edited technologies including short hairpin RNA (shRNA) and T cell receptor Inhibitory Molecule (TIM). Throughout the past twelve months, we’ve announced encouraging clinical data from our programs at major scientific conferences and further built our position as a leader in the field of allogeneic CAR T cell therapies. Reflecting and Driving the “CAR” Forward At Celyad Oncology (the “Company”), we have made it a priority to leverage our expertise, experience and technology to establish the Company as a leader in the investigational allogeneic CAR T therapy space. Although the patient-derived autologous approach has been successful in some malignancies, there remains a great need for therapies in other kinds of tumors that could benefit from the “off-the-shelf" allogeneic approach. Right now, we are particularly excited about our shRNA technology platform. This differentiated technology allows us to modulate gene expression without the need for gene-editing or the use of multiple vectors. Importantly, with shRNA technology, we can adjust expression of key genes to create investigational allogeneic cell therapies. With shRNA, we seek to interfere with the expression of the CD3ζ component of the T cell receptor complex, while improving the overall profile of these cutting-edge candidates with less complexity of multi-vector approaches. We truly believe there’s tremendous potential for implementing shRNA technology in the development of next-generation allogeneic CAR T cell therapies and we’re only beginning to scratch the surface. Focused on Execution In 2021, we reported several important clinical milestones as we continued to deliver on our goal of advancing our pipeline of investigational allogeneic CAR T therapies. At the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition we presented the latest clinical data from the dose-escalation segment of the IMMUNICY-1 Phase 1 trial evaluating CYAD-211, a shRNA-based anti-BCMA allogeneic CAR T candidate. These data showed evidence of initial clinical activity for CYAD-211 in patients with relapsed or refractory multiple myeloma (r/r MM) with a good tolerability profile, including no evidence of Graft-versus-Host Disease, or GvHD, and preliminary cell engraftment. The next segment of the IMMUNICY-1 study will evaluate CYAD-211 following enhanced lymphodepleting regimens with the aim to improve cell persistence and potentially maximize the clinical benefit of anti-BCMA cell therapy. In addition, the IMMUNICY-1 protocol allows for redosing of CYAD-211 in certain patients. Enrollment in the IMMUNICY-1 trial is ongoing with additional data expected in the second half of 2022. In December 2021, we announced dosing the first patient in the KEYNOTE-B79 Phase 1b trial evaluating our TIM-based NKG2D receptor allogeneic candidate, CYAD-101, with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory metastatic colorectal cancer (mCRC) with microsatellite stable (MSS)/mismatch-repair proficient disease. Unfortunately, February 2022 brought an unexpected challenge, and we voluntarily paused this trial and subsequently announced an FDA hold. Patient safety is our number one priority, and we are currently working to investigate these events. We plan to have an update for stakeholders in the near future. In July 2021, we introduced our armored CAR T franchise centered on the proinflammatory cytokine interleukin-18, or IL-18. IL-18’s dual mechanism of action directly potentiates the anti-cancer activity of CAR T cells while also altering the balance of pro- and anti-inflammatory cells within the tumor microenvironment. Page 8 | 180 2021 Annual Report Currently, we are conducting Investigational New Drug (IND)-enabling studies for CYAD-203, our first shRNA-based allogeneic armored CAR T candidate engineered to co-express IL-18 with the NKG2D CAR receptor. We anticipate the submission of an IND application for CYAD-203. Lastly, regarding our next-generation autologous NKG2D CAR T candidate CYAD-02, we announced the latest data from the program at ASH in December 2021. Results from the CYCLE-1 trial evaluating CYAD- 02 for the treatment of relapsed or refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) indicated that a single shRNA can target two independent genes to optimize CAR T cell phenotype. We believe clinical data from CYCLE-1 support the potential and versatility of the shRNA platform while further validating its uniqueness among currently available gene-expression control technologies for the development of next-generation CAR T therapies. Focused on the Future As we evaluate our progress, it is important to remember that the true potential for our company and its technologies reaches far beyond the current development pipeline. I’m deeply grateful to all of our team members who tirelessly deliver each and every day with dedication in pursuit of our mission to develop innovative cell therapies against cancer. The value and opportunity provided by our team, development pipeline and underlying platform technologies are key points of focus for our investors. We remain steadfast in the goal of furthering our pipeline of investigational allogeneic CAR T therapies in this new year. We appreciate the ongoing support of our investors as we execute on our growth strategy. On behalf of the entire Celyad Oncology team and board members, I wish you and your loved ones a happy, healthy and fulfilling 2022! Regards, Filippo Petti, CEO Celyad Oncology Page 9 | 180 2021 Annual Report 1. Activity Report 1.1 Who we are - Business Overview We are a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. Our goal is to discover, develop and commercialize our next-generation CAR T cell therapy product candidates, if approved. We are currently developing a diversified pipeline of allogeneic and autologous CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Our differentiated pipeline of next generation CAR T candidates is based off the two main approaches in the field of CAR T: allogeneic, or off-the-shelf, and autologous, or personalized, therapies. Allogeneic CAR T cells are prepared in advance from healthy donors and are stored frozen until a patient requires treatment. With the autologous approach, CAR T cells are derived from the patients themselves, first by collection of the patient’s immune cells through a process called leukapheresis, and then the patient’s cells are engineered and reintroduced back into the patient via infusion. Over the past few years, as the CAR T landscape has shifted towards pursuing off-the-shelf approaches, we have continued to steadily progress our allogeneic CAR T franchise and programs by exploring two proprietary, non-gene edited technology platforms to target the T cell receptor (TCR) complex – short hairpin RNA (shRNA) and T cell receptor inhibitory molecule (TIM). In allogeneic adoptive cell therapy, the infusion of donor-derived T cells to cancer patients with a different background than that of the donor may lead to multiple reactions. These reactions include the donor cells attacking the patient’s healthy tissue, known as Graft-versus-Host disease (GvHD), as well as the rejection of the therapy by the patient’s immune system known as Host-versus-Graft (HvG) reaction. The TCR, a molecule present on the surface of T cells, is principally responsible for GvHD. At the center of allogeneic CAR T therapy, the goal is to eliminate or blunt the signaling of the TCR through engineering with a specific technology. By reducing the signaling of the TCR, the engineered allogeneic CAR T cells fail to recognize the patient’s healthy tissue as foreign, which avoids GvHD. We believe non-gene edited technologies offer the opportunity to target the TCR specifically without extensive genetic manipulation. Through the co-expression of our non-gene edited technologies with a specific CAR of interest, we can design cell therapy candidates intended to inhibit the function of the TCR while allowing the donor-derived T cells to target the cancer. We believe this unique strategy offers a streamlined approach in advancing the allogeneic CAR T landscape. Our proprietary non-gene edited technologies, shRNA and TIM, offer a unique strategy and streamlined approach to allogeneic CAR T development: • Short hairpin RNA (shRNA). shRNA is a dynamic, innovative technology that relies on RNA interference. The technology allows for the development of allogeneic CAR Ts through the selection of an optimal shRNA, targeting CD3ζ, a key component of the TCR complex. This results in durable high-level knockdown of the TCR on T cells to a level equivalent to that seen if the CD3ζ gene was gene edited with CRISPR/Cas9. In preclinical experiments, the persistence of non-CAR-bearing allogeneic T cells generated with shRNA was statistically superior to similar cells generated with CRISPR/Cas9. Preclinical models have also shown the broad applicability of shRNA technology to knockdown a diverse set of gene targets, including beta-2-microglobulin (B2M), CD52, PD-1, MICA/MICB and the intracellular lipid kinase diacylglycerol kinase (DGK). In addition, we have demonstrated concurrent knockdown of multiple gene targets, or multiplexing, using our shRNA technology platform. Page 10 | 180 2021 Annual Report • T cell Inhibitory Molecule (TIM). Our novel TIM peptide interferes with the ability of the TCR to signal and is designed to prevent GvHD. TIM is a truncated form of the CD3ζ component of the TCR complex which lacks the critical signaling domains of the wild-type CD3ζ. In our allogeneic CAR T candidate CYAD-101, TIM is co-expressed with a NKG2D CAR to reduce the potential of the TCR to induce GvHD. Following the expression of TIM, the peptide acts as a competitive inhibitor to wild-type CD3ζ and is incorporated into the TCR complex. Central to our pipeline is a cutting-edge All-in-One vector approach where we focus on using a single vector to generate CAR T cells to simplify the design and development of our cell therapy candidates. The All-in- One vector approach encodes multiple components of the CAR T construct simultaneously, including the CAR, our non-gene editing technologies including shRNA and TIM, cell selection marker to assist with the enrichment of the manufactured cells and potential therapeutic add-ons such as cytokines. This single transduction, plug and play approach to CAR T development has the potential to streamline process development and manufacturing while broadening the potential applicability of our candidates. Schematic of our All-in-one Vector Approach: shARCTM Platform Our shRNA armored CAR T, or shARC, platform combines CARs developed using our shRNA technology along with the co-expression of cytokines, including interleukin-18 (IL-18), and is designed to provide a more robust CAR T cell therapy to enhance anti-tumor effects and optimize therapy for cancer patients. Specifically, IL-18 is a proinflammatory cytokine that directly potentiates the anti-cancer activity of CAR T cells while also altering the balance of pro- and anti-inflammatory cells within tumor tissue. We are currently exploring additional platform assets with specific cytokines in our preclinical pipeline. Page 11 | 180 Our CAR T Pipeline The pipeline below presents our allogeneic and autologous product candidates. 2021 Annual Report AML: Acute myeloid leukemia; BCMA: B-cell maturation antigen; mCRC: Metastatic colorectal cancer; MDS: Myelodysplastic syndrome; MM: Multiple myeloma; NKG2DL: Natural killer group 2D ligands; r/r: relapse/refractory. Our lead product candidates include: • CYAD-101. CYAD-101 is an investigational, non-gene edited, allogeneic CAR T candidate engineered to co-expresses the TIM peptide alongside a CAR based on NKG2D, a receptor expressed on natural killer (NK) and T cells, that binds to eight stress-induced ligands. CYAD-101 is currently being evaluated following FOLFOX preconditioning chemotherapy in the Phase 1b KEYNOTE-B79 trial with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in refractory metastatic colorectal cancer (mCRC) patients with microsatellite stable (MSS) / mismatch-repair proficient (pMMR) disease. In December 2021, we announced the first patient was dosed in the KEYNOTE-B79 trial. In February 2022, we announced our decision to voluntarily pause the KEYNOTE-B79 trial to investigate reports of two fatalities that presented with similar pulmonary findings and evaluate any similar events in additional patients treated on study. On March 1, 2022, we were informed via-email communication from the FDA that the KEYNOTE-B79 trial has been placed on clinical hold due to insufficient information to assess risk to study subjects. • CYAD-211. CYAD-211 is an investigational, shRNA-based allogeneic CAR T candidate for the treatment of relapsed / refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co- express a B cell maturation antigen (BCMA) targeting chimeric antigen receptor and a single shRNA, which interferes with the expression of the CD3ζ component of the TCR complex. Preliminary data reported in December 2021 from the dose-escalation segment of the IMMUNICY- 1 Phase 1 trial evaluating CYAD-211 following Cyflu chemotherapy in patients with r/r MM, showed evidence of clinical activity with a good tolerability profile including no evidence of Graft versus Host Disease (GvHD). In addition, all patients in the trial had detectable CYAD-211 cells in the peripheral blood. Enrollment is currently ongoing in the IMMUNICY-1 Phase 1 trial to evaluate enhanced lymphodepletion with the aim to improve cell persistence and potentially maximize the clinical benefit of CYAD-211. The IMMUNICY-1 protocol also allows for CYAD-211 redosing in certain patients. Page 12 | 180 2021 Annual Report • CYAD-02. CYAD-02 is an investigational, autologous CAR T therapy that co-expresses both the NKG2D CAR and a single shRNA targeting the NKG2D ligands MICA/MICB on the CAR T cells. In December 2021, the Company presented clinical results from the dose-escalation CYCLE-1 Phase 1 trial evaluating CYAD-02 for the treatment of relapsed or refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Data from the trial showed that a single shRNA can target two independent genes (MICA/MICB) to enhance the phenotype of the CAR T cells. In addition, the dual knockdown showed a positive contribution to the initial clinical activity of CYAD- 02 as well as a trend towards increased engraftment and persistence compared to the first- generation, autologous NKG2D receptor CAR T. In addition to our lead clinical product candidates, we have a portfolio of preclinical stage allogeneic product candidates targeting solid tumors and hematological malignancies, including: • CYAD-203. CYAD-203 is a preclinical, non-gene edited allogeneic CAR T candidate and our first armored CAR T candidate engineered to co-express the cytokine interleukin-18 (IL-18) with the NKG2D CAR receptor. CYAD-203 is currently being evaluated in Investigational New Drug (IND)- enabling studies and submission of the IND application for treatment of solid tumors is expected in the second half of 2022. To the Company’s knowledge, CYAD-203 is on track to be first ever IL-18 secreting allogeneic CAR T candidate to enter clinical trials. 1.2 Our Strategy Our mission is to eliminate cancer and improve life. We are developing innovative cell therapies against cancer and are driven by the promise to deliver meaningful treatment options to patients seeking hope. Overall, our objective is to discover, develop and commercialize our next-generation CAR T cell therapies. We are guided by our passion, led by our deep expertise in oncology and motivated by the patients we serve. We believe that our innovative CAR T candidates, if approved, could offer patients with advanced disease alternative therapeutic options where no other treatments exist. Delivering best-in-class cell therapies for patients with unmet medical needs is our top priority. We aim to do this with the following strategies: • Focus on the development of non-gene edited approaches to allogeneic CAR T therapies. We are pioneering a differentiated approach to the discovery and development of allogeneic CAR T cell therapy candidates for the treatment of cancer led by a pair of non-gene edited approaches including our shRNA and TIM technologies. Through the co-expression of either technology with a specific CAR of interest, we can design donor-derived cell therapy candidates intended to inhibit the function of the TCR complex while allowing the T cell product candidates to target cancer. Our unique strategy, coupled with our All-in-One vector approach, allows us to avoid multiple genetic modifications and manage costs in the production of our cell therapy candidates. We also aim to bring the broader potential advantages of allogeneic CAR T therapies to patients including faster delivery, greater uniformity, better patient accessibility and increased manufacturing scalability as compared to autologous CAR T therapies. • Advance our lead shRNA-based allogeneic candidate CYAD-211 for the treatment of r/r MM. CYAD-211 is an allogeneic CAR T candidate engineered to express a single shRNA to interfere with the expression of the TCR complex, while targeting BCMA, a clinically validated target found in multiple myeloma (MM). In 2021, we reported preliminary data from the Phase 1 IMMUNICY-1 trial evaluating CYAD-211 for the treatment of r/r MM following standard lymphodepleting chemotherapy, which showed CYAD-211 had a good tolerability profile and evidence of clinical activity in the dose-escalation segment of the trial. Enrollment in the Phase 1 IMMUNICY-1 continues for cohorts 4 and 5 with the treatment of CYAD-211 following enhanced lymphodepletion regimens consisting of increasing doses of cyclophosphamide and fludarabine. Additional data from the trial are expected in the second half of 2022. Page 13 | 180 2021 Annual Report • Advance our lead TIM-based allogeneic candidate CYAD-101 for the treatment of advanced mCRC. The clinical benefit of CAR T therapies for the treatment of solid tumors has been limited to date partially due to the hostile tumor microenvironment (TME), which surrounds the tumor and is composed of immune cells, blood vessels and extracellular matrix. Our TIM-based allogeneic CYAD-101 product candidate is engineered to co-express the chimeric antigen receptor NKG2D, a receptor expressed on natural killer and T cells that binds to eight stress-induced ligands that are overexpressed by a broad range of tumors, including mCRC, as well as cells within the TME such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). CYAD-101 is the first allogeneic CAR T candidate, to our knowledge, which has demonstrated confirmed objective responses in the treatment of a solid tumor indication, specifically advanced mCRC, with no clinical evidence of GvHD. Based on the encouraging data to date for CYAD-101, we signed a clinical trial collaboration with MSD, a tradename of Merck, to evaluate CYAD-101 with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab). In December 2021, we announced the first patient was dosed in the KEYNOTE-B79 trial. In February 2022, we announced our decision to voluntarily pause the KEYNOTE-B79 trial to investigate reports of two fatalities that presented with similar pulmonary findings and evaluate any similar events in additional patients treated on study. On March 1, 2022, we were informed via-email communication from the FDA that the KEYNOTE-B79 trial has been placed on clinical hold due to insufficient information to assess risk to study subjects. • Focus on armoring CAR Ts to enhance anti-cancer activity. We are currently exploring an armored CAR technology in conjunction with our shRNA platform to develop allogeneic CAR Ts to further optimize cell therapies for cancer patients. Armored CAR Ts are T cells engineered to co- express a CAR as well as secrete specific cytokines in order to increase the anti-tumor activity of CAR T cells. These armored CAR Ts fortify the cell therapy to overcome the hostile TME and drive a strong anti-tumor effect. Our first armored CAR Ts are focused on the expression of the cytokine Interleukin-18, or IL-18. We believe IL-18 is an ideal cytokine for our armored CAR T franchise as it directly increases the anti-cancer activity of CAR T cells while also altering the balance of pro- and anti-inflammatory cells within tumor tissue. Arming CAR Ts with IL-18 offer two key effects: (1) an autocrine effect, where the IL-18 cytokine can have a beneficial impact on the CAR T cell function and (2) a paracrine effect, where the IL-18 cytokine can drive the strongly immunosuppressive environment, present within the majority of tumors, to an environment that's more pro-inflammatory. We are currently evaluating the co-expression of IL-18 in multiple discovery-stage next-generation, shRNA-based allogeneic CAR T candidates for our armored CAR franchise, referred to as our shARC platform. Our first preclinical candidate in the armored CAR franchise is CYAD-203 – an allogeneic shRNA-based IL-18-armored NKG2D CAR T candidate. • Broaden our shRNA-based allogeneic pipeline to explore additional cancer and shRNA targets. We are building a diversified portfolio of allogeneic CAR T candidates leveraging our dynamic shRNA platform technology. We are focused on a modular approach to designing our next-generation CAR T candidates by incorporating both clinically validated and novel tumor targets, while also including the simultaneous knockdown of multiple genes of interest with the co- expression of multiple shRNAs, or multiplexing. Our current discovery programs include cancer targets such as CD19, TAG72 and GPC3, while our multiplex efforts are focused on targets such as beta-2-microglobulin (β2M) and FAS (CD95). • Explore partnership opportunities for our autologous NKG2D franchise. Despite our focus on our allogeneic franchise, we still firmly believe that autologous CAR T cell therapies will play an important role in the treatment of cancers, in particular for indications such as r/r AML and MDS where there remains a major unmet medical need. We are working to seek a potential partner to aid in the further development of our autologous NKG2D CAR T candidate CYAD-02 for the treatment of r/r AML and MDS. Page 14 | 180 2021 Annual Report • Continue to build our proprietary in-house manufacturing expertise and capabilities. We have developed a Good Manufacturing Practice (GMP)-compliant facility for production of our allogeneic candidates that we believe allows us to be flexible, rapid, and cost-efficient, while allowing us to independently improve and optimize the production of our cell therapy candidates with the capacity to treat hundreds of patients in our early-stage clinical programs. Leveraging our differentiated All-in-One vector approach, we can enrich for our allogeneic CAR T cells using an optimized process through positive selection, leading to an approach that is autologous-like for allogeneic CAR T. Our in-house manufacturing facility has been critical in enabling the delivery of our clinical programs. We will continue to develop our manufacturing expertise and capability focusing on both supporting early phase clinical testing but also concentrating on the challenges of scale-up and commercial level manufacturing of allogeneic CAR T cell therapies. Our manufacturing facility remains crucial to our long-term success. • Expand intellectual property portfolio. Our robust IP estate of twelve foundational U.S. patents associated with allogeneic CAR T for the treatment of cancer, including IP for NKG2D receptor- based cell therapies, provides a key asset to the Company. With our attractive portfolio, we are able to strategically develop both novel cell therapy candidates and potential partnerships within the allogeneic landscape. In addition, we plan to continue to expand this portfolio to help advance the field more broadly. • Drive innovation through strategic collaborations to realize the full potential of our unique CAR T therapies. We are continually exploring opportunities to build strong partnerships with strategic organizations and key international academic institutions to maximize the therapeutic potential of our current and future product candidates as well as our intellectual property. We will continue to explore additional opportunities to create value and develop our platform technologies and pipeline in pursuit of our mission. 1.3 What differentiates Celyad Oncology? The level of activity in the CAR T landscape across the globe has exploded over the last few years. The challenges in this subsection of the oncology industry are significant. Most tumors develop undetected over years, fine tuning their capacity to resist treatment, before exploding with clinically relevant disease that rapidly overcomes standard treatment paradigms. Immune-based therapies, including CAR T therapies, are now delivering clinically relevant responses in certain, limited malignancies. The hope is that this initial clinical success with CAR T therapy can be further developed to be effective against a much broader range of cancer. Encouraging results from clinical trials and several regulatory approvals of CAR T therapies across multiple indications have continued to fuel the interest in the modality. As of the date of this Annual Report, our competitors with the adoptive cell therapy landscape, including CAR Ts, TCRs and NK-based cell therapies include but is not limited to 2seventy bio, Inc., Adicet Bio, Inc, Adaptimmune Therapeutics plc, Alaunos Therapeutics Inc., Allogene Therapeutics Inc., AlloVir, Inc, Arcellx, Inc., Atara Biotherapeutics, Inc., Autolus Therapeutics plc, Beam Therapeutics Inc., Bellicum Pharmaceuticals, Inc., Caribou Biosciences, Inc., CARsgen Therapeutics Co. Ltd., Cellectis S.A., Cellular Biomedicine Group, Celularity, Inc., Century Therapeutics, Inc., CRISPR Therapeutics, Inc., Editas Medicines, Inc, Fate Therapeutics, Inc., Gracell Biotechnologies Inc., Immatics Biotechnologies GmbH, ImmunityBio, Inc., Intellia Therapeutics, Inc., Juno Therapeutics, Inc. (acquired by Celgene Corporation), Kite Pharma, Inc. (acquired by Gilead Sciences, Inc.), Legend Biotech USA, Inc., Lyell Immunopharma, Inc., Medigene AG, Mustang Bio, Inc., Nkarta Therapeutics, Inc., Novartis AG, Poseida Therapeutics, Inc., Precigen, Inc. Precision Biosciences, Inc., Sana Biotechnology, Inc., SQZ Biotech, Inc., TC BioPharm Ltd., TCR2 Therapeutics, Inc., and Tmunity Therapeutics, Inc. Within this extremely competitive space, the clinical challenges faced by all in the field are largely similar and relate to ensuring target specificity, avoiding toxicity, including on-target, off tissue effects and ensuring the therapy is sufficiently potent to generate durable clinical responses. Page 15 | 180 2021 Annual Report Our expertise in oncology, our proprietary technologies, and our differentiated approach to developing CAR Ts is providing the tools with which to tackle some of the challenges, including the difficulty of targeting a broad array of hematological and solid tumors. Our solutions include: 1. The future is silent: shRNA platform for all CAR Ts Within two years, we moved our first shRNA-based allogeneic approach from concept to the clinic. The rapidity of progressing an early-stage preclinical asset into clinical testing required a major effort across the full organization. However, this focus is important given the potential that shRNA technology offers. In 2021, we validated the use of our proprietary shRNA technology as a novel allogeneic platform through our first shRNA-based allogeneic candidate, CYAD-211. CYAD-211 is a BCMA CAR T employing a single shRNA targeting the CD3ζ component of the TCR complex that generates the allogeneic CAR T cell phenotype. This validation was established through clinical data generated from the IMMUNICY-1 trial evaluating CYAD- 211. The IMMUNCY-1 trial was key for our company for two main reasons. Firstly, evidence in the clinic that the shRNA technology shRNA-based allogeneic CAR Ts were not associated with GvHD provided an important clinical validation of this approach. Secondly, to we demonstrated the first evidence of clinical activity of the BCMA CAR T in patients with r/r MM. Our proprietary shRNA technology will underpin our future CAR T product candidates, which includes multiplexing shRNA to generate bespoke modified CAR T candidates for specific cancer indications. The initial clinical validation of the shRNA technology has provided an important milestone event for the Company. The power and versatility of the shRNA platform, including the ability to multiplex and modulate the levels of gene expression, continues to support its strength, value, and potential differentiation within the allogenic cell therapy landscape. 2. shARC Platform We introduced our armored CAR franchise, known as the shARC platform, in 2021, and are focusing our efforts on IL-18 for the first candidate, CYAD-203. Published In vivo data showed a proposed mechanism for superior proliferation and anti-tumor activity with CAR Ts secreting IL-18, as compared to CAR T cells without the cytokine1. which served as a basis for our use of IL-18 for CYAD-203, our first armored CAR candidate currently in preclinical trials. As of the date of this Annual Report, CYAD-203 is on track to be the first IL-18 secreting allogeneic CAR T candidate. We believe armoring CARs alongside our shRNA technology offers a tremendous opportunity to drive a series of differentiated candidates for both solid tumors and hematological malignancies. 1.4 Our Activities and R&D Allogeneic CAR T cells: We are working to advance the field of allogeneic CAR T therapy by exploring two proprietary, non-gene edited technology platforms to target the TCR complex. In adoptive cell therapy, the infusion of donor-derived T cells to cancer patients with a different background than that of the donor may lead to multiple reactions. These reactions include the donor cells attacking the patient’s healthy tissue, known as Graft-versus-Host Disease, or GvHD, as well as the rejection of the therapy by the patient’s immune system known as Host- versus-Graft, or HvG, reaction. 1 Chmielewski, M., & Abken, H. (2017). CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. Cell reports, 21(11), 3205–3219. https://doi.org/10.1016/j.celrep.2017.11.063 Page 16 | 180 2021 Annual Report The TCR, a molecule present on the surface of T cells, is principally responsible for GvHD. At the center of allogeneic CAR T therapy, the goal is to eliminate or blunt the signaling of the TCR through engineering with a specific technology. By reducing the signaling of the TCR, the engineered allogeneic CAR T cells fail to recognize the patient’s healthy tissue as foreign, which avoids GvHD. Our non-gene edited technologies target the TCR specifically without extensive genetic manipulation. Through the co-expression of our non-gene edited technologies with a specific CAR of interest, we can design cell therapy candidates intended to inhibit the function of the TCR while allowing the T cells to target the cancer. We believe this unique strategy offers a streamlined approach in advancing the allogeneic CAR T landscape. Our Proprietary Short Hairpin RNA (shRNA) Technology shRNA is a dynamic, innovative technology that allows for the development of allogeneic CAR Ts through the modulation of gene expression without the need for gene-editing. We are currently engineering T cells for specific desired features, including the inhibition of alloreactivity, increased persistence and enhanced antitumor activity or potentially improved tolerability. We believe that shRNA offers us the ability to design and develop next-generation, non-gene edited allogeneic CAR T therapies with any CAR across a broad array of targets. shRNA Armored CAR T (shARC) Platform In addition, we are developing an armored CAR franchise in conjunction with our shRNA technology, referred to as shRNA Armored CAR T platform, or shARC. The shARC platform uses our shRNA technology in combination with a CAR and a specific cytokine to enhance the anti-tumor effects of the cell therapy and optimize the potential treatment for cancer patients. Initial efforts using the shARC platform have been centered on the use of shRNA technology to knockdown CD3ζ for the generation of allogeneic CAR Ts in combination with the co-expression of the pro-inflammatory cytokine IL-18. Our Proprietary T cell receptor Technology Inhibitory Molecule (TIM) Our novel TIM technology is designed to interfere with the ability of the TCR to signal to prevent GvHD. TIM is a truncated form of the CD3ζ component of the TCR complex which lacks the critical signaling domains of the wild-type CD3ζ. In CYAD-101, TIM is co-expressed with a NKG2D CAR to reduce the potential of the TCR to induce GvHD. Following the expression of TIM, the peptide acts as a competitive inhibitor to wild-type CD3ζ and is incorporated into the TCR complex. Page 17 | 180 2021 Annual Report 1.5 Lead Programs Celyad Oncology is building a diversified pipeline of next-generation allogeneic and autologous CAR T candidates: • CYAD-101 CYAD-101 is an investigational, non-gene edited allogeneic CAR T candidate engineered to co-express the chimeric antigen receptor based on NKG2D, the novel inhibitory peptide TIM and a truncated CD19 selection marker. The product candidate leverages our All-In-One vector approach with a single transduction, avoiding multiple genetic modifications and costs associated with additional GMP grade materials. TIM inhibits CD3ζ and reduces signaling of the TCR complex, which reduces the potential for GvHD. alloSHRINK Phase 1 Trial Overview In December 2018, we initiated the Phase 1 alloSHRINK trial. alloSHRINK is an open-label trial assessing the safety and clinical activity of three consecutive administrations of CYAD-101 every two weeks administered following preconditioning chemotherapy in patients with refractory unresectable mCRC. The dose-escalation segment of the trial evaluated the administrations of CYAD-101 concurrently with FOLFOX (combination of 5-fluorouracil, leucovorin and oxaliplatin) chemotherapy regimen at three dose levels (1×108, 3×108, 1×109 cells per infusion). In December 2020, we began enrollment in the expansion cohort of the alloSHRINK trial, which evaluated three infusions of CYAD-101 at the recommended dose of 1×109 cells per infusion of CYAD-101 concurrently with FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapy for the treatment of advanced mCRC. Page 18 | 180 2021 Annual Report Phase 1 alloSHRINK Clinical Trial Data Initial positive data from the alloSHRINK trial were reported both at the Society for Immunotherapy of Cancer (SITC) 2019 and American Society of Clinical Oncology 2020 conferences. In January 2021, we reported additional translational data for the alloSHRINK trial at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium. A total of 15 patients with relapsed/refractory mCRC who progressed after previous treatment with oxaliplatin-based or irinotecan-based chemotherapies were enrolled in the dose-escalation, alloSHRINK Phase 1 trial. The number of prior therapies received by patients enrolled in the trial ranged from one to six with a mean of three. Data from the trial showed that CYAD-101 following preconditioning chemotherapy was observed to be generally well-tolerated with no GvHD observed, no dose-limiting toxicities reported, no patient discontinuation due to treatment-related adverse events and no treatment-related adverse events greater than Grade 3. Results also showed two patients achieved a partial response (PR) according to RECIST 1.1 criteria, including one patient with a KRAS-mutation. Nine patients achieved stable disease (SD), with seven patients demonstrating disease stabilization lasting more than or equal to three months of duration, with a disease control rate of 73%. Median progression free survival (mPFS) for this segment of the trial was 3.9 months, and median overall survival (mOS) was 10.6 months. No correlation was observed between clinical responses and the degree of human leukocyte antigen (HLA) matching between patients and CYAD-101 donor cells, indicating that CYAD-101 may be able to be used in a broad patient population regardless of the HLA haplotype. Data from the alloSHRINK trial also showed a tumor burden decrease in eight out of 15 evaluable patients, including six of nine patients at dose level 3. Clinical activity was observed across all dose levels. There was no obvious correlation between response, dose-levels nor baseline characteristics. Page 19 | 180 2021 Annual Report available Of four patients treated at the highest dose level of 1×109 CYAD-101 cells per infusion for analysis, three patients who achieved either a confirmed PR or SD also showed TCR hyper-expanded repertoire post-treatment through the emergence of new T cell clones in the peripheral blood T cell repertoire, while one patient with progressive disease displayed no evidence of new T cell clones. Cytokine modulation was also observed after the first and second infusions of CYAD-101 in the patient who achieved a confirmed PR from the highest dose level. All 15 patients from the dose-escalation segment of the alloSHRINK trial were dosed from a single cell bank of CYAD-101 that was generated in advance from two manufacturing runs each using a fraction of an apheresis from a single healthy donor. Preliminary data from the dose expansion cohort evaluating CYAD-101 (1×109 cells per infusion) following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapy showed CYAD-101 was generally well-tolerated with no dose limiting toxicities or evidence of GvHD. Overall, nine out of ten evaluable mCRC patients showed stable disease at first tumor assessment. Data also showed shorter persistence of CYAD-101 cells observed after FOLFIRI preconditioning as compared to FOLFOX preconditioning. In 2021, based on improved cell kinetic data and clinical activity data from the alloSHRINK dose-escalation segment of CYAD-101 following FOLFOX preconditioning, the Company submitted a protocol amendment to regulatory agencies to modify the Phase 1b KEYNOTE-B79 trial to incorporate FOLFOX as preconditioning chemotherapy. Phase 1b KEYNOTE-B79 Trial Overview In September 2020, we announced a clinical trial collaboration with MSD, a tradename of Merck. The KEYNOTE-B79 trial will evaluate CYAD-101 following FOLFOX preconditioning chemotherapy, with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in refractory mCRC patients with MSS / pMMR disease. In December 2021, we announced the first patient was dosed in the KEYNOTE-B79 trial. In February 2022, we announced our decision to voluntarily pause the KEYNOTE-B79 trial to investigate reports of two fatalities that presented with similar pulmonary findings and evaluate any similar events in additional patients treated on study. On March 1, 2022, we were informed via-email communication from the FDA that the KEYNOTE- B79 trial has been placed on clinical hold due to insufficient information to assess risk to study subjects. Page 20 | 180 • CYAD-211 2021 Annual Report CYAD-211 is an investigational shRNA-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a BCMA chimeric antigen receptor and a single shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR complex. Phase 1 IMMUNICY-1 Trial Overview In November 2020, we initiated the dose-escalation Phase 1 IMMUNICY-1 trial evaluating CYAD-211 for the treatment of r/r MM. IMMUNICY-1 is an open-label Phase 1, dose- escalation trial that will evaluate the safety and clinical activity of a single infusion of CYAD-211 following chemotherapy cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²) in patients with r/r MM. The trial evaluates multiple dose levels of CYAD-211: 3x107, 1x108 and 3x108 cells per infusion. preconditioning Preliminary data from the IMMUNICY-1 trial showed a favorable tolerability profile with no DLTs, no GvHD and no CAR-T-cell-related encephalopathy syndrome. Preliminary cell kinetic data showed all patients had detectable CYAD-211 cells in the peripheral blood, although engraftment was short lasting. This suggests expansion and persistence of cells might be more dependent on the depth and period of the lymphodepletion induced by the preconditioning regimen, which calls for further exploration of lymphodepletion. Initial clinical activity from the dose-escalation segment of the IMMUNICY-1 trial showed was encouraging with three patients achieving partial response (PR), one in each dose-level, while eight patients had stable disease (SD). One patient with SD of 4.5 months duration showed evidence of reduction in size of plasmacytomas on radiographic studies. Following the dose-escalation segment of the IMMUNICY-1 trial, the next segment of the study will evaluate enhanced lymphodepleting regimens with cell the aim persistence potentially and maximize the clinical benefit of CYAD-211. Enrollment in the improve to Page 21 | 180 2021 Annual Report cohorts evaluating enhanced lymphodepletion is ongoing and additional data from the trial are expected in the second half of 2022. • CYAD-02 CYAD-02 is an investigational CAR T therapy that uses an All-in-One vector approach to engineer a patient’s T cells to express both the NKG2D chimeric antigen receptor and shRNA technology to knockdown the expression of NKG2D ligands MICA and MICB on the CAR T cells. of decrease In preclinical models, targeting MICA and MICB with a single shRNA lead to a ligand expression (Figure A) on T cells and enhanced in vitro B) expansion first- compared generation autologous NKG2D CAR T product candidate. (Figure to a CYCLE-1 Trial In November 2019, we initiated the Phase 1 dose-escalation CYCLE-1 trial that evaluated the safety and clinical activity of a single following preconditioning chemotherapy with cyclophosphamide and fludarabine for the treatment of relapsed or refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). infusion of CYAD-02 In December 2021, we reported data from the Phase 1 CYCLE-1 trial at the American Society of Hematology annual meeting, which overall showed a good tolerability profile of CYAD-02 following CyFlu preconditioning. Data from the trial showed that a single shRNA can target two independent genes (MICA/MICB) to enhance the phenotype of the CAR T cells. In addition, the dual knockdown showed a positive contribution to the initial clinical activity of CYAD-02 as well as a trend towards increased engraftment and persistence compared to the first-generation, autologous NKG2D receptor CAR T. 1.6 Licensing and Collaboration Agreements • Celdara Background In January 2015, we entered into an agreement with Celdara Medical, LLC, or Celdara in which we purchased all outstanding membership interests of OnCyte, LLC, or OnCyte. In connection with this transaction, we entered into an asset purchase agreement to which Celdara sold to OnCyte certain data, protocols, regulatory documents and intellectual property, including the rights and obligations under two license agreements between OnCyte and The Trustees of Dartmouth College, or Dartmouth, related to our CAR T development programs. In March 2018, we dissolved the affairs of our wholly owned subsidiary OnCyte. As a result of the dissolution of OnCyte, all the assets and liabilities of OnCyte were fully distributed to us including our license agreement with Dartmouth. Page 22 | 180 2021 Annual Report Amended Asset Purchase Agreement In August 2017, we entered into an amendment to the asset purchase agreement described above. In connection with the amendment, the following payments were made to Celdara: (i) an amount in cash equal to $10.5 million, (ii) newly issued shares of Celyad valued at $12.5 million, (iii) an amount in cash equal to $6.0 million in full satisfaction of any payments owed to Celdara in connection with a clinical milestone related to our CAR-T NKR-2 product candidate, (iv) an amount in cash equal to $0.6 million in full satisfaction of any payments owed to Celdara in connection with our license agreement with Novartis International Pharmaceutical Ltd., and (v) an amount in cash equal to $0.9 million in full satisfaction of any payments owed to Celdara in connection with our former license agreement with Ono Pharmaceutical Co., Ltd. Under the amended asset purchase agreement, we are obligated to make certain development-based milestone payments to Celdara up to $40.0 million, certain development-based milestone payments up to $36.5 million and certain sales-based milestone payments up to $156.0 million. We are required to make tiered single-digit royalty payments to Celdara in connection with the sales of CAR-T products, subject to reduction in countries in which there is no patent coverage for the applicable product or in the event Celyad is required to secure licenses from third parties to commercialize the applicable product. We are also required to pay Celdara a percentage of sublicense income, including royalty payments, for each sublicense ranging from the mid-single digits to the mid-twenties, depending on which of a specified list of clinical and regulatory milestones the applicable product has achieved at the time the sublicense is executed. We are required to pay Celdara a single-digit percentage of any research and development funding received by us, not to exceed $7.5 million for each product group. We can opt out of the development of any product if the data does not meet the scientific criteria of success. We may also opt out of development of any product for any other reason upon payment of a termination fee of $2.0 million to Celdara. The Trustees of Dartmouth College (“Dartmouth”) As described above, as a result of our acquisition of all of the outstanding membership interests of OnCyte and the asset purchase agreement among us, Celdara and OnCyte, OnCyte became our wholly-owned subsidiary and acquired certain data, protocols, regulatory documents and intellectual property, including the rights and obligations under two license agreements between OnCyte and Dartmouth. The first of these two license agreements concerned patent rights related, in part, to methods for treating cancer involving chimeric NK and NKP30 receptor targeted therapeutics and T cell receptor-deficient T cell compositions in treating tumor, infection, GVHD, transplant and radiation sickness, or the CAR-T License, and the second of these two license agreements concerned patent rights related, in part, to anti-B7-H6 antibody, fusion proteins and methods of using the same, or the B7H6 License. In August 2017, we and Dartmouth entered into an amendment agreement in order to combine our rights under B7H6 Agreement with our rights under the CAR-T License, resulting in the termination of the B7H6 License, and in order to make certain other changes to the agreement. In connection with the amendment, we paid Dartmouth a non-refundable, non-creditable amendment fee in the amount of $2.0 million in 2017. Under the amended license agreement, Dartmouth granted us an exclusive, worldwide, royalty-bearing license to certain know-how and patent rights to make, have made, use, offer for sale, sell, import and commercialize any product or process for human therapeutics, the manufacture, use or sale of which, is covered by such patent rights or any platform product. Dartmouth reserves the right to use the licensed patent rights and licensed know-how, in the same field, for education and research purposes only. The patent rights included in the amended license agreement also include the patents previously covered by the B7H6 License. In consideration for the rights granted to us under the amended license agreement, we are required to pay to Dartmouth an annual license fee as well as a low single-digit royalty based on annual net sales of the licensed products by us, with certain minimum net sales obligations beginning April 30, 2024 and continuing for each year of sales thereafter. Under the amended license agreement, in lieu of royalties previously payable on sales by sublicensees, Celyad is required to pay Dartmouth a percentage of sublicense income, including royalty payments, (i) for each product sublicense ranging from the mid-single digits to low-single digits, depending on which of a specified list of clinical and regulatory milestones the applicable product has achieved at the time the sublicense is executed and (ii) for each platform sublicense in the mid-single digits. Additionally, the agreement requires that we exploit the licensed products, and we Page 23 | 180 2021 Annual Report have agreed to meet certain developmental and regulatory milestones. Upon successful completion of such milestones, Celyad is obligated to pay to Dartmouth certain clinical and regulatory milestone payments up to an aggregate amount of $1.5 million and a commercial milestone payment in the amount of $4.0 million. We are responsible for all expenses in connection with the preparation, filing, prosecution and maintenance of the patents covered under the agreement. As further amended in December 2021, this agreement allows Dartmouth to terminate the amended license after April 30, 2026, extended from the prior date of April 30, 2024, in the event that Celyad fails to meet the specified minimum net sales obligations for any year (USD 10 million during first year of sales, USD 40 million during the second year of sales and USD 100 million during the third year of sales and every year of sales thereafter), unless Celyad pays to Dartmouth the royalty Celyad would otherwise be obligated to pay had Celyad met such minimum net sales obligation. Dartmouth may also terminate the license if Celyad fails to meet a milestone within the specified time period, unless Celyad pays the corresponding milestone payment. In connection with the December 2021 amendment, we agreed to certain protective provisions of any sublicenses and paid Dartmouth a non-refundable, non-creditable amendment fee and an additional non-refundable, non-creditable sublicense fee to be paid on an annual basis. • Novartis On May 1st, 2017, we entered into a non-exclusive license agreement with Novartis International AG, or Novartis, regarding U.S. patents related to allogeneic CAR-T cells. The agreement includes our intellectual property rights under U.S. Patent No. 9,181,527. This agreement is related to two undisclosed targets currently under development by Novartis. Under the terms of the agreement, we received an upfront payment of $4.0 million and are eligible to receive additional milestone payments in aggregate amounts of up to $92.0 million. In addition, we are eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. We retain all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells. • Horizon Discovery / PerkinElmer In April and June 2018, we signed two research and development collaboration and license agreements with Horizon Discovery Group plc, or Horizon, to evaluate the utility of Horizon’s SMART vector shRNA reagents to reduce expression of one or more defined targets in connection with the development of our product candidates. The first agreement was focused on targets related to our autologous CAR-T candidate, CYAD- 02. The second agreement was focused on targets related to our allogenic CAR-T product candidate CYAD- 211 and one pre-clinical allogenic product candidate not yet publicly announced, called CYAD-203. In December 2018, we exercised our option to convert the second agreement into an exclusive license agreement, in connection with which we paid Horizon an up-front payment of $1 million. In September 2019, we exercised our option to convert the first agreement into an exclusive license agreement, in connection with which we have paid Horizon an up-front payment of $0.1 million and an additional milestone of $0.1 million for the first IND filed by us for CYAD-02. In September 2020, we paid an additional milestone of $0.2 million for the first IND filed by us for CYAD-211. Under these exclusive license agreements combined, Horizon is eligible to receive additional milestone payments in development, regulatory and commercial milestone payments, in addition to low single digit royalties on net sales, subject to customary reductions. In December 2020, Horizon Discovery was acquired by PerkinElmer, Inc. (Horizon/PKI). In 2021, Horizon/PKI informed us they believe we are in material breach of these agreements as a result of certain disclosures we have made in connection with our obligations as a publicly traded company in the United States and Belgium, although they have not formally delivered to us a notice of material breach or termination. We believe any such assertion of material breach would be without merit and we would expect to vigorously defend any such notice of material breach. Any dispute under these agreements would be subject to arbitration in The Hague under the International Chamber of Commerce Rules. We are currently Page 24 | 180 2021 Annual Report in discussions with Horizon about possible amendments to these agreements in connection with which we would retain freedom to operate under the in-licensed patents. Of note, we have filed patent applications which, if issued, would cover other aspects of the product candidates described above as well as products developed by third parties that deploy similar technology and targets. These patent applications encompass the downregulation of one or more of the targets covered under the Horizon/PKI agreements, the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells. We are also developing a second generation shRNA platform that does not incorporate any of the Horizon Discovery/Perkin Elmer, Inc. technology described above. Our lead allogeneic CAR T product candidate, CYAD-101, does not incorporate any of the Horizon Discovery/Perkin Elmer, Inc. technology described above. • Merck In September 2020, we entered into a clinical trial collaboration agreement and subsequent agreements with MSD International GmbH, or MSD, a subsidiary of Merck & Co., Inc. The agreements relate to the Phase 1b KEYNOTE-B79 clinical trial, which will evaluate our investigational non-gene edited allogeneic CAR-T candidate, CYAD-101, following FOLFOX preconditioning chemotherapy, with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The trial will enroll refractory metastatic colorectal cancer (mCRC) patients with microsatellite stable (MSS) / mismatch-repair proficient (pMMR) disease, with the initial goal of determining the safety and tolerability of the combination therapy. The trial began enrollment in the fourth quarter of 2021. In February 2022, we announced our decision to voluntarily pause the KEYNOTE-B79 trial to investigate reports of two fatalities that presented with similar pulmonary findings and evaluate any similar events in additional patients treated on study. On March 1, 2022, the Company was informed via-email communication from the FDA that the KEYNOTE-B79 trial has been placed on clinical hold due to insufficient information to assess risk to study subjects. • Mesoblast On May 8, 2018, we entered into an exclusive license agreement with Mesoblast, an Australian biotechnology company, to develop and commercialize our intellectual property rights relating to C-Cathez, an intra-myocardial injection catheter, related to our former cardiovascular business, for which Mesoblast has paid to Celyad an upfront fee of $1,000,000. In addition to the upfront fee, Celyad may be eligible up to $20,000,000 in clinical, regulatory, and commercial milestone payments payable in cash or, for certain milestones, in Mesoblast shares. On January 17, 2022, we entered into an amendment with Mesoblast to convert the license into non- exclusive, to remove the termination fee of $2,500,000 from Mesoblast and to extend certain payments milestones. In consideration for this amendment, Mesoblast has agreed to pay to Celyad $1,500,000 in Mesoblast ordinary shares. • Fortress Group On December 2, 2021, we entered into a Subscription Agreement (the “Subscription Agreement”) with CFIP CLYD LLC (“Fortress”), an affiliate of Fortress Investment Group, pursuant to which we agreed to sell to Fortress, in an unregistered offering, an aggregate of 6,500,000 ordinary shares at a purchase price of $5.00 per share (the “Private Placement”). The Private Placement closed on December 8, 2021 and resulted in the receipt of gross proceeds of approximately $32,500,000. In connection with the Subscription Agreement, we also entered into a Shareholders’ Rights Agreement (the “Shareholders’ Rights Agreement”) with Fortress, pursuant to which Fortress (i) has the right to select two individuals to be, at Fortress’s option, either members of our Board of Directors (the “Board”) or non-voting observers of the Board, so long as Page 25 | 180 2021 Annual Report Fortress continues to hold at least 10% of our outstanding ordinary shares; and (ii) received a right of first offer on any new indebtedness to be incurred by us and a pro rata right of first refusal on any new equity securities to be issued by us, as well as customary registration rights. We also granted Fortress certain protective provisions related to our intellectual property portfolio. 1.7 Our Manufacturing Capabilities Our established in-house process development and manufacturing expertise enables us to seamlessly and efficiently reproduce materials to advance our cell therapy candidates into early-stage clinical trials. We control our manufacturing through our 11,000 square foot GMP-compliant manufacturing facility, located in Mont-Saint-Guibert, Belgium. Our facility’s staff have been instrumental in the preparation of multiple IND and Clinical Trial Applications (CTAs) filings, through the completion of dozens of production runs, as well as in implementing multiple chemistry, manufacturing, and control (CMC) amendments associated with our CAR T programs. We have the flexibility to manufacture both our allogeneic and autologous CAR T candidates within our GMP facility and we are equipped to support the production of all doses to deliver our clinical development plan. In addition, leveraging our All-in-One vector approach for CAR T production means that we can use a consistent manufacturing process across all product candidates. We also plan to expand our manufacturing capabilities through potential partnerships with contract development and manufacturing organizations. 1.8 Our shareholding structure Celyad Oncology SA (Belgium) – 100% Biological Manufacturing Services SA (Belgium) Celyad Inc (USA) CorQuest Medical Inc (USA) 1.9 Post balance sheet events On January 17, 2022, the Company entered into an amendment with Mesoblast to convert the license into non-exclusive whereby the Company agreed, (a) to settle $2,500,000 of receivable as of December 31, 2021 with $1,500,000 and; (b) extend certain milestone payments. The consideration of $1,500,000 was agreed to be paid by Mesoblast in Mesoblast ordinary shares and the difference $1,000,000 will be recorded in the income statement in 2022. On February 28, 2022, the Company announced its decision to voluntarily pause its Phase 1b KEYNOTE- B79 trial evaluating CYAD-101 administered concurrently with FOLFOX chemotherapy followed by MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with refractory metastatic colorectal cancer following reports of two fatalities that presented with similar pulmonary findings. The Company is currently investigating these reports and evaluating any similar events in additional patients treated on study. On March 1, 2022, the Company was informed via-email communication from the FDA that the KEYNOTE-B79 trial has been placed on clinical hold due to insufficient information to assess risk to study subjects. Page 26 | 180 2021 Annual Report There were no other subsequent events that occur between 2021 year-end and the date when the financial statements have been authorized by the Board for issue. 1.10 Our capital expenditures The Company’s actual capital expenditures excluding impact of recognition of right-of-use assets for the years ended December 31, 2020 and 2021 amounted to €0.2 million and €0.3 million, respectively. These capital expenditures primarily consisted of the acquisition of laboratory equipment and industrial tools, the refurbishment of research and development laboratories and leasehold improvements of corporate offices located in Belgium. The Company expects its capital expenditures to increase in absolute terms in the near term as the Company continues to advance its research and development programs. 1.11 Financial review of the year ending December 31, 2021 1.11.1. Analysis of the consolidated income statement The table below sets forth the Group’s consolidated income statement, ending up with a €26.5 million loss for the year ended 31 December 2021, and comparative information for the year 2020. (€'000) Revenue Cost of sales Gross profit Research and Development expenses General & Administrative expenses For the year ended 31 December, 2021 2020 - 5 - - - 5 (20 773) (21 522) (9 908) (9 315) Change in fair value of contingent consideration 847 9 228 Other income Other expenses Operating Loss2 Financial income Financial expenses Loss before taxes Income taxes Loss for the period Basic and diluted loss per share (in €) 4 909 4 731 (1 466) (114) (26 391) (16 987) 144 (255) 217 (434) (26 502) (17 204) (10) - (26 512) (17 204) (1.70) (1.23) The Company’s license and collaboration agreements have generated no revenue in 2021 and 2020. The Research and Development expenses include pre-clinical, manufacturing, clinical, quality, intellectual property and regulatory expenses and other research and development expenses, which are aggregated and presented as a single line in the Company’s consolidated financial statements. 2 The operating loss arises from the Company’s loss for the period before deduction of financial income, financial expenses and income taxes. The purpose of this measure by Management is to identify the Company’s results in connection with its operating activities. Page 27 | 180 2021 Annual Report Bottom-line, the R&D expenses show a year-over-year decrease of €0.7 million. The decrease in the Company’s R&D expenses is primarily driven by (see note 5.24): • • • • • The increase of employee expenses mainly related to movement of employees through the year ended December 31, 2021 to support the Group’s preclinical and clinical programs The increase of preclinical activities associated with the CYAD-203 program (next-generation NKG2D) and other next-generation CAR T candidates, compensated by; The decrease of process development and clinical development after the Group’s decision in Q4 2020 to discontinue the development of first-generation, autologous CAR T candidate CYAD-01; The decrease of process development associated to the transition from preclinical to clinical development of the CYAD-211 program; and The decrease of the expenses associated with the share-based payments (non-cash expenses) related to the warrants plan offered to the Company’s employees, managers, and directors. The key projects driving the research and development expenses in 2021 included: • • The clinical studies conducted on the Company’s Product Candidates; The preclinical studies conducted on the Company’s CAR T product candidates in allogeneic settings for solid tumors and the development of the Company’s allogeneic platform, which evaluates multiple non-gene editing technologies. General and Administrative expenses were €9.9 million in 2021 as compared to €9.3 million in 2020, an increase of €0.6 million. This increase primarily relates to higher insurances costs (D&O insurance principally) and consulting fees related to legal, recruitment and capital raise activities have been partially compensated by the decrease of the expenses associated with the share-based payments (non-cash expenses) related to the warrants plan offered to the Group’s employees, managers and directors (see note 5.25). The fair value adjustment (€0.8 million) relating to the contingent consideration and other financial liabilities as of December 31, 2021, is mainly driven by (see note 5.28): • • • • • The update of the assumptions associated with the timing of the potential commercialization of the Group’s allogenic CYAD-101 CAR T program for mCRC which has been delayed by one year; The update of the assumptions associated with the timing, development and the potential commercialization of the Group’s autologous CYAD-02 CAR T program for r/r AML/MDS to reflect the future development of the program through potential partnership, which has been delayed by one year; The update in WACC used for fair value measurement purposes at December 31, 2021; The revaluation of the U.S. dollar against the Euro; and The updated assumptions on Probability of Success (PoS) associated with the Group’s CAR T programs. As of December 31, 2020, the change in fair value of the contingent consideration and other financial liabilities was mainly driven by updated assumptions associated with the timing of the potential commercialization of the Group’s autologous CYAD-02 CAR T program for r/r AML/MDS which had been delayed by one year. The Company’s other income (see note 5.28) is associated with grants received from the Walloon Region mainly in the form of recoverable cash advances (RCAs) and R&D tax credit income: Page 28 | 180 2021 Annual Report • Grant income (RCAs): additional grant income has been recognized in 2021 on grants in the form of recoverable cash advances (RCAs) for contracts numbered 8087, 8088, 8212, 8436 and 1910028. According to IFRS standards, the Company has recognized grant income for the period amounting to €2.7 million and a liability component of €1.6 million is accounted for as a financial liability (see disclosure notes 5.16 and 5.19.2). The increase compared to December 31, 2020 is mainly associated with additional grant income recognized on new conventions signed during the last quarter of 2020 (contracts numbered 8212 and 8436) and on convention numbered 1910028, partly compensated by the decrease on grant income recognized on conventions associated to autologous programs (contract numbered 7685, 8087 and 8088); • Grant income (Others): additional grant income has been recognized in 2021 on grants received from the Federal Belgian Institute for Health Insurance Inami (€0.3 million) and from the regional government (contracts numbered 8066 and 8516 for €1.1 million), not referring to RCAs and not subject to reimbursement. The increase compared to December 31, 2020 is mainly due to grant income recognized on new convention signed in the last quarter of 2021 with the regional government (contract numbered 8516); • the remeasurement income on the recoverable cash advances (RCAs) of €0.9 million for the year 2020, which was mainly related to the Group decision to update assumptions associated with the timing of the potential commercialization of the Group’s autologous AML/MDS CAR T program, while the remeasurement on the recoverable cash advances (RCAs) is an expense for the year ended December 31, 2021; and • with respect to R&D tax credit, the current year income is predicated on a R&D tax credit recorded (€0.7 million), which has been updated taking into account all information available at this date and is in line with previous year. For the year ended December 31, 2021, other expenses mainly refer to (see note 5.28): • • the remeasurement income on the recoverable cash advances (RCAs) of €0.3 million for the year 2021, which is mainly related to the time accretion (which reflects the development of the Group’s product candidates using CAR T technology and their progress towards market approval in both autologous and allogeneic programs) and the revaluation of the U.S. dollar against the Euro; and the other expenses are mainly associated with the amendment fees on license agreement with Dartmouth signed in December 2021 for €1.1 million. Therefore, at year-end 2021, the loss from operations amounted to €26.4 million versus €17.0 million in 2020 for the reasons stated above. Financial results refer mainly to interest on finance leases (see note 5.31). As a result of the foregoing, the net loss for the financial year 2021 amounts to €26.5 million, compared to a net loss of €17.2 million for the prior year for the reasons stated above. 1.11.2. Analysis of the consolidated statements of financial position The table below sets forth the Group’s consolidated statements of financial position for the year ended December 31, 2021, and comparative information as at December 31, 2020. (€’000) December 31, December 31, NON-CURRENT ASSETS Goodwill and Intangible assets Property, Plant and Equipment Non-current Trade and Other receivables Non-current Grant receivables Other non-current assets 2021 2020 (as adjusted) 45 651 46 379 36 168 3 248 2 209 3 764 262 36 171 4 119 2 117 3 679 293 Page 29 | 180 CURRENT ASSETS Trade and Other Receivables Current Grant receivables Other current assets Short-term investments Cash and cash equivalents TOTAL ASSETS EQUITY Share Capital Share premium Other reserves Capital reduction reserve Accumulated deficit NON-CURRENT LIABILITIES Bank loans Lease liabilities Recoverable Cash advances (RCAs) Contingent consideration payable and other financial liabilities Post-employment benefits Other non-current liabilities CURRENT LIABILITIES Bank loans Lease liabilities Recoverable Cash advances (RCAs) Trade payables Other current liabilities TOTAL EQUITY AND LIABILITIES 2021 Annual Report 34 292 19 705 668 1 395 2 211 615 145 1 711 - - 30 018 17 234 79 943 66 084 43 639 30 994 78 585 6 317 33 172 234 562 (308 997) 48 513 43 349 30 958 191 213 (283 039) 22 477 23 256 - - 1 730 5 851 14 679 53 164 2 525 4 220 15 526 614 371 13 827 11 834 - 37 902 362 6 611 5 952 1 076 371 4 736 5 614 79 943 66 084 (1) For information on voluntary change in accounting policy, see note 5.2.16. Intangible assets net book value, as described in note 5.6, mainly refers to: • • The Company’s IPR&D assets related to its oncological programs acquired in 2015 through the Oncyte business combination. Pursuant to IFRS, the Company does not capitalize research and development expenses until marketing authorization. Accordingly, all clinical, research and development spend related to the development of the Company’s CAR T product candidates and allogeneic platform are accounted for as operating expenses for the year 2021. The Company’s exclusive agreement for Horizon Discovery’s SHRNA Platform to develop next- generation allogenic CAR T Therapies acquired for $1.0 million end of December 2018. At the closing date, milestone payments are capitalized for a total amount of $0.4 million. • New licenses acquired in 2021 regarding an exclusive patent license agreement signed with the University of Pennsylvania for an engager targeting Glypican 3 (GPC3) for $0.1 million and an exclusive license from the Moffitt Cancer Center for an antibody directed to Tumor-associated glycoprotein (TAG-72), which both will form the basis of a T cell engager to be used with the shRNA platform technology of the Company for $0.2 million. Property, plant and equipment net book value mainly refers to right-of-use on leased assets in compliance with IFRS 16 standard (office and facilities, vehicles and equipment). The decrease of €0.9 million in 2021 comparatively to 2020 is explained by €1.3 million of amortization on the period compensated by the addition of €0.4 million of new assets mainly related to new laboratory equipment (see note 5.7). Non-current trade receivables (€2.2 million as of December 31, 2021) mainly refer to discounted and risk- adjusted milestone receivables, to be cashed in by the Company in accordance with the terms of the exclusive license agreement signed by the Company with Mesoblast Ltd. for C-Cathez device development (see note 5.8). Page 30 | 180 2021 Annual Report Non-current grant receivables relate to a receivable on the amounts to collect from the Federal Government as R&D tax credit recognized for the first time at year-end 2017 (€1.2 million), including a one-time catch-up effect. Since 2018, further R&D tax credit receivables are recorded on an annual base increment. For the year ended December 31, 2021, the Company recorded additional R&D tax credit of €0.7 million, taking into account all information available as of December 31, 2021. The Group received the reimbursement from the Federal Government of €0.6 million related to the fiscal year 2016 tax credit.(see note 5.8). At December 31, 2021, the current grant receivables relate to the cash proceeds to be received, associated with conventions numbered 8088 (CYAD-02 CYCLE 1), 8212 (CYAD-101), 1910028 (CwalityCAR) and 8516 (new convention signed in 2021 regarding new engagers), amount to €1.4 million (see note 5.9), an increase of €1.3 million compared to year-end 2020. The Company’s Treasury position 3 amounts to €30.0 million at December 31, 2021 which accounts for an increase of €12.8 million as compared to year-end 2020, mainly as a result of cash proceeds from capital raises during the period partly compensated by the Group’s operations expenses (see note 5.10 & 5.11). Lease liabilities reach a total amount of €2.6 million as of December 31, 2021, decreasing by €1.0 million compared to the year-end 2020. The decrease is mainly explained by the repayments of leases during the year 2021 (see note 5.19.2). The recoverable cash advances (RCAs) reach a total balance of €6.2 million as of December 31, 2021, the increase of €1.6 million compared to year-end 2020 mainly related to new liability components recognized in 2021. (see note 5.16 & 5.19.2). The contingent consideration payable and other financial liabilities amounts to €14.7 million at year-end which represents a decrease of €0.8 million compared to December 31, 2020. This decrease is mainly driven by: • • • • • The update of the assumptions associated with the timing of the potential commercialization of the Group’s allogenic CYAD-101 CAR T program for mCRC which has been delayed by one year; The update of the assumptions associated with the timing, development and the potential commercialization of the Group’s autologous CYAD-02 CAR T program for r/r AML/MDS to reflect the future development of the program through potential partnership, which has been delayed by one year; The update in WACC used for fair value measurement purposes at December 31, 2021; The revaluation of the U.S. dollar against the Euro; and The updated assumptions on Probability of Success (PoS) associated with the Group’s CAR T programs. Trade payables amount to €6.6 million at year-end, which represents an increase of €1.9 million compared to year-end 2020, which is mainly attributable to monthly effect in the timing of the expenses and the payments related (see note 5.18). The other current liabilities amount to €6.0 million at year-end which represents an increase of €0.3 million compared to prior year-end. This increase is mainly explained by: 3 ‘Treasury position’ is an alternative performance measure determined by adding Short-term investments and Cash and cash equivalents from the statement of financial position prepared in accordance with IFRS. The purpose of this measure by Management is to identify the level of cash available internally (excluding external sources of financing) within 12 months. Page 31 | 180 2021 Annual Report • An increase on social security and payroll accruals of €0.2 million compared to December 31, 2020 is mainly related to employee movements in 2021; • An accrual of €0.8 million for the reimbursement of R&D tax credit related to tax audit on fiscal year 2015. In 2020, an accrual had been established to cover for a €1.0 million reimbursement of R&D tax credit related to an assessment resulting from an audit of fiscal years 2013 and 2014. The reimbursement will be required through the first quarter of 2022 even though the management plans to appeal the assessment, compensated by; • The decrease of the other current liabilities related to RCAs and other grants by €0.7 million. The total amount of €1.1 million as of December 31, 2021 is attached to RCA conventions numbered 8087 (CYAD-01 – DEPLETHINK), 8436 (CYAD-211 Immunicy) and 8516 (new engagers) and is explained by the excess of cash proceeds received from the Walloon Region compared to the eligible expenses covered by these conventions recognized in 2021; For more details on other current liabilities, refer to note 5.18. 1.11.3. Analysis of the consolidated net cash burn rate 4 The table below summarizes the net cash burn rate of the Company for the year 2021. (€'000) For the year ended 31 December, 2021 2020 Net cash used in operations (26 643) (27 665) Net cash (used in)/from investing activities (126) 157 Net cash (used in)/from financing activities 39 521 5 396 Effects of exchange rate changes Change in Cash and cash equivalents Change in Short-term investments Net cash burned over the period 32 8 12 784 (22 104) - - 12 784 (22 104) The net cash burn rate for the year ended December 31, 2021 is a net cash inflow amounting to €12.8 million, compared to a net cash outflow of €22.1 million for the year ended December 31, 2020. The cash outflow resulting from operating activities amounted to €26.6 million for the year ended December 31, 2021, which is in line with the €27.7 million for the year ended December 31, 2020. Cash flow from investing activities represented a net cash outflow of €0.1 million for the year ended December 31, 2021, which is in line 2020 activities. The increase in cash inflow from financing activities is primarily due to: • An increase in the proceeds from capital raise of €36.6 million obtained in 2021. No capital increase had occurred in the year 2020; and • A partial offset coming from lower proceeds received from Walloon Region and Federal Government in 2021 for a total amount of €4.4 million (compared to €7.3 million in 2020). 4 ‘Net cash burn rate’ is an alternative performance measure determined by the year-on-year net variance in the Group’s treasury position as above defined. The purpose of this measure for the Management is to determine the change of the treasury position. Page 32 | 180 2021 Annual Report 1.12 Personnel As of December 31, 2021, we employed 88 full-time employees, 6 part-time employees, 7 members of the Executive Committee (among them 3 are under services agreement), and 2 managers under management services agreements. 1.13 Environment All entities of the Group continue to hold the permits required by their activities and are in compliance with all applicable environmental rules. 1.14 Going concern 5 Management made an assessment of the Company’s ability to continue as a going concern through preparation of detailed budgets and cash flow forecasts for the years 2022 and 2023. These forecasts reflect the strategy of the Group and include significant expenses and cash outflows in relation to the development of selected research programs and pipeline of products candidates. In performing this assessment, management considered factors that could indicate the presence of material uncertainties that may cast significant doubt upon the company’s ability to continue as a going concern. Factors considered included: operating losses and absence of any firm commitments for additional financing before the reporting date. As of December 31, 2021, the Company had cash and cash equivalents of €30.0 million and no short-term investments. On January 8, 2021, we entered into a committed equity purchase agreement (“Purchase Agreement”) over a 24-month term for up to $40.0 million with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which LPC’s purchases are subject to certain conditions, including that the Company may only deliver a Regular Purchase Notice (as that term is defined in the Purchase Agreement) of its ADSs so long as the adjusted price of its ADSs exceeds $1.00. Over the remaining lifetime of the Purchase Agreement, we will have the right to direct LPC to purchase up to an aggregate remaining amount of $28.0 million ADSs, each of which represents one of our ordinary shares. As of December 31, 2021, the remaining amount of $28.0 million of this equity purchase agreement is expected to strengthen the Company’s current statement of financial position while also providing the Company with access to future capital on an as needed basis and to ensure sufficient funding to cover its operations for the next 12 months from the date the financial statements are issued. Based on its current scope of activities, the Company estimates that its cash and cash equivalents as of December 31, 2021 combined with the remaining access to the equity purchase agreement established with Lincoln Park Capital Fund, LLC (remaining amount of $28.0 million as of December 31, 2021) should be sufficient to fund operating expenses and capital expenditure requirements until mid-2023. After due consideration of the above, the Board of Directors determined that Management has an appropriate basis to conclude on the business continuity over the next 12 months the date the financial statements are issued, and hence it is appropriate to prepare the financial statements on a going concern basis. 5 The uncertainly raised by the COVID-19 pandemic is not impacting going concern. Although there are lot of uncertainties, it does not impact the Company’s ability to continue operations until mid-2023 considering its treasury position as of December 31, 2021 combined with the remaining $28.0 million from Lincoln Park Capital Fund. For additional information on COVID-19 pandemic update, refer to note 5.2.1. Page 33 | 180 2021 Annual Report 1.15 Risks and uncertainties Reference is made to section 2.8 “Description of the principal risks associated to the activities of the Group“. On March 11, 2020, the World Health Organization declared the novel strain of coronavirus (COVID-19) a global pandemic and recommended containment and mitigation measures worldwide. Throughout 2020 and 2021, Belgium and the United States, where the Company operates, have been impacted by temporary closures. While progress has been made in the fight against the ongoing COVID-19 pandemic, including the broad dissemination and administration of vaccines in certain countries, the COVID-19 pandemic has continued to spread globally. The length or severity of this pandemic cannot be predicted, but the Company anticipates that there may continue to be additional impacts from a prolonged COVID-19 environment on the planned development activities of the Company. Timely enrollment in clinical trials is reliant on clinical trial sites which may be adversely affected by global health matters, including, among other things, the ongoing COVID-19 pandemic and the emerging variants, such as Delta and Omicron. With regards to the Company’s clinical programs, no major disruption in enrollment were experienced in the CYAD-101, CYAD-211 or CYAD-02 programs in 2021 due to the coronavirus pandemic. Enrollment in the respective trials for CYAD-101 and CYAD-211 is ongoing without any major disruption due to the coronavirus pandemic, however future disruptions may occur. However, since 2020, certain clinical sites and institutions have not been able to receive visits from the Company or its representatives during the coronavirus pandemic, which has delayed its data monitoring activities and delayed its ability to lock the databases for completed studies. The long-term impact of COVID-19 on the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted, including the emergence of new variants, such as Delta and Omicron, and, among other things, additional government restrictions intended to contain COVID-19’s effects, but potential prolonged closures or other business disruptions may negatively affect its operations and the operations of its agents, contractors, consultants or collaborators, which could have a material adverse impact its business, results of operations and financial condition. In addition, after enrollment in these trials, if patients contract COVID-19 during participation in the Company’s trials or are subject to isolation or shelter-in-place restrictions, they may drop out of its trials, miss scheduled follow-up visits or otherwise fail to follow trial protocols. If patients are unable to follow the trial protocols or if the Company’s trial results are otherwise disputed due to the effects of the COVID-19 pandemic or actions taken to mitigate its spread, the integrity of data from its trials may be compromised or not accepted by the FDA or other regulatory authorities, which would represent a significant setback for the applicable program. Some factors from the COVID-19 pandemic that the Company believes may adversely affect enrollment in its trials include: • The diversion of healthcare resources away from the conduct of clinical trial matters to focus on pandemic concerns, including the attention of physicians serving as the Company’s clinical trial investigators, hospitals serving as its clinical trial sites and hospital staff supporting the conduct of our clinical trials; • Some patients who would otherwise be candidates for enrollment in the Company’s clinical trials are at increased risk of severe effects of the coronavirus, which may lead to the death of some patients and render others too ill to participate, limiting the available pool of participants for its trials; • • • The fact that there can be no guarantee that any proposed changes to the Company’s protocols, if necessary, would be acceptable to regulators; Limitations on travel that interrupt key trial activities, such as clinical trial site initiations and monitoring; and Interruption in global shipping affecting the transport of clinical trial materials being used in the Company’s trials. Page 34 | 180 2021 Annual Report These and other factors arising from the COVID-19 pandemic could worsen in countries that are already afflicted with the virus or could continue to spread to additional countries, each of which may further adversely impact the Company’s clinical trials. The global outbreak of the COVID-19 pandemic continues to evolve, and the conduct of its trials may continue to be adversely affected, despite efforts to mitigate this impact. Even if the Company is able to enroll a sufficient number of patients in its clinical trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of its clinical trials, which could prevent completion of these trials and adversely affect its ability to advance the development of its product candidates. The impact of COVID-19 on the Company’s business is uncertain at this time and will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among other things, but prolonged closures or other business disruptions may negatively affect the Company’s operations and the operations of its agents, contractors, consultants or collaborators, which could have a material adverse impact its business, results of operations and financial condition. 1.16 Events and circumstances that could have a significant impact on the future The Company has not identified significant events and circumstances that could have a significant impact on the future in addition to the potential impact of risks described in section 7 of chapter 2: "Description of the principal risks associated to the activities of the Group". Page 35 | 180 2021 Annual Report 2. CORPORATE GOVERNANCE 2.1 General This section summarizes the rules and principles on the basis of which the corporate governance of the Company has been organized pursuant to the CCA, the Company's articles of association, and the Company's corporate governance charter (the “Charter”) adopted in accordance with the Belgian Corporate Code of Governance 2020 (the “CCG”) and updated regularly by the Board of Directors. The Company does not incorporate the information contained on, or accessible through, its corporate website into this Report, and you should not consider it a part of this Report. The Charter is available on the Company’s website (www.celyad.com) under the Investors/Corporate Governance tab. The text of the CCG is available on the website of the Commission of Corporate Governance at https://www.corporategovernancecommittee.be/fr/over-de-code-2020/code-belge-de-gouvernance- dentreprise-2020. The Board of Directors intends to comply with the provisions of the CCG but believes that the size and the current state of development of the Company justifies certain deviations. These deviations are further detailed in the Section 2.5 hereinafter. The Charter includes the following main chapters: • Structure and organization; • Shareholder structure; • The Board : terms of reference; • Chairman of the Board; • Company Secretary; • Board committees; • Executive Committee; • Rules preventing market abuse; • Miscellaneous and annexes. 2.2 Board of Directors 2.2.1. Composition of the Board of Directors As provided by the articles 7:85 et sq. of the CCA, the Company is managed by a Board of Directors acting as a collegiate body. The Board of Directors' role is to pursue the long-term success of the Company by providing entrepreneurial leadership and enabling risks to be assessed and managed. The Board of Directors determines the Company's values and strategy, its risk preference and key policies. The Board of Directors ensures that the necessary leadership, financial and human resources are in place for the Company to meet its objectives. The Company has opted for a one-tier governance structure. As provided by Article 7:93 of the CCA, the Board of Directors is the ultimate decision-making body in the Company, except with respect to those areas that are reserved by the law or by the Company's articles of association to the Shareholders Meeting. Page 36 | 180 2021 Annual Report The Company's articles of association state that the number of directors of the Company, who may be natural persons or legal entities and who need not be shareholders, must be at least three. At least half of the members of the Board of Directors must be non-executive directors and at least three of them must be independent directors. A meeting of the Board of Directors is validly constituted if at least half of its members are present in person or represented at the meeting. If that quorum is not met, a new board meeting may be convened by any director to deliberate and decide on the matters on the agenda of the board meeting for which a quorum was not met, provided that at least two members are present. Meetings of the Board of Directors are convened by the Chairperson of the Board or the CFO or the Chief Legal Officer, or by at least two directors, whenever the interest of the Company so requires. In principle, the Board of Directors will meet at least four times per year. The Chairperson of the Board of Directors shall have a casting vote on matters submitted to the Board of Directors in the event of a tied vote. Until such time as the Fortress Shareholders (which shall have the meaning ascribed to it in that certain shareholders’ rights agreement dated as of December 2, 2021 by and between CFIP CLYD LLC and the Company, in the form filed with the United States Securities and Exchange Commission on December 3, 2021) own in the aggregate less than 10% of the then outstanding shares (including shares underlying American Depositary Shares) for a period of more than thirty (30) consecutive days: (i) (ii) (iii) (iv) Fortress Investment Group LLC (“Fortress”) shall have the right to select two (2) individuals (the “Fortress Designees”) to be, at Fortress’s option, (a) members of the Board, (b) non-voting observers of the Board or (c) a combination thereof (provided that if Fortress selects both Fortress Designees to be members of the Board, Fortress may also select a third Fortress Designee to be a non-voting observer of the Board), and the Board, at Fortress’s option, (a) shall recommend the confirmation or (re)appointment of any two (2) Fortress Designees as members of the Board at any applicable general meeting of shareholders of the Company, (b) shall appoint any two (2) Fortress Designees as non-voting observers of the Board or (c) shall proceed to a combination thereof, and Upon the termination of the board mandate of any Fortress Designee (for whatever cause), at the option of Fortress, (a) the Company shall as soon as practicably possible co-opt to the Board a replacement Fortress Designee, and shall use best efforts to cause the confirmation of the co- optation at the next general meeting of shareholders of the Company; or (b) the Company shall as soon as practicably possible approve the appointment of a replacement Fortress Designee as a non-voting observer of the Board of Directors, and the Company shall not, directly or indirectly, without the consent of recommend, directly or indirectly, or take any action to (a) increase the size of the Board or (b) co-opt or appoint to the Board, in place of the Fortress Designees, any individual other than a Fortress Designee. At the date of this Report, the Board of Directors consists of 9 members, one of which is an executive director (with daily management authority) and 8 of which are non-executive directors, including three independent directors. The Board of Directors is composed of 6 men and 3 women. Name Mel Management SRL (1) Filippo Petti Serge Goblet Chris Buyse Position Chairman of the Board Non-Executive Director Executive Director Non-executive director Non-executive director Christopher LiPuma (2) Non-executive director Hilde Windels Independent director Term 2025 2024 2024 2024 2022 2022 Ami Patel Shah (3) Non-Executive Director 2022 Board Committee Membership Chairman of the Nomination and Remuneration Committee Member of the Audit Committee and the Nomination and Remuneration Committee Page 37 | 180 2021 Annual Report Dominic Piscitelli Independent Director Marina Udier Independent Director 2024 2025 Chairman of the Audit Committee and member of the Nomination and Remuneration Committee Member of the Audit Committee (1) Represented by Michel Lussier. (2) Christopher LiPuma has been elected as Board member as of January 20, 2022, in replacement of RAD Lifesciences BV who resigned from the Board on January 14, 2022. (3) Ami Patel Shah has been elected as Board member on December 7, 2021 in replacement of Maria Koehler who has resigned from the Board of Directors on August 5, 2021. The following paragraphs contain brief biographies of each of the directors, or in case of legal entities being director, their permanent representatives, with an indication of other relevant mandates as member of administrative, management or supervisory bodies in other companies during the previous five years. Michel Lussier serves as Chairman of the Board of Directors. Mr. Lussier co-founded Cardio3 Biosciences SA the company which became Celyad SA. Mr. Lussier currently serves also on several Boards of Directors: iSTAR Medical SA and Gabi Smart Care SA as Chairman, Occlutech AG as board member. Previously, Mr. Lussier founded MedPole SA and its North American affiliate Medpole LTD, a Medtech and cell therapy incubator for start-up companies, serving as CEO until July 2020. From May 2014 and until September 2020, Mr. Lussier also served as the CEO of Metronom Health Inc, an early stage medical device company founded by Fjord Ventures, where he also acted as a management consultant. Mr. Lussier served as a member of the Board of Directors of Biological Manufacturing Services SA until 2017. Prior to that, from 2002 to 2013, he worked for Volcano Corporation, where he served in global leadership positions. Mr. Lussier started his career with Medtronic where he held a number of technical, marketing, sales then general management roles. Mr. Lussier obtained a Bachelor of Sciences degree in Electrical Engineering and Master’s Degree in Biomedical Engineering at the University of Montreal. He also holds an MBA from INSEAD, France. Filippo Petti is Chief Executive Officer, Chief Financial Officer of the Company, and Executive Director. Prior to joining the Company, Mr. Petti worked in healthcare investment banking both at Wells Fargo Securities and William Blair & Company until 2017. Prior to his roles in investment banking, Mr. Petti spent several years in equity research covering U.S. biotechnology companies both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. focused on drug discovery and translational research, and later transitioning into corporate development with the company. Mr. Petti holds a Master of Business Administration from Cornell University, a Master of Science from St. John’s University and a Bachelor of Science from Syracuse University. Serge Goblet holds a Master Degree in Business and Consular Sciences from ICHEC, Belgium and has many years of international experience as director in Belgian and foreign companies. Mr. Goblet is the managing director of TOLEFI SA, a Belgian holding company and holds director mandates in subsidiaries of TOLEFI. Chris Buyse brings more than 30 years of international financial expertise and experience in introducing best financial management practices. He is currently Managing Director of FUND+ NV, a fund that invests in innovative Belgian Life Sciences companies. Between August 2006 and June 2014, Mr. Buyse served as the Chief Financial Officer and board member of ThromboGenics NV, a leading biotech company that is listed on NYSE Euronext Brussels. Before joining ThromboGenics, he was the Chief Financial Officer of the Page 38 | 180 2021 Annual Report Belgian biotech company CropDesign, where he coordinated the acquisition by BASF in July 2006. Prior to joining CropDesign NV he was financial manager of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecommunication companies and he was also the Chief Financial Officer, interim Chief Executive Officer and member of the Board of Directors of Keyware Technologies. Mr. Buyse holds a Master’s Degree in applied economic sciences from the University of Antwerp and a Master of Business Association from Vlerick School of Management in Gent. He currently serves, in his own name or as permanent representative of a management company, as member of the board of directors of the following publicly and privately held companies: Bio Incubator NV, Pinnacle Investments SA, CreaBuild NV, Sofia BVBA, Pienter-Jan BVBA, Life Sciences Research Partners VZW, Inventiva SA, The Francqui Foundation and EyeDPharma SA. He has also previously held a directorship position at Bone Therapeutics SA from 2008 to 2019. Mr. Buyse is also Board member at Hyloris pharmaceuticals SA and the Foundation Louis- Jeantet (CH). Hilde Windels is the Chief Executive Officer of the privately held diagnostics company Antelope Dx BV and she is also member of its boards of directors. Ms. Windels brings 20 years of experience in biotech with a track record of business and corporate strategy, building and structuring organizations, private fundraising, mergers and acquisitions and public capital markets. Ms. Windels has worked as Chief Financial Officer for several biotech companies, amongst those Belgium based molecular Dx company Biocartis where she started as Chief Financial Officer CFO in 2011. She transitioned to the co-Chief Executive Officer role in 2015, became Chief Executive Officer in 2017, and served in such role until 2019. Later that year, she joined MyCartis NV until 2021 as Chief Executive Officer and in 2019 she was appointed CEO of Mycartis’ spin- out Antelope Dx, where she now also serves as a Board member. Ms. Windels is member of the board of directors of Erytech and MdxHealth. She holds a Master’s Degrees in Economics (Commercial Engineer) from the University of Leuven (Belgium). Dominic Piscitelli brings more than 20 years of industry experience, including debt and equity financings, in-licensing launches transactions, acquisitions, marketing partnerships and commercial product (XTANDI® and Tarceva®). Since September 2019 Dominic has served as the Chief Financial Officer of ORIC Pharmaceuticals, Nasdaq-listed biotechnology company, that completed its initial public offering in April 2020. Prior to joining ORIC, Mr. Piscitelli was CFO of AnaptysBio, a Nasdaq-listed biotechnology company, where he helped raise over $500 million in an IPO and follow-on financings. From 2012 until 2017, Mr. Piscitelli was Vice President of Finance, Strategy and Investor Relations at Medivation and played a key role in its acquisition by Pfizer. Previously, he served as Senior Director of Collaborations and Operations Finance at Astellas Pharma. Prior to that, Mr. Piscitelli served in various roles of increasing responsibility culminating as the Vice President, Treasury & Management Finance at OSI Pharmaceuticals, and played a significant role in their acquisition by Astellas. Mr. Piscitelli began his career with KPMG and is a certified public accountant. He earned a bachelor’s degree in accounting and an MBA from Hofstra University (New York). Marina Udier, Ph.D., serves as CEO of Nouscom after joining as Chief Operating Officer in 2016 from Versant Ventures, where she was Operating Principal. Prior to Versant, she held senior development and commercial roles at Novartis in Basel including work as a Global Commercial Head. Previously, Dr. Udier worked for McKinsey & Company in the US, working with Healthcare Fortune 500 companies in areas of marketing, strategy and pricing. She has a Ph.D. in Organic Chemistry from Yale University. Page 39 | 180 2021 Annual Report Ami Patel Shah is a Managing Director in Fortress Investment Group LLC’s Intellectual Property Group based in San Francisco, where she focuses on a wide variety of investment opportunities in connection with intellectual property and technology. Prior to joining Fortress in 2013, Ms. Shah worked for Intel, most recently heading Intel’s Global Wireless Patents group, overseeing the Intel’s patent procurement, licensing, transaction and monetization activities for Intel and their development partners. At Intel, Ms. Shah also held wide-ranging and deep technical responsibilities, as well as led Intel’s standards bodies interactions. Before joining Intel, she was with the law firms of Dorsey & Whitney, and Fish & Richardson where she worked on patent prosecution, licensing and ITC litigation matters. Ms. Shah is recognized as one of the World’s Leading IP Strategists by Intellectual Asset Magazine in the IAM 300, awarded to individuals with an established track record in developing and rolling out world-class IP value creation programs. Ms. Shah began her legal career as an examiner in the United States Patent Office and was an engineer in the auto industry. Ms. Shah holds a J.D. from Cleveland State University along with a B.S. in Electrical and Computer Engineering from Wayne State University. Christopher LiPuma is a Director in Fortress Investment Group LLC’s Intellectual Property Group based in San Francisco, where he focuses on a wide variety of investment opportunities in connection with intellectual property, life sciences, and academic institutions. Prior to joining Fortress in 2018, Mr. LiPuma headed business development for Kastle Therapeutics, a private equity backed biotechnology company acquiring ultra-orphan drugs. Before joining Kastle, Mr. LiPuma was with OrbiMed Advisors, a life sciences focused asset management firm. At OrbiMed, Mr. LiPuma worked on royalty monetizations, direct lending to late development stage and early commercial stage life sciences companies, and several private equity transactions focused on acquiring legacy assets from big pharma. Mr. LiPuma started his career as an investment banker at Leerink Partners. Mr. LiPuma holds a B.A. from Hamilton College. 2.2.2. Board resolutions The Board meets as frequently as the interest of the Company dictate, but in any case, sufficiently regularly to enable it to discharge its duties effectively, and certainly not less than four times per year. Each meeting is chaired by the Chairman and, in his absence, by the director appointed by the Board. The Board may only validly deliberate and decide on issues before it, if at least half of its members are present or represented. A new meeting must be convened if a quorum is not reached. The second meeting may validly deliberate and decide on the items that were on the agenda of the first meeting regardless of the number of directors present or represented, to the extent that at least two members of the Board are present. Any director may represent more than one other director. Resolutions are taken by a simple majority of the votes cast, except: (i) (ii) for resolutions regarding the use of the authorized capital, and as long as Serge Goblet is a director of the Company, the majority of the votes must include the positive vote of Serge Goblet, or his abstention, to be adopted; until such time as the Fortress Shareholders own in the aggregate less than 15% of the then outstanding shares (including shares underlying American Depositary Shares) for a period of more than thirty (30) consecutive days, any decision in respect of the following require the positive vote of 90% of the directors present or validly represented: any IP Transaction (defined as the termination of the Company’s intellectual property or any license, sublicense or contribution of intellectual property rights to third parties) involving intellectual property rights licensed to the Company or any of its subsidiaries by the Trustees of Dartmouth College relating to TCR deficiency (which, for the avoidance of doubt, does not include the Company’s cardiological medical devices), (such intellectual property rights the “Dartmouth IP”) with any of the following characteristics: (i) a transfer of litigation or prosecution rights to licensees and sublicensees associated with any of the Dartmouth IP, (ii) the granting of an exclusive license to any Dartmouth IP, (iii) the termination of any rights made available to the Company or any of its subsidiaries to Page 40 | 180 2021 Annual Report any Dartmouth IP or (iv) any license or sub)license that (x) does not constitute an arms-length transaction for fair market value or (y) the terms of which, on their face, are not consistent with market practice in the jurisdictions and industry in which the Company operates.; Furthermore, until such time as the Fortress Shareholders own in the aggregate less than 10% of the then outstanding shares (including shares underlying American Depositary Shares) for a period of more than thirty (30) consecutive days, the Company shall not, directly or indirectly, without the consent of Fortress, (a) incur or issue any indebtedness that would encumber any intellectual property of the Company, (b) issue any Equity Securities (defined as any share and any other security, financial instrument, certificate or other right (including options, futures, swaps and other derivatives) representing, being exercisable, convertible or exchangeable into or for, or otherwise providing a right to acquire, directly or indirectly, any of the securities mentioned above or any other security or financial instrument the value of which is based on any of the foregoing) of the Company that are senior to the ordinary shares with respect to the right to receive (x) dividends or other distributions to shareholders or (y) proceeds in the event of the liquidation, dissolution or winding-up of the Company (including for such purposes in connection with any change of control transaction), (iii) alter, amend or change the rights, preference or privileges of the shares, including in connection with any reclassification, recapitalization, reorganization or restructuring, (iv) make any proposal to amend, repeal or otherwise modify any provision of the Company’s articles of association that would be reasonably expected to adversely affect the interests of Fortress or any Fortress Shareholder or (v) make any proposal to modify the rights of any Equity Securities of the Company in a manner adverse to any Fortress Shareholder. 2.2.3. Director Independence In application of the article 7:87 of the CCA, a director of a listed company is considered as independent if he does not entertain with the Company or an important shareholder of the Company any relation the nature of which could put his independence at risk. If the director is a legal entity, the independence must be assessed both in the case of the legal entity and its permanent representative. In order to verify if a candidate director fulfils those conditions, the independence criteria of the article 3.5 of the BCG are applied and can be summarized as follows: • • • • • • • The director has not been an executive member of the Board of Directors, or daily manager of the Company (or an affiliate of the Company, if any), during a term of three years prior to his or her election and does not possess any stock option of the Company related to that function; The director has not been a non-executive director for a cumulative period of more than 12 years; The director has not been a member of the managerial staff of the Company (or an affiliate of the Company, if any) during a term of three years prior to his or her election and does not possess any stock option of the Company related to that function; The director does not receive and has not received any remuneration or other significant financial advantage from the Company (or an affiliate of the Company, if any), other than the profit share (“tantièmes”) and remuneration received in his or her capacity as a non-executive director or as a member of the supervisory body; The director does not own any corporate rights that represent 10% or more of the share capital or voting rights of the Company, Further, the director cannot be appointed by a shareholder who falls under the conditions set forth in this criterion; The director does not and, during the year preceding his appointment, did not, have a significant business relationship with the Company (or an affiliate of the Company, if any), either directly or as a partner, shareholder, member of the Board of Directors or member of the managerial staff of a company or of a person that maintains such a relationship; The director is not and has not been at any time during the past three years, a partner or an employee of its current or former statutory auditor or of a company or person affiliated therewith; Page 41 | 180 2021 Annual Report • • The director is not an executive director of another company in which an executive director of the Company is a non-executive director or a member of the supervisory body, and has no other significant ties with executive directors of the Company through his or her involvement in other companies or bodies; The director’s spouse, unmarried legal partner and relatives (via birth or marriage) up to the second degree do not act as a member of the Board of Directors, member of the management board (“directiecomité / comité de direction”) (should such corporate body be created) or daily manager or member of the managerial staff in the Company (or an affiliate of the Company, if any), and do not meet one of the criteria set out above. The Board of Directors, assisted by the Chief Legal Officer and upon recommendation of the Remuneration and Nomination Committee, determines annually if the conditions of independence are fulfilled by the members of the Board. 2.2.4. Role of the Board in Risk Oversight The Board of Directors is primarily responsible for the oversight of its risk management activities and has delegated to the Audit Committee the responsibility to assist the Board of Directors in this task. While the Board of Directors oversees the overall risk management, the Company’s Management is responsible for the day-to-day risk management processes. The Board of Directors expects the management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the Board of Directors. The Company believes this division of responsibilities is the most effective approach for addressing the risks the Company faces. 2.2.5. Committees within the Board of Directors 2.2.5.1 General Without prejudice to the role, responsibilities and functioning of the Executive Committee as set out below under section “Executive Committee”, the Board of Directors may set up specialized committees to analyze specific issues and advise the Board of Directors on those issues. Such committees are advisory bodies only and the decision-making remains the collegiate responsibility of the Board of Directors. The Board of Directors determines the terms of reference of each committee with respect to the organization, procedures, policies and activities of the committee. 2.2.5.2 Audit Committee At the date of this Report, the Audit Committee consists of three members: Dominic Piscitelli (Chairman), Marina Udier and Hilde Windels. The role of the Audit Committee is to ensure the effectiveness of the internal control and risk management systems, the internal audit (if any) and its effectiveness and the statutory audit of the annual and consolidated accounts, and to review and monitor the independence of the external auditor, in particular regarding the provision of additional services to the Company. The Audit Committee reports regularly to the Board of Directors on the exercise of its functions. The Audit Committee informs the Board of Directors about all areas in which action or improvement is necessary in its opinion and produces recommendations concerning the necessary steps that need to be taken. The audit review and the reporting on that review cover the Company and its subsidiaries as a whole. The members of the Audit Committee are entitled to receive all information which they need to perform their function from the Board of Directors, Executive Committee and employees. Each member of the Audit Committee shall exercise this right in consultation with the Chairman of the Audit Committee. The Audit Committee’s duties and responsibilities include, among other things: the financial reporting, the review of internal controls and risk management, and managing the internal and external audit process. Page 42 | 180 2021 Annual Report Those tasks are further described in the Audit Committee charter as set out in the Charter and in the Article 7:99 §4 of the CCA. Dominic Piscitelli, and Hilde Windels have been identified by the Company’s Board of Directors as having the necessary expertise in accounting and audit matters to serve as experts on the Audit Committee. The Audit Committee holds a minimum of four meetings per year. 2.2.5.3 Nomination and Remuneration Committee As of the date of this Report, the Nomination and Remuneration Committee is composed of three members: Mel Management SRL represented by Michel Lussier (Chairman), Hilde Windels and Dominic Piscitelli. The Nomination and Remuneration Committee consists of not less than three directors, or such greater number as determined by the Board of Directors at any time. All members must be non-executive directors and at least a majority of its members must be independent in accordance with Article 7:87 of the CCA. The Company’s Board of Directors has determined that Hilde Windels and Dominic Piscitelli are independent in accordance with Article 7:87 of the CCA. The Nomination and Remuneration Committee must have the necessary expertise as regards the remuneration policy, and this condition is fulfilled if at least one member has had a higher education and has had at least three years of experience in personnel management or in the field of remunerating directors and managers. As of the date of this Annual Report, Mel Management SRL represented by Michel Lussier (Chairman), Hilde Windels and Dominic Piscitelli satisfy this requirement. The CEO has the right to attend the meetings of the Nomination and Remuneration Committee in an advisory and non-voting capacity on matters other than those concerning himself. The Nomination and Remuneration Committee will elect a chairman from amongst its members. The Chairman of the Nomination and Remuneration Committee is actually Mel Management SRL represented by Michel Lussier. The role of the Nomination and Remuneration Committee is to assist the Board of Directors in all matters: • Relating to the selection and recommendation of qualified candidates for membership of the Board of Directors; • Relating to the nomination of the CEO; • Relating to the nomination of the members of the Executive Committee, other than the CEO, upon proposal by the CEO; • Relating to the remuneration of independent directors; • Relating to the remuneration of the CEO; • Relating to the remuneration of the members of the Executive Committee, other than the CEO, upon proposal by the CEO; • On which the Board of Directors or the Chairman of the Board of Directors requests the Nomination and Remuneration Committee's advice. Additionally, with regard to matters relating to remuneration, except for those areas that are reserved by law to the Board of Directors, the Nomination and Remuneration Committee will at least have the following tasks: • Preparing the remuneration report (which is to be included in the Board of Director’s corporate governance statement); and • Explaining its remuneration report at the Annual General Shareholders Meeting. It will report to the Board of Directors on the performance of these tasks on a regular basis. These tasks are further described in the terms of reference of the Nomination and Remuneration Committee as set out in the Page 43 | 180 2021 Annual Report Charter. The Nomination and Remuneration Committee will meet at least twice per year, and whenever it deems it necessary to carry out its duties. 2.2.6. Meetings of the Board and the committees In 2021, the Board of Directors held 10 meetings by telephone or videoconference: 2021 Board Members C. Buyse S. Goblet 20 Jan 24 Mar 2 Jun 24 Jun 4 Aug 7 Sep 17 Sep 7 Oct 25 Nov 7 Dec Present Present Present Present Absent Present Absent Present Present Present Present Present Present Present Present Present Present Present Present Present M. Koehler Present Present Present Present Present Present Present Present Present Present F. Petti Present Present Present Present Present Present Present Present Present Present D. Piscitelli Present Present Present Present Present Present Present Absent Present Present M. Udier Present Present Present Present Present Present Present Present Present Present H. Windels Present Present Present Absent Present Present Present Present Present Present RAD Lifesciences BV Mel Management SRL Present Present Present Present Present Present Present Present Present Present Present Present Present Present Present Present Present Present Present Present In addition, nine notarized meetings of the Board of Directors took place in 2021 in relation to a capital increase or the issuance of warrants: 2021 8 Jan 29 Mar 9 Apr 29 Apr 29 Jun 22 Jul 11 oct 20 Oct 8 Dec Represented Represented Represented Represented Represented Present Represented Represented Represented Present Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Represented Present Present Present Present Represented Present Present Present Board Members C. Buyse S. Goblet M. Koehler F. Petti D. Piscitelli M. Udier H. Windels RAD Lifesciences BV Mel Management SRL The Nomination and Remuneration Committee held 8 meetings by telephone or videoconference: Remuneration and Nomination Committee F. Petti D. Piscitelli H. Windels 2021 18 Jan 17 Feb 22 Feb 3 Mar 21 Mar 9 Nov 24 Dec 28 Dec Present Present Present Present Present Present N/A N/A Present Present Present Present Present Present Present Present Present Present Present Present Present Present Present Present BV Mel Management SRL Present Present Present Present Present Present Present Present Page 44 | 180 2021 Annual Report The Audit Committee held 5 meetings by telephone or videoconference. Audit Committee C. Buyse D. Piscitelli H. Windels 22 Mar Present Present Present 26 May Present Present Present 2021 2 Aug Present Absent Present 23 Nov 1 Dec Present Present Present Present Present Present 2.3 Executive Committee The Board of Directors has established an Executive Committee. The terms of service of the Executive Committee have been determined by the Board of Directors and are set out in the Company’s Charter. The Executive Committee consists of the Chief Executive Officer, or CEO (who is the chairman of the Executive Committee), the Chief Financial Officer, or CFO, currently Filippo Petti ad interim, the Chief Scientific Officer, the Chief Medical Officer, the Chief Legal Officer and the Vice President Clinical Development and Medical Affairs, the Chief Business Officer, and the Chief Human Resources Officer. The Executive Committee discusses and consults with the Board of Directors and advises the Board of Directors on the day-to-day management of the Company in accordance with the Company's values, strategy, general policy and budget, as determined by the Board of Directors. Each member of the Executive Committee has been made individually responsible for certain aspects of the day-to-day management of the Company and its business (in the case of the CEO, by way of delegation by the Board of Directors; in the case of the other member of the Executive Committee, by way of delegation by the CEO). The further tasks for which the Executive Committee is responsible are described in greater detail in the sections referencing the Executive Committee, as set out in the Company’s Charter. The members of the Executive Committee are appointed and may be dismissed by the Board of Directors at any time. The Board of Directors appoints them following the recommendation of the Nomination and Remuneration Committee, which shall also assist the Board of Directors on the remuneration policy of the members of the Executive Committee, and their individual remunerations. The remuneration, duration and conditions of dismissal of Executive Committee members is governed by the contract entered into between the Company and each member of the Executive Committee with respect to their function within the Company. In principle, the Executive Committee meets every month. Additional meetings may be convened at any time by the Chairman of the Executive Committee or at the request of two of its members. The Executive Committee will constitute a quorum when all members have been invited and the majority of the members are present or represented at the meeting. Absent members may grant a power of attorney to another member of the Executive Committee. Members may attend the meeting physically or by telephone or video conference. The absent members must be notified of the discussions in their absence by the Chairman (or the Company Secretary, if the Executive Committee has appointed a Company Secretary from among its members). The members of the Executive Committee must provide the Board of Directors with information in a timely manner, if possible, in writing, on all facts and developments concerning the Company that the Board of Directors may need in order to function as required and to properly carry out its duties. The CEO (or, in the event that the CEO is not able to attend the Board of Directors' meeting, the CFO or, in the event that the CFO is not able to attend the Board of Directors' meeting, another representative of the Executive Committee) must report at every ordinary meeting of the Board of Directors on the material deliberations of the previous meeting(s) of the Executive Committee. Page 45 | 180 2021 Annual Report The following table sets forth the members of the Executive Committee who have performed during 2021. Name Filippo Petti Charles Morris Function Chief Executive Officer and Chief Financial Officer Chief Medical Officer NandaDevi SRL, represented by Philippe Dechamps Chief Legal Officer and Corporate Secretary MC Consult SRL, represented by Philippe Nobels Chief Human Resources Officer ImXense SRL, represented by Frederic Lehmann Vice President Clinical Development & Medical Affairs Stephen Rubino David Gilham Chief Business Officer Chief Scientific Officer Year of birth 1976 1965 1970 1966 1964 1958 1965 The following paragraphs contain brief biographies of each of the current members of the Executive Committee or in case of legal entities being a member of the Executive Committee or key manager, their permanent representatives. Filippo Petti, CEO and CFO ad interim – reference is made to section “2.2.1. Composition of the Board of Directors”. Philippe Dechamps (representative of NandaDevi SRL) serves as Chief Legal Officer of the Company and Secretary to the Board of Directors. Philippe started his legal career as an associate in Brussels with the law firm Linklaters De Bandt from 1994 to 1998. Until 2003, he then served as a Legal manager at Solvay Group to assist the company in its turnaround through several M&A operations in Europe, India and Far- East Asia. In 2003, he took over the position of Legal Director at Guidant, the United States company formerly active in the medical devices business before its acquisition by Boston Scientific and Abbott Laboratories in 2005. At Abbott, Philippe was leading the legal affairs of Abbott Vascular International outside of the United States. In 2008, Philippe joined Delhaize Group to lead the legal and government affairs in Europe and Asia, before becoming Group General Counsel and Secretary to the Board of Directors in 2015. In this position, he piloted the legal strategy to merge Delhaize Group with Royal Ahold in July 2016. Since December 2018, Philippe is also member of the Board of Directors of Petserco SA, the holding company of the Tom&Co group. Philippe holds law degrees from the Université Catholique de Louvain (UCL) and Vrije Universiteit Brussel (VUB), and a Master of Law (LL.M) from Harvard Law School. Philippe Nobels (representative of MC Consult SRL) serves as Vice President of Human Resources of the Company. He started his career at Price Waterhouse (now PricewaterhouseCoopers) as auditor in 1989. He also went in rotational assignment in Congo during 2 years on consulting missions for the World Bank. In 1995, he joined Fourcroy as plant controller. Then, he joined Dow Corning in 1997 where he held different positions in Finance and Human Resources. He led the HR operations in Europe, became the HR manager for Dow Corning in Belgium, and HR Business Partner for the sales and marketing functions globally. As a member of the sales and marketing Leadership teams, he contributed to Dow Corning’s major transformation initiatives to increase organizational effectiveness, employees’ engagement & performance as well as Business results. Mr. Nobels holds a Master’s Degree in Economics from the University of Namur. Frédéric Lehmann (representative of ImXense SRL) serves as Vice President Clinical Development & Medical Affairs of the Company. Dr. Lehmann is a physician by training, specialized in hematology and oncology. Dr. Lehmann has extensive experience in oncology drug development spanning early to late phase, including clinical trial design, translational research, regulatory interactions, and clinical risk management. He started his academic career at the Ludwig Institute for Cancer Research in Brussels, followed by a position at the Institute Jules Bordet. He then moved to the European Organization for Research and Treatment of Cancer (EORTC) as Medical Advisor. Dr. Lehmann began his corporate career at GlaxoSmithKline, where he led the early worldwide clinical development program for the Company’s cancer vaccines and went on for cancer immunotherapeutics. the research and development incubator lead to Page 46 | 180 2021 Annual Report David Gilham serves the Company as Chief Scientific Officer. Dr. Gilham obtained his Ph.D from the University of Dundee, UK under the supervision of Professor Roland Wolf OBE working on cytochrome P4502D6 and Parkinson’s disease. In 1996, Dr. Gilham was recruited to work with Professor Robert Hawkins at the University of Bristol, UK to work on chimeric antigen receptor (CAR) T cells as a part of the Chimeric Eurocell European Programme lead by Prof Zelig Eshhar. In 1998, the group moved to the Paterson Institute for Cancer Research, University of Manchester. The group maintained a strong translational focus delivering several clinical trials of CAR T (including the first such trial to be initiated in the UK) while developing a strong basic research core activity including the ATTACK European Programme that drew together colleagues working in T cell therapy across Europe. Along with achieving academic independence and promotion to Senior Fellow, Dr. Gilham took over the leadership of the laboratory group in 2009. The group moved to the Institute of Cancer Sciences, University of Manchester based within the Manchester Cancer Research Centre in 2015 and Dr. Gilham was appointed Reader in 2016. In September 2016, Dr. Gilham moved to the role of Vice President at Celyad to continue working upon immune based therapies for cancer and appointed to Chief Scientific Officer in May 2020. Stephen Rubino, Ph.D., serves the Company as Chief Business Officer. Dr. Rubino brings over 30 years of pharmaceutical leadership experience to the role of Chief Business Officer, with emphasis in the areas of business development and licensing, new product development, commercial operations, pharmaceutical strategy and investor relations. Dr. Rubino currently serves as an independent board member of Sermonix Pharmaceuticals and Viracta Therapeutics. Dr. Rubino has also served Novartis Pharmaceuticals in a wide range of roles and therapeutic areas, the last of which was as Global Head of Business Development and New Product Marketing, responsible for developing and building the product pipeline for Novartis’ Cell & Gene Therapies Unit. Prior to Novartis, Dr. Rubino worked for Schering–Plough (Merck) where his last role was head of the Global Solid Tumor Oncology & Autoimmune Business Unit responsible for the licensing and launch of Remicade, as well as the launch and commercialization of several global oncology brands. Dr Rubino has also previously served as Chief Business & Strategy Officer at Omega Therapeutics and Entrepreneur in Residence at Fortress Biotech. He has also previously served as a Director at Canada- based Ilkos Therapeutics Inc. between 2017 and 2020 and U.S.-based Sermonix Pharmaceutical Inc. between 2019 and 2021. Dr. Rubino received his Ph.D. from Weill Cornell University (New York) and his Master of Business Association from Baruch University (New York). Charles Morris, Ph.D., serves the Company as Chief Medical Officer. Dr. Morris is a medical oncologist with over 20 years of oncology drug development experience in the international biotech and pharmaceutical space. Prior to joining Celyad Oncology, Dr. Morris served as Chief Medical Officer of Radius Health and held leadership positions at PsiOxus Therapeutics, ImmunoGen Inc and Allos Therapeutics, where he contributed to all phases of development for solid and hematological tumor indications, as well as life-cycle management development activities for FOLOTYN (pralatrexate) while at Allos. Before serving in these positions, he was Vice President of Worldwide Clinical Research at Cephalon, Inc., where he helped the company achieve its first oncology drug approval for Treanda® (bendamustine). He spent the early years of his career in various roles at AstraZeneca, where he significantly contributed to the worldwide development of Faslodex (fulvestrant), co-authored multiple publications regarding fulvestrant and breast cancer, and supported early clinical development activities for Iressa® (gefitinib). Dr. Morris holds a Bachelor of Medicine, Bachelor of Surgery and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics degree from Sheffield University Medical School in the UK and is a Member of the Royal College of Physicians of London. Page 47 | 180 2021 Annual Report 2.4 Conflict of Interest of Directors and members of the Executive Committee and transactions with affiliated companies 2.4.1. General Each Director and member of the Executive Committee is encouraged to arrange his or her personal and business affairs so as to avoid direct and indirect conflicts of interest with the Company. The Company's Charter contains specific procedures to deal with potential conflicts. 2.4.2. Conflicts of interest of Directors The Article 7:96 of the CCA provides for a special procedure within the Board of Directors in the event of a possible personal financial conflict of interest of one or more directors with one or more decisions or transactions to be adopted by the Board of Directors. In the event of a conflict of interest, the director concerned must inform his or her fellow directors of his or her conflict of interest before the Board of Directors deliberates and takes a decision in the matter concerned. Furthermore, the conflicted director may not participate in the deliberation and voting by the Board of Directors on the matter that gives rise to the potential conflict of interest. The minutes of the meeting of the Board of Directors must contain the relevant statements made by the conflicted director, as well as a description by the Board of Directors of the conflicting interests and the nature of the relevant decision or transaction to be adopted. The minutes must also contain a justification by the Board of Directors for the decision or transaction adopted, and a description of the financial consequences thereof for the Company. The relevant minutes must be included in the (statutory) annual report of the Board of Directors. The Company must notify the Statutory Auditor of the conflict. The Statutory Auditor must describe in its statutory annual audit report the financial consequences of the decision or transaction that gave rise to the potential conflict. This procedure does not apply to decisions or transactions in the ordinary course of business at customary market conditions. 2.4.3. Existing conflicts of interest of members of the Board of Directors Except as reported hereinafter, as far as the Company is aware, none of the Directors have a conflict of interest within the meaning of Article 7:96 of the CCA which has not been disclosed to the Board of Directors. Other than potential conflicts arising in respect of compensation-related matters, the Company does not foresee any other potential conflicts of interest in the near future. In 2021, certain members of the Board declared a conflict of interest. The following declaration were made in that respect: Excerpt from the minutes of the Board meeting of January 23, 2020: “The article 7:96 of the BCAC provides that “if a director has, directly or indirectly, a conflicting financial interest in a decision or operation to be decided by the board of directors, he has to inform the other directors before the deliberation of the board of directors. His declaration, including the reasons for his conflicting financial interest, must be recorded in the minutes of the board meeting that will take the decision. The auditor must also be informed. The concerned directors cannot deliberate nor vote on the concerned decisions”. Maria Koehler informed the other directors that he has a conflicting financial interest in the proposed decision on her remuneration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the Belgian Code of the Companies and Associations. Maria Koehler left the videoconference, and the Board unanimously approved the payment of 5,000 EUR to Maria Koehler in compensation of her significant scientific and consulting services rendered to the CEO and to the Company in addition to her Board duties. Page 48 | 180 2021 Annual Report Maria Koehler then came back to the videoconference.” “The Board discussed the allocation of warrants to Board members: - Michel Lussier (10,000 warrants); - Hilde Windels (10,000 warrants); - Maria Koehler (10,000 warrants); - Serge Goblet (10,000 warrants); - Chris Buyse (10,000 warrants); - Rudy Dekeyser (10,000 warrants); - Dominic Piscitelli (10,000 warrants); - Marina Udier Blagovic (10,000 warrants). The warrants will be offered under the Warrants Plan 2019. Each warrant will give the right to its owner to acquire one new share of the Company. The exercise price will be equal to the fair market value of the Company’s shares at the time of the offer, this value corresponding to the closing price of the share on the day before the date of the offer. The article 7:96 of the BCAC provides that “if a director has, directly or indirectly, a conflicting financial interest in a decision or operation to be decided by the Board of Directors, he has to inform the other directors before the deliberation of the Board of Directors. His declaration, including the reasons for his conflicting financial interest, must be recorded in the minutes of the board meeting that will take [...] the decision. The auditor must also be informed. The concerned directors cannot deliberate nor vote on the concerned decisions”. Michel Lussier informed the other directors that he has a conflicting financial interest in the decision proposed. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Michel Lussier left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Michel Lussier. Michel Lussier then came back in the meeting room. Serge Goblet informed the other directors that he has a conflicting financial interest in the decision proposed. The Chairman thanked Serge Goblet for his declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Serge Goblet left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Serge Goblet. Serge Goblet then came back in the meeting room. Chris Buyse informed the other directors that he has a conflicting financial interest in the decision proposed. The Chairman thanked Chris Buyse for his declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Chris Buyse left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Chris Buyse. Chris Buyse then came back in the meeting room. Rudy Dekeyser informed the other directors that he has a conflicting financial interest in the decision proposed. The Chairman thanked Rudy Dekeyser for his declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Rudy Dekeyser left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Rudy Dekeyser. Rudy Dekeyser then came back in the meeting room. Hilde Windels informed the other directors that she has a conflicting financial interest in the decision proposed. The Chairman thanked Hilde Windels for her declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Hilde Windels left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Hilde Windels. Hilde Windels then came back in the meeting room. Page 49 | 180 2021 Annual Report Maria Koehler informed the other directors that she has a conflicting financial interest in the decision proposed. The Chairman thanked Maria Koehler for her declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Maria Koehler left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Maria Koehler. Maria Koehler then came back in the meeting room. Dominic Piscitelli informed the other directors that he has a conflicting financial interest in the decision proposed. The Chairman thanked Dominic Piscitelli for his declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Domonic Piscitelli left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Dominic Piscitelli. Dominic Piscitelli then came back in the meeting room. Marina Udier informed the other directors that she has a conflicting financial interest in the decision proposed. The Chairman thanked Marina Udier for her declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Marina Udier left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Marina Udier. Marina Udier then came back in the meeting room.” Excerpt from the minutes of the Board meeting of August 4, 2021: “The Board acknowledged the resignation of Maria Koehler as member of the Board with effective date as of August 5, 2021. The Board discussed the warrants allocated to Maria Koehler. The article 7:96 of the BCAC (Belgian Company Code of Companies and Associations) provides that “if a director has, directly or indirectly, a conflicting financial interest in a decision or operation to be decided by the board of directors, he has to inform the other directors before the deliberation of the board of directors. His declaration, including the reasons for his conflicting financial interest, must be recorded in the minutes of the board meeting that will take [...] the decision. The auditor must also be informed. The concerned directors cannot deliberate nor vote on the concerned decisions”. Maria Koehler informed the other directors that he has a conflicting financial interest in the decision proposed since it is envisaged to waive the condition of presence imposed by the warrants plans of the Company in favor of Mrs. Koehler. This waiver would concern the warrants that have been allocated to Mrs. Koehler and that are not already vested. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Maria Koehler left the videoconference. The Board expressly waived the condition of presence imposed by the warrants plans of the Company in favor of Maria Koehler, meaning that Maria Koehler will be allowed to exercise all her warrants during the exercise periods provided by the plans, even if she stopped his professional activities in favor of the Company on August 5, 2021, and even if her warrants have not been fully vested. The Board decided to grant power of attorney to Adrien Lanotte and/or to any other attorney from the law firm Harvest, located at 100 Boulevard du Souverain, 1170 Brussels, each with authorization to act on his own and with power to sub-delegate, to sign and fill in all documents and to take all necessary steps regarding public administration and third parties, with a view to proceeding to all required formalities for the implementation of the above-adopted resolutions and their publishing in the annexes to the Belgian Official Journal as well as for the revisions with Crossroads Bank for Enterprises and other public bodies. Maria Koehler comes back to the videoconference.” Page 50 | 180 2021 Annual Report Excerpt from the minutes of the Board meeting of October 7, 2021: “The Board discussed the allocation of warrants to Board members: - Michel Lussier (10,000 warrants); - Hilde Windels (10,000 warrants); - Serge Goblet (10,000 warrants); - Chris Buyse (10,000 warrants); - Rudy Dekeyser (10,000 warrants); - Dominic Piscitelli (10,000 warrants); - Marina Udier (10,000 warrants). The warrants will be offered under the 2021 Warrants Plan. Each warrant will give the right to its owner to acquire one new share of the Company. The exercise price will be equal to the fair market value of the Company’s shares at the time of the offer, this value corresponding to the closing price of the share on the day before the date of the offer. The article 7:96 of the BCAC provides that “if a director has, directly or indirectly, a conflicting financial interest in a decision or operation to be decided by the board of directors, he has to inform the other directors before the deliberation of the board of directors. His declaration, including the reasons for his conflicting financial interest, must be recorded in the minutes of the board meeting that will take [...] the decision. The auditor must also be informed. The concerned directors cannot deliberate nor vote on the concerned decisions”. Michel Lussier informed the other directors that he has a conflicting financial interest in the decision proposed. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Michel Lussier left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Michel Lussier. Michel Lussier then came back in the meeting room. Serge Goblet informed the other directors that he has a conflicting financial interest in the decision proposed. The Chairman thanked Serge Goblet for his declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Serge Goblet left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Serge Goblet. Serge Goblet then came back in the meeting room. Chris Buyse informed the other directors that he has a conflicting financial interest in the decision proposed. The Chairman thanked Chris Buyse for his declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Chris Buyse left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Chris Buyse. Chris Buyse then came back in the meeting room. Rudy Dekeyser informed the other directors that he has a conflicting financial interest in the decision proposed. The Chairman thanked Rudy Dekeyser for his declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Rudy Dekeyser left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Rudy Dekeyser. Rudy Dekeyser then came back in the meeting room. Hilde Windels informed the other directors that she has a conflicting financial interest in the decision proposed. The Chairman thanked Hilde Windels for her declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Hilde Windels left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Hilde Windels. Hilde Windels then came back in the meeting room. Dominic Piscitelli informed the other directors that he has a conflicting financial interest in the decision proposed. The Chairman thanked Dominic Piscitelli for his declaration. This declaration will be Page 51 | 180 2021 Annual Report communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Dominic Piscitelli left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Dominic Piscitelli. Dominic Piscitelli then came back in the meeting room. Marina Udier informed the other directors that she has a conflicting financial interest in the decision proposed. The Chairman thanked Marina Udier for her declaration. This declaration will be communicated to the statutory auditor of the Company and inserted in the annual report 2021 in accordance with the article 7:96 of the BCAC. Marina Udier left the meeting room and the Board unanimously approved the allocation of 10,000 warrants to Marina Udier. Marina Udier then came back in the meeting room.” 2.4.4. Related Party Transactions To date, no related party transaction involving the Company’s Directors, or the members of the Executive Committee, except section 2.4.3 above, has been disclosed to the Company. 2.4.5. Transactions with affiliates The Article 7:97 of the CCA provides for a special procedure that applies to intra-group or related party transactions with affiliates. The procedure will apply to decisions or transactions between the Company and affiliates of the Company that are not a subsidiary of the Company. It will also apply to decisions or transactions between any of the Company’s subsidiaries and such subsidiaries’ affiliates that are not a subsidiary of the Company. Prior to any such decision or transaction, the Board of Directors of the Company must appoint a special committee consisting of three independent directors, assisted by one or more independent experts. This committee provides the Board of Directors with a written report giving the motives for the decision of the envisaged operation, addressing at least the following elements: the nature of the decision or the operation, a description and an estimation of the equity consequences, a description of the eventual other consequences, the advantages and inconvenient resulting therefrom for the Company, as the case maybe. The committee puts the proposed decision or operation in the context of the strategy of the Company and determines if it causes any prejudice to the Company, if it is compensated by other elements of that strategy, or if it is manifestly abusive. The remarks of the expert are integrated in the opinion of the committee. The Board of Directors must then take a decision, taking into account the opinion of the committee. Any deviation from the committee’s advice must be explained. Directors who have a conflict of interest are not entitled to participate in the deliberation and vote. The committee’s advice and the decision of the Board of Directors must be communicated to the Company’s Statutory Auditor, who must render a separate opinion. The conclusion of the committee, an excerpt from the minutes of the Board of Directors and the opinion by the Statutory Auditor must be included in the (statutory) annual report of the Board of Directors. The procedure does not apply to decisions or transactions in the ordinary course of business at customary market conditions, and transactions or decisions with a value of less than 1% of the consolidated net assets of the Company. 2.4.6. Code of Business Conduct and Ethics 2018. In 2015, the Company adopted a Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of its employees, members of its Executive Committee and directors. It has been updated on October 5, at https://www.celyad.com/en/investors/corporate-governance. The Audit Committee is responsible for overseeing the Code of Conduct and is required to approve any waivers of the Code of Conduct for employees, members of its Executive Committee and directors. the Company’s website of Conduct The Code available on is Page 52 | 180 2021 Annual Report 2.4.7. Market abuse regulations On June 17, 2013, the Board of the Company defined specific rules to prevent the illegal use of inside information by board members, shareholders, managers and employees or the appearance of such use (“the Market Abuse Policy”). The Market Abuse Policy is regularly reviewed and updated by the Board of Directors and is available on the Company’s website. The Policy applies to all holders of inside information. An insider can be given access to inside information within the scope of the normal performance of his or her duties. The insider has the strict obligation to treat this information confidentially and is not allowed to trade financial instruments of the Company to which this inside information relates. In accordance with art 25bis §1 of the law of August 2, 2002 and the EU Regulation 596/2014 of April 16, 2014 on market abuse (the “MAR”), the Company has established a list of persons in the Company who, based on an employment or service agreement, have contracted with the Company and have during the course of their duties access to inside information directly or indirectly. This list is updated regularly and remains at the disposal of the FSMA for a period of 5 years. 2.5 Corporate Governance Code The Company's Board of Directors complies with the principles of the CCG. However, the Company deviates from the following principles: • Remuneration in company’s shares (principle 7.6): as per applicable laws, the Company does not meet the legal requirements to proceed with a shares buy-back and, consequently does not own treasury shares, and therefore, is not able to grant a portion of non-executive directors’ remuneration in company’s shares; • No grant of stock options to independent directors (principle 7.6): since the Company is not able to offer treasury shares, independent directors may be allocated a fixed number of subscription rights (warrants). This allocation of warrants is not related to any performance criteria. As further detailed in the Company’s Remuneration Policy, this allocation is aimed at attracting highly skilled non- executive directors in a highly dynamic and competitive market; • Absence of minimum detention of shares (principle 7.9): the Company has not fixed any minimum threshold for the detention of shares by the members of the Executive Committee, since the Company does not own treasury shares and does not have the possibility to offer shares for free. However, the members of the Executive Committee hold subscription rights (warrants) on the Company’s shares as described in the Remuneration Report; • No clawback (principle 7.12): at the date of this report, the Company has not adopted any clawback provision to claim variable remuneration from the Executive Committee members, given the practice of the industry in which the Company operates and the difficulties to recruit in this competitive environment. The Company has not adopted a diversity policy. The talents market is particularly tense and dynamic in the biopharmaceutical industry and developing a diversity policy adjusted to this fast-changing environment was not deemed to be the best instrument to meet the Company’s challenges in human resources. Over the past years, the Company has successfully achieved a broad degree of diversity from a gender, citizenship, expertise and educational background perspective at the Company’s Board of Directors, Executive Committee, Management and staff levels. The Company has attracted talents from various countries which reflects the Company’s international footprint to support the Company’s strategy. At the Board of Directors, the Company complies with Belgian laws on gender with at least one third of the members who are from a different gender. One Board member is Canadian, three are Americans, one is Americano-Croatian, and four are Belgians. Page 53 | 180 2021 Annual Report At the Executive Committee, two members are Americans, one is English, and three are from Belgium. The Company will pursue its efforts to increase the female presence at the Executive Committee. The Management team is composed of 16 members, where the Company counts 43.7 % (7) of female and 56.3% (9) of male. Those managers or directors have different nationalities (from Belgium, Mexico, and the US). Regarding the employees not included above the Company records 53% female employees and 47% male employees. In accordance with the CCG, the Board of Directors of the Company will review its Charter from time to time and make such changes as it deems necessary and appropriate. The Charter, together with the Company’s articles of association, is available on the Company's website (www.celyad.com) and can be obtained free of charge at the registered office of the Company. 2.6 Remuneration Policy 2.6.1. Introduction The remuneration policy of the Company (the “Policy”) has been approved at the shareholders meeting of May 5, 2021. The Policy is established to be competitive in the (employment) markets in which the Company operates, mainly the United States and Europe. The approach taken by the Company is to apply a remuneration policy which is overall balanced and allows tailoring individual remuneration packages to ensure a fair and competitive remuneration for the (job)market in which our key persons operate. The Company believes this adds to the long-term value creation for all our stakeholders. testing and eventually commercializing As a clinical-stage biotechnology company, the Company aims at achieving a strategy involving discovering, developing, (potential) product candidates. Successful implementation of this strategy requires an intense long-term effort of highly qualified persons. As such, this Policy is aimed at attracting and retaining highly qualified persons for executive and non-executive positions on our Board of Directors as well as executive management and to motivate them to contribute to our long- term goals and strategy. 2.6.2. Remuneration of the Board of Directors 2.6.2.1 Principles The Policy is aimed at attracting non-executive directors with the most relevant skills, knowledge and expertise in a highly competitive and quickly evolving industry. The Policy will help the Company attract and retain a diverse and international team of non-executive directors, striking a balance between scientific, financial, operational and strategic contributions, promoting an open, fair, sustainable and equitable company culture, driven by success. The remuneration of the non-executive Directors is determined by the Shareholders’ Meeting upon proposal of the Board of Directors based on a recommendation from the Nomination and Remuneration Committee. The Nomination and Remuneration Committee benchmarks non-executive Directors' compensation against peer companies to ensure that it remains fair and competitive. The Directors’ remunerations are therefore market driven. 2.6.2.2 Components The Policy is based on the following fixed components: Page 54 | 180 2021 Annual Report (a) A fixed fee, consisting of a base fee and an additional fee if the non-executive director is the Chairman of the Board or any of its Committees or if the non-executive Director is a member of a Board Committee; (b) Warrants. The remuneration of non-executive Directors does not contain any variable part and is not based on any performance conditions. As the Company has no distributable reserves, it does not meet the legal requirements to proceed to a shares buy-back, therefore does not own treasury shares and is then currently unable to grant shares to the non-executive directors as part of their remuneration. This is a deviation from principle 7.6 of the CCG. Fixed fee The fixed fee of non-executive directors consists of: (a) A fixed annual fee (retainer) of 18,000 EUR (36,000 EUR for the Chairman of the Board), including the four annual, ordinary Board meetings; (b) A supplemental fixed fee of 3,000 EUR (5,000 EUR for the Chairman of the Board) for the participation to extraordinary Board meetings of more than 2 hours, and 1,500 EUR (2,500 for the Chairman of the Board) for the participation to extraordinary Board meetings of less than 2 hours; (c) A supplemental fixed annual fee (retainer) of 15,000 EUR for membership of each Committee of the Board of Directors, increased by 5,000 EUR for the Chairmanship of such Committee; (d) An extraordinary fee of €3,000 for specific assignments to a non-executive director, on request of the CEO and with prior approval of the Board of Directors. The Board fees are paid in quarterly installments at the end of each subsequent calendar quarter. The Company will also reimburse out-of-pocket expenses (such as, without limitation, travel, meals and lodging expenses) incurred by directors in direct relation with their Board duties. Warrants In deviation from the principle 7.6 of the CCG, the Board has determined that the grant of warrants to non- executive or independent directors is in the best interest of the Company to attract and retain highly skilled directors in a very dynamic and competitive environment. The grant of warrants is a commonly used remuneration instrument in the sector in which the Company operates, in particular in the United States where the Company is active. In addition, the Company is not entitled to own treasury shares (see above) and is currently unable to offer any remuneration in shares. Finally, the grant of warrants provides an attractive additional remuneration without impacting the Company’s cash. Without this possibility, the Company would be subject to a considerable disadvantage compared to competitors offering warrants to their non-executive directors. The grant of warrants is not linked or subject to any performance conditions and consequently, does not qualify as variable remuneration. The warrants are usually issued by decision of the Board of Directors within the framework of the authorized capital (but can also be issued by decision of the Shareholders’ Meeting). The warrants are then offered to non-executive directors by decision of the Board of Directors upon recommendation of the Nomination and Remuneration Committee. Conflict of interest procedure applies to such decision of the Board. Each warrant gives its holder the right (but not the obligation) to subscribe, under the exercise conditions, during the exercise periods and against payment of the exercise price, to one Company’s share. Page 55 | 180 2021 Annual Report Company’s warrants are granted for a limited term. This term is determined by the Board of Directors, in compliance with the CCA, with a maximum of ten years. The warrants have a vesting period of minimum three (3) years and may be exercised to the extent vested. Shares obtained through the exercise of warrants are freely transferrable. The exercise price is equal to the fair market value of the Company's shares at the time of the offer. This value is determined by the Board of Directors and corresponds to either the closing price of the Company's share on the day before the date of the offer or the average of the thirty (30) calendar days preceding the date of the offer of the closing price of the Company's Share. The warrants can be immediately exercised by the beneficiaries in the following situations: (a) Share capital increase in cash without suspension of the preferential rights of the existing shareholders; (b) Takeover bid on the shares of the company as of the announcement of the public offer by the FSMA; (c) Change of control on the company; (d) Conclusion of a “strategic partnership” with an important industrial actor, active in the life-science sector, and if the “strategic partnership” is qualified as such by the board of directors. For further details on the terms and conditions of our warrants plans, we refer to the plans available on our website and as may be amended from time to time. 2.6.2.3 Contract terms and conditions The directors' mandate may be terminated "ad nutum" (at any time) without any form of compensation. There is no specific agreement between the Company and non-executive directors which waives or restrains the right of the Company to terminate “ad nutum” (at any time) the mandates of the directors. The Company has signed with its directors an engagement letter consistent with the terms of this Policy. 2.6.3. Remuneration of the Executive Committee 2.6.3.1 Principles The Company’s remuneration Policy for the members of its Executive Committee is aimed at attracting, motivating, and retaining top talents in a very competitive and international environment to deliver our strategic and operational objectives. The Company’s aim is therefore to be competitive against peer companies in its markets, to incentivize performance and not to discriminate on any manner. The remuneration Policy is driven by the employees’ and the Company’s performance. The remunerations are based on market benchmarks. The remuneration of the members of the Executive Committee is determined by the Board of Directors based on recommendations made by the Nomination and Remuneration Committee, further to a recommendation made by the CEO to the Nomination and Remuneration Committee (except where his own remuneration is concerned). The Nomination and Remuneration Committee takes into consideration the employment conditions of employees and ensures that the remuneration of the Executive Committee remains proportionate to the remuneration of the employees, taking into consideration the degree of responsibility of the Executive Committee. Both the members of Executive Committee and employees’ remunerations are market driven. For employees, the Company’s remuneration is based on an independent benchmark done by a reputed Page 56 | 180 2021 Annual Report international firm. The benchmark includes data points from biotech, medium and large pharmaceutical companies and is performed on an annual basis. 2.6.3.2 Components The remuneration of the Executive Committee is based on the following fixed and variable components: (a) Base fixed remuneration ; (b) Variable annual cash remuneration; (c) Pension; (d) Fringe benefits; and (e) Warrants. The structure of the remuneration of Executive Committee members consists in an appropriate balance between fixed and variable remuneration. The nature and magnitude of the variable remuneration is structured to align the interests of the Executive Committee members with the sustainable value-creation objectives of the Company. Pension and other fringe benefits complete the remuneration package in line with market practice. The actual relative weights of the components of the remuneration package depends on the achievement of the performance criteria, the role and the location of each Executive Committee member as specified below, and aims at ensuring remuneration packages that are competitive and in line with market practice. Base Fixed Remuneration Each member of the Executive Committee is entitled to a base fixed remuneration designed to fit responsibilities, relevant experience, and competences, in line with market rates for equivalent positions. Variable Annual Cash Remuneration The base amount of the variable remuneration is based on the Company’s performance and the individual performance of the Executive Committee members measured against the individual and Company’s objectives. For the CEO, the variable remuneration is based on 75% of the Company performance and 25% of individual performance. For the other members of the Executive Committee, the variable remuneration is based on 50% of Company performance and 50% of individual performance. The variable compensation represents 30% of the fixed compensation at target for non-US members, 35% to 40% of the fixed compensation at target for US-based members and 45% of the fixed compensation at target for the CEO. Those target percentages may be multiplied by a factor from 0% to 200%, depending on the individual performance. The Variable Annual Cash Remuneration is therefore subject to an absolute cap of 200% of the fixed compensation, in line with principle 7.10 of the CCG. The Company objectives are determined annually by the Board of Directors, ultimately at the start of the period in which the incentive may be earned. The individual performance of each member of the Executive Committee is determined by an annual assessment between the individual and the CEO (or, for the CEO, between the CEO and the Chairman of the Board). It consists of SMART (Specific, Measurable, Actionable, Realistic, Time driven) and challenging objectives. Those individual objectives are aligned and consistent with the Company’s strategic objectives. The performance assessment leads to a score that will define the overall individual performance and is Page 57 | 180 2021 Annual Report determined by the Board of Directors upon recommendation of the Nomination and Remuneration Committee. The Company’s objectives are aligned with the Mission and the Vison of the Company and contribute to the Company’s strategy, the enhancing of patients’ well-being and life and shareholders value creation, while maintaining a solid cash position. The Company’s objectives are typically based on a combination of various elements: • Clinical Product Testing and Development - Clinical trial activity (operational and medical) - Regulatory - Manufacturing - Translational Analysis • Pre-Clinical Product Development - Clinical (Protocol Development) - Regulatory (IND/CTA submission) - Manufacturing (Clinical Process Development) - Quality Assessment and Quality Control (CMC) • R&D Engine - Pre-clinical Product and Platform Development - - Target identification and validation Intellectual property creation • External Visibility - Peer reviewed and corporate publications - - Invited presentations Investors relations/media • Company funding, cash runway and the efficient use of financial and non-financial resources against budget • External partnership development and collaboration The Company’s and the individual’s performances are assessed in the first quarter of each calendar year by the Board of Directors. The variable compensation is paid to the members of the Executive Committee in the first quarter of the following year upon decision of the Board of Directors. In deviation from principle 7.12 of the CCG, there is no possibility for the Company to reclaim the variable remuneration. Pension Each member of the Executive Committee who is an employee of the Company is entitled to the participation to pension plans with defined contributions. For Belgium-based members of the Executive Committee, defined contributions pensions are paid in a Group Insurance plan which also includes a health insurance and a life insurance. Page 58 | 180 2021 Annual Report US-based members of the Executive Committee participate to an employer-sponsored defined-contribution pension account defined in subsection 401(k) of the Internal Revenue Code disability insurance and life insurance. The members of the Executive Committee who are engaged through services or consulting agreements are not entitled to a group insurance plan, or to an employer-sponsored defined-contribution pension account defined in subsection 401(k) of the US Internal Revenue Code, or to a health insurance plan. Fringe benefits Each member of the Executive Committee is entitled to several fringe benefits which may include: (a) A company car; (b) A lump-sum expense allowance; (c) If required by their specific social or tax status, a housing allowance, tax advisory services, relocation allowances, schooling allowances; (d) The reimbursement of other expenses related to their responsibilities in the company. On an exceptional basis and depending on the employment market conditions, a sign on bonus may be granted when a member of the Executive Committee is hired. The sign on bonus is approved by the Board of Directors based on recommendations made by the Nomination and Remuneration Committee. Warrants The Company may from time to time offer to the members of the Executive Committee to participate to a warrants plan at the discretion of the Board of Directors. The warrants are usually issued by decision of the Board of Directors within the framework of the authorized capital (but could also be issued by decision of the Shareholders’ Meeting). The warrants are then offered to each member of the Executive Committee by decision of the Board of Directors upon recommendation of the Nomination and Remuneration Committee. Each warrant gives its holder the right (but not the obligation) to subscribe, under the exercise conditions, during the exercise periods and against payment of the exercise price, to one Company’s share. The number of warrants offered to each of the beneficiaries is freely determined by the Board of Directors, acting upon the recommendation of the Nomination and Remuneration Committee. The number of warrants is based on a benchmarking exercise regularly performed to ensure that the grants are competitive and in line with market practice. When the offer of warrants is based on the individual performance of the member of the Executive Committee, the performance scores range from 1 (underperforming) to 5 (exceeding performance): (a) If the performance score is 1, the number of warrants is zero; (b) If the performance score is 2, the number of warrants is multiplied by a factor between 50% to 90%; (c) If the performance score is 3, the number of warrants is multiplied by a factor of 100%; (d) If the performance score is 4, the number of warrants is multiplied by a factor between 100% and 125%; (e) If the performance score is 5, the number of warrants is multiplied by a factor between 125% and 150%. In principle, the performance score is based on an assessment of the individual performance over one year. Yet, the vesting period of minimum three (3) years applied on the warrants, whose value is notably impacted by the performance of the Executive Committee, implies that the Company complies with a long term view for a major portion of the variable remuneration of the members of the Executive Committee. Page 59 | 180 2021 Annual Report Under our incentive plans, warrants are granted for a limited term. This term is determined by the Board of Directors, in compliance with the provisions of the CCA with a maximum of ten years. The warrants have a vesting period of minimum three (3) years and may be exercised to the extent vested. Shares obtained through the exercise of warrants are freely transferrable. The exercise price is equal to the fair market value of the Company's shares at the time of the offer. This value is determined by the Board of Directors and corresponds to either the closing price of the Company's share on the day before the date of the offer or the average of the thirty (30) calendar days preceding the date of the offer of the closing price of the Company's Share. The warrants can be immediately exercised by the beneficiaries in the following situations: (a) Share capital increase in cash without suspension of the preferential rights of the existing shareholders; (b) Takeover bid on the shares of the company as of the announcement of the public offer by the FSMA; (c) Change of control on the company; (d) Conclusion of a “strategic partnership” with an important industrial actor, active in the life-science sector, and if the “strategic partnership” is qualified as such by the board of directors. For further details on the terms and conditions of our warrants plans, we refer to the plans available on our website and as may be amended from time to time. In deviation from the principle 7.9 of the CCG, the Company has not fixed any minimum threshold for the detention of shares by the members of the Executive Committee. However, the members of the Executive Committee hold subscription rights (warrants) on the Company’s shares as described in above in this Remuneration Policy, enabling them to hold shares in the Company. 2.6.3.3 Contract terms and conditions The members of the Executive Committee are engaged based on a services agreement or an employment contract. Labour law applies to the contractual arrangements with the members of the Executive Management engaged on an employment contract. When the member of the Executive Committee is engaged on a services agreement, it generally provides for a notice period of six months and for the possibility to terminate the agreement with cause and without indemnity. No specific severance clauses are agreed as a rule, except when duly justified after recommendation of the Nomination and Remuneration Committee. There is no specific additional individual plan regarding supplementary pension or early retirement schemes put in place for the members of the Executive Committee. 2.6.4. Deviations from this Policy The Board has the authority to temporarily deviate from this Policy in case of exceptional circumstances, primarily those in which deviation is necessary to serve the long-term interests and sustainability of the company or to guarantee the viability of the company. Should there be a need to deviate from this remuneration Policy, the CEO will bring substantiated arguments to the Nomination and Remuneration Committee for recommendations and approval by the Board of Directors. Any deviations from this policy will be described in the Remuneration report. Page 60 | 180 2021 Annual Report 2.7 Remuneration report 2.7.1. Introduction In 2021, the remuneration of the Board of Directors was based on a fixed remuneration and a fixed grant of warrants, whereas the remuneration of the Executive Committee members was based on a base fixed remuneration, a variable annual cash remuneration, fringe benefits and long-term share-based incentives (warrants). The variable remuneration of the Executive Committee members was calculated based on the Company and the individual’s performance. The Company’s performance was measured against the Company’s objectives, and the Executive Committee members’ performance, against their individual objectives. The Company’s objectives have been determined by the Board of Directors at the beginning of the year. For 2021, the Board of Directors has decided to establish the Company’s performance at 90%, reflecting the level of achievement of the Company’s objectives based on the execution of our CYAD-02, CYAD-101 and CYAD-211 clinical programs, the building of our long-term shRNA pipeline, our licensing and business development, and the financing of the Company, taking once again into consideration the challenging sanitary conditions faced in 2021 with the pandemic of COVID-19. The individual performance of each member of the Executive Committee has been determined by an individual assessment between the Executive Committee member and the CEO (or, for the CEO, between the CEO and the Chairman of the Board). The assessment of the Executive Committee member and the CEO was reviewed by the Nomination and Remuneration Committee which made a recommendation to the Board of Directors for final decision. The CEO did not participate to any decision regarding his own individual performance. For the CEO, the variable remuneration is based on 75% of the Company performance and 25% of individual performance. For the other members of the Executive Committee, the variable remuneration is based on 50% of Company performance and 50% of individual performance. The variable compensation represents 30% of the fixed compensation at target for non-US members, 35% or 40% of the fixed compensation at target for US-based members and 45% of the fixed compensation at target for the CEO. Those target percentages may be multiplied by a factor from 0% to 200%, depending on the individual performance. Therefore, the following formula has been used to calculate the amount of the variable remuneration: (Annual salary/fee x % contractual bonus x % Company performance x ratio Company performance%) PLUS (Annual compensation/fee x % contractual bonus x % linked with the individual performance x ratio Individual performance). In 2021, the Board of Directors, upon recommendation of the Nomination and Remuneration Committee, has also decided to offer to the members of the Executive Committee the opportunity to participate to a warrants plan. Reference is made to the section 2.5 of this Annual Report regarding the deviations from certain principles of the CCG relative to the remuneration of the Board of Directors and the Executive Committee. In the wave of the shareholders’ rights reform, the company complied with the new standardized remuneration report as presented by the EU Commission currently as a draft (Draft Guidelines on the standardized presentation of the remuneration report under Directive 2007/36/EC, as amended by Directive (E1U) 2017/828, as regards the encouragement of long-term shareholder engagement). Page 61 | 180 2021 Annual Report The Company seeks to improve permanently the quality and transparency of its remuneration to the Board and to the Executive Committee and to take into account the observations of its shareholders or proxies. The remuneration Policy and this remuneration report provide for a greater degree of disclosure and transparency on all the components of the remuneration of the Board and the Executive Committee, and the link between the remuneration and the performance of the Company. The total remuneration of the Board of Directors, the CEO and the Executive Committee members is detailed hereinafter. 2.7.2. Total Remuneration In this Section, the Total Remuneration Tables are structured as follows: Table 1 - Total Remuneration (1) 1. Fixed Remuneration 2. Variable Remuneration Name, Position (2) Fixed Fees Board Fees Others Benefits (3) One Year Variale (4) Multi Year Variable (5) 3. Extraordinary items (6) 4. Pension Expense (7) 5. Total remuneration 6. Proportion of fixed & Variable Remuneration (8) (1) All components of remuneration are reported in gross amounts (2) If the officer has not been in service for the entire year of the report, the start date and/or the date of the end of his contract must be informed (3) This component includes death and disability benefits, medical expenses and other additional benefits (4) The amount reported is equal to the monetary value of the variable remuneration acquired during the year reported (2021) (5) Benefit in kind on granted warrants – according to the Belgian Act of 26 March 1999. (6) Extraordinary items paid in 2021: the grants of warrants are reported under this section, considered as extraordinary, fixed items of the remuneration. (7) The reported amount contains all contributions that were actually paid by the employer during the year to pension plans. (8) Relative share of fixed remuneration = [Fixed remuneration + cost of pension] / [Total remuneration] Relative share of variable remuneration = [Variable remuneration] / [Total remuneration] 2.7.2.1 Total Remuneration of the Board of Directors Table1 - Total remuneration (1) 2. Variable remuneration 3. Extraordinary items awarded in Name, Position (2) 1. Fixed remuneration Base salary Board fees Other benefits (3) One year variable (4) Multi- year variable (5) Mel Management (permanent representative Lussier Michel) Buyse Chris R.A.D Life Sciences (permanent € 81 000 € 46 500 € 33 000 4. Pension expense (7) 2021 (6)1 a) BIK on fixed grants warrants 5. Total Remuneration 6. Proportion of fixed and variable remuneration (8) b) Warrants awarded a) € 16 970 b) 30 000 a) b) a) b) € 16 970 30 000 € 6 730 10.000 (1) € 97 970 € 63 470 € 39 730 Fixe 100% Variable 0% Fixe Variable Fixe Variable 100% 0% 100% 0% Page 62 | 180 representative : Dekeyser Rudy) Windels Hilde € 63 000 Goblet Serge € 33 000 Koelher Maria (out 5 Aug 2021) € 18 000 Piscitelli Dominic € 65 000 Udier Marina € 33 000 Patel Ami (In 08- Dec-21) € 0 Grand Total € 372 500 2021 Annual Report Fixe Variable Fixe Variable Fixe Variable Fixe Variable Fixe Variable Fixe Variable € 63 000 € 43 480 € 18 000 € 65 000 € 33 000 € 423 650 100% 0% 100% 0% 100% 0% 100% 0% 100% 0% 0% 0% a) b) a) b) a) b) a) b) a) b) a) b) (2) € 10 480 20.000'(3) 20 000 30 000 30 000 (4) € 51 150 (1) 30.000 warrants were awarded during 2021 but 20.000 declined by the board member in 2021 (2) 30.000 warrants were awarded during 2021 but declined by the board member in 2021 (3) 30.000 warrants were awarded during 2021 but 10.000 warrants declined by the board member in 2021 (4) not applicable – non eligible In 2021, each Director, including non-executive Directors, have been offered fixed grants of 10,000 warrants. The grants were not related to any performance condition. The reasons for the variation in the number of warrants awarded (disclosed under b) are specified under footnotes (1) and (2). No taxable benefit in kind is disclosed under (a) for Directors with tax residence outside of Belgium (who are not in scope for the tax valuation under Belgian law). The details on the warrants (including the number of warrants granted, vested, and exercised, and the exercise price, can be found in the Share-Based Remuneration section below: 2.7.2.2 Total remuneration of the CEO 1. Fixed remuneration 2. Variable remuneration Table1 - Total remuneration (1) Name, Position (2) Petti Filippo - Executive, CEO Base salary Board fees Other benefits (3) '(1) One year variable (4) € 396 567 € 44 021 € 176 054 (1) Others benefits such as health insurance, … Multi-year variable on warrants granted during 2021(5) 3. Extraordi nary items (6) a) Benefit in kind b) Number of warrants c) Target value at the offer date a) b) c) € 4 565 60 000 € 307 200 4. Pension expense (7) 5. Total Remuneration 6. Proportion of fixed and variable remuneration (8) € 12 260 € 633 467 Variable Fixe 71% 29% The multi-year variable consists in the grant of warrants. The target value at the offer date may vary, depending on the share price. For the proportion between the fixed and the variable remuneration, the amount of the benefit in kind according to the Belgian Act of 26 March 1999 is taken into consideration. Page 63 | 180 2021 Annual Report 2.7.2.3 Total Remuneration of the Executive Committee (excl.-CEO) Table1 - Total remuneration (1) 1. Fixed remuneration 2. Variable remuneration Name, Position (2) Executive Committee (1) Base salary Board fees Other benefits (3) (2)'(2) One year variable (4) € 1 660 773 € 170 430 € 529 675 Multi-year variable on warrants granted during 2021(5) a) Benefit in kind b) Number of warrants c) Target value at the offer date a) b) c) € 79 635 175 000 € 990 550 3. Extraordinary items (6) 4. Pension expense (7) 5. Total Remuneration 6. Proportion of fixed and variable remuneration (8) € 31 566 € 2 472 080 Variable 25% Fixe 75% (1) Three Executive Committee members are legal entities engaged through services agreements with the Company and three Executive Committee members are natural persons. (2) Other fringe benefits are attributed to natural persons only, such as pension plan, health insurance, company car, representation allowances. The table above contains aggregate amounts for the 6 members of the Executive Committee. The multi-year variable consists in the grant of warrants. The target value at the offer date may vary depending on the share price. For the proportion between the fixed and the variable remuneration, the amount of the benefit in kind according to the Belgian Act of 26 March 1999 is taken into consideration. 2.7.2.4 Performance of Executives in the reported financial year The performance criteria, their relative weighting and the actual outcome in 2021 can be summarized as follows. The amount of the variable remuneration is based on the Company’s performance and the individual performance of the executive committee members measured against the individual and Company’s objectives. For the CEO, the variable remuneration is based on 75% of the Company performance and 25% of individual performance. For the other members of the Executive Committee, the variable remuneration is based on 50% of Company performance and 50% of individual performance. Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors has decided to grant the following variable remuneration and warrants to the CEO and the members of the Executive Committee: Name, position 1. 2. 3. Performance criteria Relative weighting of the performance criteria a) Measured performance b) Actual award outcome (cash and warrants) Company Clinical Programs shRNA platform 45% 10% a) 90% b) N/A a) 75% Page 64 | 180 CEO CEO 6 Members of the executive committee Business Development 15% Financing 25% Corporate / Other 5% Company performance 75% Individual Performance Company Performance 25% 50% 2021 Annual Report b) N/A a) 50% b) N/A a) 100% b) N/A a) 200% b) N/A a) 90% b) 128 472€ a) 100% b) 47 582 EUR + 70 000 warrants a) 90% b) 244 432EUR Individual performance 50% a) 105% in average b) 285 244 EUR +190 000 warrants 2.7.3. Share-based Remuneration The Share-Based Remuneration Tables are structured as follows: Table 2 - remuneration in Warrants The Main conditions of Warrant Plans Name of Director, position 1. Specification of plan 2. Award date 3. Vesting date 4. End of retention period 5. Exercice period 6. Exercice price Opening Balance 7. Warrants held at the beginning of the year Information regarding the reported financial year During the year (*) Closing Balance 8. a) Warrants awarded b) Price of the underlying shares @ date of the offer date 9. a) Warrants exercised b) Price of the underlying shares @date of acquisition c) Pricer @ Exercice price d) Added value @date of acquisition 10. Warrants awarded and unexercised 2.7.3.1 Board of Directors In deviation from the principle 7.6 of the CCG, the Board has determined that the grant of warrants to non- executive or independent directors is in the best interest of the Company to attract and retain highly skilled directors in a very dynamic and competitive environment. The grant of warrants is a commonly used remuneration instrument in the sector in which the Company operates, in particular in the United States where the Company is active. In addition, the Company is not entitled to own treasury shares and is currently unable to offer any remuneration in shares. Finally, the grant of warrants provides an attractive additional remuneration without impacting the Company’s cash. Without this possibility, the Company would be subject to a considerable disadvantage compared to competitors offering warrants to their non-executive directors. The grant of warrants is not linked or subject to any performance conditions and consequently, does not qualify as variable remuneration. Page 65 | 180 2021 Annual Report Table 2 - Remuneration in warrants Name of Director, position Michel Lussier, Chairman The main conditions of warrant plans Information regarding the reported financial year During the year (*) Opening Closing 1. 2. 3. 4. 5. 6. 7. WP 2021 WP 2020 WP 2020 WP 2019 WP 2019 WP 2018 WP 2017 26/10/21 26/02/21 11/12/20 28/07/20 26/10/24 N/A 26/02/24 N/A 11/12/23 N/A 28/07/23 N/A 24/10/19 24/10/22 N/A 22/01/19 22/01/22 N/A 02/08/17 02/08/20 N/A 01/01/25- 31/12/28 01/01/24- 31/12/28 01/01/24- 31/12/27 01/01/24- 31/12/25 01/01/23- 31/12/24 01/01/23- 31/12/24 01/01/21- 31/07/22 € 3,75 € 6,49 € 6,73 € 8,80 € 8,16 10 000 10 000 € 22,04 10 000 € 32,26 10 000 Total: 40 000 8. 10 000 37 500 10 000 64 900 10 000 67 300 30 000 a) b) a) b) a) b) a) b) a) b) a) b) a) b) a) b) 169 700 9. 10. 10 000 10 000 10 000 10 000 10 000 10 000 10 000 70 000 a) b) c) d) (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Name of Director , position Chris Buyse, Board Member Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closin g 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. WP202 1 26/10/21 26/10/24 WP 2020 WP 2020 WP 2019 WP 2019 WP 2018 WP 2017 26/02/21 26/02/24 11/12/20 11/12/23 24/03/20 24/03/23 24/10/19 24/10/22 22/01/19 22/01/22 02/08/17 02/08/20 N/ A N/ A N/ A N/ A N/ A N/ A N/ A 01/01/25 - 31/12/28 01/01/25 - 31/12/28 01/01/24 - 31/12/27 01/01/24 - 31/12/25 01/01/23 - 31/12/24 01/01/23 - 31/12/24 01/01/21 - 31/07/22 € 3,75 € 6,49 10 000 € 6,73 € 5,97 10 000 € 8,16 € 22,04 10 000 10 000 € 32,26 10 000 a) b) a) b) a) b) a) b) a) b) a) b) a) b) a) 10 000 37 500 10 000 64 900 20 000 Total: 50 000 b) 102 400 10 000 10 000 10 000 10 000 10 000 10 000 10 000 70 000 a) b) c) d) (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Page 66 | 180 2021 Annual Report Table 2 - Remuneration in warrants Name of Director, position Rudy De Keyser, Board Member The main conditions of warrant plans Information regarding the reported financial year During the year (*) Opening Closing 1. 2. 3. 4. 5. 6. 7. WP 2020 WP 2019 WP 2019 WP 2018 WP 2017 11/12/20 24/03/20 11/12/23 N/A 24/03/23 N/A 24/10/19 24/10/22 N/A 22/01/19 22/01/22 N/A 02/08/17 02/08/20 N/A 01/01/24- 31/12/27 01/01/24- 31/12/25 01/01/23- 31/12/24 01/01/23- 31/12/24 01/01/21- 31/07/22 € 6,73 € 5,97 10 000 € 8,16 10 000 € 22,04 10 000 € 32,26 10 000 8. 10 000 67 300 10 000 a) b) a) b) a) b) a) b) a) b) a) Total: 40 000 b) 67 300 9. 10. 10 000 10 000 10 000 10 000 10 000 50 000 a) b) c) d) (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Name of Director, position Serge Goblet, Board Member The main conditions of warrant plans Information regarding the reported financial year Table 2 - Remuneration in warrants 1. 2. 26/10/21 3. 26/10/24 11/12/20 11/12/23 24/03/20 24/03/23 24/10/19 24/10/22 22/01/22 22/01/19 02/08/17 02/08/20 WP 2021 WP 2020 WP 2019 WP 2019 WP 2018 WP 2017 4. 5. N/A 01/01/21- 31/12/28 N/A 01/01/24- 31/12/27 N/A 01/01/24- 31/12/25 N/A 01/01/23- 31/12/24 N/A 01/01/23- 31/12/24 N/A 01/01/21- 31/07/22 Opening 7. 6. € 3,75 € 6,73 € 5,97 10 000 € 8,16 10 000 € 22,04 10 000 € 32,26 10 000 Total: 40 000 a) b) a) b) a) b) a) b) a) b) a) b) a) b) During the year (*) Closing 8. 10 000 37 500 10 000 67 300 20 000 a) 104 800 b) c) d) 9. 10. 10 000 10 000 10 000 10 000 10 000 10 000 60 000 (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Name of Director, position Hilde Windels, Board Member Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 8. 1. 2. 3. 4. 5. 6. 7. 9. 10. WP 2019 24/10/19 24/10/22 WP 2018 26/10/18 26/10/21 N/A 01/01/23- 31/12/24 N/A 01/01/22- 31/12/23 € 8,16 € 22,04 10 000 10 000 Total: 20 000 a) b) a) b) a) 0 b) 0 10 000 10 000 20 000 a) b) c) d) Page 67 | 180 2021 Annual Report (*) During the year, no warrants were exercised, and no warrants expired due to the expiration of the warrant plan Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 8. 1. 2. 3. 4. 5. 6. 7. 9. 10. Name of Director, position WP 2020 Dominic Piscitelli, Board Member In : May-20 WP 2019 WP 2020 26/10/21 WP 2020 26/02/21 26/10/24 N/A 01/01/25- 31/12/28 26/02/24 N/A 01/01/25- 31/12/28 11/12/20 11/12/23 N/A 01/01/24- 31/12/27 € 3,75 € 6,49 € 6,73 20/05/20 20/05/23 N/A 01/01/24- 31/12/25 € 7,93 10 000 Total: 10 000 a) 10 000 b) 37 500 a) 10 000 b) 64 900 a) 10 000 b) 67 300 a) b) a) 30 000 a) b) 169 700 b) c) d) 10 000 10 000 10 000 10 000 40 000 (*) During the year, no warrants were exercised, and no warrants expired due to the expiration of the warrant plan Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing Name of Director, position 1. 2. 3. 4. 5. 6. 7. WP 2021 26/10/21 26/10/24 N/A WP 2020 26/02/21 26/02/24 N/A Marina Udier, Board Member WP 2020 17/12/20 17/12/23 N/A 01/01/25- 31/12/28 01/01/25- 31/12/28 01/01/24- 31/12/27 € 3,75 € 6,49 € 6,81 Total: 0 8. a) 10 000 b) 37 500 a) 10 000 b) 64 900 a) 10 000 b) 68 100 a) 30 000 a) b) 170 500 b) c) d) 9. 10. 10 000 10 000 10 000 30 000 (*) During the year, no warrants were exercised, and no warrants expired due to the expiration of the warrant plan Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Total: a) b) a) b) 0 0 a) b) c) d) of Name Director, position Ami Patel (In 08- Dec-21) * (*) Not applicable NB: Filippo Petti is not remunerated as Executive Director Page 68 | 180 2021 Annual Report 2.7.3.2 Board of Directors – Former members Name of Director, position Margo Roberts, Board Member (01/08/18- 06/05/19 Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. WP 2019 10/02/20 10/02/23 N/A WP 2018 22/01/19 22/01/22 N/A WP 2018 26/10/18 26/10/21 N/A 01/01/24- 31/12/25 01/01/23- 31/12/24 01/01/22- 31/12/23 € 9,84 10 000 € 22,04 10 000 € 22,04 10 000 Total: 30 000 a) b) a) b) a) b) a) 0 b) 0 a) b) c) d) 10 000 10 000 10 000 30 000 (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Name of Director, position Roychowdhury Debasish, Board Member (21/08/15- 06/05/19) Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. WP 2018 22/01/2019 22/01/2022 N/A 01/01/23- 31/12/24 € 22,04 10.000 WP 2017 20/07/2017 20/07/2020 N/A 01/01/21- 31/07/22 € 32,26 10.000 Total: 20.000 a) b) a) b) a) 0 b) 0 a) b) c) d) 10.000 10.000 20 000 (*) During the year, no warrants were exercised, and no warrants expired due to the expiration of the warrant plan Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 8. 1. 2. 3. 4. 5. 6. 7. 9. 10. WP 2017 20/07/2017 20/07/2020 N/A 01/01/21- 31/07/22 € 32,26 10.000 Total: 10.000 a) b) a) 0 b) 0 a) b) c) d) 10.000 10 000 Name of Director, position Hanspeter Spek, Board Member (05/05/14- 07/05/18) (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Page 69 | 180 2021 Annual Report Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Name of Director, position WP 2020 26/02/21 26/02/24 N/A WP 2020 11/12/20 11/12/23 N/A Maria Koehler, Board Member In : Mar-20 Out: Aug-21 WP 2019 24/03/20 24/03/23 N/A 01/01/25- 31/12/28 01/01/24- 31/12/27 01/01/24- 31/12/25 € 6,49 € 6,73 10.000 € 5,97 10.000 Total: 20.000 a) 10.000 b) 64.900 a) b) a) b) a) 10.000 b) 64.900 a) b) c) d) 10.000 10.000 10.000 30 000 (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan 2.7.3.3 Executive Committee In deviation from the principle 7.9 of the CCG, the Company has not fixed any minimum threshold for the detention of shares by the members of the Executive Committee. However, the members of the Executive Committee hold subscription rights (warrants) on the Company’s shares as further described hereinafter. Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Name of Director, position WP 2021 26/10/21 26/10/24 WP 2020 26/02/21 26/02/24 N/A 01/01/25- 31/12/28 € 3,75 N/A 01/01/25- 31/12/28 € 6,49 0 0 a) 30.000 b) 112.500 a) 30.000 b) 194.700 WP 2020 11/12/20 11/12/23 WP 2019 24/03/20 24/03/23 Filippo Petti Executive Director, CEO and CFO WP 2019 24/10/19 24/10/22 WP 2018 19/09/19 19/09/22 WP 2018 22/01/19 22/01/22 WP 2018 26/10/18 26/10/21 N/A 1/01/24- 31/12/27 N/A 1/01/24- 31/12/25 N/A 1/01/23- 31/12/24 N/A 1/01/23- 31/12/24 N/A 1/01/23- 31/12/24 N/A 1/01/22- 31/12/23 € 6,73 30.000 a) b) € 5,97 30.000 € 8,16 30.000 € 9,36 20.000 € 18,82 25.000 € 21,16 20.000 Total: 155 000 a) 60 000 a) b) 307 200 b) c) d) (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan 30.000 30.000 30.000 30.000 30.000 20.000 25.000 20.000 215 000 Page 70 | 180 2021 Annual Report Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Name of Director, position WP 2021 26/10/21 26/10/23 WP 2020 11/12/20 24/03/23 WP 2019 24/03/20 24/03/23 David Gilham, Chief Scientific Officer WP 2019 24/10/19 24/10/22 WP 2018 22/01/19 22/01/22 WP 2017 20/07/17 20/07/20 WP 2015 02/11/16 02/11/19 N/A 01/01/24- 31/12/28 N/A 01/01/24- 31/12/27 N/A 01/01/24- 31/12/25 N/A 01/01/23- 31/12/24 N/A 01/01/23- 31/12/24 N/A 01/01/21- 31/07/22 N/A 01/01/20- 05/11/25 € 3,75 0 € 6,73 0 € 5,97 25 000 € 8,16 20 000 € 18,82 25 000 € 31,34 6 000 € 15,90 10 000 Total: 86 000 a) 20 000 b) 75 000 a) 20 000 b) 134 600 a) b) a) b) a) b) a) b) a) b) a) 40 000 a) b) 209 600 b) c) d) 20 000 20 000 25 000 20 000 25 000 6 000 10 000 126 000 (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Name of Director, position The main conditions of warrant plans Table 2 - Remuneration in warrants Information regarding the reported financial year Opening During the year (*) Closing 1. 2. WP 2021 26/10/21 3. 26/10/24 4. 5. N/A 01/01/25- 31/12/28 6. 7. € 3,75 WP 2020 26/02/21 26/02/24 N/A 01/01/25- 31/12/28 € 6,49 Stephen Rubino, Chief Business Officer In : Feb-20 WP 2020 11/12/20 WP 2019 24/03/20 11/12/23 N/A 01/01/24- 31/12/27 € 6,73 20 000 24/03/23 N/A 01/01/24- 31/12/25 € 5,97 50 000 Total: 70 000 8. a) 20 000 b) 75 000 a) 15 000 b) 97 350 a) b) a) b) 9. 10. 20 000 15 000 20 000 50 000 a) 35 000 b) 172 350 a) b) c) d) 105 000 (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Table 2 - Remuneration in warrants Name of Director, position The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. WP 2021 26/10/21 26/10/24 N/A € 3,75 a) 20 000 20 000 Page 71 | 180  WP 2020 16/04/21 Charles Morris, Chief Medical Officer 16/04/24 Total: 01/01/25- 31/12/28 N/A 01/01/25- 31/12/28 € 5,42 2021 Annual Report b) 75 000 a) 125 000 b) 677 500 a) 145 000 b) 752 500 125 000 145 000 a) b) c) d) (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing Name of Director, position 1. 2. 3. 4. 5. 6. 7. WP 2021 26/10/21 26/10/24 WP 2020 11/12/20 11/12/23 WP 2019 24/03/20 24/03/23 Frederic Lehman, VP Clin Dev & Medical Affairs WP 2019 24/10/19 24/10/22 WP 2018 26/10/18 26/10/21 WP 2017 20/07/17 20/07/20 N/A 01/01/25- 31/12/28 N/A 01/01/24- 31/12/27 N/A 01/01/24- 31/12/25 N/A 01/01/23- 31/12/24 N/A 01/01/22- 31/12/23 N/A 01/01/21- 31/07/22 € 3,75 0 € 6,73 0 € 5,97 20 000 € 8,16 20 000 € 22,04 10 000 € 36,11 20 000 Total: 70 000 8. a) 20 000 b) 75 000 a) 20 000 b) 134 600 a) b) a) b) a) b) a) b) 9. 10. 20 000 20 000 20 000 20 000 10 000 20 000 a) 40 000 b) 209 600 a) b) c) d) 110 000 (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Name of Director, position Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 1. 2. 3. 4. 5. 6. 7. WP 2021 26/10/21 26/10/24 WP 2020 26/02/21 26/02/24 WP 2019 24/03/20 24/03/23 Philippe Nobels, VP Human Resources WP 2019 24/10/19 24/10/22 WP 2018 22/01/19 22/01/22 WP 2017 20/07/17 20/07/20 WP 2016 13/12/16 13/12/19 N/A 01/01/25- 31/12/28 N/A 01/01/25- 31/12/28 N/A 01/01/24- 31/12/25 N/A 01/01/23- 31/12/24 N/A 01/01/23- 31/12/24 N/A 01/01/21- 31/07/22 N/A 01/01/20- 08/12/21 € 3,75 0 € 6,49 0 € 5,97 20 000 € 8,16 20 000 € 22,04 10 000 € 36,11 20 000 € 17,60 10 000 8. a) 20 000 b) 75 000 a) 10 000 b) 64 900 a) b) a) b) a) b) a) b) a) b) 9. 10. 20 000 10 000 20 000 20 000 10 000 20 000 0 Total: 80 000 a) 30 000 b) 139 900 a) b) c) 100 000 Page 72 | 180 (*) During the year, no warrants were exercised but 10,000 warrants were forfeited in accordance with the warrant plan 2016 2021 Annual Report d) Name of Director, position The main conditions of warrant plans Table 2 - Remuneration in warrants Information regarding the reported financial year During the year (*) Closing 1. 2. 3. WP 2021 26/10/21 26/10/24 WP 2020 26/02/21 26/02/24 WP 2019 24/03/20 24/03/23 Philippe Dechamps, Chief Legal Officer WP 2019 24/10/19 24/10/22 WP 2018 22/01/19 22/01/22 WP 2017 20/07/17 20/07/20 WP 2016 13/12/16 13/12/19 Opening 7. 4. 5. N/A 01/01/25- 31/12/28 6. € 3,75 N/A 01/01/25- 31/12/28 € 6,49 8. a) 20 000 b) 75 000 a) 25 000 b) 162 250 N/A 01/01/24- 31/12/25 N/A 01/01/23- 31/12/24 N/A 01/01/23- 31/12/24 N/A 01/01/21- 31/07/22 N/A 01/01/20- 08/12/21 € 5,97 25 000 € 8,16 20 000 € 22,04 10 000 € 36,11 20 000 € 17,60 20 000 a) b) a) b) a) b) a) b) a) b) 9. 10. 20 000 25 000 25 000 20 000 10 000 20 000 0 Total: 95 000 a) 45 000 b) 237 250 a) b) c) d) 120 000 (*) During the year, no warrants were exercised but 20,000 warrants were forfeited in accordance with the warrant plan 2016 2.7.3.4 Executive Committee – former members Name of Director, position Christian Homsy, CEO Jul- 07>Apr- 19 1. WP 2018 WP 2016 Table 2 - Remuneration in warrants Information regarding the reported financial year The main conditions of warrant plans Opening During the year (*) Closing 8. 9. 10. 2. 3. 4. 5. 22/01/2019 22/01/2022 N/A 20/07/2017 20/07/2020 N/A 01/01/23- 31/12/24 01/01/21- 31/07/22 6. € 22,04 € 36,11 7. 40.000 40.000 Total: 80.000 a) b) 0 0 a) b) c) d) (*) During the year, no warrants were exercised and no warrants expired in accordance with the warrant plan 40.000 40.000 80.000 Page 73 | 180 2021 Annual Report Name of Director, position Patrick Jeanmart , CFO Sep- 07>Aug- 18 1. WP 201 7 Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closin g 2. 3. 4. 5. 6. 7. 8. 9. 10. 20/07/201 7 20/07/202 0 N/ A 01/01/21 - 31/07/22 € 36,11 20.000 Total: 20.000 20.000 20.000 a) b) 0 0 a) b) c) d) (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Table 2 - Remuneration in warrants Information regarding the reported financial year Name of Director , position 1. WP 2018 The main conditions of warrant plans 2. 3. 4. 5. 22/01/201 9 22/01/202 2 WP 2016 20/07/201 7 20/07/202 0 N/ A N/ A 01/01/23 - 31/12/24 01/01/21 - 31/07/22 Jean- Pierre Latere, COO Jan- 16>May- 20 Openin g 7. 3.333 2.000 6. € 22,04 € 36,11 a) b) a) b) a) b) During the year (*) Closing 8. 9. 10. 3.333 2.000 5.333 0 0 a) b) c) d) Total: 5.333 (*) During the year, no warrants were exercised and no warrants expired in accordance with the warrant plan Name of Director, position Georges Rawadi, VP Business Develop ment Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. WP 2017 WP 2015 WP 2014 20/07/2017 06/11/2015 20/07/2020 N/A 06/11/2018 N/A 16/09/2014 16/09/2017 N/A 01/01/21- 31/07/22 01/01/19- 05/11/25 01/01/18- 16/09/24 € 31,34 6.667 € 34,65 10.000 € 39,22 7.500 Total: 24.167 a) b) a) b) a) b) a) b) 0 0 6.667 10.000 7.500 24.167 a) b) c) d) (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Page 74 | 180 2021 Annual Report Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year Opening During the year (*) Closing 2. 3. 4. 5. 6. 7. 8. 9. 10. 01/03/201 9 01/03/2022 N/A € 18,10 6.667 01/01/23- 31/12/24 Total: a) b) a) b) 0 0 6.667 6.667 a) b) c) d) 1. WP 201 8 Name of Director, position Anne Moore, VP Corporat e Strategy Mar- 19>Oct- 19 (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan Name of Director, position Table 2 - Remuneration in warrants The main conditions of warrant plans Information regarding the reported financial year During the year (*) Opening Closing 5. 6. 7. 8. 9. 10. 1. 2. 3. WP 2015 06/11/2015 06/11/2018 4. N/A 08/01/2018 N/A 01/01/19- 05/11/25 01/01/19- 15/05/24 € 34,65 3.333 € 33,49 3.333 08/01/2015 WP 2014 Dieter Hauwaerts, VP Operations Jan- 15>May-17 Total: 6.666 3.333 3.333 6.666 a) 0 b) 0 a) b) c) d) (*) During the year, no warrants were exercised, and no warrants expired in accordance with the warrant plan 2.7.4. Termination Indemnities No termination indemnity was paid to any Executive Committee member in 2021. 2.7.5. Use of the possibility to reclaim the variable remuneration The Company has not provided for the possibility to reclaim the variable remuneration and did not reclaim any variable remuneration during the reported year. 2.7.6. Deviations from the Remuneration Policy This Remuneration Report does not deviate from the 2021 remuneration Policy, which can be found on the Company’s website. 2.7.7. Evolution of the remuneration and the performance of the company and ratio 2.7.7.1 Comparative information Annual change Director's average remuneration Board Members (in€'000) Executive Committee (in€'000) Company’s performance Loss for the period (in€'000) 2019 2020 2021 76 409 55 412 55 463 (28 632) (17 204) (26 502) Page 75 | 180 2021 Annual Report Treasury position at year end (in€'000) 39 338 17 234 39 338 Performance KPI's determining the company performance Clinical Programs shRNA platform Business Development Financing Corporate / others 95% 38% 33% 25% Average remuneration on a full-time equivalent basis of employees Employees of the company- Celyad Oncology (in€'000) Employees of the company - Celyad Inc (in€'000) 64 150 65 170 90% 40% 8% 8% 25% 10% 64 173 This table includes the 2019 and the 2020 data for comparison with 2021 and will be completed during the next three years to comply with the requirement on the five years evolution. In addition to the losses and the treasury position at year end, the table includes the performance criteria which determined the variable remuneration. These might differ from one year to another, in accordance with the Remuneration Policy. For 2021, the Board of Directors has decided to establish the Company’s performance at 90%, reflecting the level of achievement of the Company’s objectives based on the execution of our CYAD-02, CYAD-101 and CYAD-211 clinical programs, the building of our long-term shRNA pipeline, our licensing and business development, and the financing of the Company, taking once again into consideration the challenging sanitary conditions faced in 2021 with the pandemic of COVID-19.For the calculation of the average remuneration for the employees, the company has taken into consideration the fixed and the variable parts of the remuneration as well as the other benefits paid to employees (such as group insurance, representation allowance, company car, or health insurance). 2.7.7.2 Ratio The ratio between the lowest salary for the employees and the highest salary of the Executive Committee is 15. For the calculation of the remuneration, the Company has taken into consideration the fixed gross salary. 2.7.8. Taking into consideration of the vote of the shareholders On May 5, 2021, the shareholders have approved the 2020 remuneration report at 97.88%. Regarding the vesting period of the warrants, the Company’s warrants vest gradually during a three-year period (1/3 per year). The approved warrants plan provides for an accelerated vesting in case for instance of a change of control or a public offering on the shares of the Company. The Company believes that this accelerated vesting in a limited number of circumstances is market practice and does not prejudice the shareholders’ interests. 2.7.9. Statutory Auditor SRL EY Bedrijfsrevisoren – Réviseurs d’Entreprises, having its registered office at De Kleetlaan 2, B – 1831 Diegem, Belgium, duly represented by Carlo-Sébastien d’Addario, is the statutory auditor of the Company. Carlo-Sébastien d’Addario is a member of the Belgian Institute of Certified Auditors ("Institut des Réviseurs d'Entreprises "). The annual remuneration of the auditor for the performance of its three-year mandate for the audit of its financial statements (including the statutory financial statements) amounts to €202,000 for the year 2021 (excluding VAT). Page 76 | 180 2021 Annual Report 2.8 Description of the principal risks associated to the activities of the Group 2.8.1. Risk Management Risk management is embedded in the strategy of the Company and is of crucial importance for achieving the objectives set by the Board of Directors. The Board is responsible for assessing the risks associated with the activities of the Company and for evaluating the internal audit systems. The Board relies partially on the Executive Committee to perform this assessment. The internal audit systems play a central role in managing the risks and the activities of the Company. To safeguard the proper implementation and execution of the strategies defined by the Board, the Company has set up internal risk management and control systems. The internal audit system is based on the following pillars: • • • The compliance with and the training on the internal policies of the Company, including but not limited to the Code of Business Conduct, Standard Operating Procedures, or policies related to areas such as data protection, information systems, contract lifecycle, conflict of interest, gifts and gratuities, crisis management; The values of the Company; The monitoring of the legal environment with the support of external attorneys; • Ongoing risk analysis; • Audit activities performed by Quality Assurance and Finance departments; • Controls, supervision and corrective actions and measures. The purpose of these systems is to manage in an effective and efficient manner the significant risks to which the Company is exposed. They are designed to ensure: • • The careful monitoring of the effectiveness of the Company’s short term and long-term strategy; The Company’s sustainability by a constant evaluation of its performance (operations and cash). 2.8.2. Organization and values The Company’s organization and values as well as the legal environment surrounding the activities of the Company constitute the basis of all the internal audit components. It is determined by a composition of formal and informal rules on which the functioning of the Company relies. The organization encompasses the following elements: • Company’s Mission: “Developing innovative cell therapies against cancer”; • • The Company’s values: Passion. Respect. Innovation. Determination. Excellence; The Company’s vision: “Eliminate cancer. Improve life”; • Employees and consultants: the Company has been able to attract and retain motivated and dedicated qualified employees. Passion, pro-activity, open-mindness, commitment, trust and integrity are the essential traits of character of the Company’s team. All the Company’s employees and consultants are required to manage the Company’s resources with due diligence, integrity and to act with the necessary common sense; • A Board of Directors, including the Remuneration and Nomination Committee and the Audit Committee. See section 5 for further information on the functioning of the Board and its Committees; • Independent non-executive directors: the Company is supported by several independent directors. Their expertise and experience contribute to the Company’s effective management; Page 77 | 180 2021 Annual Report • A Chief Executive Officer, in charge of the day-to-day management, supported by the other member of the Executive Committee; • An internal set of procedures: the Company set up a Code of Business Conduct and Ethics and adopted internal rules and procedures which regulate the activities within the Company; • The external environment: the Company operates in a highly regulated environment (GMP, GCP, etc.). Compliance with all these external rules and guidelines is of critical importance to the Company. The evaluation of the Company’s organization, values and compliance with legal environment is made regularly for the supervising bodies. 2.8.3. Risks analysis The Board of Directors determines the Company’s strategy, the risk appetite and the main Company’s policies. It is the task of the Board of Directors to strive for long-term success by procuring proper risk assessment. The Executive Committee is responsible for the development of systems that identify, evaluate and monitor risks. Risk identification consists in examining the factors that could influence the Company’s strategy and objectives: • Internal factors: those are closely related to the internal organization and could have several causes (e.g., change in the group structure, staff, ERP system); • External factors: those can be the result of changes in the economic climate, regulations or competition. Besides the common risks associated to all industrial companies, the Executive Committee has identified the following specific risk factors which are described hereafter. 2.8.4. Risks related to the Company’s financial position and capital requirements The Company may need substantial additional funding, which may not be available on acceptable terms when needed, if at all. The Company’s operations have required substantial amounts of cash since inception. The Company expects to continue to spend substantial amounts to continue the clinical development of its product candidates, including its ongoing and planned clinical trials for CYAD-211, CYAD-101 and CYAD-02 (the “Product Candidates”) or any future product candidates, including but not limited to CYAD-203, CYAD-221 and CYAD-231. If approved, the Company will require significant additional amounts in order to launch and commercialize its Product Candidates. As of December 31, 2021, the Company had cash and cash equivalents of €30.0 million and no short-term investments. On January 8, 2021, we entered into a committed equity purchase agreement (“Purchase Agreement”) over a 24-month term for up to $40.0 million with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which LPC’s purchases are subject to certain conditions, including that the Company may only deliver a Regular Purchase Notice (as that term is defined in the Purchase Agreement) of its ADSs so long as the adjusted price of its ADSs exceeds $1.00. Over the remaining lifetime of the Purchase Agreement, we will have the right to direct LPC to purchase up to an aggregate amount of $28.0 million ADSs, each of which represents one of our ordinary shares. As of December 31, 2021, the remaining amount of $28.0 million of this equity purchase agreement is expected to strengthen the Company’s current statement of financial position while also providing the Company with access to future capital on an as needed basis and to ensure sufficient funding to cover its operations for the next 12 months from the date the financial statements are issued. Page 78 | 180 2021 Annual Report Based on its current scope of activities, the Company estimates that its cash and cash equivalents as of December 31, 2021 combined with the remaining access to the equity purchase agreement established with Lincoln Park Capital Fund, LLC (remaining amount of $28.0 million as of December 31, 2021) should be sufficient to fund operating expenses and capital expenditure requirements until mid-2023. However, changing circumstances may cause it to increase its spending significantly faster than it currently anticipates, and the Company may need to spend more money than currently expected because of circumstances beyond its control. The Company may require additional capital for the further development and commercialization of its Product Candidates and may need to raise additional funds sooner if the Company chooses to expand more rapidly than it presently anticipates. The achievement of milestones (R&D, scientific, clinical, regulatory, business) will trigger payment obligations towards Celdara, Dartmouth and Horizon, which will negatively impact the Company’s profitability and may require material additional funding. These commitments are detailed in the note 5.34. The Company contracted over the past year numerous funding agreements with the Walloon Region to partially finance its research and development programs. Under the terms of the agreements, the Company would need to obtain the consent of the Walloon Region for any out-licensing agreement or sale to a third party of any or all of its products, prototypes or installations which may reduce the Company’s ability to partner or sell part or all of its products. Furthermore, when the research and development programs partially financed by the Company enter in “exploitation phase”, the Company has to start reimbursing the funding received. For more information on the potential financial consequences of these exploitation decisions in terms of potential reimbursements and sales percentage fees to be paid to the Walloon Region, refer to note 5.16. The Company may not be able to reimburse such funding under the terms of the agreements or such reimbursement may jeopardize the funding of its clinical and scientific activities. The Company’s ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which it may have no or limited control, including the current geopolitical tension and military conflict between Russia and Ukraine, and the Company cannot guarantee that additional funds will be available to it when necessary, on commercially acceptable terms, if at all. If the necessary funds are not available, the Company may need to seek funds through collaborations and licensing arrangements, which may require it to reduce or relinquish significant rights to its research programs and product candidates, to grant licenses on its technologies to partners or third parties or enter into new collaboration agreements, the terms could be less favorable to the Company than those it might have obtained in a different context. If adequate funds are not available on commercially acceptable terms when needed, the Company may be forced to delay, reduce or terminate the development or commercialization of all or part of its research programs or product candidates or it may be unable to take advantage of future business opportunities. The Company has incurred net losses in each period since its inception and anticipate that the Company will continue to incur net losses in the future. The Company is not profitable and has incurred losses in each period since its inception. For the years ended December 31, 2021, 2020 and 2019, the Company incurred a loss for the year of €26.5 million, €17.2 million and €28.6 million, respectively. As of December 31, 2021, the Company had an accumulated deficit of €309.0 million. The Company expects these losses to increase as it continues to incur significant research and development and other expenses related to its ongoing operations, continues to advance its Product Candidates through preclinical studies and clinical trials, seek regulatory approvals for its Product Candidates, scale-up manufacturing capabilities and hire additional personnel to support the development of its Product Candidates and to enhance its operational, financial and information management systems. Even if the Company succeeds in commercializing one or more of its Product Candidates, it will continue to incur losses for the foreseeable future relating to its substantial research and development expenditures to develop its technologies. Page 79 | 180 2021 Annual Report The Company may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect its business. The size of its future net losses will depend, in part, on the rate of future growth of its expenses and its ability to generate revenue. Its prior losses and expected future losses have had and will continue to have an adverse effect on its shareholders’ equity and working capital. Further, the net losses the Company incurs may fluctuate significantly from quarter to quarter and year to year, such that a period to period comparison of its results of operations may not be a good indication of its future performance. 2.8.5. Risks related to Company’s business activities and industry The Company’s Product Candidates are a new approach to cancer treatment that presents significant challenges. The Company has concentrated its research and development efforts on cell-based immunotherapy technology, and its future success is highly dependent on the successful development of cell-based immunotherapies in general and in particular its approach using the NKG2D receptor, an activating receptor of NK cells, to target stress ligands. Currently, two of the Company’s clinical Product Candidates, CYAD- 101 and CYAD-02, use the NKG2D receptor. The Company cannot be sure that its T-cell immunotherapy technologies will yield satisfactory products that are safe and effective, scalable or profitable. Its approach to cancer immunotherapy and cancer treatment generally poses a number of challenges, including: • Developing and deploying consistent and reliable processes for engineering a patient’s T cells ex vivo and infusing the engineered T-cells back into the patient; • Educating medical personnel regarding the potential side effect profile of each of its Product Candidates, such as the potential adverse side effects related to cytokine release or neurotoxicity; • Developing processes for the safe administration of these Product Candidates, including long-term follow-up for all patients who receive its Product Candidates; • Developing therapies for types of cancers beyond those addressed by its current Product Candidates. Additionally, because its technology involves the genetic modification of patient cells ex vivo using a virus, the Company is subject to many of the challenges and risks that gene therapies face, including: • Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future; • Although its viral vectors are not able to replicate, there is a risk with the use of retroviral or lentiviral vectors that they could lead to new or reactivated pathogenic strains of virus or other infectious diseases; • The FDA recommends a 15-year follow-up observation period for all patients who receive treatment using certain gene therapies, and the Company may need to adopt such an observation period for its Product Candidates. Moreover, public perception of therapy safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to subscribe to the novel treatment. Physicians may not be willing to undergo training to adopt this novel and personalized therapy, may decide the therapy is too complex to adopt without appropriate training and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs. Its Product Candidates are biologics, which are complex to manufacture, and the Company may encounter difficulties in production. Page 80 | 180 2021 Annual Report Its Product Candidates are biologics and the process of manufacturing its products is complex, highly- regulated and subject to multiple risks. The manufacture of its Product Candidates involves complex processes, including harvesting cells from patients, selecting and expanding certain cell types, engineering or reprogramming the cells in a certain manner to create CAR T-cells, expanding the cell population to obtain the desired dose, and ultimately infusing the cells back into a patient’s body. As a result of the complexities, the cost to manufacture its Product Candidates, is higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. Although the Company is working, or will be working, to develop commercially viable processes for the manufacture of its Product Candidates, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for later-stage clinical trials and commercialization, including, among others, cost overruns, potential problems with process scale-out, process reproducibility, stability issues, lot consistency, and timely availability of reagents or raw materials. The Company may ultimately be unable to reduce the cost of goods for its Product Candidates to levels that will allow for an attractive return on investment if and when those Product Candidates are commercialized In addition, the manufacturing process that the Company develops for its Product Candidates is subject to regulatory authorities’ approval process, and the Company will need to make sure that the Company or its contract manufacturers, or CMO’s, if any, are able to meet all regulatory authorities requirements on an ongoing basis. If the Company or its CMO’s are unable to reliably produce Product Candidates to specifications acceptable to the regulatory authorities, the Company may not obtain or maintain the approvals the Company needs to commercialize such Product Candidates. Even if the Company obtains regulatory approval for any of its Product Candidates, there is no assurance that either the Company or its CMO’s will be able to manufacture the approved product to specifications acceptable to the regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. . Similarly, changes in our contact manufacturers, or CMOs, may require us to conduct additional comparability studies. Any of these challenges could have an adverse effect on its business, financial condition, results of operations and growth prospects. The future commercial success of the Company’s Product Candidates will depend on the degree of market acceptance among physicians, patients, hospitals and others in the medical community. The Company’s Product Candidates are at varying stages of development and the Company may never have a product that is commercially successful. The Company does not expect to be able to market any of its products for a number of years. Furthermore, when available on the market physicians may not prescribe the Company's products, which would prevent the Company from generating significant revenues or becoming profitable. Market acceptance of the Company's future products by physicians, patients and healthcare payers will depend on a number of factors, many of which are beyond the Company's control, including, but not limited to: • Acceptance by physicians, patients and healthcare payers of each product as safe, effective and cost-effective; • Relative convenience, ease of use, ease of administration and other perceived advantages over alternative products; • Prevalence and severity of adverse events; • The extent to which products are approved for inclusion and reimbursed on formularies of hospitals and managed care organizations. Page 81 | 180 2021 Annual Report The Company may face significant competition and technological change which could limit or eliminate the market opportunity for its product candidates. The market for pharmaceutical products is highly competitive. The Company’s competitors include many established pharmaceutical, biotechnology, universities and other research or commercial institutions, many of which have substantially greater financial, research and development resources than the Company. The fields in which the Company operates are characterized by rapid technological change and innovation. There can be no assurance that competitors of the Company are not currently developing or will not in the future develop technologies and products that are equally or more effective and/or are more economical as any current or future technology or product of the Company. Competing products may gain faster or greater market acceptance than the Company’s products and medical advances or rapid technological development by competitors may result in the Company’s product candidates becoming non-competitive or obsolete before the Company is able to recover its research and development and commercialization expenses. If the Company or its product candidates do not compete effectively, it may have a material adverse effect on the Company’s business. 2.8.6. Risks related to clinical development The Company may encounter substantial delays in its clinical trials or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. Before obtaining regulatory approval or marketing authorization from regulatory authorities for the sale of its Product Candidates, if at all, the Company must conduct extensive clinical trials to demonstrate the safety and efficacy of the Product Candidates in humans. Pre-clinical tests and Clinical testing are expensive, time- consuming and uncertain as to outcome. The Company cannot guarantee that any pre-clinical and clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: • Delays in obtaining required Investigational Review Board, or IRB, or Ethics Committee approval at each clinical trial site; • • Imposition of a clinical hold by regulatory agencies, after an inspection of its clinical trial operations or trial sites; Failure by its CRO’s, other third parties or the Company to adhere to clinical trial requirements; • Delays in the testing, validation, manufacturing and delivery of its Product Candidates to the clinical sites; • Occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; • Failure to perform in accordance with FDA’s good practices, or GCP’s, or applicable regulatory guidelines in other countries. Furthermore, the timely completion of clinical trials in accordance with their protocols depends, among other things, on its ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The Company may experience difficulties in patient enrolment in its clinical trials for a variety of reasons, including: • • The patient eligibility criteria defined in the protocol; Its ability to recruit clinical trial investigators with the appropriate competencies and experience; • Competing clinical trials for similar therapies; • The risk that patients enrolled in clinical trials will not complete a clinical trial. Page 82 | 180 2021 Annual Report Any inability to successfully complete preclinical and clinical development could result in additional costs to the Company or impair its ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. Clinical trial delays could also shorten any periods during which the Company may have the exclusive right to commercialize its Product Candidates or allow its competitors to bring products to market before the Company does, which could impair its ability to successfully commercialize its Product Candidates and may harm its business and results of operations. Its Product Candidates could potentially cause other adverse events that have not yet been predicted. As described above, any of these events could prevent the Company from achieving or maintaining market acceptance of its Product Candidates and impair its ability to commercialize its products if they are ultimately approved by applicable regulatory authorities. In previous clinical trials involving T-cell based immunotherapies, some patients experienced serious adverse events. The Company’s Product Candidates may demonstrate a similar effect. In previous and ongoing clinical trials involving CAR-T cell products by other companies or academic researchers, many patients experienced side effects such as neurotoxicity and CRS, which have in some cases resulted in clinical holds in ongoing clinical trials of CAR-T Product Candidates. There have been life threatening events related to severe neurotoxicity and CRS, requiring intense medical intervention such as intubation or pressor support, and in several cases, resulted in death. Severe neurotoxicity is a condition that is currently defined clinically by cerebral edema, confusion, drowsiness, speech impairment, tremors, seizures, or other central nervous system side effects, when such side effects are serious enough to lead to intensive care. In some cases, severe neurotoxicity was thought to be associated with the use of certain lymphodepletion preconditioning regimens used prior to the administration of the CAR-T cell products and product candidates. Undesirable side effects caused by its Product Candidates, or other T-cell based immunotherapy product candidates, could cause the Company or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of its trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T-cell based immunotherapies are not normally encountered in the general patient population and by medical personnel. The Company expects to have to train medical personnel regarding its T-cell based immunotherapy Product Candidates to understand their side effects for both its planned clinical trials and upon any commercialization of any T-cell based immunotherapy Product Candidates. Inadequate training in recognizing or managing the potential side effects of T-cell based immunotherapy Product Candidates could result in patient deaths. Any of these occurrences could have a material adverse effect on its business, financial condition and prospects. For example, on February 28, 2022, the Company announced its decision to voluntarily pause its Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 administered concurrently with FOLFOX chemotherapy followed by MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with refractory metastatic colorectal cancer following reports of two fatalities that presented with similar pulmonary findings. The Company is currently investigating these reports and evaluating any similar events in additional patients treated on study. On March 1, 2022, the Company was informed via-email communication from the FDA that the KEYNOTE- B79 trial has been placed on clinical hold due to insufficient information to assess risk to study subjects. The Company’s clinical trials are ongoing and not complete. Initial success in its ongoing clinical trials may not be indicative of results obtained when these trials is completed. Trial designs and results from previous or ongoing trials are not necessarily predictive of future clinical trial results, and initial or interim results may not continue or be confirmed upon completion of the trial. Page 83 | 180 2021 Annual Report There are limited data concerning long-term safety and efficacy following treatment with CYAD-02, CYAD- 101 and CYAD-211. Our Product Candidates may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through initial clinical trials. There can be no assurance that any of these trials will ultimately be successful or support further clinical advancement or regulatory approval of Product Candidates. In December 2017, the Company made the strategic decision to discontinue the development of its first- generation autologous NKG2D CAR T candidate CYAD-01 for the treatment of relapsed / refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) based on data from the Phase 1 THINK and DEPLETHINK trials which did not achieve the necessary internal clinical activity threshold set for the program. The Company may be adversely affected by natural disasters and/or global health pandemics, and its business, financial conditions and results of operations could be adversely affected. On March 11, 2020, the World Health Organization declared the novel strain of coronavirus (COVID-19) a global pandemic and recommended containment and mitigation measures worldwide. Throughout 2020 and 2021, Belgium and the United States, where the Company operates, have been impacted by temporary closures. The length or severity of this pandemic cannot be predicted, but the Company anticipates that there may be an additional impact from a prolonged COVID-19 environment on the planned development activities of the Company. Timely enrollment in clinical trials is reliant on clinical trial sites which may be adversely affected by global health matters, including, among other things, the ongoing COVID-19 pandemic and the emerging variants, such as Delta and Omicron. With regards to our clinical programs, CYAD-02, CYAD-101 and CYAD-211 were slightly impacted by the coronavirus pandemic throughout 2020. Enrollment in the respective trials for these assets is ongoing without any major disruption, partially due to the staggered enrollment associated with the dose-escalation trials for CYAD-02 and CYAD-211, respectively, and the expansion segment of the CYAD-101 trial which began in late 2020. However, certain clinical sites and institutions have not been able to receive visits from us or our representatives, which has delayed our data monitoring activities and delayed our ability to lock the databases for completed studies. The long-term impact of COVID-19 on the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted, including a potential second wave of the pandemic, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among other things, but potential prolonged closures or other business disruptions may negatively affect its operations and the operations of its agents, contractors, consultants or collaborators, which could have a material adverse impact its business, results of operations and financial condition. In addition, after enrollment in these trials, if patients contract COVID-19 during participation in the Company’s trials or are subject to isolation or shelter-in-place restrictions, they may drop out of the trials, miss scheduled follow-up visits or otherwise fail to follow trial protocols. If patients are unable to follow the trial protocols or if the Company’s trial results are otherwise disputed due to the effects of the COVID-19 pandemic or actions taken to mitigate its spread, the integrity of data from the trials may be compromised or not accepted by the FDA or other regulatory authorities, which would represent a significant setback for the applicable program. Celyad has not experiences such issues to date regarding COVID-19. Some factors from the COVID-19 pandemic that the Company believes may adversely affect enrollment in our trials include: • The diversion of healthcare resources away from the conduct of clinical trial matters to focus on pandemic concerns, including the attention of physicians serving as the Company’s clinical trial investigators, hospitals serving as the clinical trial sites and hospital staff supporting the conduct of the clinical trials; Page 84 | 180 2021 Annual Report • Some patients who would otherwise be candidates for enrollment in the Company’s clinical trials are at increased risk of severe effects of the coronavirus, which may lead to the death of some patients and render others too ill to participate, limiting the available pool of participants for the trials; • • • The fact that there can be no guarantee that any proposed changes to our protocols, if necessary, would be acceptable to regulators; Limitations on travel that interrupt key trial activities, such as clinical trial site initiations and monitoring; and Interruption in global shipping affecting the transport of clinical trial materials being used in our trials. Except as mentioned above, Celyad has not experienced such issues to date regarding COVID-19. These and other factors arising from the COVID-19 pandemic could worsen in countries that are already afflicted with the virus or could continue to spread to additional countries, each of which may further adversely impact the Company’s clinical trials. The global outbreak of the COVID-19 pandemic continues to evolve, and the conduct of the Company’s trials may continue to be adversely affected, despite efforts to mitigate this impact. Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of the Company’s clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of the Company’s product candidates. 2.8.7. Risks related to legal and regulatory risks The Company is heavily dependent on the regulatory approval of its Product Candidates in the United States and Europe. The Company is a clinical-stage biopharmaceutical company with no products approved by regulatory authorities or available for commercial sale. The Company may be unable to develop or commercialize a product, product candidate or research program, or may cease some of its operations, which may have a material adverse effect on the Company’s business. The Company has generated limited revenue to date and does not expect to generate any revenue from product sales for the foreseeable future. The Company’s ability to generate revenues in the near term will depend on its ability to obtain regulatory approval and successfully commercialize Product Candidates in the United States, the first country in which the Company intends to seek approval for these candidates. The Company may experience delays in obtaining regulatory approval in the United States for these Product Candidates, if it is approved at all, and the price of its ordinary shares and/or ADSs may be negatively impacted. Even if the Company receives regulatory approval, the timing of the commercial launch of the Product Candidates in the United States is dependent upon a number of factors, including, but not limited to, hiring sales and marketing personnel, pricing and reimbursement timelines, the production of sufficient quantities of commercial drug product and implementation of marketing and distribution infrastructure. Nearly all aspects of the Company’s activities are subject to substantial regulation. No assurance can be given that any of the Company’s product candidates will fulfill regulatory compliance. The international pharmaceutical and medical technology industry is highly regulated by government bodies (hereinafter the “Competent Authorities”) that impose substantial requirements covering nearly all aspects of the Company’s activities notably on research and development, manufacturing, preclinical tests, clinical trials, labelling, marketing, sales, storage, record keeping, promotion and pricing of its research programs and product candidates. Compliance with standards laid down by local Competent Authorities is required in each country where the Company, or any of its partners or licensees, conducts said activities in whole or in Page 85 | 180 2021 Annual Report part. The Competent Authorities notably include the European Medicine Agency (“EMA”) in the European Union and the Food and Drug Administration (“FDA”) in the United States. There can be no assurance that product candidates of the Company will fulfill the criteria required to obtain necessary regulatory authorization to access the market. Also, at this time, the Company cannot guarantee or know the exact nature, precise timing and detailed costs of the efforts that will be necessary to complete the remainder of the development of its research programs and product candidates. The specific regulations and laws, as well as the time required to obtain Competent Authorities approvals, may vary from country to country, but the general regulatory procedures are similar in the European Union and the United States. At any time, Competent Authorities may require discontinuation or holding of clinical trials or require additional data prior to completing their review or may issue restricted authorization or authorize products for clinical trials or marketing for narrower indications than requested or require further data or studies be conducted and submitted for their review. There can be no guarantee that such additional data or studies, if required, will corroborate earlier data. 2.8.8. Risks related to intellectual property The Company could be unsuccessful in obtaining or maintaining adequate patent protection for one or more of its Product Candidates. The patent application process is expensive and time-consuming, and the Company and its current or future licensors and licensees may not be able to apply for or prosecute patents on certain aspects of its Product Candidates or deliver technologies at a reasonable cost, in a timely fashion, or at all. It is also possible that the Company or its current licensors, or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, its patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of its business. It is possible that defects of form in the preparation or filing of its patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. Under its existing license agreements with the Trustees of Dartmouth College, the Company has the right, but not the obligation, to enforce its licensed patents. If its current licensors, or any future licensors or licensees, are not fully cooperative or disagree with the Company as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised and the Company might not be able to prevent third parties from making, using, and selling competing products. If there are material defects in the form or preparation of its patents or patent applications, such patents or applications may be invalid and unenforceable The Company currently has issued patents and patent applications directed to its Product Candidates and medical devices, and the Company anticipates that it will file additional patent applications in several jurisdictions, including several European Union countries and the United States, as appropriate. The Company cannot be certain, however, that the claims in its pending patent applications will be considered patentable by patent offices in various countries, or that the claims in any of its issued patents will be considered valid and enforceable by local courts. The strength of patents in the biotechnology and pharmaceutical field can be uncertain and evaluating the scope of such patents involves complex legal and scientific analyses. The patent applications that the Company owns, or in-licenses may fail to result in issued patents with claims that cover its Product Candidates or uses thereof in the European Union, in the United States or in other jurisdictions. Even if the patents do successfully issue, third parties may challenge the validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. Furthermore, even if they are unchallenged, its patents and patent applications may not adequately protect its intellectual property or prevent others from designing their products to avoid being covered by its claims. If the breadth or strength of protection provided by the patent applications the Company holds with respect to its Product Candidates is threatened, this could dissuade companies from collaborating with the Company to develop, and could Page 86 | 180 2021 Annual Report threaten its ability to commercialize, its Product Candidates. Further, because patent applications in most countries are confidential for a period of time after filing, the Company cannot be certain that the Company was the first to file any patent application related to its Product Candidates. Patents have a limited lifespan. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Further, the extensive period of time between patent filing and regulatory approval for a product candidate limits the time during which the Company can market a product candidate under patent protection, which may particularly affect the profitability of its early-stage Product Candidates. If the Company encounters delays in its clinical trials, the period of time during which the Company could market its Product Candidates under patent protection would be reduced. Without patent protection for its Product Candidates, the Company may be open to competition from biosimilar versions of its Product Candidates. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the European Union or the United States. Consequently, the Company may not be able to prevent third parties from practicing its inventions in all countries, or from selling or importing products made using its inventions in and into other jurisdictions. The Company’s patents and other intellectual property rights portfolio is relatively young and may not adequately protect its research programs and product candidates. The Company’s success will depend in part on the ability of the Company to obtain, maintain and enforce its patents and other intellectual property rights. The Company’s research programs, and product candidates are covered by several patent application families, which are either licensed to the Company or owned by the Company. Out of the numerous patent applications controlled by the Company, fifteen national patents have been granted in the US relating to the field of immuno-oncology. The Company cannot guarantee that it will be in a position in the future to develop new patentable inventions or that the Company or its licensors will be able to obtain or maintain these patent rights against challenges to their validity, scope and/or enforceability. Moreover, the Company may have little or no control over its licensors’ abilities to prevent the infringement of their patents or the misappropriation of their intellectual property. There can be no assurance that the technologies used in the Company’s research programs and product candidates are patentable If the Company or its licensors do not obtain meaningful patents on their technologies or if the patents of the Company or its licensors are invalidated, third parties may use the technologies without payment to the Company. A third party’s ability to use unpatented technologies is enhanced by the fact that the published patent application contains a detailed description of the relevant technology. The Company cannot guarantee that third parties, contract parties or employees will not claim ownership rights over the patents or other intellectual property rights owned or held by the Company. The Company also relies on proprietary know-how to protect its research programs and product candidates. Know-how is difficult to maintain and protect. The Company uses reasonable efforts to maintain its know- how, but it cannot assure that its partners, employees, consultants, advisors or other third parties will not willfully or unintentionally disclose proprietary information to competitors. As far as the Company is aware, its intellectual property has not been challenged otherwise than by patent offices in the normal course of examination of its patent applications or misappropriated. The Company depends on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm its business. The Company is dependent on patents, know-how, and proprietary technology, both its own and licensed from others. The Company’s licenses technology from the Trustees of Dartmouth College, or Dartmouth College. Dartmouth College may terminate the Company’s license, if the Company fails to meet a milestone within the specified time period, unless the Company pays the corresponding milestone payment. Dartmouth College may terminate either the license in the event the Company defaults or breach any of the provisions Page 87 | 180 2021 Annual Report of the applicable license, subject to 30 days’ prior notice and opportunity to cure. In addition, the license automatically terminates in the event the Company becomes insolvent, make an assignment for the benefit of creditors or file, or have filed against us, a petition in bankruptcy. Furthermore, Dartmouth College may terminate the Company’s license, after April 30, 2024, if the Company fails to meet the specified minimum net sales obligations for any year (USD 10 million during first year of sales, USD 40 million during the second year of sales and USD 100 million during the third year of sales and every year of sales thereafter), unless the Company pays to Dartmouth College the royalty the Company would otherwise be obligated to pay had the Company met such minimum net sales obligation. Since 2018, the Company also licenses technology from Horizon Discovery Limited (recently acquired by Perkin Elmer) (“Horizon/PKI”) through research and development collaboration and license agreements. Horizon/PKI may terminate the Company’s license in case of insolvency, material breach or force majeure. Any termination of these licenses or any of the Company’s other licenses could result in the loss of significant rights and could harm its ability to commercialize its Product Candidates. On February 18, 2021, Horizon Discovery Group plc / PerkinElmer, Inc. (Horizon/PKI) informed Celyad they believe Celyad is in material breach of those agreements as a result of certain disclosures Celyad has made in connection with its obligations as a publicly traded company in the United States and Belgium. Horizon/PKI recently informed Celyad that unless Celyad is able to reach agreement regarding the purported material breach, they may elect to serve Celyad a notice of termination. We believe any such assertion of material breach would be without merit and we would expect to vigorously defend any such notice of material breach. Any dispute under these agreements would be subject to arbitration in The Hague under the International Chamber of Commerce Rules. We are currently in discussions with Horizon/PKI to settle this matter. Of note, we have filed patent applications which, if issued, would cover other aspects of the product candidates described above as well as products developed by third parties that deploy similar technology and targets. These patent applications encompass the downregulation of one or more of the targets covered under the Horizon /PKI agreements, the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells. We are also developing a second generation shRNA platform that does not incorporate any of the Horizon/PKI technology described above. Our lead allogeneic CAR T product candidate, CYAD-101, does not incorporate any of the Horizon/PKI technology described above. Currently CYAD-211 and CYAD-203 (next generation NKG2D) use the HD/PKI shRNA scaffold. We believe that CYAD-211 could be impacted by a potential termination. We believe the timeline associated with the clinical development and potential commercialization of the preclinical asset may fall after the IP exclusivity of the HD/PKI shRNA scaffold. However, the emerging data from the program is likely to have an impact on the future prospects of the asset. For CYAD-203, we believe the timeline associated with the clinical development and potential commercialization of the preclinical asset are likely to fall after the IP exclusivity of the HD/PKI shRNA scaffold. As such, would have less of a material impact on the asset. Disputes may also arise between the Company and its licensors regarding intellectual property subject to a license agreement, including those relating to: • The scope of rights granted under the license agreement and other interpretation-related issues; • Whether and the extent to which its technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement; • • Its right to sublicense patent and other rights to third parties under collaborative development relationships; The amount and timing of milestone and royalty payments; • Whether the company is complying with its diligence obligations with respect to the use of the licensed technology in relation to its development and commercialization of its product candidates; • The allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by the company and its partners and by its licensors. If disputes over intellectual property that the Company has licensed prevent or impair its ability to maintain its current licensing arrangements on acceptable terms, the Company may be unable to successfully develop and commercialize the affected Product Candidates. The Company is generally also subject to all of the Page 88 | 180 2021 Annual Report same risks with respect to protection of intellectual property that the Company licenses as it is for intellectual property that the Company owns, which are described below. If the Company or its licensors fail to adequately protect this intellectual property, the Company’s ability to commercialize its products could suffer. The licenses of the Company may be terminated if it is unable to meet the payment obligations under the agreements (notably if the Company is unable to obtain additional financing). The Company may infringe on the patents or intellectual property rights of others and may face patent litigation, which may be costly and time consuming. The Company’s success will depend in part on its ability to operate without infringing on or misappropriating the intellectual property rights of others. The Company cannot guarantee that its activities will not infringe on the patents or other intellectual property rights owned by others. The Company may expend significant time and effort and may incur substantial costs in litigation if it is required to defend against patent or other intellectual property right suits brought against the Company regardless of whether the claims have any merit. Additionally, the Company cannot predict whether it or its licensors will be successful in any litigation. If the Company or its licensors are found to infringe on the patents or other intellectual property rights of others, it may be subject to substantial claims for damages, which could materially impact the Company’s cash flow and financial position. The Company may also be required to cease development, use or sale of the relevant research program, product candidate or process or it may be required to obtain a license on the disputed rights, which may not be available on commercially reasonable terms, if at all. There can be no assurance that the Company is even aware of third-party rights that may be alleged to be relevant to any particular product candidate, method, process or technology. The Company may spend significant time and effort and may incur substantial costs if required to defend against any infringement claims or to assert its intellectual property rights against third parties. The risk of such a claim by a third party may be increased by the Company’s public announcement regarding its research programs and product candidates. The Company may not be successful in defending its rights against such procedures or claims and may incur as a consequence thereof significant losses, costs or delays in its intended commercialization plans as a result thereof. 2.8.9. Post-authorisation risks The Company has not yet finalized its clinical development program for CYAD-02 for the treatment of patients with relapsed / refractory AML and MDS or for CYAD-101, the allogeneic NKG2D CAR-T for the treatment of mCRC or CYAD-211, the allogeneic BCMA CAR-T for the treatment of r/r multiple myeloma (MM). Regulators may not agree with its proposed protocols for these clinical trials, which could result in delays. The Company is still considering the clinical development program for CYAD-02 in relapsed / refractory AML and MDS, CYAD-101 for mCRC and CYAD-211 for relapsed / refractory MM. Prior to initiating new clinical trials for its Product Candidates, the Company is required to submit clinical trial protocols for these trials to the FDA and comparable foreign regulators in other jurisdictions where the Company plans to undertake clinical trials. The Company may not reach agreement with these regulators, or there may be a delay in reaching agreement. These regulators may want to see additional clinical or preclinical data regarding its Product Candidates before the Company initiates new clinical trials. Any of these decisions could have a material adverse effect on its expected clinical and regulatory timelines, business, prospects, financial condition and results of operations. 2.8.10. Risks linked to the Company’s reliance on third parties Cell-based therapies rely on the availability of specialty raw materials, which may not be available to the Company on acceptable terms or at all. Page 89 | 180 2021 Annual Report Engineered-cell therapies require many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product. The suppliers may be ill-equipped to support the Company’s needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. The Company also does not have contracts with many of these suppliers and may not be able to contract with them on acceptable terms or at all. Accordingly, the Company may experience delays in receiving key raw materials to support clinical or commercial manufacturing. In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. The Company cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of its competitors or another Company that is not interested in continuing to produce these materials for its intended purpose. Since the beginning of the COVID-19 pandemic, three vaccines for COVID-19 were granted Emergency Use Authorization by the FDA, and more are likely to be authorized in the coming months. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for the Company’s clinical trials, which could lead to delays in these trials. However, for the time being, Celyad has not experienced such issue. If third parties conducting clinical trials do not successfully carry out their contractual duties, the Company may not be able to obtain regulatory approval for or commercialize its Product Candidates. The Company relies on clinical research organizations, or CROs, clinical investigators and clinical trial sites to ensure its clinical trials are conducted properly and on time. While the Company will have agreements governing their activities, the Company will have limited influence over their actual performance. The Company will control only certain aspects of its CRO’s activities. Nevertheless, the Company will be responsible for ensuring that each of its clinical trials is conducted in accordance with the applicable protocol, legal, and regulatory requirements and scientific standards, and its reliance on these third parties does not relieve the Company of its regulatory responsibilities. The Company and these third parties are required to comply with the GCP’s (from both FDA and EMA) for conducting, recording and reporting the results of clinical trials to assure that the data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. If the Company or its CROs fail to comply with applicable GCP’s, the clinical data generated in its future clinical trials may be deemed unreliable and the FDA, the EMA, or other foreign regulatory authorities may require the Company to perform additional clinical trials before approving any marketing applications. Upon inspection, the FDA or the EMA may determine that its clinical trials did not comply with GCP’s. In addition, its future clinical trials will require a sufficient number of test subjects to evaluate the safety and effectiveness of its Product Candidates. Accordingly, if its CRO’s fail to comply with these regulations or fail to recruit a sufficient number of patients, the Company may be required to repeat such clinical trials, which would delay the regulatory approval process. Its CRO’s are not the Company’s employees, and the Company is therefore unable to directly monitor whether or not they devote sufficient time and resources to its clinical and preclinical programs. These third parties may also have relationships with other commercial entities, including its competitors, for whom they may also be conducting clinical trials or other product development activities that could harm the Company’s competitive position. If these third parties do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to the Company’s clinical protocols or regulatory requirements, or for any other reasons, the Company’s clinical trials may be extended, delayed or terminated, and the Company may not be able to obtain regulatory approval for, or successfully commercialize, its Product Candidates. If any such event were to occur, the Company’s financial results and the commercial prospects for its Product Candidates would be harmed, its costs could increase, and its ability to generate revenues could be delayed. Page 90 | 180 2021 Annual Report If any of the Company’s relationships with these third-party CRO’s terminate, the Company may not be able to enter into arrangements with alternative CRO’s or to do so on commercially reasonable terms. Further, switching or adding additional CRO’s involves additional costs and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which could materially impact its ability to meet its desired clinical development timelines. Though the Company carefully manages its relationships with its CRO’s, there can be no assurance that the Company will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on its business, financial condition and prospects. The Company relies and will continue to rely on collaborative partners regarding the development of its research programs and product candidates. The Company is and expects to continue to be dependent on collaborations with partners relating to the development and commercialization of its existing and future research programs and product candidates. The Company had, has and will continue to have discussions on potential partnering opportunities with various pharmaceutical and medical device companies. If the Company fails to enter into or maintain collaborative agreements on reasonable terms or at all, the Company's ability to develop its existing or future research programs and product candidates could be delayed, the commercial potential of its products could change, and its costs of development and commercialization could increase. The Company's dependence on collaborative partners subjects it to a number of risks, including, but not limited to, the following: • • The Company may be required to relinquish significant rights, including intellectual property, marketing and distribution rights; The Company relies on the information and data received from third parties regarding its research programs and product candidates and will not have control of the process conducted by the third party in gathering and composing such data and information. The Company may not have formal or appropriate guarantees from its contract parties with respect to the quality and the completeness of such data; • A collaborative partner may develop a competing product either by itself or in collaboration with others, including one or more of the Company's competitors; 2.8.11. Risks related to the shares The market price of the shares may fluctuate widely in response to various factors. A number of factors may significantly affect the market price of the Shares. The main factors are changes in the operating results of the Company and its competitors, announcements of technological innovations or results concerning the product candidates, changes in earnings estimates by analysts. Other factors which could cause the price of the shares to fluctuate or could influence the reputation of the Company include, amongst other things: • Developments concerning intellectual property rights, including patents; • Public information regarding actual or potential results relating to products and product candidates under development by the company’s competitors; • Actual or potential results relating to products and product candidates under development by the company itself; • Developments concerning intellectual property rights, including patents; • Regulatory and medicine pricing and reimbursement developments in Europe, the United States and other jurisdictions; Page 91 | 180 2021 Annual Report • Any publicity derived from any business affairs, contingencies, litigation or other proceedings, the company’s assets (including the imposition of any lien), its management, or its significant shareholders or collaborative partners; • Divergences in financial results from stock market expectations; • Changes in the general conditions in the pharmaceutical industry and general economic, financial market and business conditions in the countries in which the company operates; and • Any publicity derived from data protection or cybersecurity breaches. In addition, stock markets have from time to time experienced extreme price and volume volatility which, in addition to general economic, financial and political conditions, could affect the market price for the Shares regardless of the operating results or financial condition of the Company. Future sales of substantial amounts of shares, or the perception that such sales could occur, could adversely affect the market value of the shares Sales of a substantial number of shares in the public markets, notably by its major shareholders (CFIP CLYD LLC holding 28.77% and TOLEFI SA holding 10.16 % of the Shares), or the perception that such sales might occur, might cause the market price of the shares to decline. The Company cannot make any prediction as to the effect of any such sales or perception of potential sales on the market price of the shares. Certain significant shareholders of the Company may have different interests from the Company and may be able to control the outcome of shareholder votes On the basis of the transparency notifications received by the Company as of the date of this Report, the two main shareholders are CFIP CLYD LLC (who holds 28.77% of the shares and 26.04 % of the voting rights) and TOLEFI SA (who holds 10.16% of the shares and 18.39 % of the voting rights). As a consequence, the two main shareholders of the Company hold together 44.43 % of the voting rights attached to the Shares of the Company. The Company is not aware of shareholders of the Company that have entered into a voting agreement or have otherwise agreed to act in concert. Nevertheless, they could, alone or together, have the ability to elect or dismiss directors (in addition to the nomination right granted by the Company to CFIP CLYD LLC), and, depending on how widely the Company’s shares are held and represented at shareholders’ meeting, take certain shareholders’ decisions that require at least 50%, two thirds, 75% or 80% of the votes of the shareholders that are present or represented at general shareholders’ meetings where such items are submitted to voting by the shareholders. Alternatively, to the extent that these shareholders have insufficient votes to impose certain shareholders’ decisions, they could still have the ability to block proposed shareholders’ resolutions that require at least 50%, two thirds, 75% or 80% of the votes of the shareholders that are present or represented at general shareholders’ meetings where such decisions are submitted to voting by the shareholders. Any such voting by the shareholders may not be in accordance with the interests of the Company or the other shareholders of the Company. Sustainability of a liquid public market The Company cannot guarantee the extent to which a liquid market for the Company’s shares will be sustained. In the absence of such liquid market for the shares, the price of the shares could be impacted negatively. The liquidity of the market for the shares could be affected by various causes, including the factors identified in the next risk factor (below) or by a reduced interest of investors in biotechnology sector. If securities or industry analysts do not publish research or publish inaccurate research or unfavorable research about the Company’s business, the price of the shares and trading volume could decline. The trading market for the shares depends in part on the research and reports that securities or industry analysts publish about the Company or its business. At the date of this report the Company is followed by Page 92 | 180 2021 Annual Report nine analysts (Bryan Garnier, KBC Securities, Kempen, Kepler Cheuvreux, H.C. Wainwright, Jones Trading, Portzamparc, Wells Fargo and William Blair). If no or few securities or industry analysts cover the Company, the trading price would be negatively impacted. If one or more of the analysts who covers the Company downgrades the shares or publishes incorrect or unfavorable research about its business, the price of the shares would likely decline. If one or more of these analysts eases coverage of the Company or fails to publish reports on the Company regularly, or downgrades the shares, demand for the shares could decrease, which could cause the price of the shares or trading volume to decline. The Company has no present intention to pay dividends on its ordinary shares in the foreseeable future. The Company has no present intention to pay dividends in the foreseeable future. Any recommendation by its Board of Directors to pay dividends will depend on many factors, including its financial condition (including losses carried-forward), results of operations, legal requirements and other factors. Furthermore, pursuant to Belgian law, the calculation of amounts available for distribution to shareholders, as dividends or otherwise, must be determined on the basis of its non-consolidated statutory accounts prepared in accordance with Belgian accounting rules. In addition, in accordance with Belgian law and its Articles of Association, the Company must allocate each year an amount of at least 5% of its annual net profit under its non-consolidated statutory accounts to a legal reserve until the reserve equals 10% of its share capital. Therefore, the Company is unlikely to pay dividends or other distributions in the foreseeable future. If the price of the shares declines before the Company pays dividends, investors will incur a loss on their investment, without the likelihood that this loss will be offset in part or at all by potential future cash dividends. 2.8.12. Audit activities Internal audit activities are performed by the departments of Finance, for all matters related to accounting and financial information, and Quality Assurance for all matters related to the operational activities of the Company. As of the date of this report, there is not yet a dedicated internal audit function. In order to properly manage identified risks, the Company has set up the following audit measures: • Access and security systems at the premises and offices; • Establishment, under the supervision of the quality assurance department, of a set of procedures covering all activities of the company; • Weekly modifications and updates of the existing procedures; • Development of electronic approval system in the existing ERP system; • Implementation of extra controls in the existing ERP system; • Development of a monthly financial reporting tool which allow a close monitoring of the financial information and KPI’s; • Updated risks and controls matrix are in place for the internal controls processes (entity level, it, financial operations). 2.8.13. Controls, supervision and correctives actions Controls are performed by all persons in charge of departments and services. When deviations are identified, there are reported to, depending of their relative importance, the head of department or the Executive Committee. The Executive Committee supervises the implementation of internal audit and risk management, taking into consideration the recommendations on the Audit Committee. Page 93 | 180 2021 Annual Report The Executive Committee is also in charge of proposing the Audit Committee corrective actions when identified. External audit On May 5, 2020, the shareholders meeting approved the appointment of SRL EY Bedrijfsrevisoren – Réviseurs d’Entreprises, having its registered office at De Kleetlaan 2, B – 1831 Diegem, Belgium, duly represented by Carlo-Sébastien d’Addario, as Statutory Auditor, for a term of 3 years, i.e. until the ordinary general meeting approving the accounts closed on 31 December 2022. EY’s mission includes the auditing of the statutory annual accounts, the consolidated annual accounts of the Company and its subsidiaries. The Company is also subject to ad hoc audit performed by the competent authorities to ensure compliance with GMP, GCP or other regulations. Page 94 | 180 2021 Annual Report 3. GROUP STRUCTURE, SHAREHOLDING AND SHARE CAPITAL 3.1 Group structure The Company conducts its main business through Celyad Oncology SA. In 2011, the Company incorporated Cardio3 Inc, a fully owned subsidiary, in the U.S. for the purposes of supporting its clinical and regulatory activities of the Group in the US. Cardio3 Inc became Celyad Inc on May 12, 2015. The growth of the activities of Celyad Inc. is associated to the development of the US clinical and regulatory activities of the Company in the US. On November 5, 2014, the Company acquired CorQuest Medical, Inc., a private U.S. company, for a single cash payment of €1.5 million and on-going earn-out royalty payments based on sales milestones. CorQuest Medical, Inc. is developing Heart-XS, a new access route to the left atrium. The development of Heart-XS and the activities of CorQuest Medical, Inc. have been on hold following the decision of the Company to abandon the development of its cardio business program (C Cure). On November 22, 2019, CorQuest Medical Inc. has sold to Corquest MedTech SRL, a company established under Belgian laws, its portfolio of patents and related rights for a consideration of €1 and the reimbursement of certain maintenance costs of these patents. CorQuest Medical Inc. has also the right to receive royalties on the future sales and a percentage on the capital gains in case of re-sale or change of control of Corquest MedTech SRL. On January 21, 2015, the Company purchased OnCyte, LLC, or OnCyte, a wholly-owned subsidiary of Celdara Medical, LLC, a privately-held U.S. biotechnology company for an upfront payment of $10.0 million, of which, $6.0 million was paid in cash and $4.0 million was paid in the form of 93,087 of its ordinary shares. As a result of this transaction the Company acquired its CAR-T cell Product Candidates and related technology, including technology licensed from the Trustees of Dartmouth College. OnCyte, LLC was the company holding the CAR-T Cell portfolio of clinical-stage immuno-oncology assets. In March 2018, the Company has dissolved OnCyte, and all the assets and liabilities of OnCyte, have been fully distributed to and assumed by the Company. On May 1, 2016, the Company acquired Biological Manufacturing Services SA (BMS). BMS owns GMP laboratories. BMS rent its laboratories to the Company since 2009 and until April 30, 2016. Until the acquisition, BMS was considered as a related party to the Company. On June 8, 2020, the Company announced the launch of its corporate rebranding, including changing its name to Celyad Oncology. The new name highlights the Company’s significant progress with its next- generation CAR T programs and emphasizes its commitment to cancer patients. The Company’s ordinary shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris regulated markets and the Company’s American Depositary Shares (ADSs) are listed on the Nasdaq Global Market, all under the ticker symbol CYAD. The Company does not exercise any activities through a branch office. Page 95 | 180 The consolidation perimeter of the Company is as follows: 2021 Annual Report Name Celyad Oncology SA Celyad Inc CorQuest Medical Inc of Country Incorporation and Place of Business Nature Business of Proportion of ordinary shares directly held by parent (%) Proportion of ordinary shares held by the Company (%) Proportion of ordinary shares held by non- controlling interests (%) BE US US Biopharma Biopharma Parent company 100% Medical Device 100% 100% 100% 100% 0% 0% 0% Biological Manufacturing Services SA BE Manufacturing 100% 3.2 Capital increase and issuance of shares On January 1, 2021, the share capital of the Company amounted to €48,512,614,57 and was represented by 13,942,344 shares. The following transactions took place since January 1, 2021: • On January 8, 2021, the Company has entered into a committed equity purchase agreement (“Purchase Agreement”) for up to $40.0 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. Over the 24-month term of the Purchase Agreement, the Company will have the right to direct LPC to purchase up to an aggregate amount of $40.0 million American Depositary Shares (“ADSs”), each of which represents one ordinary share of the Company. From January 8, 2021 until December 31, 2021, a total of 1,962,812 new shares have been issued by the Company and subscribed by LPC for a cash proceed of €9.2 million. As of December 31, 2021, there is a remaining access to the equity purchase agreement established with LPC for an amount of $28.0 million. • During the extraordinary shareholders meeting of May, 25 2021, the shareholders, in accordance with Belgian Company Law, approved the absorption of approximately €43.3 million of accounting losses into share premium. As a result, share premium has been reduced by a cumulative amount of €43.3 million in the 12 months period ended December 31, 2021 (€234.6 million of loss absorption has been approved and recorded from inception to December 31, 2021) against capital reduction reserve. This transaction has no impact on the total equity, comprehensive income (loss), assets (including cash) nor liabilities. • On May, 21 2021 and June 14, 2021, a total of 188,800 new shares have been issued by the Company and subscribed by Jefferies under the ATM for a cash proceed of €0.9 million. • On December 8, 2021, 6,500,000 new shares were issued by decision of the board of directors and subscribed for by CFIP CLYD LLC in the framework of a private placement for a global cash proceed of €28.9 million ($32.5 million). As of December 31, 2021, the share capital of the Company amounted to €78,584,224,33 and was represented by 22,593,956 shares. All shares are issued and fully paid up and are of the same class. Each share (i) entitles its holder to one vote at the Shareholders’ Meetings (except for what is said below regarding shares with double voting rights); (ii) represents an identical fraction of the capital and has the same rights and obligations and participates equally in the profit of Celyad; and (iii) gives its holder a preferential subscription right to subscribe to new shares, convertible bonds or warrants in proportion to the part of the share capital represented by the shares already held. Page 96 | 180 2021 Annual Report The preferential subscription right can be restricted or cancelled by a resolution approved by the Shareholders’ Meeting, or by the Board of Directors subject to an authorization of the Shareholders’ Meeting, in accordance with the provisions of the CCA and the Company’s articles of association. Further to the Initial Public Offering (IPO) made on the Nasdaq on June 19, 2015, some shares of the Company are represented in the form of American Depositary Shares (ADS). As of December 31, 2021, there were 1,340,644 ADS outstanding. 3.3 Warrants plans The Company has created various incentive plans under which warrants were granted to its employees, consultants or directors (all warrants are together referred to as “Warrants”). This section provides an overview of the outstanding warrants as of December 31, 2021. Upon proposal of the Board of Directors, the extraordinary shareholders’ meeting approved the issuance of, in the aggregate, warrants giving right to subscribe to shares as follows: • On September 26, 2008, warrants giving right to 90,000 shares. Of these 90,000 Warrants, 50,000 were accepted by the beneficiaries. None are outstanding as of December 31, 2021; • On May 5, 2010, warrants giving right to 50,000 shares. Of these 50,000 warrants (15,000 A warrants, 5,000 B warrants and 30,000 C warrants), 12,710 A warrants, 5,000 B warrants, and 21,700 C warrants C were accepted by the beneficiaries. None are outstanding as of December 31, 2021; • On October 29, 2010, warrants giving right to 79,500 shares. Out of the 79,500 warrants offered, 61,050 Warrants were accepted by the beneficiaries, and none are outstanding as of December 31, 2021; • On January 31, 2013, warrants giving right to 140,000 shares. Out of the 140,000 warrants, 120,000 were granted to certain members of the Executive Committee and a pool of 20,000 warrants was created. The warrants attributed to certain members of the Executive Committee were fully vested at December 31, 2013 and were all exercised in January 2014 and therefore converted into ordinary shares. The remaining 20,000 warrants were not granted and therefore lapsed; • On May 6, 2013, 11 investor warrants are attached to each Class B Share subscribed in the capital increase in cash, which was decided on the same date, with each investor warrant giving right to subscribe to one ordinary share – as a result, these warrants give right to a maximum 2,433,618 ordinary shares. On May 31, 2013, warrants giving right to 2,409,176 ordinary shares were issued and accepted, which have all been exercised as of December 31, 2021; • On May 6, 2013, warrants giving right to 266,241 ordinary shares. Out of the 266,241 warrants offered, 253,150 Warrants were accepted by the beneficiaries and 2,500 warrants are outstanding as of December 31, 2021; • On June 11, 2013, overallotment warrant giving right to a maximum number of shares equal to 15% of the new shares issued in the context of the U.S. initial public offering, i.e., 207,225 shares). The overallotment warrant was exercised on July 17, 2013; • On May 5, 2014, warrants giving right to 100,000 shares; a plan of 100,000 warrants was approved. Warrants were offered to Company’s newcomers (employees, non-employees and directors) in several tranches. Out of the warrants offered, 94,400 warrants were accepted by the beneficiaries and 35,698 warrants are outstanding as of December 31, 2021; • On November 5, 2015, warrants giving right to 466,000 shares; a plan of 466,000 warrants was approved. Warrants were offered to Company’s newcomers (employees, non-employees and directors) in several tranches. Out of the warrants offered, 353,550 warrants were accepted by the beneficiaries and 79,315 warrants are outstanding as of December 31, 2021; Page 97 | 180 2021 Annual Report • On December 8, 2016, warrants giving right to 100,000 shares; a plan of 100,000 warrants was approved. Warrants were offered to Company’s newcomers (employees, non-employees and directors) in two tranches. Out of the warrants offered, 45,000 warrants were accepted by the beneficiaries and 7,500 warrants are outstanding as of December 31, 2021; • On June 29, 2017, warrants giving right to 520,000 shares; a plan of 520,000 warrants was approved. Warrants were offered to employees, non-employees and directors in several tranches. Out of the warrants offered, 334,400 warrants were accepted by the beneficiaries and 282,251 warrants are outstanding as of December 31, 2021; • On October 26, 2018, warrants giving rights to 700,000 shares; 700,000 warrants have been issued in the framework of the authorized capital. 426,050 warrants were accepted by the beneficiaries, out of which 365,817 warrants are still outstanding as of December 31, 2021; • On October 25, 2019, warrants giving rights to 939,500 shares; 939,500 warrants have been issued in the framework of the authorized capital. 602,025 warrants were accepted by the beneficiaries, out of which 549,842 warrants are still outstanding as of December 31, 2021; • On December 11, 2020, warrants giving rights to 561,525 shares; 561,525 warrants have been issued in the framework of the authorized capital. 555,300 warrants were accepted by the beneficiaries, out of which 532,133 warrants are still outstanding as of December 31, 2021. • On October 11, 2021, warrants giving rights to 777,050 shares; 777,050 warrants have been issued in the framework of the authorized capital. 281,500 warrants were accepted by the beneficiaries, out of which 281,500 warrants are still outstanding as of December 31, 2021. As a result, as of December 31, 2021 there are 2,136,556 warrants outstanding which represent respectively 8.64% of the total number of all its issued and outstanding shares and 7.88% of the total voting financial instruments. For further information and overview of the features of the various warrant plans, refer to disclosure note 5.14. 3.4 Changes to the share capital In accordance with the CCA, the Company may increase or decrease its capital by decision of the Extraordinary General Shareholders’ Meeting taken with a majority of 75% of the votes cast, at a meeting where at least 50% of the share capital of the Company is present or represented. If the attendance quorum of 50% is not met, a new Extraordinary General Shareholders’ Meeting must be convened at which the shareholders may decide on the agenda items, irrespective of the percentage of share capital present or represented at such meeting. There are in this respect no conditions imposed by the Company’s articles of association that are more stringent than those required by law. Within the framework of the powers granted to it under the authorized capital, the Board of Directors may also increase the Company’s capital as specified in its articles of association. 3.5 Major Shareholders The information in the table below is based on information known to the Company or ascertained by the Company from public filings made by the shareholders as of the date of this Annual Report. On May 23, 2019 the Shareholders’ Meeting decided to voluntarily “opt in” and submit the Company to the new Belgian Code of Companies and Associations. Furthermore, the Shareholders’ Meeting decided to activate the possibility offered by Article 7:53 of the code of companies and associations and approved the grant of double voting right to the registered shares held by a shareholder in a registered form for more than two years. Page 98 | 180 2021 Annual Report As from May 3, 2021, Tolefi SA, a major shareholder of the Company, has been entitled to a double voting right for its 2,295,701 shares. NAME OF BENEFICIAL OWNER SHARES BENEFICIALLY OWNED 5% Shareholders CFIP CLYD LLC TOLEFI SA Directors and Members of the Executive Committee Michel Lussier [1] Serge Goblet Directors and Members of the Executive Committee as a group [1] Of which 145,150 are ordinary shares and 11,400 are ADSs. Number 6 500 000 2 295 701 156 550 56 180 212 730 Percentage 28.77% 10.16% 0.69% 0.25% 0,94% On the basis of the transparency notifications received by the Company as of the date of this Report, the two main shareholders are CFIP CLYD LLC (who holds 28.77% of the shares and 26.04 % of the voting rights) and TOLEFI SA (who holds 10.16% of the shares and 18.39 % of the voting rights). As a consequence, the two main shareholders of the Company hold together 44.43 % of the voting rights attached to the shares of the Company. 3.6 Anti-takeover provisions under Belgian laws Under Belgian law, public takeover bids for all the outstanding voting securities issued by the issuer are subject to the supervision of the FSMA. If the latter determines that a takeover violates Belgian law, it may lead to suspension of the exercise of the rights attached to any shares that were acquired in connection with the envisaged takeover. Pursuant to the Belgian law of April 1, 2007 on public takeovers, a mandatory takeover bid must be made when, as a result of its own acquisition or the acquisition by persons acting in concert with it, a person owns, directly or indirectly, more than 30% of the securities with voting rights in a company with registered office in Belgium whose securities are admitted to trading on a regulated or recognized market. The acquirer must offer to all other shareholders the opportunity to sell their shares at the highest of (i) the highest price offered by the acquirer for shares of the issuer during the 12 months preceding the announcement of the bid or (ii) the weighted average price of the shares on the most liquid market of the last 30 calendar days prior to the date on which the obligation of the acquirer to offer the takeover of the shares of other shareholders starts. As required by the article 34 of the Royal Decree of 14 November 2007, the following elements must be disclosed which may have an impact in the event of a takeover bid: a) Celyad’s capital structure, with an indication of the different classes of shares and, for each class of shares, the rights and obligations attached to it and the percentage of total share capital that it represents on 31 December 2020 As from the date of this Report, the share capital of the Company amounts to 49,427,200.33 EUR, represented by 14,205,156 shares of no-par value, fully paid up. There are no different classes of Celyad shares. b) Restrictions, either legal or prescribed by the articles of association, on the transfer of securities The articles of association of the Company do not contain any restriction on the transfer of the shares. c) Holders of any securities with special control rights and a description of those rights There are no such holders except specific shareholders with a double voting rights as described above. Page 99 | 180 2021 Annual Report d) System of control of any employee share scheme where the control rights are not exercised directly by the employees There is no such system. e) Restrictions, either legal or prescribed by the articles of association, on the exercise of voting rights There are no such restrictions. f) Agreements between shareholders which are known to Celyad and may result in restrictions on the transfer of securities and/or the exercise of voting rights The Company has no knowledge of agreements which may result in restrictions on the transfer of its securities and/or the exercise of voting rights. g) Rules governing the appointment and replacement of directors: The Chairperson of the Board is in charge of the nomination procedure. The Board is responsible for proposing members for nomination to the shareholders’ meeting, in each case based on the recommendation of the Nomination & Remuneration Committee. For any new appointment to the Board, the skills, knowledge and experience already present and those needed on the Board will be evaluated and, in the light of that evaluation, a description of the role and skills, experience and knowledge needed will be prepared (a “profile”). When dealing with a new appointment, the Chairperson of the Board must ensure that, before considering the candidate, the Board has received sufficient information such as the candidate’s curriculum vitae, an assessment of the candidate based on the candidate’s initial interview, a list of the positions the candidate currently holds, and, if applicable, the necessary information for assessing the candidate’s independence. If a legal entity is appointed as a director, it is obliged to appoint, in accordance with the provisions of the CCA, a natural person as a permanent representative, who may represent the legal entity in all its dealings with the Company. The legal entity director may not dismiss its permanent representative without simultaneously appointing a new representative. Any proposal for the appointment of a director by the shareholders’ meeting should include a recommendation from the Board based on the advice of the Nomination & Remuneration Committee. This provision also applies to shareholders’ proposals for appointment. The proposal must specify the proposed term of the mandate, which must not exceed four years. It must be accompanied by relevant information on the candidate’s professional qualifications together with a list of the positions the candidate already holds. The Board will indicate whether the candidate satisfies the independence criteria. Until such time as the Fortress Shareholders own in the aggregate less than 10% of the then outstanding shares (including shares underlying American Depositary Shares) for a period of more than thirty (30) consecutive days: (i) (ii) Fortress shall have the right to select two (2) individuals (the “Fortress Designees”) to be, at Fortress’s option, (a) members of the Board, (b) non-voting observers of the Board or (c) a combination thereof (provided that if Fortress selects both Fortress Designees to be members of the Board, Fortress may also select a third Fortress Designee to be a non- voting observer of the Board), and the Board, at Fortress’s option, (a) shall recommend the confirmation or (re)appointment of any two (2) Fortress Designees as members of the Board at any applicable general meeting of shareholders of the Company, (b) shall appoint any two (2) Fortress Designees as non- Page 100 | 180 2021 Annual Report voting observers of the Board or (c) shall proceed to a combination thereof, and (iii) (iv) Upon the termination of the board mandate of any Fortress Designee (for whatever cause), at the option of Fortress, (a) the Company shall as soon as practicably possible co-opt to the Board a replacement Fortress Designee, and shall use best efforts to cause the confirmation of the co-optation at the next general meeting of shareholders of the Company; or (b) the Company shall as soon as practicably possible approve the appointment of a replacement Fortress Designee as a non-voting observer of the Board of Directors, and the Company shall not, directly or indirectly, without the consent of recommend, directly or indirectly, or take any action to (a) increase the size of the Board or (b) co-opt or appoint to the Board, in place of the Fortress Designees, any individual other than a Fortress Designee. Outgoing directors will remain in office for as long as the shareholders’ meeting, for whatever reason, has not filled the vacancy. Appointments are generally made for a maximum term of four years. Outgoing directors will be eligible for re-election. However, when an independent director has served on the Board for more than 12 years, he is in not eligible for a fourth term as independent director of the Company. Before proposing any director for re-election, the Board should take into account the evaluations made by the Nomination & Remuneration Committee. The mandates of those directors who are not re- appointed for a new term will terminate immediately after the shareholders’ meeting which decides on any re-appointment or appointment. The directors may be revoked by the shareholders’ meeting at any time. If at any time a vacancy is created on the Board of Directors, the remaining directors may temporarily appoint a director to the board to fill the vacancy. Any director so appointed will hold office for the remainder of the term of appointment of the director that it replaces. The definitive appointment of the replacing director is added to the agenda of the following shareholders’ meeting. h) Rules governing the amendment of the articles of association Pursuant to the CCA, any amendment to the articles of association such as an increase or decrease in the capital of the Company, and certain other matters such as the approval of the dissolution, merger or de-merger may only be authorized with the approval of at least 75% of the votes validly cast at an Extraordinary General Shareholders’ Meeting where at least 50% of the Company’s share capital is present or represented. If the attendance quorum of 50% is not met, a new Extraordinary General Shareholders’ Meeting must be convened at which the shareholders may decide on the agenda items, irrespective of the percentage of share capital present or represented at such meeting. i) Powers of the Board of Directors in particular to issue or buy back shares The Board of Directors has the most extensive powers in order to perform all acts which are useful or necessary so as to complete the Company’s corporate purpose. The Board of Directors has the power to perform all acts which are not expressly assigned by law or by the articles of association to the shareholders’ meeting. However, until such time as the Fortress Shareholders own in the aggregate less than 10% of the then outstanding shares (including shares underlying American Depositary Shares) for a period of more than thirty (30) consecutive days, the Company shall not, directly or indirectly, without the consent of Fortress, (a) incur or issue any indebtedness that would encumber any intellectual property of the Company, (b) issue any Equity Securities (defined as any share and any other security, financial instrument, certificate or other right (including options, futures, swaps and other derivatives) representing, being exercisable, convertible or exchangeable into or for, or otherwise providing a right to acquire, directly or indirectly, any of the securities mentioned above or any other security or financial instrument the value of which is based on any of the foregoing) of the Company Page 101 | 180 2021 Annual Report that are senior to the ordinary shares with respect to the right to receive (x) dividends or other distributions to shareholders or (y) proceeds in the event of the liquidation, dissolution or winding- up of the Company (including for such purposes in connection with any change of control transaction), (iii) alter, amend or change the rights, preference or privileges of the shares, including in connection with any reclassification, recapitalization, reorganization or restructuring, (iv) make any proposal to amend, repeal or otherwise modify any provision of the Company’s articles of association that would be reasonably expected to adversely affect the interests of Fortress or any Fortress Shareholder or (v) make any proposal to modify the rights of any Equity Securities of the Company in a manner adverse to any Fortress Shareholder. The Board of Directors has to power to establish an audit committee and other committees, the powers of which it will determine. On June 8, 2020, an extraordinary shareholders meeting of the Company granted to the Board of Directors the power to increase the share capital in accordance with the articles 7:198 et sq. of the CCA, in one or several times, for a maximum amount of €48,512,614.57 (excluding issue premium), for a period of 5 years as of the publication of the modification to the articles of association of the Company. Furthermore, in accordance with article 7:202 of the CCA, the Board of Directors is empowered to proceed with a share capital increase even after receipt by the Company of a notification by the FSMA of a takeover bid for the Company’s share, for a period of three years from June 8, 2020. When increasing the share capital within the limits of the authorized capital, the Board of Directors may, in the Company’s interest, restrict or cancel the shareholders’ preferential subscription rights, even if such restriction or cancellation is made for the benefit of one or more specific persons other than the employees of the Company or its subsidiaries. The Board of Directors is not allowed to buy back shares. Regarding agreements on severance pay, reference is made to the Remuneration Report. j) Significant agreements to which the Celyad is a party and which take effect, alter or terminate upon a change of control of Celyad following a takeover bid, and the effects thereof, except where their nature is such that their disclosure would be seriously prejudicial to Celyad; this exception shall not apply where Celyad is specifically obliged to disclose such information on the basis of other legal requirements There are no such agreements. k) Agreements between Celyad and its Board members or employees providing for compensation if the Board members resign or are made redundant without valid reason or if the employment of the employees ceases because of a takeover bid There are no such agreements. 3.7 Financial services Citibank N.A. is acting as depositary bank for the ADS issued by the Company. Page 102 | 180 2021 Annual Report 4. CONSOLIDATED FINANCIAL STATEMENTS 4.1 Responsibility statement We hereby certify that: • • To the best of our knowledge, the consolidated financial statements as of December 31, 2021, prepared in accordance with the International Financial Reporting Standards as issued by the International Accounting Standards Board and as adopted by the European Union, and the legal requirements applicable in Belgium, give a true and fair view of the assets, liabilities, financial position, comprehensive loss, changes in equity and cash flows of the Company and the undertakings included in the consolidation taken as a whole; and that The management report includes a fair review of the development and the performance of the business and the position of the Company and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties that they face. March 24, 2022 on behalf of the Board of Directors, MEL Management SRL Represented by Michel Lussier Chairman Filippo Petti CEO Page 103 | 180 4.2 Statutory auditor’s report to the general meeting of shareholders of Celyad Oncology SA for the year ended December 31, 2021 (consolidated financial statements) 2021 Annual Report Page 104 | 180 2021 Annual Report Page 105 | 180 2021 Annual Report Page 106 | 180 2021 Annual Report Page 107 | 180 2021 Annual Report Page 108 | 180 4.3 Consolidated financial statements as at December 31, 2021 4.3.1. Consolidated statements of financial position 2021 Annual Report (€’000) NON-CURRENT ASSETS Goodwill and Intangible assets Property, Plant and Equipment Non-current Trade and Other receivables Non-current Grant receivables Other non-current assets CURRENT ASSETS Trade and Other Receivables Current Grant receivables Other current assets Short-term investments Cash and cash equivalents TOTAL ASSETS EQUITY Share Capital Share premium Other reserves Capital reduction reserve Accumulated deficit NON-CURRENT LIABILITIES Bank loans Lease liabilities Recoverable Cash advances (RCAs) Contingent consideration payable and other financial liabilities Post-employment benefits Other non-current liabilities CURRENT LIABILITIES Bank loans Lease liabilities Recoverable Cash advances (RCAs) Trade payables Other current liabilities TOTAL EQUITY AND LIABILITIES Notes December 31, 2021 December 31, 2020 (as adjusted)1 5.6 5.7 5.8 5.8 5.8 5.9 5.9 5.9 5.10 5.11 5.13 5.13 5.13, 5.22 5.2.16, 5.13 5.2.16, 5.13 5.19 5.19 5.16 5.20 5.15 5.17 5.19 5.19 5.16 5.18 5.18 45 651 36 168 3 248 2 209 3 764 262 34 292 668 1 395 2 211 46 379 36 171 4 119 2 117 3 679 293 19 705 615 145 1 711 - - 30 018 79 943 43 639 78 585 6 317 33 172 234 562 (308 997) 22 477 - 1 730 5 851 14 679 53 164 13 827 - 902 362 6 611 5 952 79 943 17 234 66 084 30 994 48 513 43 349 30 958 191 213 (283 039) 23 256 - 2 525 4 220 15 526 614 371 11 834 37 1 076 371 4 736 5 614 66 084 (1) For information on voluntary change in accounting policy, see note 5.2.16. The accompanying disclosure notes form an integral part of these consolidated financial statements. Page 109 | 180 4.3.2. Consolidated statements of comprehensive loss 2021 Annual Report (€'000) Revenue Cost of sales Gross profit Research and Development expenses General & Administrative expenses Change in fair value of contingent consideration Other income Other expenses Operating Loss6 Financial income Financial expenses Loss before taxes Income taxes Loss for the period Basic and diluted loss per share (in €) 5.32 Other comprehensive income/(loss) Items that will not be reclassified to profit and loss Remeasurements of post-employment benefit obligations, net of tax Items that may be subsequently reclassified to profit or loss Currency translation differences Other comprehensive income / (loss) for the period, net of tax Total comprehensive loss for the period Total comprehensive loss for the period attributable to Equity Holders (1) For the year ended December 31, Notes 2021 2020 5.23 - 5 5.24 5.25 5.28 5.28 5.28 5.31 5.31 - - - 5 (20 773) (21 522) (9 908) (9 315) 847 9 228 4 909 4 731 (1 466) (26 391) 144 (255) (114) (16 987) 217 (434) (26 502) (17 204) 5.21 (10) (26 512) (1.70) 554 554 42 42 596 - (17 204) (1.23) (197) (197) (5) (5) (202) (25 916) (25 916) (17 406) (17 406) [1] For 2021 and 2020, the Group does not have any non-controlling interests and the losses for the year are fully attributable to owners of the parent. The accompanying disclosure notes form an integral part of these consolidated financial statements. 6 The operating loss arises from the Company’s loss for the period before deduction of financial income, financial expenses and income taxes. The purpose of this measure by Management is to identify the Company’s results in connection with its operating activities. Page 110 | 180 4.3.3. Consolidated statements of changes in equity 2021 Annual Report (€’000) Balance as of January 1, 2020 (as adjusted)1 Share-based payments Total transactions with owners, recognized directly in equity Loss for the period Currency Translation differences Remeasurements of defined benefit obligation Total comprehensive loss for the period Balance as of December 31, 2020 (as adjusted)1 Balance as of January 1, 2021 (as adjusted)1 Capital increase Transaction costs associated with capital increases Reduction of share premium by absorption of losses Share-based payments Total transactions with owners, recognized directly in equity Loss for the period Currency Translation differences Remeasurements of defined benefit obligation Total comprehensive loss for the period Balance as of December 31, 2021 Share capital (non- distributabl e) Share premium (non- distributabl e) Other reserves 7 (distributab le²) Capital reduction reserve (distributab le²) Accumulated deficit (distributable ²) Total Equity 48 513 43 349 28 181 191 213 (265 637) 45 619 - - - - - - - - - - - - 2 782 2 782 - (5) - (5) - - - - - - - - 2 782 2 782 (17 204) - (17 204) (5) (197) (197) (17 402) (17 406) 48 513 43 349 30 958 191 213 (283 039) 30 994 48 513 43 349 30 958 191 213 (283 039) 30 994 30 072 8 900 (2 583) (43 349) - - - - - - - - 43 349 - - 38 972 - - - (2 583) - 2 172 - 2 172 30 072 (37 032) 2 172 43 349 - 38 561 - - - - - - - - - 42 - 42 - - - - (26 512) - (26 512) 42 554 554 (25 958) (25 916) 78 585 6 317 33 172 234 562 (308 997) 43 639 (1) For information on voluntary change in accounting policy, see note 5.2.16. (2) Pursuant to Belgian law (“CCA”), the calculation of amounts available for distribution to shareholders, as dividends or otherwise, must be determined on the basis of the Company’s standalone non-consolidated statutory financial statements of Celyad Oncology SA prepared under Belgian GAAP, and not on the basis of IFRS consolidated financial statements. For more information, see note 5.13. The accompanying disclosure notes form an integral part of these consolidated financial statements. 7 Other reserves includes Share-base payment reserve, Other equity reserve from conversion of convertible loan in 2013 and Currency Translation Difference. Page 111 | 180 4.3.4. Consolidated statements of Cash flows (€'000) Cash Flow from operating activities Loss for the period Non-cash adjustments Intangibles - Amortization and impairment Property, plant & equipment - Depreciation Loss on disposal of Property, plant and equipment Gain on sales of Property, plant & equipment Provision for onerous contract Change in fair value of contingent consideration payable and other financial liabilities Remeasurement of Recoverable Cash Advances (RCAs) Grant income (RCAs and others) Share-based payment expense Post-employment benefits Change in working capital Trade receivables, other (non-)current receivables Trade payables, other (non-)current liabilities Net cash used in operations Cash Flow from investing activities Acquisition of Property, Plant & Equipment Acquisitions of Intangible assets Disposals of Property, Plant & Equipment Proceeds from net investment in lease Proceeds from short-term investments Net cash from/(used in) investing activities Cash Flow from financing activities Repayments of bank borrowings Repayments of leases Proceeds from issuance of shares and exercise of warrants Proceeds from RCAs & other grants Repayment of RCAs & other grants Net cash from/(used in) financing activities Net cash and cash equivalents at beginning of the period Change in Cash and cash equivalents Effects of exchange rate changes on cash and cash equivalents Net cash and cash equivalents at the end of the period 2021 Annual Report For the year ended December 31, Notes 2021 2020 4.3.2 (26 512) (17 204) 5.6 5.7 5.28 5.28 217 1 303 1 197 1 635 10 - (35) 5.17, 5.18 29 858 5.20 5.19 5.28 5.14 5.15 (847) (9 228) 328 (933) (4 178) (3 089) 2 172 (561) 2 782 216 (1 559) (1 148) 2 964 (1 726) (26 643) (27 665) 5.7 5.6 5.7 5.9 (331) (150) (62) (169) - 267 235 241 5.10 - - (126) 157 5.19 5.19 5.13 5.19 (37) (192) (1 099) (1 255) 36 568 - 4 369 7 272 5.18, 5.19 (280) (429) 39 521 17 234 5 396 39 338 5.11 12 752 (22 112) 32 30 018 8 17 234 The accompanying disclosure notes form an integral part of these consolidated financial statements. Page 112 | 180 2021 Annual Report 5. Notes to the consolidated financial statements 5.1 General information Celyad Oncology SA and its affiliates will be collectively referred to as “the Company”, “the Group”, “Celyad”, “we” or “us”. The Company is a clinical-stage biopharmaceutical company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. Celyad Oncology SA was incorporated on July 24, 2007 under the name “Cardio3 BioSciences”. Celyad is a limited liability company (Société Anonyme) governed by Belgian law with its registered office at Axis Parc, Rue Edouard Belin 2, B-1435 Mont-Saint-Guibert, Belgium (company number 0891.118.115). On June 8, 2020, the Company announced the launch of its corporate rebranding, including changing its name to Celyad Oncology. The new name highlights the Company’s significant progress with its next- generation CAR T programs and emphasizes its commitment to cancer patients. The Company’s ordinary shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris regulated markets and the Company’s American Depositary Shares (ADSs) are listed on the Nasdaq Global Market, all under the ticker symbol CYAD. The Company has three fully owned subsidiaries (together, the Group) located in Belgium (Biological Manufacturing Services SA) and in the United States (Celyad Inc. and Corquest Medical, Inc.). These consolidated financial statements have been approved for issuance by the Company’s Board of Directors on March 24, 2022. These statements have been audited by SRL EY Bedrijfsrevisoren-Réviseurs d’Entreprises, the statutory auditor of the Company and independent registered public accounting firm. The annual report is available to the public free of charge to the above-mentioned address or via the Company’s website (https://celyad.com/investors/regulated-information/). 5.2 Basis of preparation and significant accounting policies The consolidated financial statements of the Group for the twelve months ended December 31, 2021 and 2020 (the “year” or “the period”) include Celyad Oncology SA and its subsidiaries. The significant accounting policies used for preparing these consolidated financial statements are explained below. 5.2.1. Basis of preparation The consolidated financial statements have been prepared on an historical cost basis, except for: • Financial instruments – Fair value through profit or loss • Contingent consideration and other financial liabilities • Post-employment benefits liability The policies have been consistently applied to all the years presented, unless otherwise stated. The consolidated financial statements are presented in euro and all values are presented in thousands (€000) except when otherwise indicated. Amounts have been rounded off to the nearest thousand and in certain cases, this may result in minor discrepancies in the totals and sub totals disclosed in the financial tables. ‐ Page 113 | 180 2021 Annual Report Statement of compliance The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards, International Accounting Standards and Interpretations (collectively, IFRSs) as issued by the International Accounting Standards Board (IASB) and as endorsed by the European Union. The preparation of the consolidated financial statements in accordance with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgment or complexity, are areas where assumptions and estimates are significant to the financial statements. They are disclosed in note 5.4. Going concern The Group is pursuing a strategy to develop therapies to treat medical needs in oncology. Management has prepared detailed budgets and cash flow forecasts for the years 2022 and 2023. These forecasts reflect the strategy of the Group and include significant expenses and cash outflows in relation to the development of selected research programs and product candidates, partly compensated by grants funding and tax incentives. As of December 31, 2021, the Company had cash and cash equivalents of €30.0 million and no short-term investments. On January 8, 2021, the Company entered into a committed equity purchase agreement (“Purchase Agreement”) over a 24-month term for up to $40.0 million with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which LPC’s purchases are subject to certain conditions, including that the Company may only deliver a Regular Purchase Notice (as that term is defined in the Purchase Agreement) of its ADSs so long as the adjusted price of its ADSs exceeds $1.00. Over the remaining lifetime of the Purchase Agreement, the Company will have the right to direct LPC to purchase up to an aggregate remaining amount of $28.0 million ADSs, each of which represents one of our ordinary shares. As of December 31, 2021, the remaining amount of $28.0 million of this equity purchase agreement is expected to strengthen the Company’s current statement of financial position while also providing the Company with access to future capital on an as needed basis and to ensure sufficient funding to cover its operations for the next 12 months from the date the financial statements are issued. Based on its current scope of activities, the Company estimates that its cash and cash equivalents as of December 31, 2021 combined with the remaining access to the equity purchase agreement established with Lincoln Park Capital Fund, LLC (remaining amount of $28.0 million as of December 31, 2021) should be sufficient to fund operating expenses and capital expenditure requirements until mid-2023. COVID-19 update On March 11, 2020, the World Health Organization declared the novel strain of coronavirus (COVID-19) a global pandemic and recommended containment and mitigation measures worldwide. Throughout 2020 and 2021, Belgium and the United States, where the Company operates, were impacted by temporary closures. While progress has been made in the fight against the ongoing COVID-19 pandemic, including the broad dissemination and administration of vaccines in certain countries, the COVID-19 pandemic has continued to spread globally. The length or severity of this pandemic cannot be predicted, but the Company anticipates that there may continue to be additional impacts from a prolonged COVID-19 environment on the planned development activities of the Company. To date, COVID-19 has had no impact on the Group’s financial statements and corporate cash flow, and the Group expects that its existing cash and cash equivalents combined with the remaining access to the equity purchase agreement established with Lincoln Park Capital Fund, LLC (remaining amount of $28.0 million as of December 31, 2021) should be sufficient, based on the current scope of activities, to fund operating expenses and capital expenditure requirements until mid-2023. With regards to the Company’s clinical programs, no major disruption in enrollment were experienced in the CYAD-101, CYAD-211 or CYAD-02 programs in 2021 due to the coronavirus pandemic. Enrollment in the respective trials for CYAD-101 and CYAD-211 is ongoing without any major disruption due to the coronavirus pandemic, however future Page 114 | 180 2021 Annual Report disruptions may occur. However, since 2020, certain clinical sites and institutions have not been able to receive visits from the Company or its representatives during the coronavirus pandemic, which has delayed its data monitoring activities and delayed its ability to lock the databases for completed studies. The long-term impact of COVID-19 on the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted, including the emergence of new variants, such as Delta and Omicron, and, among other things, additional government restrictions intended to contain COVID-19’s effects, but potential prolonged closures or other business disruptions may negatively affect its operations and the operations of its agents, contractors, consultants or collaborators, which could have a material adverse impact its business, results of operations and financial condition. Changes to accounting standards and interpretations The Group has applied the same accounting policies and methods of computation in its 2021 year-end consolidated financial statements as compared to 2020, except for those that relate to new standards and interpretations. None of the new standards, interpretations and amendments, which are effective for periods beginning after January 1, 2021 which have been issued by the IASB and the IFRIC have a material effect on the Group’s financial statements. None of the new standards, interpretations and amendments, which will be effective for periods beginning after January 1, 2022 and are not yet effective as of December 31, 2021 and/or not yet adopted by the European Union as of December 31, 2021, are expected to have a material effect on the Group's future financial statements as either they are not relevant to the Group’s activities, or they require accounting which is consistent with the Group’s current accounting policies. 5.2.2. Consolidation Subsidiaries Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date control ceases. Inter-company transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group’s accounting policies. 5.2.3. Foreign currency translation Functional and presentation currency Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The consolidated financial statements are presented in Euros, which is the Group’s presentation currency. Transactions and balances Foreign currency transactions (mainly USD) are translated into the functional currency using the applicable exchange rate on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are retranslated at the presentation currency spot rate of exchange ruling at the reporting date. Page 115 | 180 2021 Annual Report Foreign currency exchange gains and losses arising from settling foreign currency transactions and from the retranslation of monetary assets and liabilities denominated in foreign currencies at the reporting date are recognized in the income statement. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as of the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. Group companies The results and financial position of all group entities that have a functional currency different from the presentation currency are translated into the presentation currency as follows: • Assets and liabilities for each statement of financial position presented are translated at the closing rate at the date of that statement of financial position; • Income and expenses for each income statement are translated at average exchange rate (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions); and • All resulting translation differences are recognized in other comprehensive income. 5.2.4. Revenue So far, the primary revenue generated by the Group relates to the sale of licenses. Licensing revenue The Group enters into license and/or collaboration agreements with third-party biopharmaceutical partners. Revenue under these arrangements may include non-refundable upfront payments, product development milestone payments, commercial milestone payments and/or sales-based royalty payments. Upfront payments License fees representing non-refundable payments received at the time of signature of license agreements are recognized as revenue upon signature of the license agreements when the Group has no significant future performance obligations and collectability of the fees is assured. Milestone payments Milestone payments represent amounts received from the Group’s customers or collaborators, the receipt of which is dependent upon the achievement of certain scientific, regulatory, or commercial milestones. Under IFRS 15, milestone payments generally represent a form of variable consideration as the payments are likely to be contingent on the occurrence of future events. Milestone payments are estimated and included in the transaction price based on either the expected value (probability-weighted estimate) or most likely amount approach. The most likely amount is likely to be most predictive for milestone payments with a binary outcome (i.e., the Group receives all or none of the milestone payment). Variable consideration is only recognized as revenue when the related performance obligation is satisfied, and the Group determines that it is highly probable that there will not be a significant reversal of cumulative revenue recognized in future periods. Royalty revenue Royalty revenues arise from the Group’s contractual entitlement to receive a percentage of product sales achieved by co-contracting parties. As the Group’s co-contracting partners currently have no products based on a Celyad-technology approved for sale. The Group has not received any royalty revenue to date. Royalty Page 116 | 180 revenues, if earned, will be recognized on an accrual basis in accordance with the terms of the contracts with the Group’s customers when sales occur and there is reasonable assurance that the receivables from outstanding royalties will be collected. 2021 Annual Report 5.2.5. Other income Government Grants The Group’s grant income reported under ‘Other income’ in the consolidated statement of comprehensive loss is generated from: (i) recoverable cash advances (RCAs) granted by the Regional government of Wallonia; (ii) R&D tax credits granted by the Belgian federal government; and (iii) grants received from the European Commission under the Seventh Framework Program (“FP7”), Federal Belgian Institute for Health Insurance (Inami) and Regional authorities. Government grants are recognized at their fair value (calculated based on present value of future repayment of grants) where there is reasonable assurance that the grant will be received, and the Group will comply with all attached conditions. Once a government grant is recognized, any related contingent liability (or contingent asset) is treated in accordance with IAS 37. Government grants relating to costs are deferred and recognized in the consolidated statement of comprehensive loss over the period necessary to match them with the costs that they are intended to compensate. Based on the nature of transactions, cash inflows received from government grants provide the entity with financing for the designated activity. They are in substance financing cash inflows consistent with the cash proceeds from RCAs and other grants and are disclosed in the consolidated statements of cash flows as “Cash Flow from financing activities”. The Group’s grant income is recognized in the consolidated statement of comprehensive loss under “Other income/expense” and as a non-cash adjustment in “cash flows from operating activities” in the consolidated statements of cash flows. Recoverable cash advances (RCAs) The Group receives grants from the Walloon Region in the form of recoverable cash advances (RCAs). RCAs are dedicated to support specific development programs. All RCA contracts, in essence, consist of three phases, i.e., the “research phase”, the “decision phase” and the “exploitation phase”. During the research phase, the Group receives funds from the Region based on statements of expenses. In accordance with IAS 20.10A and IFRS Interpretations Committee (IC)’s conclusion that contingently repayable cash received from a government to finance a research and development (R&D) project is a financial liability under IAS 32, ‘Financial instruments; Presentation’, the RCAs are initially recognized, concomitantly with the occurrence of subsidized expense, as a financial liability at fair value (calculated based on present value of future repayment of grants), determined as per IFRS 9. The benefit (RCA grant component) consisting in the difference between the cash received (RCA proceeds) and the above-mentioned financial liability’s fair value (RCA liability component) is treated as a government grant in accordance with IAS 20. The RCA grant component is recognized in profit or loss under "Other income" on a systematic basis over the periods in which the entity recognizes the underlying R&D expenses subsidized by the RCA. The fair market value adjustments to the RCA liability are recognized in the consolidated statement of comprehensive loss under “Other income/expense” and as a non-cash adjustment in “cash flows from operating activities” in the consolidated statements of cash flows. Page 117 | 180 2021 Annual Report The RCAs liability contains two components: • • The fixed part of the reimbursement of 30% is refundable based upon an agreed repayment schedule. The initial recognition at fair value is performed using the discount rate at the date of the convention and the assumption of exploitation until the end of repayment schedule. The variable part (from 70% and up to 170%) is refundable to the extent of the revenue generated within exploitation phase. The initial recognition at fair value of the variable part of the component is based on probability-weighted discounted cash flows estimated using Key assumptions listed in note 5.6.2. The sales-independent reimbursements and sales-dependent reimbursements are, in the aggregate (including the accrued interests), capped at 200% of the principal amount paid out by the Walloon Region. The RCAs liability component (RCA financial liability) is subsequently measured at amortized cost using the cumulative catch-up approach under which the carrying amount of the liability is adjusted to the present value of the future estimated revenue, discounted at the liability’s original effective interest rate. The resulting adjustment is recognized within profit or loss under “Other income/expense”. At the end of the research phase, the Group should within a period of six months decide whether or not to exploit the results of the research phase (decision phase). The exploitation phase may have a duration of up to 20 years. In the event the Group decides to exploit the results under an RCA, the relevant RCA becomes contingently refundable, and the fair value of the RCA liability adjusted accordingly, if required. For more information on the potential financial consequences of these exploitation decisions in terms of potential reimbursements and sales % fees to be paid to the Walloon Region, refer to note 5.16. When the Group does not exploit (or ceases to exploit) the results of programs under an RCA, it has to notify the Region of this decision. This decision is the sole responsibility of the Group. The related liability is then discharged by the transfer of such results to the Region. Also, when the Group decides to renounce its rights to patents which may result from the research, title to such patents will be transferred to the Region. In that case, the RCA liability is extinguished and reflected in the statement of income (loss) under “Other income/expense”. R&D Tax credits Since 2013, the Group applies for R&D tax credits, a tax incentive measure for European SME’s established by the Belgian federal government. When capitalizing its R&D expenses under the tax reporting framework, the Group may either i) get a reduction of its taxable income (at current income tax rate applicable); or ii) if no sufficient taxable income is available, apply for the refund of the unutilized tax credits, calculated on the R&D expenses amount for the year. Such settlement occurs at the earliest 5 financial years after the tax credit application filed by the Group. Considering that R&D tax credits are ultimately paid by the public authorities, the related benefit is treated as a government grant under IAS 20 and booked into other income, in order to match the R&D expenses subsidized by the grant. Other government grants The Group has received and will continue to apply for grants from European (FP7), Regional authorities and Federal Belgian Institute for Health Insurance (Inami). These grants are dedicated to partially finance early stage projects such as fundamental research, applied research, prototype design, etc. To date, all grants received are not associated with any conditions. As per each grant contract, grants are paid upon submission by the Group of a statement of eligible expenses. The Group incurs project expenses first and asks for partial refunding according to the terms of the contracts. Page 118 | 180 2021 Annual Report These government grants are recognized in profit or loss under "Other income" on a systematic basis over the periods in which the entity recognizes the underlying R&D expenses subsidized. 5.2.6. Intangible assets The following categories of intangible assets apply to the current Group operations: Separately acquired intangible assets Intangible assets acquired from third parties are recognized at cost, if and only if it is probable that future economic benefits associated with the asset will flow to the Group, and that the cost can be measured reliably. Subsequent payments of contingent consideration are capitalized when incurred. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. The useful life of intangible assets is assessed as finite, except for Goodwill. They are amortized over the expected useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates and applied prospectively. The amortization expense on intangible assets with finite lives is recognized in the income statement in the expense category consistent with the function of the intangible asset. Patents, Licenses and Trademarks Licenses for the use of intellectual property are granted for a period corresponding to the intellectual property of the assets licensed. Amortization is calculated on a straight-line basis over this useful life. Patents and licenses are amortized over the period corresponding to the intellectual property (IP) protection and are assessed for impairment whenever there is an indication these assets may be impaired. Indication of impairment is related to the value of the patent demonstrated by the preclinical and clinical results of the technology. Software Software only concerns acquired computer software licenses. Software is capitalized on the basis of the costs incurred to acquire and bring to use the specific software. These costs are amortized over their estimated useful lives of three to five years on a straight-line basis. Intangible assets acquired in a business combination Goodwill Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is measured as a residual at the acquisition date, as the excess of the fair value of the consideration transferred and the assets and liabilities recognized (in accordance with IFRS 3). Goodwill has an indefinite useful life and is not amortized but tested for impairment at least annually or more frequently whenever events or changes in circumstances indicate that goodwill may be impaired, as set forth in IAS 36 (Impairment of Assets). Page 119 | 180 2021 Annual Report Goodwill arising from business combinations is allocated to cash generating units, which are expected to receive future economic benefits from synergies that are most likely to arise from the acquisition. These cash generating units form the basis of any future assessment of impairment of the carrying value of the acquired goodwill. In-process research and development costs The In-process research and development costs (“IPR&D”) acquired as part of a business combination are measured at fair value at the date of acquisition. Subsequent to initial recognition, it is reported at cost and is subject to annual impairment testing until the date the projects are available for use and from that moment, the IPR&D will be amortized over its remaining useful economic life. Subsequent R&D expenditure can be capitalized as part of the IPR&D only to the extent that IPR&D is in development stage, i.e., when such expenditure meets the recognition criteria of IAS 38. In line with biotech industry practice, the Group determines that ‘development stage’ under IAS 38 is reached when the product candidate gets regulatory approval (upon Phase III completion). Therefore, any R&D expenditure incurred between the acquisition date and the development stage should be treated as part of research phase and expensed periodically in the income statement. Internally generated intangible assets Except qualifying development expenditure (discussed below), internally generated intangible assets are not capitalized. Expenditure is reflected in the income statement in the year in which the expenditure is incurred. Research and development costs Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset when the Group can demonstrate: (a) The technical feasibility of completing the intangible asset so that it will be available for use or sale. (b) Its intention to complete the intangible asset and use or sell it. (c) Its ability to use or sell the intangible asset. (d) How the intangible asset will generate probable future economic benefits. Among other things, the entity can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset. (e) The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset. (f) Its ability to measure reliably the expenditure attributable to the intangible asset during its development. For the industry in which the Group operates, the life science industry, criteria a) and d) tend to be the most difficult to achieve. Experience shows that in the Biotechnology sector technical feasibility of completing the project is met when such project completes successfully Phase III of its development. For medical devices this is usually met at the moment of CE marking. Following initial recognition of the development expenditure as an asset, the cost model is applied requiring the asset to be carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when development has been completed and the asset is available for use. It is amortized over the period of expected future benefit. Amortization is recorded in Research & Development expenses. During the period of development, the asset is tested for impairment annually, or earlier when an impairment indicator occurs. As of statement of financial position dates, only the Page 120 | 180 2021 Annual Report development costs of C-Cathez have been capitalized and are being amortized over a period of 17 years which corresponds to the period over which the intellectual property is protected. 5.2.7. Property, plant and equipment Property, plant and equipment is stated at cost, net of accumulated depreciation and/or accumulated impairment losses, if any. Repair and maintenance costs are recognized in the income statement as incurred. Depreciation is calculated on a straight-line basis over the estimated useful life of the asset as follows: • Land and buildings: 15 to 20 years • Plant and equipment: 5 to 15 years • Laboratory equipment: 3 to 5 years • Office furniture: 3 to 10 years • Leasehold improvements: based on remaining duration of office building lease • Right-of-use assets: over lease term An item of property, plant and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the asset is derecognized. The assets’ residual values, useful lives and methods of depreciation are reviewed at each financial year end, and adjusted prospectively, if applicable. 5.2.8. Leases The determination of whether an arrangement is, or contains, a lease is based on the substance of the arrangement at inception date: whether fulfilment of the arrangement is dependent on the use of a specific asset or assets or the arrangement conveys a right to use the asset. The Group leases various offices, facilities, cars and IT-equipment. Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: • Fixed payments (including in-substance fixed payments), less any lease incentives receivable; • Variable lease payment that are based on an index or a rate; • Amounts expected to be payable by the lessee under residual value guarantees; • The exercise price of a purchase option if the lessee is reasonably certain to exercise that option; and • Payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. Page 121 | 180 2021 Annual Report The lease term covers the non-cancellable period for which the Group has the right to use an underlying asset, together with both: (a) Periods covered by an option to extend the lease if the Group is reasonably certain to exercise that option; and (b) Periods covered by an option to terminate the lease if the Group is reasonably certain not to exercise that option. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be determined, the lessee’s incremental borrowing rate is used, being the rate that the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions. Right-of-use assets are measured at cost comprising the following: • The amount of the initial measurement of lease liability; • Any lease payments made at or before the commencement date less any lease incentives received; • Any initial direct costs; and • Restoration costs. Payments associated with short-term leases and leases of low-value assets are recognized on a straight- line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less. Low-value assets primarily comprise IT-equipment. The Group subleases some office space it leases from a head lessor. In its capacity as intermediate lessor, the Group assesses whether the sublease is a finance or operating lease in the context of the right-of-use asset being leased. The sublease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership of the underlying right-of-use asset. It is classified as an operating lease if it does not transfer substantially all the risks and rewards incidental to ownership of the underlying right-of- use asset. From time to time, the Group may enter into sale and leaseback transactions. When a sale occurs, both the seller-lessee and the buyer-lessor account for the leaseback in the same manner as any other lease. Specifically, the seller-lessee recognizes a lease liability and right-of-use asset for the leaseback (subject to the optional exemptions for short-term leases and leases of low-value assets). 5.2.9. Impairment of non-financial assets The Group assesses at each reporting date whether there is an indication that an asset may be impaired, unless there are indications of impairment at other points throughout the period. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset’s recoverable amount. An asset’s recoverable amount is the higher of an asset’s or cash-generating unit’s (CGU) fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre- tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs to sell, an appropriate valuation model is used based on the discounted cash-flow model. For intangible assets under development (like IPR&D), only the fair value less costs to sell reference is allowed in the impairment testing process. Where the carrying amount of an asset or CGU exceeds its recoverable amount, an impairment loss is immediately recognized as an expense and the asset carrying value is written down to its recoverable amount. Page 122 | 180 2021 Annual Report An assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the Group estimates the asset’s or cash-generating unit’s recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset’s recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the income statement unless the asset is carried at a revalued amount, in which case the reversal is treated as a revaluation increase. An impairment loss recognized on goodwill is however not reversed in a subsequent period. As of the statement of financial position dates, the Group has two cash-generating units which consist of the development and commercialization activities on: • CYAD products candidate series based on CAR-T technology, for the immune-oncology segment; and • C-Cathez commercialized medical device, for the cardiology segment. Indicators of impairment used by the Group are the preclinical and clinical results obtained with the technology. 5.2.10. Cash and cash equivalents Cash and cash equivalents in the statement of financial position comprise cash at banks and on hand and very short-term deposits with an original maturity of three months or less. Cash and cash equivalents are carried in the statement of financial position at their nominal value. 5.2.11. Financial assets 5.2.11.1 Classification The Group classifies its financial assets in accordance with IFRS 9 categories for measurement purposes. The classification depends on the purpose for which the financial assets were acquired. Management determines the classification of its financial assets at initial recognition. ‘Amortized cost’ measurement category refers to loans and receivables which are non-derivative financial assets, with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for maturities greater than 12 months after the end of the reporting period which are classified as non-current assets. This measurement category comprises “cash and cash equivalents”, “short- term investments”, and relevant financial assets within “(non-) current trade and other receivables”, “(non-) current grant receivables” and “other (non-) current assets”. 5.2.11.2 Initial recognition and measurement All financial assets are recognized initially at fair value plus or minus, in the case of a financial asset not at fair value through profit or loss, directly attributable transaction costs. 5.2.11.3 Subsequent measurement After initial measurement, financial assets are subsequently measured at amortized cost using the effective interest rate method (EIR), less impairment. Amortized cost is calculated by taking into account any discount or premium on acquisition and fee or costs that are an integral part of the EIR. The EIR amortization is included in finance income in the income statement under “Financial income”. The losses arising from impairment are recognized in the income statement under “Other expenses”. Page 123 | 180 2021 Annual Report 5.2.11.4 Impairment of financial assets In relation to the impairment of financial assets, IFRS 9 requires an expected credit loss model. The expected credit loss model requires the Group to account for expected credit losses and changes in those expected credit losses at each reporting date to reflect changes in credit risk since initial recognition of the financial assets. In other words, it is no longer necessary for a credit event to have occurred before credit losses are recognized. Specifically, IFRS 9 requires the Group to recognize a loss allowance for expected credit losses on trade receivables and contract assets. In particular, IFRS 9 requires the Group to measure the loss allowance for a financial instrument at an amount equal to the lifetime expected credit losses (ECL) if the credit risk on that financial instrument has increased significantly since initial recognition, or if the financial instrument is a purchased or originated credit impaired financial asset. However, if the credit risk on a financial instrument has not increased impaired financial asset), significantly since initial recognition (except for a purchased or originated credit the Group is required to measure the loss allowance for that financial instrument at an amount equal to 12 months ECL. IFRS 9 also requires a simplified approach for measuring the loss allowance at an amount equal to lifetime ECL for trade receivables, contract assets and lease receivables in certain circumstances. ‐ ‐ ‐ Given the current nature and size of operations of the Group, these requirements mainly apply to the financial assets reported under ‘non-current trade receivables’. The carrying value of these receivables (resulting mainly from Mesoblast license agreement commented further in note 5.8) take into account a discount rate equal to the Group’s partner’s incremental borrowing rate and, accordingly, is already credit risk-adjusted. The Group considers there is no significant additional credit risk related to this receivable, which would not have been captured by the discounting effect, both at inception of the receivable and at the reporting date. As such, no additional ECL allowance has been recognized for this financial asset or any other financial asset. 5.2.11.5 Financial assets carried at amortized cost For financial assets carried at amortized cost the Group first assesses individually whether objective evidence of impairment exists individually for financial assets that are individually significant, or collectively for financial assets that are not individually significant. If the Group determines that no objective evidence of impairment exists for an individually assessed financial asset, it includes the asset in a group of financial assets with similar credit risk characteristics and collectively assesses them for impairment. Assets that are individually assessed for impairment and for which an impairment loss is, or continues to be, recognized are not included in a collective assessment of impairment. If there is objective evidence that an impairment loss has been incurred, the amount of the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows. The present value of the estimated future cash flows is discounted at the financial assets’ original effective interest rate. If a loan has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate. The carrying amount of the asset is reduced through the use of an allowance account and the amount of the loss is recognized in the income statement under “Other expenses”. Interest income continues to be accrued on the reduced carrying amount and is accrued using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss. The interest income is recorded as part of finance income in the income statement. Loans together with the associated allowance are written off when there is no realistic prospect of future recovery. If, in a subsequent year, the amount of the estimated impairment loss increases or decreases because of an event occurring after the impairment was recognized, the previously recognized impairment loss is increased or reduced by adjusting the allowance account. If a future write-off is later recovered, the recovery is credited to the income statement. Page 124 | 180 2021 Annual Report 5.2.12. Financial liabilities 5.2.12.1 Classification The Group’s financial liabilities include “bank loans”, “lease liabilities”, “recoverable cash advances”, “contingent consideration and other financial liabilities”, “trade payables” and relevant financial liabilities within “Other (non-) current liabilities”. The Group classifies and measures its financial liabilities at ‘amortized cost’ using the effective interest method, except “contingent consideration and other financial liabilities” which are classified and measured at ‘fair value through profit or loss’. 5.2.12.2 Initial recognition and measurement Financial liabilities are initially measured at fair value. Transactions costs that are directly attributable to the acquisition or issue of financial liabilities are added or deducted from the fair value of the financial liabilities, as appropriate, on initial recognition. 5.2.12.3 Subsequent measurement The subsequent measurement of financial liabilities depends on their classification as explained above. In particular: Contingent consideration and other financial liabilities The contingent consideration and other financial liabilities are recognized and measured at fair value at the acquisition date. After initial recognition, contingent consideration arrangements that are classified as liabilities are re-measured at fair value with changes in fair value recognized in profit or loss in accordance with IFRS 3 and IFRS 9. Therefore, contingent payments will not be eligible for capitalization but will simply reduce the contingent consideration liability. Details regarding the valuation of the contingent consideration are disclosed in note 5.20.2. Recoverable cash advances Recoverable cash advances granted by the Walloon Region are subsequently measured at amortized cost using the cumulative catch-up approach, as described in section 5.2.5 above. Trade payables and other payables After initial recognition, trade payables and other payables are measured at amortized cost using the effective interest method. Loans and borrowings After initial recognition, interest bearing loans and borrowings are subsequently measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the income statement when the liabilities are derecognized. 5.2.12.4 Derecognition A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. Page 125 | 180 2021 Annual Report When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognized in the income statement under “Change in fair value of contingent consideration” or “Other expenses”. 5.2.13. Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the income statement net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost. 5.2.13.1 Employee benefits Post-employment plan The Group operates a pension plan which requires defined contributions (DC) to be funded by the Group externally at a third-party insurance company. Under Belgian law, an employer must guarantee a minimum rate of return on the Group’s contributions and thus it is treated as defined benefit plan under IAS 19. At the statement of financial position dates, the minimum rates of return guaranteed by the Group are as follows, in accordance with the law of 18 December 2015: • • 1.75% for the employer’s contributions paid as from 1 January 2016 (variable rate based on Governmental bond OLO rates, with a minimum of 1.75% and a maximum of 3.75%); 3.25% (fixed rate) for the employer’s contributions paid until 31 December 2015. The cost of providing benefits is determined using the projected unit credit (PUC) method, with actuarial valuations being carried out at the end of each annual reporting period, with the assistance of an independent actuarial firm. The liability recognized in the statement of financial position in respect of the pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related pension obligation. The current service cost of the defined benefit plan, recognized in the income statement as part of the operating costs, reflects the increase in the defined benefit obligation resulting from employee service in the current year, benefit changes, curtailments and settlements. Past-service costs are recognized immediately in the income statement. The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in the operating costs in the income statement. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are charged or credited to other comprehensive income in the period in which they arise. Page 126 | 180 2021 Annual Report Short-term benefits Short-term employee benefits are those expected to be settled wholly before twelve months after the end of the annual reporting period during which employee services are rendered, but do not include termination benefits such as wages, salaries, profit-sharing and bonuses and non-monetary benefits paid to current employees. The undiscounted amount of the benefits expected to be paid in respect of services rendered by employees in an accounting period is recognized in that period. The expected cost of short-term compensated absences is recognized as the employees render services that increase their entitlement or, in the case of non- accumulating absences, when the absences occur, and includes any additional amounts the entity expects to pay as a result of unused entitlements at the end of the period. Share-based payments Certain employees, managers and members of the Board of Directors of the Group receive remuneration, as compensation for services rendered, in the form of share-based payments which are “equity-settled”. Measurement The cost of equity-settled share-based payments is measured by reference to the fair value at the date on which they are granted. The fair value is determined by using an appropriate pricing model, further details are given in note 5.14. Recognition The cost of equity-settled share-based payments is recorded as an expense, together with a corresponding increase in equity, over the period in which the service conditions are fulfilled. The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. Modification Where the terms of an equity-settled transaction award are modified, the minimum expense recognized is the expense as if the terms had not been modified, if the original terms of the award were met. An additional expense is recognized for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee as measured at the date of modification. The incremental fair value granted is the difference between the fair value of the modified equity instrument and the original equity instrument, both estimated as at the date of the modification. If the modification occurs during the vesting period, the incremental fair value granted is included in the measurement of the amount recognized for services received over the period from the modification date until the date when the modified equity instruments vest, in addition to the amount based on the grant date fair value of the original equity instruments, which is recognized over the remainder of the original vesting period. If the modification occurs after vesting date, the incremental fair value granted is recognized immediately, or over the vesting period if the employee is required to complete an additional period of service before becoming unconditionally entitled to those modified equity instruments. Forfeiture An equity-settled award can be forfeited with the departure of a beneficiary before the end of the vesting period, or cancelled and replaced by a new equity settled award. If a new award is substituted for the cancelled award, and designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph. Page 127 | 180 2021 Annual Report Cancellation If the cancellation occurs during the vesting period, it is treated as an acceleration of vesting, and the Group recognizes immediately the amount that would otherwise have been recognized for services received over the remainder of the vesting period. If the cancellation occurs after the vesting period, no adjustments will be made to the accounting. 5.2.14. Income Taxes Tax is recognized in the income statement, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively. Deferred tax Deferred tax is provided using the liability method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred tax liabilities are recognized for all taxable temporary differences, except: • Where the deferred tax liability arises from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; • In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. Deferred tax assets are recognized for all deductible temporary differences, carry forward of unused tax credits and unused tax losses (except if the deferred tax asset arises from the initial recognition of an asset or liability in a transaction other than a business combination and that, at the time of the transaction affects neither accounting nor taxable profit or loss), to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is not probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to income taxes levied by the same taxation authority or either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis. 5.2.15. Earnings (loss) per share The basic net profit/(loss) per share is calculated based on the weighted average number of shares outstanding during the period. The diluted net profit/(loss) per share is calculated based on the weighted average number of shares outstanding including the dilutive effect of potentially dilutive ordinary shares such as warrants and Page 128 | 180 2021 Annual Report convertible debts. Potentially dilutive ordinary shares should be included in diluted earnings (loss) per share when and only when their conversion to ordinary shares would decrease the net profit per share (or increase net loss per share). 5.2.16. Equity The basic net profit/(loss) per share is calculated based on the weighted average number of shares outstanding during the period. The equity is comprised of the following (further details are given in note 5.13); • Share capital: Share capital is comprised of the nominal amount of the parent’s ordinary shares. This capital is not distributable in the form of dividends under Belgian Company Code. • Share premium: Share premium is comprised of: (1) the amount received attributable to share capital, in excess of the nominal amount of shares issued by the parent company, reduced by; (2) issuance costs directly attributable to the capital increase; and (3) absorption of the accumulated deficit into the share premium, as approved by the Company’s shareholders in accordance with Belgian Company Code. • Other reserves: Other reserves are comprised of: (1) Share-base payment reserve; (2) Other equity reserve from conversion of convertible loan in 2013; and (3) Currency Translation differences. • Capital reduction reserve: Capital reduction reserve is comprised of the absorption of historical losses of the Company into the share premium, as approved by the Company’s shareholders in accordance with Belgian Company Code. • Accumulated deficit: Accumulated deficit is comprised of cumulative historical losses of the Company. Voluntary change in accounting policy: During the year ended December 31, 2021, the Company changed its accounting policy related to the presentation of capital reduction reserve to reflect the absorption of historical accounting losses into share premium. Under the previous policy, the Company presented the transfer of losses into share premium as a component of accumulated deficit. The Company changed its policy to present the amount of transfer losses into the share premium separately from accumulated deficit on the Statements of Financial Position and Changes in Shareholders’ Equity. The change in presentation was made to provide a more faithful presentation of the nature of components of the Company’s shareholders’ equity. This change has no impact on the Company’s financial position, results of operations or cash flows for any periods presented. The Company has applied this change in accounting policy to all periods presented for comparative purposes. 5.3 Risk Management Financial risk factors Interest rate risk The interest rate risk is very limited as the Group has only a limited amount of finance leases and no outstanding bank loans. So far, because of the immateriality of the exposure, the Group did not enter into any interest hedging arrangements. Credit risk The Group has a limited amount of trade receivables due to the fact that sales to third parties are not significant and thus the Group’s credit risk arises mainly from cash and cash equivalents and deposits with Page 129 | 180 2021 Annual Report banks and financial institutions. The Group only works with international reputable commercial banks and financial institutions. The maximum credit risk, to which the Group is theoretically exposed as at the statement of financial position date, is the carrying amount of financial assets. Given the current nature and size of operations of the Group, the requirement of the Group to measure the loss allowance for a financial instrument at an amount equal to the lifetime expected credit losses (ECL), mainly apply to the financial assets reported under ‘non-current trade receivables’. The carrying value of these receivables (resulting mainly from Mesoblast license agreement commented further in note 5.8) take into account a discount rate equal to the Group’s partner’s incremental borrowing rate and, accordingly, is already credit risk-adjusted. The Group considers there is no significant additional credit risk related to this receivable, which would not have been captured by discounting effect, both at inception of the receivable and at the reporting date. As such, no additional ECL allowance has been recognized for this financial asset or any other financial asset. Foreign exchange risk The Group is exposed to foreign exchange risk as certain collaborations or supply agreements of raw materials are denominated in USD. Moreover, the Group has also investments in foreign operations, whose net assets are exposed to foreign currency translation risk (USD). So far, because of the immateriality of the exposure, the Group did not enter into any currency hedging arrangements. At December 31, 2021, the foreign exchange risk exposure exists mainly on the cash denominated in USD. A depreciation of 1% on the USD versus EUR would translate into an unrealized foreign exchange loss of €48k for the Group at December 31, 2021. Liquidity risk The Group monitors its risk to a shortage of funds using a recurring liquidity planning tool. The Group’s objective is to maintain a balance between continuity of funding and flexibility through the use of bank deposit and leases. Refer to note 5.19 for an analysis of the Group’s non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the statement of financial position date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows. Capital management The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an adequate structure to limit to cost of capital. 5.4 Critical accounting estimates and judgments 8 The preparation of the Group’s financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the end of the reporting period. 8 The uncertainly raised by the COVID-19 pandemic is not impacting the critical accounting estimates and judgments. For additional information on COVID-19 pandemic update, refer to note 5.2.1. Page 130 | 180 2021 Annual Report Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods. In the process of applying the Group’s accounting policies, management has made judgments and has used estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below. Going Concern When assessing going concern, the Board of Directors considers mainly the following factors: • • • • The treasury available at the statement of financial position date; and, The cash burn projected in accordance with the approved budget for next 12-month period as the date the financial statements are issued, which are subject to judgments by management while considering all information available at the reporting date such as significant expenses and cash outflows in relation to – among others- the ongoing clinical trials, the continuation of research and development projects, and the scaling-up of the Company’s manufacturing facilities; The availability of grant funding and outcome of ongoing and future grant applications payback loan to be received for the next 12-month period; and The financial facilities open to the company for raising new funds by capital increase operations. Revenue The recognition of revenue relating to license and collaboration agreements involves management estimates and requires judgement as to: (i) (ii) (iii) (iv) (v) (vi) Classifying the license agreement (right-to-use or right-to-access license) in accordance with ‘Licensing’ Application Guidance set forth in IFRS 15; Identifying the performance obligations comprised in the contract; Estimating probability for (pre-)clinical development or commercial milestone achievement; Determining the agreed variable considerations to be included in the transaction price taking into account the constraining limit of the “highly probable” criteria; Allocating the transaction price according to the stand-alone selling price of each of the performance obligations; and Estimating the finance component in the transaction price, based on the contract expected duration and discount rate. Management makes its judgment taking into account all information available about clinical status of the underlying projects at the reporting date and the legal analysis of each applicable contracts. Further details are contained in Note 5.23. Recoverable Cash Advances received from the Walloon Region As explained in note 5.2.5, accounting for RCAs requires initial recognition of the fair value of the loan received to determine the benefit of the below-market rate of interest, which shall be measured as the difference between the initial carrying value of the loan and the proceeds received. Loans granted to entities in their early stages of operations, for which there is significant uncertainty about whether any income will ultimately be generated and for which any income which will be generated will not arise until a number of Page 131 | 180 2021 Annual Report years in the future, normally have high interest rates. Judgment is required to determine a rate which may apply to a loan granted on an open market basis and to determine projected revenue that will derive in the future from the products that benefited from the support of the Walloon Region. The estimated projected revenue by management is similar to the ones used for impairment of non-financial assets (see note 5.6.2). In accordance with the RCA agreements, the following two components are assessed when calculating estimated future cash flows: • 30% of the initial RCA, which is repayable when the Group exploits the outcome of the research financed; and • A remaining amount, which is repayable based on a royalty percentage of future sales milestones, up to a level of 170% of the initial granted amount. After initial recognition, RCA liabilities are measured at amortized cost using the cumulative catch up method requiring management to regularly revise its estimates of payments and to adjust the carrying amount of the financial liability to reflect actual and revised estimated cash flows. Measurement and impairment of non-financial assets With the exception of goodwill and certain intangible assets for which an annual impairment test is required, the Group is required to conduct impairment tests where there is an indication of impairment of an asset. Measuring the fair value of non-financial assets requires judgement and estimates by management. These estimates could change substantially over time as new facts emerge or new strategies are taken by the Group. Further details (including sensitivity analysis) are contained in note 5.6.2. Contingent consideration and other financial liabilities The Group recorded a liability for the estimated fair value of contingent consideration arising from business combinations. The estimated amounts are the expected payments and timing of such payments, determined by considering the possible scenarios of forecast sales and other performance criteria, the amount to be paid under each scenario, and the probability of each scenario, which is then discounted to a net present value. The estimates could change substantially over time as new facts emerge and each scenario develops. Further details on management’s estimations and sensitivity analysis are contained in note 5.20.2. 5.5 Operating segment information The chief operating decision-maker (CODM), who is responsible for making strategic decisions, allocating resources and assessing performance of the Group, has been identified as the Board of Directors. Since the acquisition of the oncological platform in 2015, the management and the CODM have determined that there are two operating segments, being: • • the immuno-oncology segment regrouping all assets developed based on the CAR-T cell platform; and the cardiology segment, regrouping the Cardiopoiesis platform, C-Cathez. Corporate segment includes costs for general and administration functions not allocated to the other business segments. Although the Group is currently active in Europe and in the US, no geographical financial information is currently available given the fact that the core operations are currently still in a study phase. No disaggregated information on product level or geographical level or any other level currently exists and hence also not considered by the Board of Directors for assessing performance or allocating resources. Page 132 | 180 2021 Annual Report The CODM does not review assets by segments, hence no segment information per assets is disclosed. As of December 31, 2021, the main Group’s non-current assets are located in Belgium. Since 2017, the Group is fully focused on the development of its immuno-oncology platform. Therefore, for the year ended December 31, 2021, most of the R&D expenses were incurred in the immuno-oncology segment, in line with prior year. € '000 For the year ended December 31, 2021 Revenue recognized at a point in time - - - - Revenue recognized over time - - - - Cardiology Immuno-oncology Corporate Group Total Total Revenue Cost of Sales Gross Profit - - - - - - - - - - - - Research & Development expenses (142) (20 631) - (20 773) General & Administrative expenses - - (9 908) (9 908) Change in fair value of contingent consideration - 847 - 847 Net Other income/(expenses) (108) 3 507 44 3 443 Operating Profit/(Loss) (250) (16 277) (9 864) (26 391) Net financial income/(expenses) 107 (165) (53) (111) Profit/(Loss) before taxes Income Taxes (143) (16 442) (9 917) (26 502) - - (10) (10) Profit/(Loss) for the year 2021 (143) (16 442) (9 927) (26 512) € '000 For the year ended December 31, 2020 Revenue recognized at a point in time 5 - - 5 Revenue recognized over time - - - - Cardiology Immuno-oncology Corporate Group Total Total Revenue Cost of Sales Gross Profit 5 - - 5 - - - - 5 - - 5 Research & Development expenses (124) (21 398) - (21 522) General & Administrative expenses - - (9 315) (9 315) Change in fair value of contingent consideration - 9 228 - 9 228 Net Other income/(expenses) Operating Profit/(Loss) (2) 4 582 38 4 617 (121) (7 589) (9 277) (16 987) Net financial income/(expenses) (33) (183) (3) (217) Profit/(Loss) before taxes Income Taxes (154) (7 771) (9 280) (17 204) - - - - Profit/(Loss) for the year 2020 (154) (7 771) (9 280) (17 204) 5.6 Intangible assets 5.6.1. Intangible assets details and balance roll forward The change in intangible assets is broken down as follows, per class of assets: (€'000) Goodwill In-process research and development Development costs Patents, licenses, trademarks Software Total Capitalized costs At January 1, 2020 Additions Divestiture Transfer 883 33 678 1 084 12 903 179 48 726 - - - - - - - - - 168 - - 1 - 100 169 - 100 Page 133 | 180 2021 Annual Report At December 31, 2020 883 33 678 1 084 13 071 279 48 995 Additions Currency translation adjustments Divestiture Transfer - - - - - - - - - - - - 214 - - - - - (16) - 214 - (16) - At December 31, 2021 883 33 678 1 084 13 285 263 49 193 Accumulated amortization At January 1, 2020 Amortization charge Divestiture Transfer At December 31, 2020 Amortization charge Divestiture Currency translation adjustments Transfer - - - - - - - - - - - - - - - - - - (477) (66) (11 938) (114) - - - - (543) (67) (12 052) (134) - - - - - - (112) (16) - (100) (229) (16) 16 - - (12 527) (197) - (100) (12 824) (217) 16 - - At December 31, 2021 - - (610) (12 185) (229) (13 025) Net book value Capitalized costs Accumulated amortization 883 - 33 678 - 1 084 (543) 13 071 (12 052) 279 48 995 (229) (12 824) At December 31, 2020 883 33 678 540 1 019 51 36 171 Capitalized costs Accumulated amortization 883 - 33 678 - 1 084 (610) 13 285 (12 186) 263 49 193 (229) (13 025) At December 31, 2021 883 33 678 474 1 099 34 36 168 The capitalized development costs relate to the development of C-Cathez. Since May 2012 and the CE marking of C-Cathez, the development costs of C-Cathez are capitalized and amortized over the estimated residual intellectual property protection as of the CE marking (i.e., until 2029). No other development costs have been capitalized up till now. All other programs’ (C-Cure, CYAD-01, CYAD-02, CYAD-101, CYAD- 211…) related development costs have been assessed as not being eligible for capitalization and have therefore been recognized in the income statement as research and development expenses. Software is amortized over a period of 3 to 5 years. Goodwill, IPR&D, Patents, Licenses and Trademarks mainly relate to the following items: • Goodwill and IPR&D resulted from the purchase price allocation exercise performed for the acquisition of Oncyte LLC in 2015. As of December 31, 2021 and 2020, Goodwill and IPR&D are not amortized but tested for impairment. • Exclusive Agreement for Horizon Discovery’s shRNA Platform to develop next-generation allogenic CAR-T Therapies acquired for $1.0 million at the end of December 2018. In October 2019, the Company capitalized milestone payments for a total amount of $0.2 million related to the exercise of the option on the Exclusive Agreement and to the first effective IND filing related to CYAD-02. In November 2020, the Group capitalized the milestone payments for an amount of $0.2 million related to the first effective IND, filed by the Group, relating to the product CYAD-211. At December 31, 2021, milestone payments are capitalized for a total amount of $0.4 million. This patent is amortized over the remaining intellectual property protection of 20 years, with the first patent application filed in 2008. • Exclusive license from the Moffitt Cancer Center for an antibody directed to Tumor-associated glycoprotein (TAG-72), which will form the basis of a T cell engager to be used with the shRNA platform technology of the Company acquired for $0.1 million in January 2021. • Exclusive license agreement signed with the University of Pennsylvania for an engager targeting Glypican 3 (GPC3) acquired for $0.2 million in October 2021. The Immuno-oncology cash generating unit (CGU) has a net book value of €35.7 million at December 31, 2021. This CGU is mainly composed of: Page 134 | 180 2021 Annual Report • • • The goodwill and IPR&D resulting from the purchase price allocation exercise performed for the acquisition of Oncyte LLC in 2015; The Horizon Discovery’s shRNA platform; The new licenses acquired in 2021 from the Moffitt Cancer Center and University of Pennsylvania. The variance on the total intangible assets as of December 31, 2021, in comparison to December 31, 2020, resulted primarily from the regular amortization of C-Cathez costs and the Group’s Patents & Licenses, compensated by new licenses acquired in 2021 regarding an exclusive patent license agreement signed with the University of Pennsylvania for an engager targeting Glypican 3 (GPC3) and an exclusive license from the Moffitt Cancer Center for an antibody directed to Tumor-associated glycoprotein (TAG-72), which both will form the basis of a T cell engager to be used with the shRNA platform technology of the Company. 5.6.2. Impairment testing Impairment testing is detailed below. Immuno-oncology CGU impairment test 9 Goodwill and IPR&D exclusively relate to the acquisition of the former entity Oncyte LLC (meanwhile liquidated into Celyad SA) which was acquired in 2015. Management performs an annual impairment test on goodwill and on 'indefinite lived assets' that are not amortized in accordance with the accounting policies stated in notes 5.2.6 and 5.2.9. The impairment test has been performed at the level the immuno-oncology segment corresponding to the CGU to which the goodwill and the IPR&D belong as well as the Horizon Discovery’s shRNA platform. The recoverable amount associated to this CGU is calculated based on the fair value less costs to sell model using Level 3 fair value measurements for which the Group developed unobservable inputs and requires the use of assumptions. The calculations use cash flow projections based on business plan ending in 2040 based on probability of success of CYAD-02, CYAD-101 and CYAD-211 product candidates as well as extrapolations of projected cash flows resulting from the future expected sales on CYAD-101 and CYAD-211 and sublicense income associated with CYAD-02. CGU recoverable value, determined accordingly, exceeds its carrying amount. Accordingly, no impairment loss was recognized either on goodwill, on the IPR&D, on the Horizon Discovery’s shRNA platform or other immuno-oncology licenses at December 31,2021. Management’s key assumptions (assumptions to which the unit’s or group of units’, recoverable amount is most sensitive) about projected cash flows when determining fair value less costs to sell are as follows: • Discount rate (WACC) Management estimated the discount rate (WACC) as of December 31, 2021 to be 13.4% (14.8% as of December 31, 2020) based on following components: the US Government Treasury bill 20- Y, the Group’s Beta, the equity Market Risk Premium and the small firm/illiquidity premium. The decrease of the WACC is mainly driven by a decrease of the Beta of the Group which is associated with the volatility of the Group’s equity influenced by its ongoing clinical programs and overall competitive landscape within the immuno-oncology field. Management corroborates its estimation with industry standards for biotechnology companies, the WACC used by Equity Research companies following the Group and transactions that have been sourced by the Group over the past 24 months. 9 The uncertainly raised by the COVID-19 pandemic is not impacting impairment testing. Although there are lot of uncertainties, it does not impact the Group’s assets valuation as of December 31, 2021. For additional information on COVID-19 pandemic update, refer to note 5.2.1. Page 135 | 180 2021 Annual Report • Projected Revenue Management estimated the projected revenue (using cash flow projections ending in 2040) based on the following components: total market and market share, time-to-market, treatment price and terminal value. Management based its estimation of projected revenue and related components with the Group’s business plan, industry data for biotechnology companies, evolution of similar R&D programs, comparable prices, expected patent expiration period. The weight of this assumption is partially alleviated by the probability of success (PoS) presented hereunder. • Probabilities of Success (PoS) Management estimated the PoS based on Clinical Development Success Rates observed by independent business intelligence consulting companies for hematological and solid tumor diseases. Probability of the Group’s product candidates reaching the market used were updated compared to prior year-end based on most recent Clinical Development Success Rates observed by independent business intelligence consulting companies for hematological and solid tumor diseases as follows: o Probabilities of Success as of December 31, 2021: PoS Phase I Phase Phase II I to Phase Phase III II to Phase BLA III to BLA Approval to Cumulative PoS CYAD-02 CYAD-101 CYAD-211 100% 100% 100% 50% 49% 50% 28% 23% 28% 60% 43% 60% 90% 93% 90% 7.5% 4.6% 7.5% o Probabilities of Success as of December 31, 2020: PoS Phase I Phase Phase II I to Phase Phase III II to Phase BLA III to BLA Approval to Cumulative PoS CYAD-02 CYAD-101 CYAD-211 100% 100% 100% 62% 64% 62% 29% 23% 29% 53% 34% 53% 86% 80% 86% 8.1% 4.0% 8.1% The PoS estimates used by management as of December 31, 2020 utilized clinical development success rates compiled by independent business intelligence consulting companies which sourced data from clinical development programs from 2006 – 2015. The Group’s updated PoS rates for its clinical programs as of December 31, 2021 incorporates data for clinical development success rates from 2011 – 2020, which the Group believes is a more accurate reflection of clinical development success rates across stage of development and in aggregate. The sensitivity analyses are based on a change in an assumption while holding all other assumptions constant. The following table presents the sensitivity analyses of the recoverable amount of the CGU associated to the immuno-oncology operations: Sensitivity analysis Discount rate (WACC) e u n e v e R d e t c e j o r P Impact on model value 13.4% 14.0% 14.7% 95.0% 97.5% -9% -2% 100.0% Model Reference -18% -14% -10% -26% -22% -19% Page 136 | 180 2021 Annual Report Regarding the sensitivity analysis related to PoS based on a change in this assumption while holding all other assumptions constant, a decrease by -10% or -20% to the bottom-line cumulative PoS would imply a decrease by -10% or -20% respectively of the recoverable amount of the CGU associated to the immuno- oncology operations. This sensitivity analyze would imply that the recoverable value of the CGU exceeds its carrying amount at December 31, 2021. On February 28, 2022, the Group announced its decision to voluntarily pause its Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 administered concurrently with FOLFOX chemotherapy followed by MSD’s anti- PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with refractory metastatic colorectal cancer following reports of two fatalities that presented with similar pulmonary findings. The Group is currently investigating these reports and evaluating any similar events in additional patients treated on study. On March 1, 2022, the Group was informed via-email communication from the FDA that the KEYNOTE-B79 trial has been placed on clinical hold due to insufficient information to assess risk to study subjects (see note 5.36). Given the uncertain impact of this event on the future of KEYNOTE-B79 trials at this time, the Group is not able to assess the impact of such outcomes on the valuation of related assets and contingent liabilities and, therefore, has not adjusted the related fair value calculations for the clinical hold. C-Cure (Cardio) impairment test Pursuant to 2017 strategic decision to focus all the efforts of the Group on the development of the immuno- oncology platform and the lack of strategic business development opportunities identified for the C-Cure (Mayo Licenses), this asset had been fully impaired as of December 31, 2017. CGU’s recoverable amounts being confirmed to be zero at current year-end, the 100% impairment allowance has been carried forward at December 31, 2021. 5.7 Property, plant and equipment (€’000) Capitalized costs At January 1, 2020 Additions Disposals Property Equipment Furniture Leasehold Total 2 810 4 099 307 4 193 11 409 191 670 10 56 926 - (932) (67) (372) (1 371) Currency translation adjustments - (1) - (17) (18) Transfers - (271) - 171 (100) At December 31, 2020 3 001 3 563 250 4 032 10 846 Additions Disposals 24 388 - 10 422 - (192) - - (192) Currency translation adjustments - 1 - 15 16 Transfers At December 31, 2021 Accumulated depreciation At January 1, 2020 Depreciation charge Disposals - - - - 3 025 3 760 250 4 057 - 11 092 (399) (2 967) (205) (2 776) (6 347) (428) (691) (46) (470) (1 635) - 760 38 352 1 150 Currency translation adjustments - 1 - 4 5 Transfers At December 31, 2020 Depreciation charge Disposals - 271 - (171) 100 (827) (2 625) (214) (3 061) (6 727) (454) (512) (24) (313) (1 303) - 191 - - 191 Currency translation adjustments - (2) - (3) (5) Transfers - - - At December 31, 2021 (1 281) (2 948) (238) - (3 377) - (7 844) Net book value Capitalized costs 3 001 3 563 Accumulated depreciation (827) (2 625) 250 (214) 4 032 10 846 (3 061) (6 727) Page 137 | 180 2021 Annual Report At December 31, 2020 Capitalized costs 2 174 938 3 025 3 760 36 250 971 4 119 4 057 11 092 Accumulated depreciation (1 281) (2 948) (238) (3 377) (7 844) At December 31, 2021 1 744 812 12 680 3 248 Property, Plant and Equipment is mainly composed of right-of-use on leased offices, facilities and equipment (including vehicles), office furniture, leasehold improvements, and laboratory equipment. The variance on the total tangible assets as of December 31, 2021 resulted primarily in new laboratories equipment compensated by yearly depreciation. The additions for the period amounting €0.4 million are mainly driven by new laboratories equipment for €0.3 million. At December 31, 2020, the variance on the total tangible assets resulted primarily in new leased assets compensated by yearly depreciation. The additions for the year 2020 amounting to €0.9 million were mainly driven by the renewal of leased buildings relating to the Group’s R&D and manufacturing facilities for €0.2 million and new leased laboratories equipment for €0.5 million, see disclosure 5.30 Leases. 5.8 Non-current trade receivables and other non-current assets (€'000) Non-current trade receivables Mesoblast license agreement Net investment in Lease Total Non-current Trade and Other receivables As at December 31, 2021 2020 2 209 - 2 209 1 923 195 2 117 In May 2018, the Group entered into an exclusive license agreement with Mesoblast, an Australian biotechnology company, to develop and commercialize our intellectual property rights relating to C-Cathez, an intra-myocardial injection catheter. This license agreement refers to the right to use the company’s intellectual property as it exists at the point in time the license has been granted (May 2018) and foresees contingent milestone payments. The related receivable is reported for its discounted value (€2.2 million) under ‘Non-current trade receivables’. There are no corresponding contract liabilities reported at December 31, 2021, as no performance obligation was outstanding. The Group has signed an amendment of the license agreement on January 17, 2022. For further detailed information, see disclosure 5.36. At December 31, 2020, the non-current net investment in lease referred to the non-current receivable recorded under IFRS16 Leases accounting standard as the Group subleases some office spaces it leases from a head lessor. At December 31, 2021, there is no non-current net investment in lease. (€'000) R&D Tax credit receivable Total Non-current Grant recevables Deposits Total Other non-current assets As at December 31, 2021 2020 3 764 3 764 262 262 3 679 3 679 293 293 In 2017, the Group recognized for the first time a R&D tax credit (€1.2 million) receivable from the Federal Government that included a one-time catch-up effect. Since 2018, further R&D tax credit receivables are recorded on an annual basis. For the year ended December 31, 2021, the Group recorded additional R&D tax credit of €0.7 million, taking into account all information available as of December 31, 2021. The Group received the reimbursement from the Federal Government of €0.6 million related to the fiscal year 2016 tax credit. The non-current assets refer to security deposits paid to the lessors of the building leased by the Group and a deposit to the Social Security administration. Page 138 | 180 5.9 Trade receivables and other current assets (€'000) Trade receivables Advance deposits Net Investment in Lease Other receivables Total Trade and Other receivables Current Grant receivables (RCAs) Current Grant receivables (Others) Total Current Grant receivables Prepaid expenses VAT receivable Income and other tax receivables Total Other current assets Total Trade receivables, advances and other current assets 2021 Annual Report As at December 31, 2021 2020 203 246 219 165 220 230 - - 668 1 121 274 1 395 1 688 483 40 2 211 4 274 615 145 - 145 1 343 342 25 1 711 2 471 Impairment of receivables is assessed on an individual basis at the end of each accounting year. At December 31, 2021 and 2020, no receivable was overdue. There were no carrying amounts for trade and other receivables denominated in foreign currencies, except for the net investment in lease for which carrying amount is under USD. No impairments were recorded on trade receivables and other current assets (see note 5.3). The current net investment in lease refers to the receivable recorded under IFRS16 Leases accounting standard as the Group subleases some office spaces it leases from a head lessor. As of December 31, 2021, grant receivables for a total amount of €1.4 million has been recorded due to Walloon Region recoverable cash advances regarding CYAD-02 (numbered 8088), CYAD-101 (numbered 8212), CwalityCAR (numbered 1910028) and new grant convention signed with the Walloon Region in 2021 regarding the new engagers (numbered 8516). The increase of the current grant receivables between the years 2020 and 2021 is mainly explained by lower cash proceeds from the Walloon Region in 2021 compared to expenses subsidized by these RCAs and other grants recognized in 2021. The increase in prepaid expenses as of December 31, 2021 compared to December 31, 2020 for €0.3 million is mainly driven by the increase on prepaid expenses on insurances combined with transaction costs linked to the LPC equity facility for an amount of €0.2 million subject to capitalization and to be offset against a future capital raise. 5.10 Short-term investments Given the level of market interest rates for corporate deposits of short-term maturities, the Group has not invested in short-term deposits over the years 2021 and 2020. 5.11 Cash and cash equivalents (€'000) Cash at bank and on hand Total As at December 31, 2021 2020 30 018 30 018 17 234 17 234 Page 139 | 180 2021 Annual Report The Group’s cash and cash equivalents amounted to €30.0 million at December 31, 2021 which accounts for an increase of €12.8 million as compared to year-end 2020, mainly as a result of cash proceeds from capital raises during the period partly compensated by the Group’s operations expenses. Cash at banks earn interest at floating rates based on daily bank deposit rates. For the years ended December 31, 2021 and 2020, the earned bank interests have been insignificant. 5.12 Subsidiaries fully consolidated The consolidation scope of the Group is as follows, for both current and comparative years presented in these year-end financial statements: Name Country of Incorporation and Place of Business Nature of Business Proportion of ordinary shares directly held by parent (%) Proportion of ordinary shares held by the Group (%) Proportion of ordinary shares held by non- controlling interests (%) Celyad Oncology SA Celyad Inc CorQuest Medical Inc Biological Manufacturing Services SA BE US US BE Biopharma Biopharma Medical Device Manufacturing Parent company 100% 100% 100% 100% 100% 100% 0% 0% 0% Cardio3 Inc was incorporated in 2011 to support clinical and regulatory activities of the Group in the US. Cardio3 Inc was renamed in Celyad Inc in 2015. CorQuest Medical Inc was acquired on November 5, 2014. CorQuest Medical Inc. was developing Heart- XS, a new access route to the left atrium. In November 2019, the patent rights related to Heart-XS were sold to CorQuest MedTech SRL, a newly constituted Belgian company developing innovative cellular medicines. The Group does not hold any ordinary shares of CorQuest MedTech SRL. Biological Manufacturing Services SA (BMS) was acquired in May 2016. BMS owns Good Manufacturing Practices (‘GMP’) laboratories. BMS rent its laboratories to Celyad SA since 2009 and until April 30, 2016. 5.13 Share Capital The number of shares issued is expressed in units. Total number of issued and outstanding shares Total share capital (€'000) As of December 31, 2021 2020 22 593 956 13 942 344 78 585 48 513 As of December 31, 2021, the share capital amounts to €78,585 represented by 22,593,956 fully authorized and subscribed and paid-up shares with a nominal value of €3.48 per share. This number does not include warrants issued by the Group and granted to certain directors, employees and non-employees of the Group. As of December 31, 2021, the authorized capital which has been used over the period 2021 by the board of directors amounts to €32,119. The remaining available from the authorized capital amounts to €4,773 as of December 31, 2021. History of the capital of the Company The Company was incorporated on July 24, 2007 with a share capital of €62,500 by the issuance of 409,375 class A shares. On August 31, 2007, the Company issued 261,732 class A shares to Mayo Clinic by way of Page 140 | 180 2021 Annual Report a contribution in kind of the upfront fee that was due upon execution of the Mayo License for a total amount of €9,500,000. Round B Investors participated in a capital increase of the Company by way of a contribution in kind of a convertible loan (€2,387,049) and a contribution in cash (€4,849,624 of which €1,949,624 was uncalled) on December 23, 2008; 204,652 class B shares were issued at the occasion of that capital increase. Since then, the capital is divided in 875,759 shares, of which 671,107 are class A shares and 204,652 are class B shares. On October 29, 2010, the Company closed its third financing round resulting in a capital increase totaling €12,100,809. The capital increase can be detailed as follows: • Capital increase in cash by certain existing investors for a total amount of €2,609,320.48 by the issuance of 73,793 class B shares at a price of €35.36 per share; • Capital increase in cash by certain existing investors for a total amount of €471,240 by the issuance of 21,000 class B shares at a price of €22.44 per share; • Capital increase in cash by certain new investors for a total amount of €399,921.60 by the issuance of 9,048 class B shares at a price of €44.20 per share; • Exercise of 12,300 warrants (“Warrants A”) granted to the Round C investors with total proceeds of €276,012 and issuance of 12,300 class B shares. The exercise price was €22.44 per Warrant A; • Contribution in kind by means of conversion of the loan C for a total amount of €3,255,524.48 (accrued interest included) by the issuance of 92,068 class B shares at a conversion price of €35.36 per share; • Contribution in kind by means of conversion of the loan D for a total amount of €2,018,879.20 (accrued interest included) by the issuance of 57,095 class B shares at a conversion price of €35.36 per share. The loan D is a convertible loan granted by certain investors to the Company on 14 October 2010 for a nominal amount of €2,010,000. • Contribution in kind of a payable towards Mayo Foundation for Medical Education and Research for a total amount of €3,069,911 by the issuance of 69,455 class B shares at a price of €44.20 per share. The payable towards Mayo Clinic was related to (i) research undertaken by Mayo Clinic in the years 2009 and 2010, (ii) delivery of certain materials, (iii) expansion of the Mayo Clinical Technology License Contract by way the Second Amendment dated October 18, 2010. On May 5, 2011, pursuant the decision of the Extraordinary General Meeting, the capital was reduced by an amount of €18,925,474 equivalent to the outstanding net loss as of December 31, 2010. On May 31, 2013, the Company closed its fourth financing round, the ‘Round D financing’. The convertible loans E, F, G and H previously recorded as financial debt were converted in shares which led to an increase in equity for a total amount of €28,645k of which € 5,026k is accounted for as capital and € 6,988k as share premium. The remainder (€ 16,631k) is accounted for as other reserves on fully settled contribution in kind convertible loans. Furthermore, a contribution in cash by existing shareholders of the Company led to an increase in share capital and issue premium by an amount of €7,000k. At the Extraordinary Shareholders Meeting of June 11, 2013 all existing classes of shares of the Company have been converted into ordinary shares. Preferred shares have been converted at a 1 for 1 ratio. On July 5, 2013, the Company completed its Initial Public Offering. The Company issued 1,381,500 new shares at €16.65 per shares, corresponding to a total of €23,002k. On July 15, 2013, the over-allotment option was fully exercised for a total amount of €3,450k corresponding to 207,225 new shares. The total IPO proceeds amounted to €26,452k and the capital and the share premium of the Company increased accordingly. The costs relating to the capital increases performed in 2013 amounted to €2.8 million and are presented as a deduction of share premium. Page 141 | 180 2021 Annual Report On June 11, 2013, the Extraordinary General Shareholders’ Meeting of Celyad SA authorized the Board of Directors to increase the share capital of the Company, in one or several times, and under certain conditions set forth in extenso in the articles of association. This authorization is valid for a period of five years starting on July 26, 2013 and until July 26, 2018. The Board of Directors may increase the share capital of the Company within the framework of the authorized capital for an amount of up to €21,413k. Over the course of 2014, the capital of the Company was increased in June 2014 by way of a capital increase of €25,000k represented by 568,180 new shares fully subscribed by Medisun International Limited. In 2014, the capital of the Company was also increased by way of exercise of Company warrants. Over four different exercise periods, 139,415 warrants were exercised resulting in the issuance of 139,415 new shares. The capital and the share premium of the Company were therefore increased respectively by €488k and €500k. In January 2015, the shares of Oncyte LLC were contributed to the capital of the Company, resulting in a capital increase of €3,452k and the issuance of 93,087 new shares. In 2015, the Company conducted two fund raisings. A private placement was closed in March resulting in a capital increase of €31,745k represented by 713,380 new shares. The Company also completed an IPO on Nasdaq in June, resulting in a capital increase of €87,965k represented by 1,460,000 new shares. Also, in 2015, the capital of the Company was also increased by way of exercise of Company warrants. Over three different exercise periods, 6,749 warrants were exercised resulting in the issuance of 6,749 new shares. The capital and the share premium of the Company were therefore increased respectively by €23k and €196k. Over 2017 the capital of the Company was also increased by way of exercise of Company warrants. Over four different exercise periods, 225,966 warrants were exercised resulting in the issuance of 225,966 new shares. The capital of the Company was therefore increased by €625k. In August 2017, pursuant to the amendment of the agreements with Celdara Medical LLC and Dartmouth College, the CAR T technology inventors, the capital of the Company was increased by way of contribution in kind of a liability owed to Celdara Medical LLC. 328,275 new shares were issued at a price of €32.35 (being Celyad share’s average market price for the 30 days preceding the transaction) and the capital and the share premium of the Company were therefore increased respectively by €1,141k and €9,479k without an impact on the cash and cash equivalents, explaining why such transaction is not disclosed in the consolidated statements of cashflows. In May 2018, the Company completed a global offering of $54.4 million (€46.1 million), resulting in cash proceeds for an amount of €43.0 million net of bank fees and transaction costs. In May 2019, share premium decreased as a result of the absorption of accounting losses for an amount of €172.3 million, with a counterpart in the financial statements line item ‘Accumulated Deficit’. The absorption of the accumulated deficit into share premium is a non-cash accounting transaction. In September 2019, the Company completed a global offering of $20.0 million (€18.2 million), resulting in cash proceeds for an amount of €16.4 million net of bank fees and transaction costs. On January 8, 2021, the Company has entered into a committed equity purchase agreement (“Purchase Agreement”) for up to $40.0 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. Over the 24-month term of the Purchase Agreement, the Company will have the right to direct LPC to purchase up to an aggregate amount of $40.0 million American Depositary Shares (“ADSs”), each of which represents one ordinary share of the Company. From the inception of the Purchase Agreement through December 31, 2021, a total of 1,962,812 new shares have been issued by the Company and subscribed by LPC for a cash proceed of €9.2 million. As of December 31, 2021, there is a remaining access to the Purchase Agreement established with LPC for an amount of $28.0 million. Page 142 | 180 2021 Annual Report During the extraordinary shareholders meeting of May, 25 2021, the shareholders, in accordance with Belgian Company Law, approved the absorption of approximately €43.3 million of accounting losses into share premium. As a result, share premium has been reduced by a cumulative amount of €43.3 million in the 12 months period ended December 31, 2021 (€234.6 million of loss absorption has been approved and recorded from inception to December 31, 2021) against capital reduction reserve. This transaction has no impact on the total equity, comprehensive income (loss), assets (including cash) nor liabilities. On May, 21 2021 and June 14, 2021, a total of 188,800 new shares have been issued by the Company and subscribed by Jefferies under the ATM for a cash proceed of €0.9 million. On December 8, 2021, 6,500,000 new shares were issued by decision of the board of directors and subscribed for by CFIP CLYD LLC10 in the framework of a private placement for a global cash proceed of €28.9 million. As of December 31, 2021, all shares issued have been fully paid. The following share issuances occurred since the incorporation of the Company: 11 June 2013 Conversion of Class A and Class B shares in ordinary shares 4 744 067 - Category Transaction date Description Class A shares Class A shares 24 July 2007 Company incorporation 31 August 2007 Contribution in kind (upfront fee Mayo License) Class B shares 23 December 2008 Capital increase (Round B) Class B shares 23 December 2008 Contribution in kind (Loan B) Class B shares 28 October 2010 Contribution in cash Class B shares 28 October 2010 Contribution in kind (Loan C) Class B shares 28 October 2010 Contribution in kind (Loan D) Class B shares 28 October 2010 Contribution in cash Class B shares 28 October 2010 Exercise of warrants Class B shares 28 October 2010 Contribution in kind (Mayo receivable) Class B shares 28 October 2010 Contribution in cash Class B shares Class B shares Class B shares Class B shares Class B shares Class B shares Ordinary shares Ordinary shares Ordinary shares 31 May 2013 Contribution in kind (Loan E) 31 May 2013 Contribution in kind (Loan F) 31 May 2013 Contribution in kind (Loan G) 31 May 2013 Contribution in kind (Loan H) 31 May 2013 Contribution in cash 4 June 2013 Conversion of warrants 5 July 2013 Initial Public Offering 15 July 2013 Exercise of over-allotment option Ordinary shares 31 January 2014 Exercise of warrants issued in September 2008 Ordinary shares 31 January 2014 Exercise of warrants issued in May 2010 Ordinary shares 31 January 2014 Exercise of warrants issued in January 2013 Ordinary shares Ordinary shares Ordinary shares Ordinary shares Ordinary shares 30 April 2014 Exercise of warrants issued in September 2008 16 June 2014 Capital increase 30 June 2014 Capital increase 4 August 2014 Exercise of warrants issued in September 2008 4 August 2014 Exercise of warrants issued in October 2010 Ordinary shares 3 November 2014 Exercise of warrants issued in September 2008 Ordinary shares 21 January 2015 Contribution in kind (Celdara Medical LLC) Ordinary shares 7 February 2015 Exercise of warrant issued in May 2010 Ordinary shares Ordinary shares 3 March 2015 Capital increase 11 May 2015 Exercise of warrant issued in May 2010 10 CFIP CLYD LLC (“Fortress”), an affiliate of Fortress Investment Group. # of shares 409 375 Par value (in €) 0.15 261 732 36.30 137 150 35.36 67 502 35.36 21 000 22.44 92 068 35.36 57 095 35.36 73 793 35.36 12 300 22.44 69 455 44.20 9 048 44.20 118 365 38.39 56 936 38.39 654 301 4.52 75 755 30.71 219 016 31.96 2 409 176 0.01 1 381 500 16.65 207 225 16.65 5 966 22.44 333 22.44 120 000 4.52 2 366 22.44 284 090 44.00 284 090 44.00 5 000 22.44 750 35.36 5 000 22.44 93 087 37.08 333 22.44 713 380 44.50 500 22.44 Page 143 | 180 Ordinary shares Ordinary shares Ordinary shares 24 June 2015 Capital increase 4 August 2015 Exercise of warrant issued in May 2010 4 August 2015 Exercise of warrant issued in October 2010 Ordinary shares 1 February 2017 Exercise of warrant issued in May 2013 Ordinary shares Ordinary shares 2 May 2017 Exercise of warrant issued in May 2013 1 August 2017 Exercise of warrant issued in May 2013 Ordinary shares 23 August 2017 Contribution in kind (Celdara Medical LLC) Ordinary shares 9 November 2017 Exercise of warrant issued in May 2013 Ordinary shares 9 November 2017 Exercise of warrant issued in October 2010 Ordinary shares 7 February 2018 Exercise of warrant issued in May 2013 Ordinary shares Ordinary shares Ordinary shares Ordinary shares Ordinary shares Ordinary shares Ordinary shares Ordinary shares Ordinary shares Ordinary shares 22 May 2018 Capital increase 16 Sept 2019 Capital increase 8 January 2021 Capital increase 29 March 2021 Capital increase 9 April 2021 Capital increase 29 April 2021 Capital increase 21 May 2021 Capital increase 14 June 2021 Capital increase 28 June 2021 Capital increase 22 July 2021 Capital increase Ordinary shares 20 October 2021 Capital increase Ordinary shares 8 December 2021 Capital increase 2021 Annual Report 1 460 000 60.25 666 22.44 5 250 35.36 207 250 4 900 7 950 2.64 2.64 2.64 328 275 32.35 5 000 2.64 866 35.36 4 500 2.64 2 070 000 22.29 2 000 000 262 812 200 000 300 000 300 000 182 000 6 800 300 000 300 000 300 000 6 500 000 9.08 4.94 6.19 5.83 5.23 4.58 4.98 4.46 3.46 3.38 4.44 (€000) Nature of the transactions Share Capital Share premium Capital reduction reserve Other reserves Accumulated Deficit Number of shares Balance as at January 1, 2020 (as adjusted) Share Based Payment Currency Translation differences Loss for the period Remeasurements of defined benefit obligation Balance as at December 31, 2020 (as adjusted) Reduction of share premium by absorption of losses Capital increase Transaction costs associated with capital increases Loss for the period Share Based Payment Currency Translation differences Remeasurements of defined benefit obligation Balance as at December 31, 2021 48 513 43 349 191 213 28 181 (265 637) 13 942 344 - - - 2 782 - - - - - - - - - (5) - - - - (17 204) - (197) - - - 48 513 43 349 191 213 30 958 (283 039) 13 942 344 - (43 349) 43 349 30 072 8 900 - - (2 583) - - - - - - - - - - 8 651 612 - - - - (26 512) - - - 2 172 - - - - - - - - 42 - - 554 - - 78 585 6 317 234 562 33 172 (308 997) 22 593 956 The total number of shares issued and outstanding as of December 31, 2021 totals 22,593,956 ordinary common shares Capital reduction reserve Pursuant to Belgian law (“CCA”), the calculation of amounts available for distribution to shareholders, as dividends or otherwise, must be determined on the basis of our standalone non-consolidated statutory financial statements of Celyad Oncology SA prepared under Belgian GAAP, and not on the basis of IFRS consolidated financial statements. In addition, under the CCA, the Company may declare or pay dividends only if, following the declaration and issuance of the dividends, the amount of the Company’s net assets on Page 144 | 180 2021 Annual Report the date of the closing of the last financial year according to the Company’s statutory annual accounts (i.e., the amount of the assets as shown in the balance sheet, decreased with provisions and liabilities, all as prepared in accordance with Belgian accounting rules), decreased with the non-amortized costs of incorporation and expansion and the non-amortized costs for research and development, does not fall below the amount of the paid-up capital (or, if higher, the called capital), increased by the amount of non- distributable reserves. Finally, prior to distributing dividends, the Company must allocate at least 5% of the annual net profits (under the Company’s non-consolidated statutory accounts prepared in accordance with Belgian accounting rules) to a legal reserve, until the reserve amounts to 10% of the Company’s share capital. In addition to the above test, the Company must also meet a liquidity test in order to be able to declare and/or distribute dividends. During the extraordinary shareholders meeting of May, 25 2021, the shareholders, in accordance with Belgian Company Law, approved the absorption of approximately €43.3 million of accounting losses into share premium. As a result, share premium has been reduced by a cumulative amount of €43.3 million in the 12 months period ended December 31, 2021 (€234.6 million of loss absorption has been approved and recorded from inception to December 31, 2021) against capital reduction reserve. This transaction has no impact on the total equity, comprehensive income (loss), assets (including cash) nor liabilities. 5.14 Share-based payments The Group operates an equity-based compensation plan, whereby warrants are granted to directors, management and selected employees and non-employees. The warrants are accounted for as equity-settled share-based payment plans since the Group has no legal or constructive obligation to repurchase or settle the warrants in cash. Each warrant gives the beneficiaries the right to subscribe to one common share of the Group. The warrants are granted for free and have an exercise price equal to the lower of the average closing price of the Group’s share over the 30 days prior to the offer, and the last closing price before the day of the offer, as determined by the Board of Directors of the Group. Changes in the number of warrants outstanding and their related weighted average exercise prices are as follows: Outstanding as at January 1, Granted Forfeited Exercised Expired At December 31, Weighted average exercise price (in €) 17.00 5.29 4.94 - 10.23 13.06 2021 Number of warrants 1 488 006 760 800 (77 250) - (35 000) 2 136 556 Weighted average exercise price (in €) 22.56 6.33 6.35 - 22.45 17.00 2020 Number of warrants 1 292 380 404 525 (36 466) - (172 433) 1 488 006 Warrants outstanding at the end of the year have the following expiry date and exercise price: Warrant plan issuance date Vesting date Expiry date of Number warrants outstanding as at December 31, 2021 of Number warrants outstanding at as December 31, 2020 Average exercise price share per 06 May 2013 05 May 2014 06 May 2016 05 May 2017 06 May 2023 05 May 2024 05 November 2015 05 November 2018 05 November 2025 08 December 2016 08 December 2019 08 December 2021 2 500 35 698 79 315 7 500 2 500 35 698 79 315 42 500 29 June 2017 29 June 2020 31 July 2022 282 251 282 251 2.64 38.25 30.67 32.04 31.44 Page 145 | 180 2021 Annual Report 26 October 2018 26 October 2021 31 December 2023 25 October 2019 25 October 2022 31 December 2024 365 817 549 842 11 December 2020 11 October 2021 10 December 2023 11 October 2024 31 December 2027 31 December 2028 532 133 281 500 381 600 588 142 76 000 - 18.26 7.12 6.25 3.75 2 136 556 1 488 006 The Group has a reserve of 839,250 authorized warrants for share based compensation plan as of December 31, 2021. Warrants issued on May 6, 2013 At the Extraordinary Shareholders Meeting of May 6, 2013, a plan of 266,241 warrants was approved. Warrants were offered to Group’s employees and management team. Out of the 266,241 warrants offered, 253,150 warrants were accepted by the beneficiaries and 2,500 warrants are outstanding as of December 31, 2021. The 253,150 warrants were vested in equal tranches over a period of three years. The warrants become 100% vested after the third anniversary the issuance. The warrants that are vested can only be exercised at the end of the third calendar year following the issuance date, thus starting on January 1, 2017. The exercise price amounts to €2.64. Warrants not exercised within 10 years after issue become null and void. Warrants issued on May 5, 2014 At the Extraordinary Shareholders Meeting of May 5, 2014, a plan of 100,000 warrants was approved. Warrants were offered to Group’s employees, non-employees and directors in five different tranches. Out of the warrants offered, 94,400 warrants were accepted by the beneficiaries and 35,698 warrants are outstanding as of December 31, 2021. The 100,000 warrants were vested in equal tranches over a period of three years. The warrants become 100% vested after the third anniversary the issuance. The warrants that are vested can only be exercised at the end of the third calendar year following the issuance date, thus starting on January 1, 2018. The exercise price of the different tranches ranges from €33.49 to €45.05. Warrants not exercised within 10 years after issue become null and void. Warrants issued on 5 November 2015 At the Extraordinary Shareholders Meeting of 5 November 2015, a plan of 466,000 warrants was approved. Warrants were offered to Group’s employees, non-employees and directors in five different tranches. Out of the warrants offered, 353,550 warrants were accepted by the beneficiaries and 79,315 warrants are outstanding as of December 31, 2021. These warrants vest in equal tranches over a period of three years. The warrants become 100% vested after the third anniversary of issuance. The warrants that are vested can only be exercised as from the end of the third calendar year following the issuance date, thus starting on January 1, 2019. The exercise price of the different tranches ranges from €15.90 to €34.65. Warrants not exercised within 10 years after issue become null and void. Warrants issued on December 8, 2016 On December 8, 2016, the Board of Directors issued a new plan of 100,000 warrants. An equivalent number of warrants were cancelled from the remaining pool of warrants of the plan of November 5, 2015. Warrants were offered to Group’s employees and non-employees in two different tranches. Out of the warrants offered, 45,000 warrants were accepted by the beneficiaries and 7,500 warrants are outstanding as of December 31, 2021. These warrants will vest in equal tranches over a period of three years. The warrants become 100% vested after the third anniversary of issuance. The warrants that are vested can only be exercised as from the end Page 146 | 180 2021 Annual Report of the third calendar year following the issuance date, thus starting on January 1, 2020. The exercise price of the different tranches ranges from €17.60 to €36.81. Warrants not exercised within 5 years after issue become null and void. Warrants issued on June 29, 2017 At the Extraordinary Shareholders Meeting of June 29, 2017, a plan of 520,000 warrants was approved. Warrants were offered in different tranches to beneficiaries (employees, non-employees and directors). Out of the warrants offered, 334,400 warrants were accepted by the beneficiaries and 282,251 warrants are outstanding as of December 31, 2021. These warrants will be vested in equal tranches over a period of three years. The warrants become 100% vested after the third anniversary of issuance. The warrants that are vested can only be exercised as from the end of the third calendar year following the issuance date, thus starting on January 1, 2021. The exercise price of the different tranches ranges from €31.34 to €48.89. Warrants not exercised within 5 years after issue become null and void. Warrants issued on October 26, 2018 On October 26, 2018, the Board of Directors issued a new plan of 700,000 warrants. Warrants were offered in different tranches to beneficiaries (employees, non-employees and directors). Out of the warrants offered, 426,050 warrants were accepted by the beneficiaries and 365,817 warrants are outstanding as of December 31, 2021. These warrants will vest in equal tranches over a period of three years. The warrants become 100% vested after the third anniversary of issuance. The warrants that are vested can only be exercised as from the end of the third calendar year following the issuance date, thus starting on January 1, 2022. The exercise price of the different tranches ranges from €9.36 to €22.04. Warrants not exercised within 5 years after issue become null and void after the 31st of December of the 5th year. Warrants issued on October 25, 2019 On October 25, 2019, the Board of Directors issued a new plan of 939,500 warrants. Warrants were offered in different tranches to beneficiaries (employees, non-employees and directors). Out of the warrants offered, 602,025 warrants were accepted by the beneficiaries and 549,842 warrants are outstanding as of December 31, 2021. The increase in the number of warrants issued / granted in 2019 follows an update to our benchmark analysis which now incorporates development-stage, biotechnology peers from both Europe and the United States. In addition, the Group had a double allocation of warrants granted in 2019 (Q1:2019 and Q4:2019, respectively). Future double allocation of warrants may be considered. Finally, over the past two years, the Group recruited new EC members as well as new managers which are remunerated in warrants. These warrants will vest in equal tranches over a period of three years. The warrants become 100% vested after the third anniversary of issuance. The warrants that are vested can only be exercised as from the end of the third calendar year following the issuance date, thus starting on January 1, 2023. The exercise price of the different tranches ranges from €5.97 to €9.84. Warrants not exercised within 5 years after issue become null and void after the 31st of December of the 5th year. Warrants issued on December 11, 2020 On December 11, 2020, the Board of Directors issued a new plan of 561,525 warrants. Warrants were offered in different tranches to beneficiaries (employees, non-employees and directors). Out of the warrants offered, 555,300 warrants were accepted by the beneficiaries and 532,133 warrants are outstanding as of December 31, 2021. These warrants will vest in equal tranches over a period of three years. The warrants become 100% vested after the third anniversary of issuance. The warrants that are vested can only be exercised as from the end Page 147 | 180 2021 Annual Report of the third calendar year following the issuance date, thus starting on January 1, 2024. The exercise price of the different tranches ranges from €3.72 to €6.81. Warrants not exercised within 7 years after issue become null and void after the 31st of December of the 7th year. Warrants issued on October 11, 2021 On October 11, 2021, the Board of Directors issued a new plan of 777,050 warrants. Warrants were offered in different tranches to beneficiaries (employees, non-employees and directors). Out of the warrants offered, 281,500 warrants were accepted by the beneficiaries and 281,500 warrants are outstanding as of December 31, 2021. These warrants will vest in equal tranches over a period of three years. The warrants become 100% vested after the third anniversary of issuance. The warrants that are vested can only be exercised as from the end of the third calendar year following the issuance date, thus starting on January 1, 2025. The exercise price of the first offer was of €3.75. Warrants not exercised within 7 years after issue become null and void after the 31st of December of the 7th year. As a result, as of December 31, 2021 there are 2,136,556 warrants outstanding which represent respectively 8.64% of the total number of all its issued and outstanding shares and 7.88% of the total voting financial instruments. The fair value of the warrants has been determined at grant date based on the Black-Scholes formula. The variables, used in this model, are: Warrants issued on 06 May 2013 05 May 2014 05 Nov. 2015 08 Dec. 2016 29 Jun. 2017 26 Oct. 2018 25 Oct. 2019 10 Dec. 2020 11 Oct. 2021 Total 266 241 100 000 466 000 100 000 520 000 700 000 939 500 561 525 777 050 4 649 816 253 150 94 400 353 550 45 000 334 400 426 050 602 025 555 300 281 500 3 146 425 2 500 35 698 79 315 7 500 282 251 365 817 549 842 532 133 281 500 2 136 556 2.64 38.25 30.67 32.04 31.44 18.26 7.12 6.25 3.75 13.06 39.55% 67.73% 60.53% 61.03% 60.61% 58.82% 59.14% 58.84% 56.86% 2.06% 1.09% 0.26% -0.40% -0.23% -0.06% -0.38% -0.66% -0.30% 12.44 25.19 20.04 16.18 15.65 8.90 3.99 3.45 2.04 6.98 1.34 2.34 3.84 (0.07) 0.49 1.82 2.81 5.94 6.95 Number of warrants issued Number of warrants granted Number of warrants not fully vested as of 31 December 2021 Average exercise price (in €) Expected share value volatility Risk-free interest rate Average fair value (in €) Weighted average remaining contractual life The total expense recognized in the income statement for the outstanding warrants totals €2.2 million for the year 2021 (€2.8 million of expense for the prior year 2020). Page 148 | 180 5.15 Post-employment benefits (€’000) Pension obligations Total 2021 Annual Report As at December 31, 2021 2020 53 53 614 614 The Group operates a pension plan which requires contributions to be made by the Group to an insurance company. The pension plan is a defined contribution plan. However, because of the Belgian legislation applicable to 2nd pillar pension plans (so-called "Law Vandenbroucke"), the Group’s defined contribution plan is accounted under IAS 19. At the end of each year, the Group is measuring and accounting for the potential impact of defined benefit accounting for these pension plans with a minimum fixed guaranteed return. The contributions to the plan are determined as a percentage of the yearly salary. There are no employee contributions. The benefit also includes a death in service benefit. The amounts recognized in the statement of financial position are determined as follows: (€'000) As at December 31, Present value of funded obligations Fair value of plan assets Deficit of funded plans Total deficit of defined benefit pension plans Liability position in the statement of financial 2021 2 408 (2 355) 53 53 53 The change in the defined benefit liability over the year is as follows: 2020 2 748 (2 134) (€'000) At January 1, 2020 Current service cost Interest expense/(income) Remeasurements - Return on plan assets, excluding amounts included in interest expense/(income) - Actuarial (Gain)/loss due to change in actuarial assumptions - Actuarial (Gain)/Loss due to experience Employer contributions: Benefits Paid At December 31, 2020 At January 1, 2021 Current service cost Interest expense/(income) Remeasurements - Return on plan assets, excluding amounts included in interest expense/(income) - Actuarial (Gain)/loss due to change in actuarial assumptions - Actuarial (Gain)/loss due to change in demographic assumptions - Actuarial (Gain)/Loss due to experience Employer contributions: Benefits Paid At December 31, 2021 The plan assets are 100% invested in an insurance product. Present value of obligation 2 330 233 30 2 593 - 187 24 212 - (57) 2 747 2 747 206 18 2 971 - (17) 36 (537) (518) - (45) 2 408 Fair value of plan assets 1 932 - 38 1 970 - - - - 220 (57) 2 133 2 133 - 49 2 182 - - - - - 218 (45) 2 355 614 614 614 Total 398 233 (8) 623 - 187 24 212 (220) - 614 614 206 (31) 789 - (17) 36 (537) (518) (218) - 53 Page 149 | 180 2021 Annual Report The income statement charge included in operating profit for post-employment benefits amount to: (€'000) Current service cost Interest expense on DBO Expected return on plan assets Net periodic pension cost 2021 2020 206 18 233 30 (13) (24) 211 239 The re-measurements included in other comprehensive loss amount to: (€'000) Effect of changes in actuarial assumptions Effect of experience adjustments Effect of changes in demographic assumptions (Gain)/Loss on assets for the year Remeasurement of post-employment benefit obligations 2021 2020 (17) (537) 36 (36) (554) 187 24 - (14) 197 Plan assets relate all to qualifying insurance policies. The significant actuarial assumptions as per December 31, 2021 were as follows: Demographic assumptions (for both current and comparative years presented in these year-end financial statements): • Mortality tables: mortality rates-5 year for the men and 5 year for the women • Withdrawal rate: 13.5% for age <55, 0.0% for age ≥55 (vs 15% each year at December 31, 2020) • Retirement age: 65 years Economic assumptions: • Yearly inflation rate: 2.0% (vs 1.8% compared to comparative period) • Yearly salary raise: 1.5% (above inflation), no change compared to last year • Yearly discount rate: 1.0% (vs 0.6% last year). The discount rate reflects the yield on high quality (AA) long-term corporate bonds (within the EURO zone) having the same duration as the duration of the pension liabilities at the valuation date. If the discount rate would decrease by 0.5% then, the defined benefit obligation would increase by 1.32%. If the discount rate would increase by 0.5% then the defined benefit obligation would decrease by 0.35%. The above sensitivity analysis is based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligation to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the projected unit credit method at the end of the reporting period) has been applied as when calculating the pension liability recognized within the statement of financial position. Through its defined benefit pension plan, the Group is exposed to several risks, the most significant of which are detailed below: • Changes in discount rate: a decrease in discount rate will increase plan liabilities; • Inflation risk: the pension obligations are linked to inflation, and higher inflation will lead to higher liabilities. The majority of the plan’s assets are either unaffected by or loosely correlated with inflation, meaning that an increase in inflation will also increase the deficit. The investment positions are managed by the insurance company within an asset-liability matching framework that has been developed to achieve long-term investments that are in line with the obligations under the pension schemes. Page 150 | 180 2021 Annual Report Expected contributions to pension plans for next financial year amount to €0.2 million. 5.16 Recoverable Cash Advances (€'000) Non-Current portion as at January 1, Non-Current portion as at December 31, Current portion as at January 1, Current portion as at December 31, Total Recoverable Cash Advances as at January 1, Total Recoverable Cash Advances as at December 31, As at December 31, 2021 2020 4 220 5 851 371 362 4 590 6 213 4 139 4 220 346 371 4 484 4 590 The Group receives government support in the form of recoverable cash advances from the Walloon Region in order to compensate the research and development costs incurred by the Group. Refer to note 5.2.5 and note 5.19.2. At December 31, 2021, the Group has been granted recoverable cash advances amounting to €25.8 million related active contracts. Out of this amount: i) €19.3 million have been received to date; ii) €6.5 million should be received in 2022 or later depending on the progress of the different programs partially funded by the Region. In addition, the Group has received recoverable cash advances amounting to €15.3 million related to contracts for which the exploitation has been abandoned (mainly related to the C-Cure program). For further details, reference is made to the table below which shows, for active contracts (i) the year for which amounts under those agreements have been received and initially recognized on the statement of financial position for the financial liability and deferred grant income components and (ii) a description of the specific characteristics of those recoverable cash advances including repayment schedule and information on other outstanding advances. Underlying R&D is ongoing. In 2022 and beyond, the Group will have to make exploitation decisions on the remaining RCAs (agreements numbered 8087, 8088, 1910028, 8212, 8436 and 8516). (in €'000) Amounts received for the years ended December 31, Id Project Contractual amount Prior years 2020 2021 5915 C-Cathez 910 910 - - Cumula ted cashed in 910 Amount s to be received 2022 and beyond Status - Exploitation 6633 C-Cathez 1 020 1 020 - - 1 020 - Exploitation As at December 31, 2021 Amount reimbursed (cumulative ) 670 296 7027 C-Cathez 2 500 2 500 - - 2 500 Exploitation 7502 CAR T Cell 2 000 2 000 - - 2 000 - - Exploitation 600 60 7685 8087 8088 THINK CYAD01 Deplethink CYAD02 Cycle1 - - 1910028 CwalityCAR 8212 8436 8516 CYAD-101 Immunicy New engagers Total 3 496 2 492 3 146 623 350 1 447 - - 3 496 2 070 - 422 Exploitation Research 70 - 3 538 885 615 746 2 246 1 292 Research 2 102 3 300 3 394 1 095 - - - - 749 825 1 697 - 199 1 370 - 274 948 2 195 1 697 274 1 154 1 105 1 697 821 Research Research Research Research - - - - - 25 847 11 083 5 684 2 589 19 356 6 491 1 696 Regarding active contracts (in exploitation or research status): The contract 5915 has the following specific characteristics: Page 151 | 180 2021 Annual Report • Funding by the Region covers 70% of the budgeted project costs; • Certain activities have to be performed within the Region; • In case of an outlicensing agreement or a sale to a third party, the Group will have to pay 10% of the price received (excl. Of VAT) to the Region; • Sales-independent reimbursements, sales-dependent reimbursements, and amounts due in case of an outlicensing agreement or a sale to a third party, are, in the aggregate, capped at 100% of the principal amount paid out by the Region; • Sales-dependent reimbursements payable in any given year can be set-off against sales- independent reimbursements already paid out during that year; • The amount of sales-independent reimbursement and sales-dependent reimbursement may possibly be adapted in case of an outlicensing agreement, a sale to a third party or industrial use of a prototype or pilot installation, when obtaining the consent of the Walloon Region to proceed thereto. The RCA liability associated to the contract 5915 amounted to €0.3 million. The other contracts have the following specific characteristics: • Funding by the Region covers from 45 to 70% of the budgeted project costs; • Certain activities have to be performed within the European Union; • Sales-independent reimbursements represent in the aggregate 30% of the principal amount; • Sales-independent reimbursements and sales-dependent reimbursements are, in the aggregate (including the accrued interests), capped at 200% of the principal amount paid out by the Region; • • • Interests (at Euribor 1 year (as applicable on the first day of the month in which the decision to grant the relevant RCA was made + 100 basis points) accrue as of the 1st day of the exploitation phase; The amount of sales-independent reimbursement and sales-dependent reimbursement may possibly be adapted in case of an outlicensing agreement, a sale to a third party or industrial use of a prototype or pilot installation, when obtaining the consent of the Region to proceed thereto. In case of bankruptcy, the research results obtained by the Group under those contracts are expressed to be assumed by the Region by operation of law. The RCA liability associated to the other contracts amounted to €5.9 million, which mainly incorporate the sales-independent reimbursements for €4.4 million and the sales-dependent reimbursements for €1.5 million. The table below summarizes, in addition to the specific characteristics described above, certain terms and conditions for the recoverable cash advances: Contract number Research phase Percentage of total project costs Turnover- dependent reimbursement Turnover-independent reimbursement Interest rate accrual (€’000) 5915 6633 7027 7502 01/08/08- 30/04/11 01/05/11- 30/11/12 01/11/12- 31/10/14 01/12/15- 30/11/18 70% 5.00% €40k in 2012 and €70k each year after N/A 60% 50% 45% 0.27% 0.33% 0.19% From €10k to €51k starting in 2013 until 30% of advance is reached From €25k to €125k starting in 2015 until 30% of advance is reached From €20k to €50k starting in 2019 until 30% is reached. Starting on 01/06/13 Starting on 01/01/15 Starting 2019 Amounts due in case of licensing (per year) resp. Sale 10% with a minimum of 100/Y N/A N/A N/A Page 152 | 180 2021 Annual Report 7685 8087 8088 1910028 8212 8436 8516 1/01/17- 31/12/19 01/05/19- 30/06/21 01/05/19- 31/12/21 06/06/19- 05/06/22 01/01/20- 31/12/21 01/11/20- 31/12/23 01/04/21- 31/03/23 45% 45% 45% 45% 45% 45% 45% 0.33% 0.22% 0.21% 0.01% 0.46% 0.32% 0.10% From €35k to €70k starting in 2019 until 30% is reached. From €25k to €75k starting in 2022 until 30% is reached From €35k to €106k starting in 2022 until 30% is reached From €21k to €42k starting in 2022 until 30% is reached From €33K to €99K starting in 2022 until 30% is reached From €34K to €102K starting in 2024 until 30% is reached From €11K to 33K starting in 2024 until 30% is reached Starting 2020 Starting 01/07/22 Starting 01/01/22 Starting 06/06/22 Starting 01/01/22 Starting 01/01/24 Starting 01/04/24 N/A N/A N/A N/A N/A N/A N/A 5.17 Other non-current liabilities (€'000) Onerous contracts - non-current liabilities Other non-current liabilities Total Other non-current liabilities As at December 31, 2021 2020 - 371 164 - 164 371 As of December 2020, the Group recorded a provision for onerous contracts for a total amount of €0.9 million in order to cover the contractual obligations, mainly on clinical activities follow-up and studies closing costs, after the Group’s decision to discontinue the development of first-generation, autologous CAR T candidate CYAD-01. There is no remaining non-current portion of this provision as of December 31, 2021. The current portion of the provision reaches an amount of €0.4 million as of December 31, 2021 (see note 5.18). As of December 31, 2021, the Group recorded a non-current liability of €0.2 million regarding a non- refundable, non-creditable sublicense fee to be paid on an annual basis to Dartmouth in connection with the December 2021 amendment agreement (see note 5.34.1). 5.18 Trade payables and other current liabilities (€'000) Total Trade payables Other current liabilities Social security Payroll accruals Onerous contracts - current liabilities Other current grant liabilities Other current liabilities Total Other current liabilities As at December 31, 2021 2020 6 611 332 1 798 388 1 096 2 338 5 952 4 736 319 1 653 488 1 838 1 317 5 614 Total Trade payables and other current liabilities 12 563 10 350 Trade payables Trade payables are non-interest-bearing liabilities and are normally settled on a 90-day terms. Their increase is mainly attributable to monthly effect in the timing of the expenses and the related payments. Page 153 | 180 2021 Annual Report Other current liabilities As of December 31, 2021, the increase on social security and payroll accruals of €0.2 million compared to December 31, 2020 is mainly related to employee movements in 2021. As of December 31, 2020, the Group recorded a provision for onerous contracts in order to cover the contractual obligations, mainly on clinical activities follow-up and studies closing costs, after the Group’s decision to discontinue the development of first-generation, autologous CAR T candidate CYAD-01. As of December 31, 2021, the remaining provision recorded to cover for contractual obligations through 2022 reaches an amount of €0.4 million. The other non-current liabilities attached to grants is mainly explained by the excess of cash proceeds compared to the eligible expenses subsidized by the convention numbered 8087 (CYAD-01 – DEPLETHINK), 8436 (CYAD-211 Immunicy) and 8516 (new engagers) recognized in 2021 for €1.1 million. The decrease compared to year-end 2020 is mainly related to the convention 8436 due to eligible expenses subsidized by the convention recognized in 2021. Other current liabilities increase of €1.0 million mainly explained by an accrual of €0.8 million for the reimbursement of R&D tax credit related to tax audit on fiscal year 2015. In 2020, an accrual had been established to cover for a €1.0 million reimbursement of R&D tax credit related to an assessment resulting from an audit of fiscal years 2013 and 2014. The reimbursement will be required through the first quarter of 2022 even though the management plans to appeal the assessment. No discounting was performed to the extent that the amounts do not present payments terms longer than one year at the end of each financial year presented. 5.19 Financial liabilities 5.19.1. Maturity analysis The table below analyses the Group’s non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the statement of financial position date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows, except for advances repayable which are presented at amortized cost. Contingent consideration liability has not been disclosed in the table below, because as of statement of financial position date, it does not meet the definition of a contractual obligation. Commitments relating to contingent consideration are detailed in the disclosure note 5.34.1. Financial liabilities reported as at December 31, 2021: (€'000) Total Less than one year One to five years More than five years As at December 31, 2021 Bank loan Lease liabilities (undiscounted) Advances repayable Trade payables Total financial liabilities - 2 965 6 213 6 611 15 789 - 1 057 362 6 611 8 030 - 1 908 1 356 - 3 264 - - 4 495 - 4 495 Page 154 | 180 2021 Annual Report Financial liabilities reported as at December 31, 2020: (€'000) Total Less than one year One to five years More than five years As at December 31, 2020 Bank loan Lease liabilities (undiscounted) Advances repayable Trade payables Total financial liabilities 37 4 129 4 590 4 736 13 493 37 1 306 371 4 736 6 450 - 2 732 1 022 - 3 754 - 92 3 197 - 3 289 5.19.2. Changes in liabilities arising from financing activities The change in bank loans balances is detailed as follows: BANK LOANS FINANCIAL LIABILITY ROLL FORWARD (€'000) Opening balance at January 1, New bank loans Payments For the year ended 2021 2020 37 229 - - (37) (192) Closing balance at December 31, - 37 The change in lease liability balances is detailed as follows: LEASES FINANCIAL LIABILITY ROLL FORWARD (€'000) Opening balance at January 1, New leases Payments For the year ended 2021 2020 3 602 4 134 129 723 (1 099) (1 255) Closing balance at December 31, 2 632 3 602 New leases 2021 are mainly related to new leased company cars. The change in recoverable cash advance liability balances is detailed as follows: RECOVERABLE CASH ADVANCE LIABILITY ROLL FORWARD (€'000) Opening balance at January 1, Repayments New Liability component Remeasurement Closing balance at December 31, For the year ended 2021 2020 4 590 4 484 (280) (246) 1 575 1 284 328 (933) 6 213 4 590 The RCAs are initially recognized as a financial liability at fair value, calculated based on present value of future repayment of grants (using initial effective discount rates ranging between 0% and 7% for the fixed part and between 13% to 25% for the variable part, depending on RCAs listed in note 5.16), determined as per IFRS 9. The benefit (RCA grant component) consisting in the difference between the cash received (RCA proceeds) and the financial liability’s fair value (RCA liability component) is treated as a government grant in accordance with IAS 20. The RCAs liability component (RCA financial liability) is subsequently measured at amortized cost using the cumulative catch-up approach under which the carrying amount of the liability is adjusted to the present value of the future estimated cash flows (future estimated cash flow are measured by the management using same key assumptions than for the impairment testing in note 5.6.2). The resulting adjustment is recognized within profit or loss (note 5.2.12). Page 155 | 180 2021 Annual Report The change in the recoverable cash advances liability at the statement of financial position date mainly reflects both the new grants received in current year as well as the remeasurement of the liability at amortized cost, based on the Group’s updated business plan and sales forecast for its CAR T product candidates. See disclosure note 5.28. The year-end balance also captures the repayments of contractual turnover independent lump sums to the Walloon Region (relating to C-Cathez agreements). 5.20 Financial instruments 5.20.1. Financial instruments not reported at fair value on statement of financial position The carrying and fair values of financial instruments that are not reported at fair value in the consolidated financial statements were as follows for the current and comparative periods: (€'000) Financial Assets (‘Amortized cost’ category) within: As at December 31, 2021 2020 Non-current Trade receivables 2 209 2 117 Other non-current assets 262 293 Trade receivables and other current assets 668 615 Short-term investments Cash and cash equivalents Total - - 30 018 17 234 33 157 20 259 For the above-mentioned financial assets, the carrying amount reported as per December 31, 2021 is a reasonable approximation of their fair value. (€'000) As at December 31, 2021 2020 Financial Liabilities (‘Financial liabilities at amortized cost’ category) within: Bank loans Lease liabilities RCAs liability Trade payables Total - 37 2 632 3 602 6 213 4 590 6 611 4 736 15 456 12 965 For the above-mentioned financial liabilities, the carrying amount reported as per December 31, 2021 is a reasonable approximation of their fair value. 5.20.2. Financial instruments reported at fair value on statement of financial position Contingent consideration and other financial liabilities are reported at fair value in the statement of financial position using Level 3 fair value measurements for which the Group developed unobservable inputs. (€'000) Liabilities Level I Level II Level III Total Contingent consideration and other financial liabilities - - 14 679 Total Liabilities - - 14 679 14 679 14 679 After initial recognition, contingent consideration liabilities are re-measured at fair value with changes in fair value recognized in profit or loss in accordance with IFRS 3. The calculations use cash flow projections based on business plan ending in 2040 based on probability of success of CYAD-02 and CYAD-101 product candidates (eligible for milestone payments to Dartmouth and Celdara as disclosed within note 5.34.1) as well as extrapolations of projected cash flows resulting from the future expected sales associated with CYAD-101 and sublicense income on CYAD-02. Page 156 | 180 The change in the balance is detailed as follows: (€'000) Opening balance Contingent consideration at January 1, Milestone payment Fair value adjustment 2021 Annual Report For the year ended 2021 2020 15 526 24 754 - - (847) (9 228) Closing balance Contingent consideration at December 31, 14 679 15 526 The contingent consideration and other financial liabilities refer to the acquisition of the Group’s immuno- oncology platform and corresponds to the fair value of the potential future payments due to Celdara Medical, LLC and Dartmouth College. The liability evolution reflects the development of the Group’s product candidates using CAR T technology and their progress towards market approval in both autologous and allogeneic programs, as well as the update of its underlying business plans and revenue forecast. There has not been any change in valuation technique in 2021 compared to 2020. The valuation is prepared by the Finance Team on a quarterly basis and reviewed by the Management. The Management’s key assumptions about projected cash flows when determining fair value less costs to sell are the same key assumptions than for impairment testing purposes (see note 5.6.2). Management’s key assumptions (assumptions to which the unit’s or group of units’, recoverable amount is most sensitive) about projected cash flows when determining fair value less costs to sell are the same key assumptions utilized for impairment testing purposes (see note 5.6.2): • Discount rate (WACC) The Management has determined that the Weighted Average Cost of Capital (WACC) is the most appropriate rate to use as it represents the risk associated with both equity and the debt. Contingent consideration is a liability and thus the discount rate should represent debt features, but the “contingent” nature of the liability has similar features as equity, e.g., return is not guaranteed and thus equity risk should be considered as well. Management estimated the discount rate (WACC) as of December 31, 2021 to be 13.4% (14.8% as of December 31, 2020) based on following components: the US Government Treasury bill 20-Y, the Group’s Beta, the equity Market Risk Premium and the small firm/illiquidity premium. The decrease of the WACC is mainly driven by a decrease of the Beta of the Group which is associated with the volatility of the Group’s equity influenced by its ongoing clinical programs and overall competitive landscape within the immuno- oncology field. Management corroborates its estimation with industry standards for biotechnology companies, the WACC used by Equity Research companies following the Group and transactions that have been sourced by the Group over the past 24 months. • Projected Revenue Management estimated the projected revenue (using cash flow projections ending in 2040) based on the following components: total market and market share, time-to-market, treatment price and terminal value. Management based its estimation of projected revenue and related components with the Group’s business plan, industry data for biotechnology companies, evolution of similar R&D programs, comparable prices, expected patent expiration period. The weight of this assumption is partially alleviated by the probability of success (PoS) presented hereunder. • Probabilities of Success (PoS) Management estimated the PoS based on Clinical Development Success Rates observed by independent business intelligence consulting companies for hematological and solid tumor diseases. Probability of the Group’s product candidates reaching the market used were updated compared to prior year-end based on most recent Clinical Development Success Rates observed by independent business intelligence consulting companies for hematological and solid tumor diseases as follows: Page 157 | 180 2021 Annual Report o Probabilities of Success as of December 31, 2021: PoS Phase I Phase I to Phase II Phase II to Phase III Phase III to BLA BLA to Approval Cumulative PoS CYAD-02 CYAD-101 100% 100% 50% 49% 28% 23% 60% 43% 90% 93% 7.5% 4.6% o Probabilities of Success as of December 31, 2020: PoS Phase I Phase I to Phase II Phase II to Phase III Phase III to BLA BLA to Approval Cumulative PoS CYAD-02 CYAD-101 100% 100% 62% 64% 29% 23% 53% 34% 86% 80% 8.1% 4.0% The PoS estimates used by management as of December 31, 2020 utilized clinical development success rates compiled by independent business intelligence consulting companies which sourced data from clinical development programs from 2006 – 2015. The Group’s updated PoS rates for its clinical programs as of December 31, 2021 incorporates data for clinical development success rates from 2011 – 2020, which the Group believes is a more accurate reflection of clinical development success rates across stage of development and in aggregate. As of December 31, 2020, the change in fair value of the contingent consideration and other financial liabilities was mainly driven by updated assumptions associated with the timing of the potential commercialization of the Group’s autologous CYAD-02 CAR T program for r/r AML/MDS which had been delayed by one year. The liability decrease at December 31, 2021 is mainly due to: • • • • • The update of the assumptions associated with the timing of the potential commercialization of the Group’s allogenic CYAD-101 CAR T program for mCRC which has been delayed by one year; The update of the assumptions associated with the timing, development and the potential commercialization of the Group’s autologous CYAD-02 CAR T program for r/r AML/MDS to reflect the future development of the program through potential partnership, which has been delayed by one year; The update in WACC used for fair value measurement purposes at December 31, 2021; The revaluation of the U.S. dollar against the Euro; and The updated assumptions on Probability of Success (PoS) associated with the Group’s CAR T programs. The contingent consideration liability captures the commitments disclosed under note 5.34.1. It does not include any amount for contingent consideration payable relating to any sub-licensing agreements entered into or to be entered into by the Group for the reasons that: • Any contingent consideration payable would be due only when the Group earns revenue from such sub-licensing agreements, and in an amount representing a fraction of that revenue; and • The development of the underlying product candidates by the sub-licensees is not under the Group’s control, making a reliable estimate of any future liability impossible. Page 158 | 180 2021 Annual Report Contingent consideration liability sensitivity analysis A sensitivity analysis has been performed on the key assumptions driving the fair value of the contingent consideration liability. The key assumptions are i) the discount rate (WACC), ii) the projected revenue and iii) the probabilities of success (PoS) for the Group’s product candidates to get commercialized. Cont. consideration (€ million) Impact (%) Cont. consideration (€ million) Impact (%) Discount rate (WACC) 12.0% 15.9 8% 12.7% 15.3 13.4% 14.7 4% - 14.0% 14.7% 14.1 -4% 13.6 -7% Projected revenue 95.0% 97.5% 100.0% 102.5% 105.0% 12.4 -3% 14.4 -2% 14.7 - 14.9 1% 15.2 4% In order to assess the sensitivity to this driver, the Group applies here an incremental probability factor to the bottom-line cumulative PoS disclosed below: Probabilities of Success -20.0% -10.0% PoS model 10.0% 20.0% Cont. consideration (€ million) 11.7 13.2 Impact (%) -20% -10% 14.7 - 16.1 10% 17.6 20% On February 28, 2022, the Group announced its decision to voluntarily pause our Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 administered concurrently with FOLFOX chemotherapy followed by MSD’s anti- PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with refractory metastatic colorectal cancer following reports of two fatalities that presented with similar pulmonary findings. The Group is currently investigating these reports and evaluating any similar events in additional patients treated on study. On March 1, 2022, the Group was informed via-email communication from the FDA that the KEYNOTE-B79 trial has been placed on clinical hold due to insufficient information to assess risk to study subjects (see note 5.36). Given the uncertain impact of this event on the future of KEYNOTE-B79 trials at this time, the Group is not able to assess the impact of such outcomes on the valuation of related assets and contingent liabilities and, therefore, has not adjusted the related fair value calculations for the clinical hold. 5.21 Income taxes The Group reports income taxes in the income statement as detailed below: INCOME TAX EXPENSE IN PROFIT OR LOSS (€'000) Current tax (expense) / income Deferred tax (expense) / income For the year ended December 31, 2021 2020 (10) - - - Total income tax expense in profit or loss (10) - The Group has a history of losses. The following table shows the reconciliation between the effective and theoretical income tax at the nominal Belgian income tax rate of 25.00% for the years 2021 and 2020: Page 159 | 180 EFFECTIVE INCOME TAX RECONCILIATION (€'000) Loss before tax Permanent differences Tax disallowed expenses Share-based payment Nominal tax rate Income tax at nominal tax rate1 Deferred tax assets not recognized Effective tax expense Effective tax rate 2021 Annual Report For the year ended December 31, 2021 2020 (26 502) (17 204) 1 185 2 172 25.00% 5 786 (5 796) (10) 1 092 2 782 25.00% 3 333 (3 333) - 0% 0% 1 The difference in foreign tax rate in the US (25.80%) compared to the Belgian rate (25.00%) is not distinctively disclosed in this table due to non-materiality of the operations of the Group’s subsidiary Celyad Inc. As having not yet reached the commercialization step, the Group accumulates tax losses that are carried forward indefinitely for offset against future taxable profits of the Group. Significant uncertainty exists however surrounding the Group’s ability to realize taxable profits in a foreseeable future. Therefore, the Group has not recognized any net deferred tax assets in its statements of financial position. Deferred tax assets and liabilities are detailed below by nature of temporary differences for the current year: DEFERRED TAX ASSETS AND LIABILITIES, PER TAX BASES (€'000) Intangibles assets Tangible assets Recoverable cash advances liability Contingent consideration liability Employee Benefits liability Other temporary difference Tax-losses carried forward Unrecognized Gross Deferred Tax assets/(liabilities) Netting by tax entity Unrecognized Net Deferred Tax assets/(liabilities) For the year ended December 31, 2021 Assets Liabilities Net - - 1 503 3 670 13 - 72 671 77 857 (3 295) 74 562 (2 709) - - - - (586) - (3 295) 3 295 - (2 709) - 1 503 3 670 13 (586) 72 671 74 562 - 74 562 Deferred tax assets and liabilities are detailed below by nature of temporary differences for the prior year: DEFERRED TAX ASSETS AND LIABILITIES, PER TAX BASES (€'000) Intangibles assets Tangible assets Recoverable cash advances liability Contingent consideration liability Employee Benefits liability Other temporary difference Tax-losses carried forward Unrecognized Gross Deferred Tax assets/(liabilities) Netting by tax entity Unrecognized Net Deferred Tax assets/(liabilities) For the year ended December 31, 2020 Assets Liabilities Net - - 1 067 3 881 154 - 63 302 68 405 (2 174) 66 231 (1 826) (26) - - - (346) - (2 197) 2 174 (23) (1 826) (26) 1 067 3 881 154 (346) 63 302 66 208 - 66 208 The Group’s main deductible tax base relates to tax losses carried forward, which have indefinite term under both BE and US tax regimes applicable to its subsidiaries. Page 160 | 180 2021 Annual Report The remaining temporary differences refer to differences between IFRS accounting policies and local tax reporting policies. The Group has not recognized any net deferred tax asset on its statements of financial position, for the same reason as explained above (uncertainty relating to taxable profits in a foreseeable future). The change in the Group’s net deferred tax asset balance is detailed below: UNRECOGNIZED DEFERRED TAX ASSET BALANCE ROLL FORWARD (€'000) Opening balance at January 1, Temporary difference creation or reversal Change in Tax-losses carried forward Change in US tax rate applicable Closing balance at December 31, For the year ended 2021 2020 66 208 61 300 (1 014) (2 981) 8 820 8 064 548 (176) 74 562 66 208 The net increase in the balance mainly relates to the additional losses reported for the current year. As of December 31, 2021, the Group has a total accumulated tax losses of €290.3 million, which generate unrecognized deferred tax assets, not subject to expiration. 5.22 Other reserves (€’000 ) based Share payment reserve equity Other reserve from conversion of convertible loan in 2013 Currency Translation Difference Total Balance as at January 1, 2020 Vested share-based payments Currency Translation differences subsidiaries Balance as at December 31, 2020 Vested share-based payments Currency Translation differences subsidiaries 13 021 2 782 - 15 803 2 172 - (5) (5) 16 631 (1 472) - - - 16 631 (1 476) - - - 42 28 181 2 782 30 958 2 172 42 33 172 Balance as at December 31, 2021 17 975 16 631 (1 434) The amount of €16.6 million has been accounted for as other reserves following the conversion of the loans E, F, G and H on May 31, 2013, as a legacy IFRS adjustment on fully settled contribution-in-kind convertible loans. 5.23 Revenue (€'000) Out-licensing revenue Other revenue Total For the year ended December 31, 2021 - - 2020 - 5 - 5 The Group’s license and collaboration agreements have generated no revenue for the year ended December 31, 2021 similar to the year ended December 31, 2020. The Group did not enter into any new license agreements for the 12-month period ended December 31, 2021. The Group does not expect to generate material revenue unless and until the Group receives regulatory approval for one of its drug product candidates. Page 161 | 180 2021 Annual Report 5.24 Research and Development expenses The following table is a summary of manufacturing expenses, clinical, quality and regulatory expenses and other research and development expenses, which are aggregated and presented as research and development expenses in the Group’s consolidated financial statements. (€'000) Employee expenses Travel & Living Clinical study costs Preclinical study costs Process development and scale-up Consulting fees IP filing and maintenance fees Share-based payments Depreciation Rent and utilities Delivery systems Others Total R&D expenses For the year ended December 31, 2021 2020 9 475 85 4 000 2 473 770 568 353 644 1 276 670 - 459 20 773 8 564 116 5 555 1 976 1 056 372 230 927 1 511 800 47 369 21 522 Research and development expenses totaled €20.8 million for the year ended December 31, 2021, which represents a decrease of 3% compared to 2020. The Group’s R&D internal resources are allocated to the continuous development of its immuno-oncology platform mainly in allogenic setting with its products candidate CYAD-101, CYAD-211 and preclinical programs (such as CYAD-203). The decrease in the Group’s R&D expenses is primarily driven by: • • • • • The increase of employee expenses mainly related to movement of employees through the year ended December 31, 2021 to support the Group’s preclinical and clinical programs The increase of preclinical activities associated with the CYAD-203 program (next-generation NKG2D) and other next-generation CAR T candidates, compensated by; The decrease of process development and clinical development after the Group’s decision in Q4 2020 to discontinue the development of first-generation, autologous CAR T candidate CYAD-01; The decrease of process development associated to the transition from preclinical to clinical development of the CYAD-211 program; and The decrease of the expenses associated with the share-based payments (non-cash expenses) related to the warrants plan offered to the employees, managers and directors. 5.25 General and Administrative expenses (€'000) Employee expenses Share-based payments Rent Insurances For the year ended December 31, 2021 2020 3 575 3 363 1 529 1 855 50 87 1 642 1 182 Communication & Marketing 434 454 Consulting fees Travel & Living 2 254 1 747 31 91 Post-employment benefits (7) 19 Depreciation Other 243 320 157 197 Total General and Administration expenses 9 908 9 315 Page 162 | 180 2021 Annual Report General and Administrative expenses increased by €0.6 million over the year ended December 31, 2021, which represents an increase of 6.4% compared to 2020. The increase in insurances costs (D&O insurance principally) and consulting fees associated with legal, recruitment and capital raise opportunities have been partially compensated by the decrease of the expenses associated with the share-based payments (non- cash expenses) related to the warrants plan offered to the employees, managers and directors 5.26 Depreciation and amortization (€'000) For the year ended December 31, 2021 2020 Depreciation of property, plant and equipment 1 303 1 635 Amortization of intangible assets 217 197 Total depreciation and amortization 1 520 1 832 The amortization expenses decreased compared to the year 2020 mainly due to end of depreciation of tangible assets. The depreciation of property, plant and equipment are mainly driven by the amortization expenses relating to right-to-use of leased assets. See disclosure notes 5.2.28 and 5.30. 5.27 Employee benefit expenses (€'000) Salaries, wages and fees Executive Management team compensation Share-based payments Social security Post-employment benefits Hospitalization insurance Other benefit expense Total Employee expenses For the year ended December 31, 2021 2020 7 975 3 115 2 172 1 444 251 142 116 15 215 7 139 2 773 2 782 1 487 263 146 138 14 727 Total employee expenses increased in 2021 compared to 2020. Salaries, wages and fees expenses show a net increase year-on-year, which reflects the organic growth of the Group, in line with a total staff headcount increased by 10.6% at December 31, 2021. Headcount Research & Development General and administrative staff Total Headcount For the year ended December 31, 2021 2020 96.0 19.6 115.6 85.7 18.8 104.5 5.28 Change in fair value of contingent consideration, other income and other expenses Change in fair value of contingent consideration (€'000) For the year ended December 31, 2021 2020 Change in fair value of contingent consideration 847 9 228 Total Change in fair value of contingent consideration 847 9 228 Page 163 | 180 2021 Annual Report The fair value adjustment (€0.8 million, non-cash expenses) relating to reassessment as of December 31, 2021 required by International Financial Reporting Standards (IFRS) of the contingent consideration and other financial liabilities associated with the advancement in the Company’s NKG2D-based CAR T candidates, is mainly driven by: • • • • • The update of the assumptions associated with the timing of the potential commercialization of the Group’s allogenic CYAD-101 CAR T program for mCRC which has been delayed by one year; The update of the assumptions associated with the timing, development and the potential commercialization of the Group’s autologous CYAD-02 CAR T program for r/r AML/MDS to reflect the future development of the program through potential partnership, which has been delayed by one year; The update in WACC used for fair value measurement purposes at December 31, 2021; The revaluation of the U.S. dollar against the Euro; and The updated assumptions on Probability of Success (PoS) associated with the Group’s CAR T programs. As of December 31, 2020, the change in fair value of the contingent consideration and other financial liabilities was mainly driven by updated assumptions associated with the timing of the potential commercialization of the Group’s autologous CYAD-02 CAR T program for r/r AML/MDS which had been delayed by one year. Other income (€'000) Grant income (RCAs) Grant income (Other) Remeasurement of RCAs R&D tax credit For the year ended December 31, 2021 2020 2 731 2 311 1 448 779 - 933 687 657 Gain on sales of Property, plant & equipment - 35 Other Total Other Income 43 17 4 909 4 731 Other income is mainly related to: • Grant income (RCAs): additional grant income has been recognized in 2021 on grants in the form of recoverable cash advances (RCAs) for contracts numbered 8087, 8088, 8212, 8436 and 1910028. According to IFRS standards, the Company has recognized grant income for the period amounting to €2.7 million and a liability component of €1.6 million is accounted for as a financial liability (see disclosure notes 5.16 and 5.19.2). The increase compared to December 31, 2020 is mainly associated with additional grant income recognized on new conventions signed during the last quarter of 2020 (contracts numbered 8212 and 8436) and on convention numbered 1910028, partly compensated by the decrease on grant income recognized on conventions associated to autologous programs (contract numbered 7685, 8087 and 8088); • Grant income (Others): additional grant income has been recognized in 2021 on grants received from the Federal Belgian Institute for Health Insurance Inami (€0.3 million) and from the regional government (contracts numbered 8066 and 8516 for €1.1 million), not referring to RCAs and not subject to reimbursement. The increase compared to December 31, 2020 is mainly due to grant income recognized on new convention signed in the last quarter of 2021 with the regional government (contract numbered 8516); Page 164 | 180 2021 Annual Report • the remeasurement income on the recoverable cash advances (RCAs) of €0.9 million for the year 2020, which was mainly related to the Group decision to update assumptions associated with the timing of the potential commercialization of the Group’s autologous AML/MDS CAR T program, while the remeasurement on the recoverable cash advances (RCAs) is an expense for the year ended December 31, 2021; and • with respect to R&D tax credit, the current year income is predicated on a R&D tax credit recorded (€0.7 million), which has been updated taking into account all information available at this date and is in line with previous year. Other expenses (€'000) For the year ended December 31, 2021 2020 Clinical Development milestone payment - 69 Remeasurement of RCAs 328 - Loss on disposals of Property, plant & equipment 1 10 Other Total Other Expenses 1 137 35 1 466 114 For the year ended December 31, 2021, other expenses mainly refer to: • • the remeasurement income on the recoverable cash advances (RCAs) of €0.3 million for the year 2021, which is mainly related to the time accretion (which reflects the development of the Group’s product candidates using CAR T technology and their progress towards market approval in both autologous and allogeneic programs) and the revaluation of the U.S. dollar against the Euro, refer to disclosure note 5.16; and the other expenses are mainly associated with the amendment fees on license agreement with Dartmouth signed in December 2021 for €1.1 million (see note 5.34.1). For the year ended December 31, 2020, other expenses mainly referred to clinical development milestones for (€0.1 million) paid to Dartmouth after that the Group successfully dosed the first patient with CYAD-02 in CYCLE-1 trial for r/r AML and MDS treatment. 5.29 Non-recurring operating income and expenses Non-recurring operating income and expenses are defined as one-off items, not directly related to the operational activities of the Group. No operations qualify for such a presentation for the years 2021 and 2020. 5.30 Leases Amounts recognized in the consolidated statements of financial position “Property, plant and equipment” comprise owned and leased assets that do not meet the definition of investment property. (€’000) Property, Plant and Equipment owned (excluding right-of-use assets) Right-of-use assets As of December 31, 2021 2020 1 033 2 215 1 115 3 004 Page 165 | 180 2021 Annual Report Total Property, Plant and Equipment 3 248 4 119 The statement of financial position shows the following amounts relating to leases for which the Group is a lessee: (€’000) Cost At 1 January 2020 Additions Disposals Transfers At 31 December 2020 Additions Disposals Transfers At 31 December 2021 Accumulated depreciation At 1 January 2020 Depreciation charge Disposals Transfers At 31 December 2020 Depreciation charge Disposals Transfers At 31 December 2021 Net book value Cost Accumulated depreciation At 31 December 2020 Cost Accumulated depreciation At 31 December 2021 Property Vehicles Equipment Total 2 810 191 - - 3 001 24 - - 3 025 (399) (428) - - (827) (454) - - (1 281) 3 001 (827) 2 174 3 025 (1 281) 1 744 363 105 (39) - 429 67 (41) - 454 (90) (114) 39 - (165) (117) 41 - (241) 429 (165) 263 454 (241) 213 1 564 470 - (543) 1 491 - - (950) 541 (901) (567) - 543 (924) (309) - 950 (283) 1 491 (924) 567 541 (283) 258 4 737 765 (39) (543) 4 920 91 (41) (950) 4 020 (1 390) (1 109) 39 543 (1 916) (880) 41 950 (1 805) 4 920 (1 916) 3 004 4 020 (1 805) 2 215 Amounts recognized in the consolidated statements of comprehensive loss The consolidated statements of comprehensive loss show the following amounts relating to leases: (€’000) For the 12-month period ended December 31, Depreciation charge of right-of-use assets Property Vehicles Equipment Interest on lease liabilities (including in Financial expenses)1 Interest on sublease receivable (including in Financial income)1 2021 2020 454 76 309 217 428 75 567 259 (26) (46) Variable lease payments not included in the measurement of lease liabilities - - Expenses relating to short-term leases and leases of low-value assets 137 166 Total expenses related to leases 1 167 1 449 1 Interests on leases are presented as operating cash flow. Page 166 | 180 Total cash outflows for leases (€’000) Total cash outflow for leases 2021 Annual Report For the 12-month period ended December 31, 2021 1 453 2020 1 681 5.31 Finance income and expenses (€’000) For the year ended December 31, 2021 2020 Interest finance leases 217 260 Interest on overdrafts and other finance costs 21 19 Interest on RCAs Foreign Exchange differences Finance expenses 17 18 - 137 255 434 Finance income on the net investment in lease 26 46 Interest income bank account Foreign Exchange differences Other financial income Finance income Net Financial result 1 5 5 - 112 166 144 217 (111) (217) The net financial result increased from a net financial loss of €0.2 million for the year ended December 31, 2020 to €0.1 million of net financial loss for the year ended December 31, 2021, which is mainly driven by the decrease from €0.1 million of loss on foreign exchange differences due to the revaluation of the USD through the year ended December 31, 2021 and its impact on the valuation of the Mesoblast receivable. 5.32 Loss per share The loss per share is calculated by dividing loss for the year by the weighted average number of ordinary shares outstanding during the period. As the Group is incurring net losses, outstanding warrants have an anti-dilutive effect. As such, there is no difference between the basic and the diluted earnings per share. In case the warrants would be included in the calculation of the loss per share, this would decrease the loss per share. (€’000) As at December 31, 2021 2020 Loss of the year attributable to Equity Holders (26 512) (17 204) Weighted average number of shares outstanding 15 604 014 13 942 344 Earnings per share (non-fully diluted) in € (1.70) (1.23) Outstanding warrants 2 136 556 1 488 006 5.33 Contingent assets and liabilities As described in note 5.2.5, the Group has to reimburse certain government grants received in the form of recoverable cash advances under certain conditions. For more information on the potential financial consequences of these exploitation decisions in terms of potential reimbursements and sales percentage fees to be paid to the Walloon Region, refer to note 5.16. Page 167 | 180 In 2022 and beyond, the Group will have to make exploitation decisions on the remaining RCAs (agreements numbered 8087, 8088, 1910028, 8212, 8436 and 8516). 2021 Annual Report 5.34 Commitments 5.34.1. Celdara Background In January 2015, the Group entered into an agreement with Celdara Medical, LLC, or Celdara in which the Group purchased all outstanding membership interests of OnCyte, LLC, or OnCyte. In connection with this transaction, the Group entered into an asset purchase agreement to which Celdara sold to OnCyte certain data, protocols, regulatory documents and intellectual property, including the rights and obligations under two license agreements between OnCyte and The Trustees of Dartmouth College, or Dartmouth, related to the Group’s CAR T development programs. In March 2018, the Group dissolved the affairs of its wholly owned subsidiary OnCyte. As a result of the dissolution of OnCyte, all the assets and liabilities of OnCyte were fully distributed to the Group including its license agreement with Dartmouth. Amended Asset Purchase Agreement In August 2017, the Group entered into an amendment to the asset purchase agreement described above. In connection with the amendment, the following payments were made to Celdara: (i) an amount in cash equal to $10.5 million, (ii) newly issued shares of Celyad valued at $12.5 million, (iii) an amount in cash equal to $6.0 million in full satisfaction of any payments owed to Celdara in connection with a clinical milestone related to the Group’s CAR-T NKR-2 product candidate, (iv) an amount in cash equal to $0.6 million in full satisfaction of any payments owed to Celdara in connection with the Group’s license agreement with Novartis International Pharmaceutical Ltd., and (v) an amount in cash equal to $0.9 million in full satisfaction of any payments owed to Celdara in connection with the Group’s former license agreement with Ono Pharmaceutical Co., Ltd. Under the amended asset purchase agreement, the Group is obligated to make certain development-based milestone payments to Celdara up to $40.0 million, certain development-based milestone payments up to $36.5 million and certain sales-based milestone payments up to $156.0 million. The Group is required to make tiered single-digit royalty payments to Celdara in connection with the sales of CAR-T products, subject to reduction in countries in which there is no patent coverage for the applicable product or in the event Celyad is required to secure licenses from third parties to commercialize the applicable product. The Group is also required to pay Celdara a percentage of sublicense income, including royalty payments, for each sublicense ranging from the mid-single digits to the mid-twenties, depending on which of a specified list of clinical and regulatory milestones the applicable product has achieved at the time the sublicense is executed. The Group is required to pay Celdara a single-digit percentage of any research and development funding received by us, not to exceed $7.5 million for each product group. The Group can opt out of the development of any product if the data does not meet the scientific criteria of success. The Group may also opt out of development of any product for any other reason upon payment of a termination fee of $2.0 million to Celdara. The Trustees of Dartmouth College (“Dartmouth”) As described above, as a result of the Group’s acquisition of all of the outstanding membership interests of OnCyte and the asset purchase agreement among the Group, Celdara and OnCyte, OnCyte became the Group’s wholly-owned subsidiary and acquired certain data, protocols, regulatory documents and intellectual property, including the rights and obligations under two license agreements between OnCyte and Dartmouth. The first of these two license agreements concerned patent rights related, in part, to methods for treating cancer involving chimeric NK and NKP30 receptor targeted therapeutics and T cell receptor-deficient T cell Page 168 | 180 2021 Annual Report compositions in treating tumor, infection, GVHD, transplant and radiation sickness, or the CAR-T License, and the second of these two license agreements concerned patent rights related, in part, to anti-B7-H6 antibody, fusion proteins and methods of using the same, or the B7H6 License. In August 2017, the Group and Dartmouth entered into an amendment agreement in order to combine its rights under B7H6 Agreement with its rights under the CAR-T License, resulting in the termination of the B7H6 License, and in order to make certain other changes to the agreement. In connection with the amendment, the Group paid Dartmouth a non-refundable, non-creditable amendment fee in the amount of $2.0 million in 2017. Under the amended license agreement, Dartmouth granted the Group an exclusive, worldwide, royalty-bearing license to certain know-how and patent rights to make, have made, use, offer for sale, sell, import and commercialize any product or process for human therapeutics, the manufacture, use or sale of which, is covered by such patent rights or any platform product. Dartmouth reserves the right to use the licensed patent rights and licensed know-how, in the same field, for education and research purposes only. The patent rights included in the amended license agreement also include the patents previously covered by the B7H6 License. In consideration for the rights granted to the Group under the amended license agreement, the Group is required to pay to Dartmouth an annual license fee as well as a low single-digit royalty based on annual net sales of the licensed products by the Group, with certain minimum net sales obligations beginning April 30, 2024 and continuing for each year of sales thereafter. Under the amended license agreement, in lieu of royalties previously payable on sales by sublicensees, the Group is required to pay Dartmouth a percentage of sublicense income, including royalty payments, (i) for each product sublicense ranging from the mid-single digits to low-single digits, depending on which of a specified list of clinical and regulatory milestones the applicable product has achieved at the time the sublicense is executed and (ii) for each platform sublicense in the mid-single digits. Additionally, the agreement requires that the Group exploits the licensed products, and the Group has agreed to meet certain developmental and regulatory milestones. Upon successful completion of such milestones, the Group is obligated to pay to Dartmouth certain clinical and regulatory milestone payments up to an aggregate amount of $1.5 million and a commercial milestone payment in the amount of $4.0 million. The Group is responsible for all expenses in connection with the preparation, filing, prosecution and maintenance of the patents covered under the agreement. As further amended in December 2021, this agreement allows Dartmouth to terminate the amended license after April 30, 2026, extended from the prior date of April 30, 2024, in the event that Celyad fails to meet the specified minimum net sales obligations for any year ($10 million during first year of sales, $40 million during the second year of sales and $100 million during the third year of sales and every year of sales thereafter), unless Celyad pays to Dartmouth the royalty Celyad would otherwise be obligated to pay had Celyad met such minimum net sales obligation. Dartmouth may also terminate the license if Celyad fails to meet a milestone within the specified time period, unless Celyad pays the corresponding milestone payment. In connection with the December 2021 amendment, the Group agreed to certain protective provisions of any sublicenses and paid Dartmouth a non-refundable, non-creditable amendment fee and an additional non- refundable, non-creditable sublicense fee to be paid on an annual basis. In accordance with IFRS 3, these contingencies are recognized on the statement of financial position at year-end, on a risk-adjusted basis. 5.34.2. Horizon Discovery / PerkinElmer In April and June 2018, the Group signed two research and development collaboration and license agreements with Horizon Discovery Group plc, or Horizon, to evaluate the utility of Horizon’s SMART vector shRNA reagents to reduce expression of one or more defined targets in connection with the development of the Group’s product candidates. The first agreement was focused on targets related to Group’s autologous CAR-T candidate, CYAD-02. The second agreement was focused on targets related to its allogenic CAR-T product candidate CYAD-211 and one pre-clinical allogenic product candidate not yet publicly announced, called CYAD-203. In December 2018, the Group exercised its option to convert the second agreement into an exclusive license agreement, in connection with which the Group paid Horizon an up-front payment of $1 million. In September Page 169 | 180 2021 Annual Report 2019, the Group exercised its option to convert the first agreement into an exclusive license agreement, in connection with which the Group has paid Horizon an up-front payment of $0.1 million and an additional milestone of $0.1 million for the first IND filed by us for CYAD-02. In September 2020, the Group paid an additional milestone of $0.2 million for the first IND filed by the Group for CYAD-211. Under these exclusive license agreements combined, Horizon is eligible to receive additional milestone payments in development, regulatory and commercial milestone payments, in addition to low single digit royalties on net sales, subject to customary reductions. In December 2020, Horizon Discovery was acquired by PerkinElmer, Inc. (Horizon/PKI). In 2021, Horizon/PKI informed the Group they believe the Group is in material breach of these agreements as a result of certain disclosures the Group has made in connection with its obligations as a publicly traded company in the United States and Belgium, although they have not formally delivered to the Group a notice of material breach or termination. The Group believes any such assertion of material breach would be without merit and the Group would expect to vigorously defend any such notice of material breach. Any dispute under these agreements would be subject to arbitration in The Hague under the International Chamber of Commerce Rules. The Group is currently in discussions with Horizon about possible amendments to these agreements in connection with which the Group would retain freedom to operate under the in-licensed patents. Of note, the Group has filed patent applications which, if issued, would cover other aspects of the product candidates described above as well as products developed by third parties that deploy similar technology and targets. These patent applications encompass the downregulation of one or more of the targets covered under the Horizon/PKI agreements, the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells. The Group is also developing a second generation shRNA platform that does not incorporate any of the Horizon Discovery/Perkin Elmer, Inc. technology described above. The Group’s lead allogeneic CAR T product candidate, CYAD-101, does not incorporate any of the Horizon Discovery/Perkin Elmer, Inc. technology described above. 5.34.3. Other Commitments In 2021, the Group signed two license agreements. Under these license agreements, the licensors are eligible to receive additional milestone payments in development, regulatory and commercial milestone payments, in addition to low single digit royalties on net sales, subject to customary reductions, if the Group decides to continue the exploitation of these licenses. 5.35 Related-party transactions 5.35.1. Remuneration of key management Key management consists of the members of the Executive Committee and the entities controlled by any of them. Number of Executive Committee members 7 6 As at 31 December, 2021 2020 (€’000) For the year ended 31 December 2021 2020 Short term employee benefits[1] 1 866 1 349 Page 170 | 180 2021 Annual Report Post employee benefits Share-based compensation Other employment costs[2] Management fees Total benefits Executive Committee outstanding fees payables (in ‘000€) (1) Include salaries, social security, bonuses, lunch vouchers (2) Company cars 45 928 148 1 163 4 150 844 Number of warrants granted Number of warrants lapsed Cumulative outstanding warrants Exercised warrants As at 31 December, 2021 2020 395 000 (30 000) 921 000 - 34 1 110 110 1 335 3 939 660 220 000 (20 000) 556 000 - 5.35.2. Transactions with non-executive directors (€'000) Share-based compensation Management fees Total benefits Non-executive directors outstanding fees payables (in ‘000€) Number of warrants granted Number of warrants lapsed Number of exercised warrants Cumulative outstanding warrants For the year ended 31 December, 2021 2020 337 373 710 93 396 366 762 94 As at 31 December, 2021 2020 150 000 80 000 - - 30 000 - 340 000 220 000 5.35.3. Transactions with shareholders There were no transactions with the Group’s shareholders, for 2021 or 2020. 5.36 Events after the close of the fiscal year On January 17, 2022, the Company entered into an amendment with Mesoblast to convert the license into non-exclusive whereby the Company agreed, (a) to settle $2,500,000 of receivable as of December 31, 2021 with $1,500,000 and; (b) extend certain milestone payments. The consideration of $1,500,000 was agreed to be paid by Mesoblast in Mesoblast ordinary shares and the difference $1,000,000 will be recorded in the income statement in 2022. On February 28, 2022, the Company announced its decision to voluntarily pause our Phase 1b KEYNOTE- B79 trial evaluating CYAD-101 administered concurrently with FOLFOX chemotherapy followed by MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with refractory metastatic colorectal cancer following reports of two fatalities that presented with similar pulmonary findings. The Company is currently investigating these reports and evaluating any similar events in additional patients treated on study. On March 1, 2022, the Company was informed via-email communication from the FDA that the KEYNOTE-B79 trial has been placed on clinical hold due to insufficient information to assess risk to study subjects. Page 171 | 180 There were no other subsequent events that occur between 2021 year-end and the date when the financial statements have been authorized by the Board for issue. 2021 Annual Report 5.37 Statutory accounts as of December 31, 2021 and 2020 according to Belgian GAAP This section contains selected financial information, consisting of the balance sheet, income statement and certain notes, as derived from the statutory financial statements of Celyad Oncology SA as of and for the year ended December 31, 2021 (including comparative information as of and for the year ended December 31, 2020). These financial statements were prepared in accordance with the applicable accounting framework in Belgium and with the legal and regulatory requirements applicable to the financial statements in Belgium and are filed with the National Bank of Belgium. These statutory financial statements are approved by the Shareholders’ Meeting on May 5, 2022 and the statutory auditor has issued an unqualified audit opinion with respect to these statutory financial statements. The full set of the statutory financial statements is available on the website of the National Bank of Belgium (www.nbb.be). 5.37.1. Balance Sheet (in €) ASSETS FIXED ASSETS II. Intangible fixed assets III. Tangible fixed assets Land and buildings Installations machinery and equipment Furniture and vehicles Leasing and similar rights Other fixed assets Fixed assets under construction and advance payments IV. Financial fixed assets CURRENT ASSETS VI. Stocks and contracts in progress Goods purchase for resale VII. Amounts receivable within one year Trade debtors Others amounts receivable VIII. Amounts receivable more than one year Others amounts receivable IX. Investment X. Cash at bank and in hand XI. Deferred charges and accrued income TOTAL ASSETS CAPITAL AND RESERVES I. Capital Issued capital 2021 2020 39 512 659 40 734 524 24 450 692 27 986 462 939 525 - 271 634 75 528 138 980 453 383 - 1 087 290 - 80 089 55 029 367 923 584 249 - 14 122 442 11 660 773 37 534 143 24 171 087 - - 2 392 123 475 292 1 916 831 5 207 946 5 207 946 - - 1 771 464 422 822 1 348 643 5 128 817 5 128 817 - - 28 968 595 16 422 938 965 479 847 868 77 046 802 64 905 612 62 777 236 53 265 948 78 584 224 78 584 224 48 512 615 48 512 615 Page 172 | 180 Uncalled capital (-) II. Share Premium V. Accumulated profits (losses) PROVISIONS AND DEFERRED TAXES VII.A. Provisions for liabilities and charges 2021 Annual Report - - 13 653 439 59 599 665 (29 460 427) (54 846 331) - - - - PAYABELS 14 269 566 11 639 663 VIII. Amounts payable after more than one year Credit institutions; leasing and other similar obligations Other financial loans Other debts IX. Amounts payable within one year Current portion of amounts payable after one year Trade debts Suppliers Taxes; remunerations and social security costs Taxes Remunerations and social security costs Other amounts payable X. Accrued charges and deferred income 2 046 115 125 178 1 708 835 212 102 12 223 450 253 072 6 719 692 6 719 692 4 100 585 2 261 280 1 839 305 1 150 101 1 3 023 108 156 217 1 918 992 947 898 8 614 824 516 987 5 088 332 5 088 332 2 118 591 301 073 1 817 518 890 914 1 732 TOTAL LIABILITIES 77 046 802 64 905 612 5.37.2. Income statement (in €) Operating income Turnover Capitalization of development costs Other operating income Non recurring operating income Operating charges Direct Material Services and other goods Remuneration; social security and pensions Depreciation of and other amounts written off formations expenses; intangible and tangible fixed assets (-) Write-downs on inventories, on orders in progress and on trade receivables (appropriations -; write-backs +) Provisions for liabilities and charges (appropriations -; use and write-backs +) Other operating charges (-) Non recurring operating expenses Operating profit (loss) Financial income Income from current assets Income from financial assets Other financial income Financial charges (-) Interest on financial debts Other financial charges Non-recurring financial charges 2021 2020 27 788 089 24 408 732 - 4 707 20 343 657 18 444 030 7 443 825 5 959 953 607 41 (56 776 393) (50 952 881) (3 337 391) (3 472 216) (18 568 543) (14 538 134) (9 145 602) (9 019 398) (24 570 724) (22 855 773) - - - - (1 153 961) (1 057 583) (172) (9 776) (28 988 304) (26 544 149) 920 332 125 495 639 - 5 373 - 919 693 120 122 (239 500) (3 113) (236 387) - (965 810) (5 465) (960 345) (2) Profit (loss) on ordinary activities before taxes (-) (28 307 472) (27 384 464) Page 173 | 180 2021 Annual Report Profit (Loss) for the period before taxes (-) Income taxes (-) (+) - - (1 152 955) 622 889 Profit (loss) for the period available for appropriation (29 460 427) (26 761 574) 5.37.3. Notes Statement of intangibles assets (in €) 2021 2020 Acquisition value at the end of the preceding period 190 249 350 171 536 439 Movements during the period Acquisitions, included produced fixed assets Sale, transfer and withdraw Acquisition value at the end of the period 20 556 802 15 939 210 787 212 18 712 911 0 190 249 350 Depreciation and amounts written down at end of the preceding period 162 262 888 139 984 462 Movements during the period Recorded Sale, transfer and withdraw 24 092 573 15 939 22 278 426 0 Depreciation and amounts written down at the end of the period 186 336 521 162 262 888 Net book value at the end of the period 24 450 691 27 986 462 Statement of tangible fixed assets (in €) LAND AND BUILDINGS Acquisition value at the end of the preceding period Movements during the period Acquisitions, included produced fixed assets Acquisition value at the end of the period Depreciation and amounts written down at end of the preceding period Movements during the period Recorded Depreciation and amounts written down at end of the period Net book value at the end of the period INSTALLATIONS, MACHINERY & EQUIPMENT Acquisition value at the end of the preceding period Movements during the period Acquisitions, included produced fixed assets Sale, transfer and withdraw Acquisition value at the end of the period Depreciation and amounts written down at end of the preceding period Movements during the period Recorded Sale, transfer and withdraw Depreciation and amounts written down at end of the period Net book value at the end of the period FURNITURE AND VEHICLES Acquisition value at the end of the preceding period Movements during the period Acquisitions, included produced fixed assets Sale, transfer and withdraw 2021 2020 - - - - - - - - - - - - - - 692 095 1 094 125 279 161 25 409 945 847 612 006 87 616 25 409 674 213 271 634 1 189 483 865 405 41 685 27 263 71 532 686 231 692 095 911 291 39 854 551 808 612 006 80 089 1 499 426 59 272 23 810 393 025 Page 174 | 180 Acquisition value at the end of the period Depreciation and amounts written down at end of the preceding period Movements during the period Recorded Sale, transfer and withdraw Depreciation and amounts written down at end of the period Net book value at the end of the period LEASING AND OTHER SIMILAR RIGHT Acquisition value at the end of the preceding period Movements during the period Acquisitions, included produced fixed assets Sale, transfer and withdraw Acquisition value at the end of the period Sale, transfer and withdraw Depreciation and amounts written down at end of the preceding Movements during the period Recorded Recorded Sale, transfer and withdraw Depreciation and amounts written down at end of the period Net book value at the end of the period Whereof: Land and buildings Installation, machinery & equipment Furniture and vehicles OTHER TANGIBLE ASSETS Acquisition value at the end of the preceding period Movements during the period Acquisitions, included produced fixed assets Sale, transfer and withdraw Acquisition value at the end of the period Depreciation and amounts written down at end of the preceding period Movements during the period Recorded Sale, transfer and withdraw Depreciation and amounts written down at end of the period Net book value at the end of the period FIXED ASSETS UNDER CONSTRUCTION AND ADVANCE PAYMENTS Acquisition value at the end of the preceding period Movements during the period Acquisitions, included produced fixed assets Transfers from one heading to another Acquisition value at the end of the period Depreciation and amounts written down at end of the preceding period Movements during the period Recorded Depreciation and amounts written down at end of the period Recorded Net book value at the end of the period 2021 Annual Report 1 189 483 1 389 138 59 272 13 602 327 558 1 134 454 55 029 1 408 421 (543 016) 194 000 - 1 059 405 750 545 (543 016) 483 953 - 691 482 367 923 - 347 368 20 555 1 252 294 171 174 16 026 148 254 1 291 240 536 493 171 174 139 839 140 514 706 992 584 249 - - - - - - - - - - 2 069 310 1 134 454 865 405 20 268 26 345 1 993 782 75 528 1 059 405 (865 405) - - 194 000 691 482 (865 405) 228 943 - 55 020 138 980 - 138 980 - 1 291 240 - 10 458 - 1 301 699 706 992 - 141 324 - 848 316 453 383 - - - - - - - - - - Other investments and deposits (in €) Other Investments and deposits 2021 2020 Acquisition value at the end of the preceding period 290 633 254 572 Movements during the period Additions - 36 061 Page 175 | 180  Reimbursements (-) Net book value at the end of the period (31 173) 259 460 - 290 633 2021 Annual Report Investment and deposits (in €) Less than one year More than one year Net book value at the end of the period Statement of capital 2021 (in €) Issued capital Structure of the capital Different categories of shares Registered Dematerialized Unpaid capital Uncalled capital Capital called, but unpaid Shareholders having yet to pay up in full Authorized unissued capital Statement of capital 2020 (in €) Issued capital Structure of the capital Different categories of shares Registered Dematerialized Unpaid capital Uncalled capital Capital called, but unpaid Shareholders having yet to pay up in full Authorized unissued capital 2021 2020 - - - - - - Amounts Number of shares 78 584 224 22 593 956 xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx 2 368 025 20 225 931 xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx 4 773 124 Amounts Number of shares 48 512 615 13 942 344 2 368 025 11 574 319 xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx 36 891 844 Statement of amounts payable (in €) 2021 2020 Analysis of amounts payable after more than one year Current portion of amounts initially payable after more than one year Amounts payable expiring over one year and before 5 years Amounts payable expiring over five year Analysis by current position of amounts initially payable after more than one year Leasing charges and similar Other debts (loans) Other debt Tax, wage and social amounts payable Taxes Non expired taxes payable Remuneration and social security 253 072 951 935 1 094 181 162 942 2 136 246 516 987 1 829 013 1 194 094 387 739 3 152 355 2 261 280 301 073 Page 176 | 180 Other amounts payable related to remuneration and social security 1 839 305 1 817 518 2021 Annual Report Operating results (in €) Other operating income 2021 2020 Subsidies and recoverable cash advance received from the Walloon Region 7 111 354 5 620 796 Operating charges Employees recorded in the personnel register Total number at the closing date Average number of employees calculated in full-time equivalents Number of actual worked hours Personnel costs Remuneration and direct social benefits Employer’s social security contributions Employer’s premiums for extra statutory insurances Other personnel costs (+)/(-) Pensions Impairment of trade receivables On trade receivables Record Withdrawal Provisions for risks and charges Addition Use of and withdrawal Other operating charges Taxes related to operations Other charges 89 87 83 86 144 347 143 509 6 278 525 1 483 557 1 074 277 309 243 - - - - 6 282 555 1 533 053 914 436 289 354 - - - - 1 126 1 152 835 1 087 1 056 496 Hired temporary staff and persons placed at the enterprise’s disposal Total number at the closing date Average number calculated as full-time equivalents Number of actual worked hours Charges to the enterprise - 0,3 664 32 101 Financial results (in €) Interest income Other financial income Interest charges Foreign exchange difference Other financial charges Income and charge of exceptional size or incidence (in €) Non-recurring income Non-recurring financial income Non-recurring operating charges Non-recurring financial charges 2021 2020 639 919 693 3 113 200 778 34 788 2021 2020 607 - 172 - - - 64 2 884 5 373 120 122 5 465 25 458 934 887 41 - 9 776 - Page 177 | 180 Income tax (in €) Status of deferred taxes 2021 Annual Report 2021 2020 Accumulated tax losses deductible from future taxable profits 278 899 876 247 107 718 The total amount of value added tax and taxes borne by third parties (in €) 2021 2020 The total amount of value added tax and taxes borne by third parties The total amount of value added tax charged To the enterprise (deductible) By the enterprise Amounts retained on behalf of third parties Payroll withholding taxes 4 163 762 2 370 943 3 948 069 2 320 642 2 120 036 2 148 288 Financial relationship with Amount of direct and indirect remunerations and pensions, included in the income statement, as long as this disclosure does not concern exclusively or mainly, the situation of a single identifiable person (in €) To non-executive directors 2021 2020 372 500 365 750 Financial relationship with auditors (in €) Auditor’s fees Auditor’s special missions fees Fees for special missions executed by related parties to the Auditor 5.37.4. Summary of valuation rules 2020 2019 202 000 141 788 - 200 000 66 850 - Valuation rules are determined by the Board of Directors in accordance with the Royal Decree of 30 January 2001, executing Belgian Company Code and related to the annual accounts requirements for companies. Formation expenses are booked as intangible fixed assets and amortized over 5 years. Intangible fixed assets acquired from a third party or acquired through a contribution in kind are recorded at the acquisition value. Intangible fixed assets not acquired from a third party are valued at their cost of production in such a way that they do not exceed a prudent estimation of their future economical use or their future return. Intangible assets developed internally are capitalized when perspectives of future return are probable and clearly identified. Clinical development expenses are capitalized when authorization to start a phase III trial of the related program is obtained. Development expenses of a medical device are capitalized when the device is CE marked. These intangible fixed assets are – in principle – amortized prorate temporis over 5 years starting the year of the first revenue generation associated with the related asset. Furniture and fixtures are depreciated over 3, 5 or 10 years depending on the economic life of the assets. An impairment test is performed each year at year end on all tangible and intangible assets. Exceptional depreciation or amortization expenses may result from such impairment analysis. Page 178 | 180 2021 Annual Report Financial fixed assets are booked at acquisition value. A write-off is accounted for when the financial fixed asset is permanently impaired. There is no inventory. Direct materials purchased are directly expensed taken into account their short lifetime. Amounts receivable are booked as asset at nominal value. Amounts receivable in foreign currencies are converted in EUR at the exchange rate at closing date. Negative exchange differences resulting from the conversion in EUR at the exchange rate at closing date are expensed; positive exchange differences are accounted for as deferred income. Amounts receivable are written-off when their realizable value is estimated to be lower than their carrying value. Bank deposits are valued at their acquisition value. Cash and cash equivalents are valued at nominal value. When the nominal value includes interests, these latter are accounted for through the balance sheet caption “deferred charges and accrued income”. A write-off is accounted for when their realizable value is estimated to be lower than their carrying value. Amount payables are booked at nominal value. Amount payables in foreign currencies are converted in EUR at the exchange rate at closing date. Negative exchange differences resulting from the conversion in EUR at the exchange rate at closing date are expensed; positive exchange differences are accounted for as deferred income. Recoverable advances are recognized in operating income prorated on the associated R&D costs as soon as there is reasonable assurance that these advances are acquired. Recoverable cash advances contracted with the Walloon Region are subject to reimbursement plans that are both fixed (30% of the recoverable advance) and variable. When the decision to exploit the outcome of the research and development program partially financed by the Walloon Region is notified to the Region, the fixed part of the reimbursements is recognized in debts. The presentation of short-term and long-term debt is based on perspectives of revenue generation and reviewed on a yearly basis. The variable part of reimbursements, depending on turnover, will be paid in the year of income. An off-balance sheet commitment is presented in the appendix and corresponds to the Company’s best estimate of the amount potentially reimbursable to the Region and not recognized in debts (including variable part). Page 179 | 180 2021 Annual Report FINANCIAL CALENDAR  Annual shareholders meeting  First quarter 2022 business update  First half interim results 2022  Third quarter 2022 business update May 5, 2022 May 5, 2022 August 5, 2022 November 10, 2022 CELYAD CONTACT DETAILS Filippo Petti Chief Executive Officer / Chief Financial Officer Email: investors@celyad.com Paper copy in French and English can be obtained free of charge via the Company’s registered office. CELYAD ONCOLOGY SA Axis Business Park Rue Edouard Belin 2 1435 – Mont-Saint-Guibert Belgium Tel: +32 10 39 41 00 RPM: Nivelles – BE0891 118 115 Email: info@celyad.com Website: www.celyad.com Page 180 | 180 CELYAD AND THE STOCK EXCHANGE The Company is listed on Euronext Paris and Brussels since July 2013 and on Nasdaq since June 2015. Mnemo: CYAD ISIN:BE0974260896 PEA and PEA PME Eligibility Total outstanding shares: 22,593,956 (as of December 8, 2021) MORE INFORMATION ON: www.celyad.com MORE INFORMATION FOR SHAREHOLDERS ON: www.celyad.com/investors CONTACT: investors@celyad.com 

Continue reading text version or see original annual report in PDF format above